Amedeo Smart

Free Medical Literature Service


 

Amedeo

Influenza

  Free Subscription

Articles published in
Vaccine
    March 2024
  1. HILL-BATORSKI L, Bowen R, Bielefeldt-Ohmann H, Moser MJ, et al
    Mucosal immunization with dual influenza/COVID-19 single-replication virus vector protects hamsters from SARS-CoV-2 challenge.
    Vaccine. 2024 Mar 19:S0264-410X(24)00327-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  2. KRASILNIKOV I, Isaev A, Djonovic M, Ivanov A, et al
    Transformative vaccination: A pentavalent shield against COVID-19 and influenza with betulin-based adjuvant for enhanced immunity.
    Vaccine. 2024 Mar 19:S0264-410X(23)01421-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  3. LLOYD PC, Lufkin B, Moll K, Ogilvie RP, et al
    Incidence rates of thrombosis with thrombocytopenia syndrome (TTS) among adults in United States commercial and Medicare claims databases, 2017-2020.
    Vaccine. 2024;42:2004-2010.
    >> Share

  4. LANG JC, Kura K, Garba SM, Elbasha EH, et al
    Comparison of a static cohort model and dynamic transmission model for respiratory syncytial virus intervention programs for infants in England and Wales.
    Vaccine. 2024;42:1918-1927.
    >> Share

  5. LUISI M, Geana MV, Pei J
    Pandemic antecedents - Exploring predictivity and relationships between COVID-19 vaccine uptake and influenza, shingles, and HPV vaccination.
    Vaccine. 2024 Mar 8:S0264-410X(24)00275-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  6. ST-LOUIS P, Martin C, Khatri V, Bourgault S, et al
    Intranasal delivery of a self-adjuvanted nanovaccine composed of the curli filaments and the highly conserved M2e epitope confers protection against influenza a virus in mice.
    Vaccine. 2024 Mar 8:S0264-410X(24)00222-6. doi: 10.1016/j.vaccine.2024.
    >> Share


  7. Expression of Concern: "Cross-protection against H7N9 influenza strains using a live-attenuated H7N3 virus vaccine" [Vaccine [33/1], 1 January 2015, Pages 108-116].
    Vaccine. 2024;42:1851.
    >> Share

    February 2024
  8. YADEGARYNIA D, Keyvanfar A, Keyvani H, Tehrani S, et al
    Immunogenicity and safety of a quadrivalent recombinant influenza vaccine manufactured in Iran (FluGuard) in volunteers aged 18-60 years: A double-blind, non-inferiority, randomized controlled trial.
    Vaccine. 2024 Feb 29:S0264-410X(24)00249-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  9. GUO J, Chen X, Guo Y, Liu M, et al
    Real-world effectiveness of seasonal influenza vaccination and age as effect modifier: A systematic review, meta-analysis and meta-regression of test-negative design studies.
    Vaccine. 2024 Feb 28:S0264-410X(24)00218-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  10. MARINDA E, Mathentamo Q, Coulson N, Parker S, et al
    Impact evaluation of a youth led intervention to increase COVID-19 vaccine uptake in Kwazulu-Natal, South Africa.
    Vaccine. 2024 Feb 28:S0264-410X(24)00211-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  11. YANG XY, Liu T, Jiang SC, Zhang ZW, et al
    Antibodies against SARS-CoV-2 non-structural protein 3 cross-react with human muscle cells and neuroglial cells.
    Vaccine. 2024;42:1259-1267.
    >> Share

  12. JABBAR F, Kadhim KA, Alhilfi RA, Chitheer A, et al
    Intensification of integrated immunization services to recover routine vaccination coverage and bring COVID-19 vaccine to the population of Iraq in 2022.
    Vaccine. 2024 Feb 27:S0264-410X(24)00197-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  13. KRISTINSDOTTIR I, Haraldsson A, Thors V
    Influenza vaccination in pregnant women in Iceland 2010-2020 and the burden of influenza in pregnant women and their infants.
    Vaccine. 2024 Feb 26:S0264-410X(24)00205-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  14. MUNDO ORTIZ A, Nasri B
    Socio-demographic determinants of COVID-19 vaccine uptake in Ontario: Exploring differences across the Health Region model.
    Vaccine. 2024 Feb 26:S0264-410X(24)00204-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  15. NEWALL AT, Nazareno AL, Muscatello DJ, Boettiger D, et al
    The association between influenza vaccination uptake and influenza and pneumonia-associated deaths in the United States.
    Vaccine. 2024 Feb 24:S0264-410X(24)00113-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  16. MURPHY C, Kwan MYW, Chan ELY, Wong JSC, et al
    Influenza vaccine effectiveness against hospitalizations associated with influenza A(H3N2) in Hong Kong children aged 9 months to 17 years, June-November 2023.
    Vaccine. 2024 Feb 22:S0264-410X(24)00215-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  17. SHETTY AN, Morgan HJ, Phuong LK, Mallard J, et al
    Audiovestibular adverse events following COVID-19 vaccinations.
    Vaccine. 2024 Feb 22:S0264-410X(24)00210-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  18. XU S, Sy LS, Hong V, Farrington P, et al
    Mortality risk after COVID-19 vaccination: A self-controlled case series study.
    Vaccine. 2024 Feb 21:S0264-410X(24)00191-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  19. SHOUKAT A, Bawden CE, Rost G, LeBlanc JJ, et al
    Impact and cost-effectiveness analyses of vaccination for prevention of respiratory syncytial virus disease among older adults in Ontario: A Canadian Immunization Research Network (CIRN) study.
    Vaccine. 2024 Feb 16:S0264-410X(24)00200-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  20. CHERRY N, Adisesh A, Burstyn I, Charlton C, et al
    Determinants of SARS-CoV-2 IgG response and decay in Canadian healthcare workers: A prospective cohort study.
    Vaccine. 2024;42:1168-1178.
    >> Share

  21. JIN F, Qiu Y, Wu Z, Wang YH, et al
    Immunogenicity and safety of a SARS-CoV-2 mRNA vaccine (SYS6006) in healthy Chinese participants: A randomized, observer-blinded, placebo-controlled phase 2 clinical trial.
    Vaccine. 2024 Feb 15:S0264-410X(24)00124-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  22. MZIOU E, Hchaichi A, Letaief H, Dhaouadi S, et al
    Vaccine effectiveness against COVID-19: A test negative case-control study in Tunisia, August 2021.
    Vaccine. 2024 Feb 15:S0264-410X(24)00174-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  23. ROCKSON ADJEI M, Longsignikuu A, Saeed Iddris I, Nang Suuri T, et al
    Trend of measles-rubella vaccination coverage and impact on measles epidemiology in the Savannah Region, Ghana; 2018-2022: A secondary data analysis.
    Vaccine. 2024 Feb 15:S0264-410X(24)00170-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  24. KIM HK, Park SK, Choe SA, Gwak ES, et al
    Risk of SARS-CoV-2 breakthrough infection following NVX-CoV2373 and BNT162b2 vaccinations in Korean Adults: A population-based observational study.
    Vaccine. 2024 Feb 15:S0264-410X(24)00168-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  25. KUTER BJ, Brien K, Anderson S, Bass SB, et al
    COVID-19 vaccine perspectives and uptake among university students three years into the pandemic.
    Vaccine. 2024 Feb 15:S0264-410X(24)00162-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  26. OKOLI GN, Righolt CH, Zhang G, Van Caeseele P, et al
    A population-based, province-wide, record-linkage interrupted time series analysis of impact of the universal seasonal influenza vaccination policy on seasonal influenza vaccine uptake among 5-64-year-olds in the province of Manitoba, Canada.
    Vaccine. 2024 Feb 14:S0264-410X(24)00104-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  27. BATHEJA A, Balkrishnan R
    Rhode Island as a model for promoting flu vaccination in the United States.
    Vaccine. 2024 Feb 14:S0264-410X(24)00161-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  28. KLASSEN AC, Lee G, Chiang S, Murray R, et al
    Did the COVID-19 experience change U.S. parents' attitudes towards HPV vaccination? Results from a national survey.
    Vaccine. 2024 Feb 14:S0264-410X(24)00142-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  29. DONATO F, Pilotto A, Foca E, Tresoldi M, et al
    The impact of time since SARS-Cov-2 vaccination, age, sex and comorbidities on COVID-19 outcome in hospitalized patients with SARS-CoV-2 infection.
    Vaccine. 2024 Feb 13:S0264-410X(24)00147-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  30. HEARN EB, Kehinde G, Sambamoorthi U
    Food insecurity and COVID-19 vaccine hesitancy among adults in the United States (US).
    Vaccine. 2024 Feb 13:S0264-410X(24)00102-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  31. AMDISEN L, Pedersen L, Abildgaard N, Benn CS, et al
    The coverage of influenza vaccination and predictors of influenza non-vaccination in Danish cancer patients: A nationwide register-based cohort study.
    Vaccine. 2024 Feb 12:S0264-410X(24)00155-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  32. VALENTIN J, Ingrao F, Rauw F, Lambrecht B, et al
    Protection conferred by an H5 DNA vaccine against highly pathogenic avian influenza in chickens: The effect of vaccination schedules.
    Vaccine. 2024 Feb 12:S0264-410X(23)01422-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  33. WHITAKER HJ, Hassell K, Hoschler K, Power L, et al
    Influenza vaccination during the 2021/22 season: A data-linkage test-negative case-control study of effectiveness against influenza requiring emergency care in England and serological analysis of primary care patients.
    Vaccine. 2024 Feb 10:S0264-410X(24)00150-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  34. LIJESKIC O, Bauman N, Markovic M, Srbljanovic J, et al
    SARS-CoV-2 specific antibody response after an mRNA vaccine as the third dose: Homologous versus heterologous boost.
    Vaccine. 2024 Feb 10:S0264-410X(24)00110-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  35. WEI J, Tan TC, Moa AM, MacIntyre CR, et al
    Cost-benefit of influenza vaccination in preventing sudden cardiac arrest amongst Australian adults.
    Vaccine. 2024 Feb 9:S0264-410X(24)00154-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  36. BUEKENS P, Berrueta M, Ciapponi A, Bardach A, et al
    Safe in pregnancy: A global living systematic review and meta-analysis of COVID-19 vaccines in pregnancy.
    Vaccine. 2024 Feb 9:S0264-410X(24)00158-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  37. WADAPURKAR R, Singh S, Singh A
    Leveraging the immunoinformatics approach for designing the SARS-CoV-2 omicron-specific antigenic cassette of mRNA vaccine.
    Vaccine. 2024 Feb 8:S0264-410X(24)00111-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  38. RANDELL M, Sheel M, Dynes M, Li M, et al
    Influence of the COVID-19 pandemic on caregiver beliefs and experiences of routine childhood immunisation in Indonesia.
    Vaccine. 2024;42:812-818.
    >> Share

  39. KOLANDAI K, Milne B, von Randow M, Bullen C, et al
    Public opinion on global COVID-19 vaccine procurement and distribution policies: A nationally representative survey in Aotearoa New Zealand 2022.
    Vaccine. 2024 Feb 6:S0264-410X(24)00115-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  40. MAEDA M, Murata F, Fukuda H
    The age-specific impact of COVID-19 vaccination on medical expenditures and hospitalization duration after breakthrough infection: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) Study.
    Vaccine. 2024 Feb 5:S0264-410X(24)00106-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  41. MIYAMOTO S, Suzuki T
    Infection-mediated immune response in SARS-CoV-2 breakthrough infection and implications for next-generation COVID-19 vaccine development.
    Vaccine. 2024 Feb 2:S0264-410X(24)00112-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  42. RIVERS P, Porter C, LeClair LB, Jeddy Z, et al
    Longitudinal parental perception of COVID-19 vaccines for children in a multi-site, cohort study.
    Vaccine. 2024 Feb 2:S0264-410X(24)00010-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  43. BENNETT JC, Luiten KG, O'Hanlon J, Han PD, et al
    Utilizing a university testing program to estimate relative effectiveness of monovalent COVID-19 mRNA booster vaccine versus two-dose primary series against symptomatic SARS-CoV-2 infection.
    Vaccine. 2024 Feb 1:S0264-410X(24)00103-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  44. DATTA S, Vattiato G, Maclaren OJ, Hua N, et al
    The impact of Covid-19 vaccination in Aotearoa New Zealand: A modelling study.
    Vaccine. 2024 Feb 1:S0264-410X(24)00128-2. doi: 10.1016/j.vaccine.2024.
    >> Share

    January 2024
  45. SOOD S, Matar MM, Kim J, Kinsella M, et al
    Strong immunogenicity & protection in mice with PlaCCine: A COVID-19 DNA vaccine formulated with a functional polymer.
    Vaccine. 2024 Jan 31:S0264-410X(24)00077-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  46. HUANG Y, Shi H, Forgacs D, Ross TM, et al
    Flu-COVID combo recombinant protein vaccines elicited protective immune responses against both influenza and SARS-CoV-2 viruses infection.
    Vaccine. 2024 Jan 30:S0264-410X(23)01543-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  47. JI Y, Sui X, Miao W, Wang C, et al
    Immunogenicity of an adenovirus-vectored bivalent vaccine against wild type SARS-CoV-2 and Omicron variants in a murine model.
    Vaccine. 2024 Jan 30:S0264-410X(24)00097-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  48. SHAPIRO BEN DAVID S, Baruch Gez S, Adler L, Kovatch R, et al
    Short term safety of BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine among children aged 5-11 years, a nationwide parental survey.
    Vaccine. 2024 Jan 27:S0264-410X(24)00067-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  49. BALSELLS E, Vicente M, Reyes S, Figueroa M, et al
    Impact of the 'Health on Wheels' (HoW) strategy on COVID-19 vaccination coverage in hard-to-reach communities in Alta Verapaz, Guatemala, 2022.
    Vaccine. 2024 Jan 27:S0264-410X(24)00033-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  50. OKPANI AI, Adu P, Paetkau T, Lockhart K, et al
    Are COVID-19 vaccination mandates for healthcare workers effective? A systematic review of the impact of mandates on increasing vaccination, alleviating staff shortages and decreasing staff illness.
    Vaccine. 2024 Jan 27:S0264-410X(24)00052-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  51. FILIPAS DK, Labban M, Beatrici E, Stone BV, et al
    Exploring preventive care practices among unvaccinated individuals in the United States during the COVID-19 pandemic.
    Vaccine. 2024;42:441-447.
    >> Share

  52. TAKALANI A, Robinson M, Jonas P, Bodenstein A, et al
    Safety of a second homologous Ad26.COV2.S vaccine among healthcare workers in the phase 3b implementation Sisonke study in South Africa.
    Vaccine. 2024 Jan 25:S0264-410X(24)00078-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  53. RUSS S, Bennett N, van Wijngaarden E, Hill E, et al
    Influence of Community Determinants on Barriers and Facilitators to COVID-19 Vaccine Uptake: Regional Stakeholders' Perspectives.
    Vaccine. 2024 Jan 24:S0264-410X(24)00051-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  54. LIU R, Fan Y, Patel A, Liu H, et al
    The association between influenza vaccination, cardiovascular mortality and hospitalization: A living systematic review and prospective meta-analysis.
    Vaccine. 2024 Jan 23:S0264-410X(24)00053-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  55. HAMAD SAIED M, van Straalen JW, de Roock S, Verduyn Lunel FM, et al
    Humoral and cellular immunogenicity, effectiveness and safety of COVID-19 mRNA vaccination in patients with pediatric rheumatic diseases: A prospective cohort study.
    Vaccine. 2024 Jan 22:S0264-410X(24)00059-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  56. PAL R, Ferrari MG, Honda-Okubo Y, Wattay L, et al
    Study of immunogenicity and efficacy against Omicron BA.5 of recombinant protein-based COVID-19 vaccine delivered by intramuscular and mucosal routes in nonhuman primates.
    Vaccine. 2024 Jan 22:S0264-410X(24)00034-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  57. GEINITZ H, Silberberger E, Spiegl K, Feichtinger J, et al
    SARS-CoV-2 vaccination willingness and humoral vaccination response in radiation oncology patients.
    Vaccine. 2024 Jan 20:S0264-410X(24)00004-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  58. HILL PL, Morstead T, Pfund GN, Burrow AL, et al
    Examining changes in sense of purpose before, during, and after COVID-19 vaccination.
    Vaccine. 2024 Jan 20:S0264-410X(24)00027-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  59. MITCHELL MM, Klott A, Scholtes J, Braden BB, et al
    Mixed-methods examination of attitudes and behaviors related to COVID-19 vaccines among parents of children with autism and autistic adults.
    Vaccine. 2024 Jan 19:S0264-410X(24)00013-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  60. HICKEN A, Jones P, Menon A, Rozek LS, et al
    Can endorsement by religious leaders move the needle on vaccine hesitancy?
    Vaccine. 2024 Jan 18:S0264-410X(24)00006-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  61. MEMEDOVICH A, Orr T, Hollis A, Salmon C, et al
    Social network risk factors and COVID-19 vaccination: A cross-sectional survey study.
    Vaccine. 2024 Jan 18:S0264-410X(24)00005-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  62. GRIMA AA, Kwong JC, Richard L, Reid J, et al
    The safety of seasonal influenza vaccination among adults prescribed immune checkpoint inhibitors: A self-controlled case series study using administrative data.
    Vaccine. 2024 Jan 17:S0264-410X(24)00023-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  63. LEMMER Y, Chapman R, Abolnik C, Smith T, et al
    Protective efficacy of a plant-produced beta variant rSARS-CoV-2 VLP vaccine in golden Syrian hamsters.
    Vaccine. 2024 Jan 17:S0264-410X(24)00036-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  64. FAN J, Song Y, Cong S, Millman AJ, et al
    Assessing interventions to encourage primary care health workers to recommend influenza vaccination and the impact on vaccination uptake for persons with Non-Communicable diseases in China.
    Vaccine. 2024 Jan 16:S0264-410X(24)00011-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  65. HARALAMBIEVA IH, Monroe JM, Ovsyannikova IG, Warner ND, et al
    Restricted Omicron-specific cross-variant memory B-cell immunity after a 3rd dose/booster of monovalent Wuhan-Hu-1-containing COVID-19 mRNA vaccine.
    Vaccine. 2024 Jan 16:S0264-410X(24)00032-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  66. KING ML
    How manufacturing won or lost the COVID-19 vaccine race.
    Vaccine. 2024 Jan 15:S0264-410X(23)01477-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  67. MCADAM E, Hayashi K, Barker B, Reddon H, et al
    COVID-19 vaccination among young people who use drugs in Vancouver, Canada.
    Vaccine. 2024 Jan 14:S0264-410X(24)00009-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  68. NAUTA J
    Estimand for non-inferiority influenza vaccine immunogenicity trials.
    Vaccine. 2024 Jan 13:S0264-410X(24)00014-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  69. RATISHVILI T, Quach HQ, Haralambieva IH, Suryawanshi YR, et al
    A multifaceted approach for identification, validation, and immunogenicity of naturally processed and in silico-predicted highly conserved SARS-CoV-2 peptides.
    Vaccine. 2024;42:162-174.
    >> Share

  70. VAN ROEKEL C, Labuschagne L, Pijpers J, van Roon A, et al
    Factors associated with COVID-19 autumn 2022 booster uptake in the Netherlands among older adults aged >/= 60 years and younger adults with chronic conditions.
    Vaccine. 2024;42:146-155.
    >> Share

  71. PARK SI, Park S, Lee K, Kwak HW, et al
    Intranasal immunization with the recombinant measles virus encoding the spike protein of SARS-CoV-2 confers protective immunity against COVID-19 in hamsters.
    Vaccine. 2024;42:69-74.
    >> Share

  72. REN S, Chen Q, Zhang Y, Yi L, et al
    Modeling the optimal seasonal monoclonal antibody administration strategy for respiratory syncytial virus (RSV) prevention based on age-season specific hospitalization rate of RSV in Suzhou, China, 2016-2022.
    Vaccine. 2024;42:352-361.
    >> Share

  73. QURESHI NS, Miller LG, Judge SP, Tran NDT, et al
    Characterizing predictors of COVID-19 vaccine refusal in an urban southern California jail population.
    Vaccine. 2024 Jan 9:S0264-410X(24)00017-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  74. HINSON-ENSLIN AM, Espinoza LE
    The mental health symptoms of individuals with sensory disabilities and the reasons that lead to COVID-19 vaccine refusal and hesitancy.
    Vaccine. 2024 Jan 9:S0264-410X(24)00012-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  75. STELETOU E, Giannouchos T, Dimitriou G, Karatza A, et al
    Parental concerns and vaccine hesitancy against COVID-19 vaccination for children in Greece: A cross-sectional survey.
    Vaccine. 2024 Jan 6:S0264-410X(24)00003-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  76. KRANZLER EC, Ihongbe TO, Marshall MC, Denison B, et al
    Racial and ethnic differences in COVID-19 vaccine readiness among adults in the United States, January 2021-April 2023.
    Vaccine. 2024 Jan 4:S0264-410X(23)01537-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  77. BUHL C, Jacobsen R, Almarsdottir AB, Abtahi S, et al
    Public's perspective on COVID-19 adenovirus vector vaccines after thrombosis with thrombocytopenia syndrome (TTS) reports and associated regulatory actions - A cross-sectional study in six EU member states.
    Vaccine. 2024 Jan 4:S0264-410X(23)01511-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  78. CHARPIGNON ML, Gupta S, Shahnaz Majumder M
    Massachusetts companion program bolsters COVID-19 vaccine rates among seniors.
    Vaccine. 2024 Jan 3:S0264-410X(23)01494-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  79. DAVIDSON AM, Burns S, White LA, Perlman M, et al
    "I shall not poison my child with your human experiment": Investigating predictors of parents' hesitancy about vaccinating younger children (<12) in Canada.
    Vaccine. 2024 Jan 2:S0264-410X(23)01519-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  80. AGASSE E, Rodriguez GF, Vilarino V, Galli JH, et al
    Social determinants of health and vaccine uptake in pregnancy: Disparities in a diverse, predominately foreign-born population.
    Vaccine. 2024 Jan 2:S0264-410X(23)01515-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  81. VASHI MD, Watkins M
    Missed opportunities: Reducing zero dose children amongthe urban poor after COVID, Mumbai India, 2022.
    Vaccine. 2024;42:59-63.
    >> Share

    December 2023
  82. RUBIO-CASILLAS A, Rodriguez-Quintero CM, Redwan EM, Gupta MN, et al
    Do vaccines increase or decrease susceptibility to diseases other than those they protect against?
    Vaccine. 2023 Dec 28:S0264-410X(23)01506-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  83. BARZEN G, Rieber F, Stangl K, Hahn K, et al
    mRNA vaccines for COVID-19 are safe and clinically effective in patients with cardiac amyloidosis.
    Vaccine. 2023 Dec 28:S0264-410X(23)01487-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  84. GHARPURE R, Akumu AO, Dawa J, Gobin S, et al
    Costs of seasonal influenza vaccine delivery in a pediatric demonstration project for children aged 6-23 months - Nakuru and Mombasa Counties, Kenya, 2019-2021.
    Vaccine. 2023 Dec 27:S0264-410X(23)01475-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  85. FONSECA HAR, Zimerman A, Monfardini F, Guimaraes HP, et al
    In-Hospital influenza vaccination to prevent cardiorespiratory events in the first 45 days after acute coronary syndrome: A prespecified analysis of the VIP-ACS trial.
    Vaccine. 2023 Dec 27:S0264-410X(23)01531-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  86. SHENTON P, Schrader S, Smith J, Alafaci A, et al
    Long term follow up and outcomes of Covid-19 vaccine associated myocarditis in Victoria, Australia: A clinical surveillance study.
    Vaccine. 2023 Dec 27:S0264-410X(23)01516-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  87. NGUYEN KH, Coy KC, Black CL, Scanlon P, et al
    Comparison of adult hesitancy towards COVID-19 vaccines and vaccines in general in the USA.
    Vaccine. 2023 Dec 23:S0264-410X(23)01488-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  88. SEPPALA E, Dahl J, Veneti L, Rydland KM, et al
    Covid-19 and influenza vaccine effectiveness against associated hospital admission and death among individuals over 65 years in Norway: A population-based cohort study, 3 October 2022 to 20 June 2023.
    Vaccine. 2023 Dec 22:S0264-410X(23)01496-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  89. KACHKO A, Selvaraj P, Liu S, Kim J, et al
    Vaccine-associated respiratory pathology correlates with viral clearance and protective immunity after immunization with self-amplifying RNA expressing the spike (S) protein of SARS-CoV-2 in mouse models.
    Vaccine. 2023 Dec 22:S0264-410X(23)01498-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  90. LO E, Brousseau N, Defay F, Fortin E, et al
    Neighborhood-level vaccine impact on COVID-19 infection and hospital admission in Quebec, Canada, during the Delta and early Omicron periods.
    Vaccine. 2023 Dec 22:S0264-410X(23)01489-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  91. KURIYAMA K, Murakami K, Sugiura K, Sakui S, et al
    Immunogenicity and safety of a second heterologous booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Interim analysis report of a phase 3 open-label trial.
    Vaccine. 2023 Dec 20:S0264-410X(23)01482-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  92. WOLFF M, Charpentier P, Canals A, Vial C, et al
    Humoral immune response in people living with HIV after administration of SARS-CoV-2 vaccine CoronaVac or BNT162b2 or CoronaVac/BNT162b2 booster sequence: A cross-sectional study.
    Vaccine. 2023 Dec 19:S0264-410X(23)01481-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  93. MIRIERI H, Nasimiyu C, Dawa J, Mburu C, et al
    Resilience of routine childhood immunization services in two counties in Kenya in the face of the COVID-19 pandemic.
    Vaccine. 2023;41:7695-7704.
    >> Share

  94. STUMPF J, Anders L, Siepmann T, Schwobel J, et al
    9-Month observational Dia-Vacc study of vaccine type influence on SARS-CoV-2 immunity in dialysis and kidney transplant patients.
    Vaccine. 2023 Dec 18:S0264-410X(23)01479-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  95. ARASHIRO T, Miwa M, Nakagawa H, Takamatsu J, et al
    COVID-19 vaccine effectiveness against severe COVID-19 requiring oxygen therapy, invasive mechanical ventilation, and death in Japan: A multicenter case-control study (MOTIVATE study).
    Vaccine. 2023 Dec 18:S0264-410X(23)01480-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  96. DAWA J, Jalang'o R, Mirieri H, Kalani R, et al
    Comparing performance of year-round and campaign-mode influenza vaccination strategies among children aged 6-23 months in Kenya: 2019-2021.
    Vaccine. 2023 Dec 16:S0264-410X(23)01380-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  97. JACKSON LA, Stapleton JT, Walter EB, Chen WH, et al
    Immunogenicity and safety of varying dosages of a fifth-wave influenza A/H7N9 inactivated vaccine given with and without AS03 adjuvant in healthy adults.
    Vaccine. 2023 Dec 16:S0264-410X(23)01434-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  98. JIANG W, Lu C, Yan X, Tucker JD, et al
    Vaccine confidence mediates the association between a pro-social pay-it-forward intervention and improved influenza vaccine uptake in China: A mediation analysis.
    Vaccine. 2023 Dec 15:S0264-410X(23)01392-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  99. ZHAN XY, Chen Y, Zhang X, Shi Q, et al
    Characterization of SARS-CoV-2-specific humoral immunity and associated factors in the healthy population post-vaccination.
    Vaccine. 2023 Dec 15:S0264-410X(23)01465-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  100. BAJRACHARYA D, Jansen RJ
    Observations of COVID-19 vaccine coverage and vaccine hesitancy on COVID-19 outbreak: An American ecological study.
    Vaccine. 2023 Dec 15:S0264-410X(23)01441-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  101. BURNS KE, Dube E, Godinho Nascimento H, Meyer SB, et al
    Examining vaccine hesitancy among a diverse sample of Canadian adults.
    Vaccine. 2023 Dec 15:S0264-410X(23)01476-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  102. DONG C, Ma Y, Zhu W, Wang Y, et al
    Influenza immune imprinting synergizes PEI-HA/CpG nanoparticle vaccine protection against heterosubtypic infection in mice.
    Vaccine. 2023 Dec 14:S0264-410X(23)01485-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  103. FERRONI E, Gennaro N, Maifredi G, Leoni O, et al
    Access to SARS-CoV-2 vaccination in immigrants in Italy, by geographical area of origin.
    Vaccine. 2023 Dec 13:S0264-410X(23)01387-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  104. CAO Z, Yu R, Yuan Q, Ji W, et al
    Impact of the COVID-19 pandemic on routine vaccination coverage under varying prevalence Conditions: A cohort study in Beijing, China.
    Vaccine. 2023 Dec 13:S0264-410X(23)01447-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  105. O'NEIL SS, Pendl-Robinson EL, Carosella EA, Sullivan BD, et al
    The importance of community-specific survey data in understanding behavioral and social drivers of COVID-19 vaccination: Lessons learned from urban neighborhoods in four United States cities.
    Vaccine. 2023 Dec 12:S0264-410X(23)01450-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  106. OPRIESSNIG T, Gauger PC, Filippsen Favaro P, Rawal G, et al
    An experimental universal swine influenza a virus (IAV) vaccine candidate based on the M2 ectodomain (M2e) peptide does not provide protection against H1N1 IAV challenge in pigs.
    Vaccine. 2023 Dec 11:S0264-410X(23)01445-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  107. LYTRAS T, Di Gregorio AAA, Apostolopoulos D, Naziris D, et al
    Effectiveness of COVID-19 vaccine mandates in raising vaccination rates among the elderly and general population in Europe: Controlled interrupted time series analysis.
    Vaccine. 2023 Dec 11:S0264-410X(23)01472-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  108. AKMATOVA R, Dzhangaziev B, Ebama MS, Otorbaeva D, et al
    Knowledge, attitudes, and practices (KAP) towards seasonal influenza and influenza vaccine among pregnant women in Kyrgyzstan: A cross-sectional study.
    Vaccine. 2023 Dec 9:S0264-410X(23)01453-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  109. MESIDOR M, Liu Y, Talbot D, Skowronski DM, et al
    Test negative design for vaccine effectiveness estimation in the context of the COVID-19 pandemic: A systematic methodology review.
    Vaccine. 2023 Dec 9:S0264-410X(23)01446-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  110. SUI Y, Andersen H, Li J, Hoang T, et al
    SARS-CoV-2 mucosal vaccine protects against clinical disease with sex bias in efficacy.
    Vaccine. 2023 Dec 8:S0264-410X(23)01426-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  111. DI CHIARA C, Cantarutti A, Raffaella Petrara M, Bonfante F, et al
    Stronger and durable SARS-CoV-2 immune response to mRNA vaccines in 5-11 years old children with prior COVID-19.
    Vaccine. 2023 Dec 8:S0264-410X(23)01439-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  112. CHENG DR, Reimer H, Le D, Crawford NW, et al
    Analyzing an immunization resource website: User browsing trends.
    Vaccine. 2023;41:7498-7502.
    >> Share

  113. YU Y, Zhang X, Lau MMC, Lau JTF, et al
    The intention to get COVID-19 booster vaccination and its association with cognitive and emotional factors: A survey of Chinese COVID-19 infected people in Hong Kong.
    Vaccine. 2023 Dec 7:S0264-410X(23)01448-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  114. GRAMACHO W, Turgeon M, Santos Mundim P, Pereira I, et al
    Why did Brazil fail to vaccinate children against COVID-19 during the pandemic? An assessment of attitudinal and behavioral determinants.
    Vaccine. 2023 Dec 6:S0264-410X(23)01432-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  115. CANEVARI JT, Cheng AC, Wu L, Rowe SL, et al
    The relative effectiveness of three and four doses of COVID-19 vaccine in Victoria, Australia: A data linkage study.
    Vaccine. 2023 Dec 5:S0264-410X(23)01393-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  116. MADNI SA, Sharma AJ, Zauche LH, Waters AV, et al
    CDC COVID-19 Vaccine Pregnancy Registry: Design, data collection, response rates, and cohort description.
    Vaccine. 2023 Dec 5:S0264-410X(23)01423-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  117. PRASERT K, Praphasiri P, Lerdsamran H, Nakphook S, et al
    Safety and immunogenicity of locally produced trivalent inactivated influenza vaccine (Tri Fluvac) in healthy Thai adults aged 18-64 years in Nakhon Phanom: A Phase III double blinded, three-arm, randomized, controlled trial.
    Vaccine. 2023 Dec 1:S0264-410X(23)01396-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  118. GASHTI AB, Agbayani G, Hrapovic S, Nassoury N, et al
    Production, purification and immunogenicity of Gag virus-like particles carrying SARS-CoV-2 components.
    Vaccine. 2023 Dec 1:S0264-410X(23)01394-4. doi: 10.1016/j.vaccine.2023.
    >> Share

    November 2023
  119. WANG Y, Hu Y, Ma Y, Li P, et al
    RBD class 1 and 2 antibody epitopes elicit around 70% neutralizing capacity against SARS-CoV-2 virus following boosting with inactivated virus vaccine.
    Vaccine. 2023 Nov 27:S0264-410X(23)01381-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  120. NISHIYAMA T, Miyamatsu Y, Park H, Nakamura N, et al
    Modeling COVID-19 vaccine booster-elicited antibody response and impact of infection history.
    Vaccine. 2023 Nov 25:S0264-410X(23)01384-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  121. DUCASA N, Benencio P, Mauro E, Anders M, et al
    Evaluation of the humoral response to the third dose of SARS-COV-2 vaccines in liver transplant recipients.
    Vaccine. 2023 Nov 24:S0264-410X(23)01383-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  122. PAYNE AB, Ciesla AA, Rowley EAK, Weber ZA, et al
    Impact of accounting for correlation between COVID-19 and influenza vaccination in a COVID-19 vaccine effectiveness evaluation using a test-negative design.
    Vaccine. 2023 Nov 23:S0264-410X(23)01337-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  123. FITZPATRICK MC, Laufer RS, Baral R, Driscoll AJ, et al
    Report of the WHO technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, April 7-8, 2022.
    Vaccine. 2023;41:7047-7059.
    >> Share

  124. WANG B, McDonough J, Chen G, Ong JJ, et al
    Sociodemographic factors and attitudes associated with Australian parental acceptance of paediatric COVID-19 vaccination.
    Vaccine. 2023 Nov 22:S0264-410X(23)01336-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  125. NEELY SR, Hao F
    Breakthrough COVID-19 infections and perceived vaccine effectiveness.
    Vaccine. 2023 Nov 22:S0264-410X(23)01365-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  126. LAW AW, Judy J, Atwell JE, Willis S, et al
    Maternal Tdap and influenza vaccination uptake 2017-2021 in the United States: Implications for maternal RSV vaccine uptake in the future.
    Vaccine. 2023 Nov 21:S0264-410X(23)01307-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  127. NAUGLE D, Tibbels N, Dosso A, Benie W, et al
    "I'd do it for my baby": Lessons learned from qualitative research on COVID-19 vaccination among pregnant women in Cote d'Ivoire.
    Vaccine. 2023 Nov 19:S0264-410X(23)01333-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  128. HAEDER SF
    Assessing parental intention to vaccinate against COVID-19, influenza, and RSV in the United States in late 2023.
    Vaccine. 2023 Nov 15:S0264-410X(23)01303-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  129. AMITAI N, Wertheimer R, Prais D, Wertheimer KO, et al
    Influenza vaccination in children with pulmonary disease during the COVID-19 pandemic.
    Vaccine. 2023 Nov 15:S0264-410X(23)01338-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  130. CHOI Y, Park S, Lee J, Kim Y, et al
    Who gets COVID-19 booster vaccination? Trust in public health institutions and promotion strategies post-pandemic in the Republic of Korea.
    Vaccine. 2023 Nov 15:S0264-410X(23)01294-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  131. SARAFIAN JT, Eucker SA, Gillman M, DeLaroche AM, et al
    Impact of a hypothetical COVID-19 vaccine mandate on parental likelihood to vaccinate children: Exploring school-related concerns and vaccination decision-making.
    Vaccine. 2023 Nov 14:S0264-410X(23)01334-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  132. GUBERNOT D, Menis M, Whitaker B
    Background rates for severe cutaneous reactions in the US: Contextual support for safety assessment of COVID-19 vaccines and novel biologics.
    Vaccine. 2023;41:6922-6929.
    >> Share

  133. LASRADO N, Collier AY, Hachmann NP, Miller J, et al
    Neutralization escape by SARS-CoV-2 Omicron subvariant BA.2.86.
    Vaccine. 2023;41:6904-6909.
    >> Share

  134. GOTO T, Chong Y, Tani N, Susai N, et al
    Distinct features of SARS-CoV-2 humoral immunity against Omicron breakthrough infection.
    Vaccine. 2023;41:7019-7025.
    >> Share

  135. CUBIZOLLES C, Barjat T, Chauleur C, Bruel S, et al
    Evaluation of intentions to get vaccinated against influenza, COVID 19, pertussis and to get a future vaccine against respiratory syncytial virus in pregnant women.
    Vaccine. 2023 Nov 12:S0264-410X(23)01280-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  136. JIANG X, Wang J, Li C, Yeoh EK, et al
    Impact of the surge of COVID-19 Omicron outbreak on the intention of seasonal influenza vaccination in Hong Kong: A cross-sectional study.
    Vaccine. 2023 Nov 11:S0264-410X(23)01304-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  137. GRABENSTEIN JD, Ferrara P, Mantovani LG, McGovern I, et al
    Evaluating risk of bias using ROBINS-I tool in nonrandomized studies of adjuvanted influenza vaccine.
    Vaccine. 2023 Nov 10:S0264-410X(23)01302-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  138. HERZIG VAN WEES S, Stalgren M, Viberg N, Puranen B, et al
    "Who is Anders Tegnell?" Unanswered questions hamper COVID-19 vaccine uptake: A qualitative study among ethnic minorities in Sweden.
    Vaccine. 2023 Nov 10:S0264-410X(23)01328-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  139. BRUXVOORT KJ, Sy LS, Hong V, Lewin B, et al
    Factors associated with uptake of bivalent mRNA COVID-19 vaccines in a large US health care system.
    Vaccine. 2023 Nov 10:S0264-410X(23)01324-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  140. DUDLEY MZ, Schwartz B, Brewer J, Kan L, et al
    COVID-19 vaccination attitudes, values, intentions: US parents for their children, September 2021.
    Vaccine. 2023 Nov 9:S0264-410X(23)01295-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  141. ANDERSON EC, Blair PS, Finn A, Ingram J, et al
    Maternal vaccination provision in NHS maternity trusts across England.
    Vaccine. 2023 Nov 9:S0264-410X(23)01284-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  142. YANG C, Zheng Z, Zheng P, Chen J, et al
    Inactivated COVID-19 vaccines in peri-pregnancy period: Evaluation of safety for both pregnant women and neonates.
    Vaccine. 2023 Nov 8:S0264-410X(23)01322-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  143. INOUE Y, Li Y, Yamamoto S, Fukunaga A, et al
    The association between antipyretic analgesics use and SARS-CoV-2 antibody titers following the second dose of the BNT162b2 mRNA vaccine: An observational study.
    Vaccine. 2023 Nov 7:S0264-410X(23)01220-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  144. SPACKMAN E, Suarez DL, Lee CW, Pantin-Jackwood MJ, et al
    Efficacy of inactivated and RNA particle vaccines against a North American Clade 2.3.4.4b H5 highly pathogenic avian influenza virus in chickens.
    Vaccine. 2023 Nov 4:S0264-410X(23)01285-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  145. HANSEN LG, Larsen LE, Rasmussen TB, Miar Y, et al
    Investigation of the SARS-CoV-2 post-vaccination antibody response in Canadian farmed mink.
    Vaccine. 2023 Nov 4:S0264-410X(23)01288-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  146. JONES G, Perry M, Bailey R, Arumugam S, et al
    Dimensions of equality in uptake of COVID-19 vaccination in Wales, UK: A multivariable linked data population analysis.
    Vaccine. 2023 Nov 4:S0264-410X(23)01279-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  147. AKHTAR Z, Gotberg M, Erlinge D, Christiansen EH, et al
    Optimal timing of influenza vaccination among patients with acute myocardial infarction - Findings from the IAMI trial.
    Vaccine. 2023 Nov 2:S0264-410X(23)01211-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  148. CHEN GL, Yu XY, Luo LP, Zhang F, et al
    Phase I study of a non-S2P SARS-CoV-2 mRNA vaccine LVRNA009 in Chinese adults.
    Vaccine. 2023 Nov 2:S0264-410X(23)01278-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  149. ALIZADEH M, Raj S, Shojadoost B, Matsuyama-Kato A, et al
    In ovo administration of retinoic acid enhances cell-mediated immune responses against an inactivated H9N2 avian influenza virus vaccine.
    Vaccine. 2023 Nov 1:S0264-410X(23)01261-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  150. JAMES WG, Stanberry LR, LaRussa PS, Grodman MD, et al
    Vaccines and global health: COVID-19 vaccine development, strategy, and implementation symposium - Summary of the meeting at Vagelos College of Physicians and Surgeons (February 22-26, 2021, New York).
    Vaccine. 2023 Nov 1:S0264-410X(23)01254-9. doi: 10.1016/j.vaccine.2023.
    >> Share

    October 2023
  151. RAMSAY JA, Jones M, Vande More AM, Hunt SL, et al
    A single blinded, phase IV, adaptive randomised control trial to evaluate the safety of coadministration of seasonal influenza and COVID-19 vaccines (The FluVID study).
    Vaccine. 2023 Oct 28:S0264-410X(23)01250-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  152. SALLOUM M, Paviotti A, Bastiaens H, Van Geertruyden JP, et al
    The inclusion of pregnant women in vaccine clinical trials: An overview of late-stage clinical trials' records between 2018 and 2023.
    Vaccine. 2023 Oct 28:S0264-410X(23)01259-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  153. LIU Y, Sanchez-Ovando S, Carolan L, Dowson L, et al
    Superior immunogenicity of mRNA over adenoviral vectored COVID-19 vaccines reflects B cell dynamics independent of anti-vector immunity: Implications for future pandemic vaccines.
    Vaccine. 2023 Oct 28:S0264-410X(23)01217-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  154. NYAMBAYO PPM, Gold MS, Mehta UC, Clarke S, et al
    Efficacy and feasibility of SMS m-Health for the detection of adverse events following immunisation (AEFIs) in resource-limited setting-The Zimbabwe stimulated telephone assisted rapid safety surveillance (Zm-STARSS) randomised control trial.
    Vaccine. 2023;41:6700-6709.
    >> Share

  155. TANI N, Ikematsu H, Goto T, Kondo S, et al
    Correlation between specific antibody response to wild-type BNT162b2 booster and the risk of breakthrough infection with omicron variants: Impact of household exposure in hospital healthcare workers.
    Vaccine. 2023;41:6672-6678.
    >> Share

  156. WALLIAR T, Khan B, Newstead S, Al-Assadi G, et al
    "Fighting the pandemic!" Western Australian pharmacists' perspectives on COVID-19 vaccines: A qualitative study.
    Vaccine. 2023 Oct 25:S0264-410X(23)01243-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  157. ANASTASSOPOULOU C, Boufidou F, Hatziantoniou S, Vasileiou K, et al
    Adverse events of acute nephrotoxicity reported to EudraVigilance and VAERS after COVID-19 vaccination.
    Vaccine. 2023 Oct 25:S0264-410X(23)01214-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  158. CENAT JM, Moshirian Farahi SMM, Broussard C, Dalexis RD, et al
    The state of COVID-19 vaccine confidence and need in Black individuals in Canada: Understanding the role of sociodemographic factors, health literacy, conspiracy theories, traumatic stressors and racial discrimination.
    Vaccine. 2023 Oct 25:S0264-410X(23)01246-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  159. KITIKOON P, Knetter SM, Mogler MA, Morgan CL, et al
    Quadrivalent neuraminidase RNA particle vaccine protects pigs against homologous and heterologous strains of swine influenza virus infection.
    Vaccine. 2023 Oct 24:S0264-410X(23)01175-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  160. FLOR N, Garcia MI, Molineri A, Bottasso O, et al
    Antibodies to SARS-CoV2 induced by vaccination and infection correlate with protection against the infection.
    Vaccine. 2023 Oct 24:S0264-410X(23)01221-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  161. BRESEE J, Koh M, Chadwick C, Jit M, et al
    The need and ongoing efforts to understand the full value of improved influenza vaccines.
    Vaccine. 2023 Oct 21:S0264-410X(23)01245-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  162. WANGCHUK S, Prabhakaran AO, Dhakal GP, Zangmo C, et al
    Introducing seasonal influenza vaccine in Bhutan: Country experience and achievements.
    Vaccine. 2023 Oct 20:S0264-410X(23)01255-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  163. IRVING SA, Groom HC, Belongia EA, Crane B, et al
    Influenza vaccination coverage among persons ages six months and older in the Vaccine Safety Datalink in the 2017-18 through 2022-23 influenza seasons.
    Vaccine. 2023 Oct 20:S0264-410X(23)01206-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  164. TUNIS M, Deeks S, Harrison R, Quach C, et al
    Canada's National Advisory Committee on immunization: Adaptations and challenges during the COVID-19 pandemic.
    Vaccine. 2023;41:6538-6547.
    >> Share

  165. MORI Y, Uchida N, Wake A, Miyawaki K, et al
    Impact of a third dose of anti-SARS-CoV-2 vaccine in hematopoietic cell transplant recipients: A Japanese multicenter observational study.
    Vaccine. 2023 Oct 20:S0264-410X(23)01022-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  166. HART R, Feygin Y, Kluthe T, Quinn KG, et al
    Emergency departments: An underutilized resource to address pediatric influenza vaccine coverage.
    Vaccine. 2023 Oct 19:S0264-410X(23)01222-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  167. MCCLYMONT E, Atkinson A, Albert A, Av-Gay G, et al
    Reactogenicity, pregnancy outcomes, and SARS-CoV-2 infection following COVID-19 vaccination during pregnancy in Canada: A national prospective cohort study.
    Vaccine. 2023 Oct 19:S0264-410X(23)01215-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  168. HONDA-OKUBO Y, Bowen R, Barker M, Bielefeldt-Ohmann H, et al
    Advax-CpG55.2-adjuvanted monovalent or trivalent SARS-CoV-2 recombinant spike protein vaccine protects hamsters against heterologous infection with Beta or Delta variants.
    Vaccine. 2023 Oct 18:S0264-410X(23)01190-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  169. RIEFOLO F, Castillo-Cano B, Martin-Perez M, Messina D, et al
    Effectiveness of homologous/heterologous booster COVID-19 vaccination schedules against severe illness in general population and clinical subgroups in three European countries.
    Vaccine. 2023 Oct 17:S0264-410X(23)01181-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  170. HAEDER SF
    U.S. public support and opposition to vaccination mandates in K-12 education in light of the COVID-19 pandemic.
    Vaccine. 2023 Oct 17:S0264-410X(23)01188-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  171. YANG H, Wang Z, Zhang Y, Xu M, et al
    Effectiveness of inactivated COVID-19 vaccines against SARS-CoV-2 Omicron subvariant BF.7 among outpatients in Beijing, China.
    Vaccine. 2023 Oct 17:S0264-410X(23)01219-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  172. PLATENBURG PPLI, Deschamps F, Jung J, Leonard C, et al
    Carbohydrate fatty acid monosulphate ester is a potent adjuvant for low-dose seasonal influenza vaccines.
    Vaccine. 2023 Oct 16:S0264-410X(23)01189-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  173. LOPEZ-GOMEZ A, Pelaez-Prestel HF, Juarez I
    Approaches to evaluate the specific immune responses to SARS-CoV-2.
    Vaccine. 2023;41:6434-6443.
    >> Share

  174. MOSCA S, Lin Q, Stokes R, Bharucha T, et al
    Innovative method for rapid detection of falsified COVID-19 vaccines through unopened vials using handheld Spatially Offset Raman Spectroscopy (SORS).
    Vaccine. 2023 Oct 13:S0264-410X(23)01182-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  175. ARASHIRO T, Arima Y, Kuramochi J, Muraoka H, et al
    Immune escape and waning immunity of COVID-19 monovalent mRNA vaccines against symptomatic infection with BA.1/BA.2 and BA.5 in Japan.
    Vaccine. 2023 Oct 13:S0264-410X(23)01194-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  176. SATHE N, Shaikh S, Bhavsar M, Parte L, et al
    Safety, immunogenicity and efficacy of Relcovax(R), a dual receptor binding domain (RBD) and nucleocapsid (N) subunit protein vaccine candidate against SARS-CoV-2 virus.
    Vaccine. 2023 Oct 8:S0264-410X(23)01176-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  177. LOPEZ-ZAMBRANO MA, Pita CC, Escribano MF, Galan Melendez IM, et al
    Factors associated to influenza vaccination among hospital's healthcare workers in the Autonomous Community of Madrid, Spain 2021-2022.
    Vaccine. 2023 Oct 6:S0264-410X(23)01117-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  178. OZAWA S, Schuh HB, Nakamura T, Yemeke TT, et al
    How to increase and maintain high immunization coverage: Vaccination Demand Resilience (VDR) framework.
    Vaccine. 2023 Oct 3:S0264-410X(23)01097-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  179. ZACHRESON C, Tobin R, Szanyi J, Walker C, et al
    Individual variation in vaccine immune response can produce bimodal distributions of protection.
    Vaccine. 2023 Oct 2:S0264-410X(23)01095-2. doi: 10.1016/j.vaccine.2023.
    >> Share

    September 2023
  180. OKOLI GN, Righolt CH, Zhang G, Alessi-Severini S, et al
    Impact of the universal seasonal influenza vaccination policy in the province of Manitoba, Canada: A population-based, province-wide record-linkage study.
    Vaccine. 2023 Sep 29:S0264-410X(23)01133-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  181. DIONNE M, Sauvageau C, Kiely M, Rathwell M, et al
    "The problem is not lack of information": A qualitative study of parents and school nurses' perceptions of barriers and potential solutions for HPV vaccination in schools.
    Vaccine. 2023 Sep 28:S0264-410X(23)01140-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  182. HARBOE ZB, Hald A, Ekenberg C, Ete Wareham N, et al
    Implementation of a vaccination clinic for adult solid organ transplant candidates: A single-center experience.
    Vaccine. 2023 Sep 27:S0264-410X(23)01106-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  183. LAVELL AHA, Schramade AE, Sikkens JJ, van der Straten K, et al
    25-Hydroxyvitamin D concentrations do not affect the humoral or cellular immune response following SARS-CoV-2 mRNA vaccinations.
    Vaccine. 2023 Sep 27:S0264-410X(23)00957-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  184. SHEN X, Hao Y, Wang S, Li D, et al
    Sequential heterologous immunization with COVID-19 vaccines induces broader neutralizing responses against SARS-CoV-2 variants in comparison with homologous boosters.
    Vaccine. 2023 Sep 26:S0264-410X(23)01100-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  185. CASSARINO N, Ahnger-Pier KK, Wurcel A
    Trends in COVID-19 and influenza vaccine ordering and distribution in Massachusetts jails.
    Vaccine. 2023 Sep 25:S0264-410X(23)01115-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  186. SANA S, Merkelbach I, Magnee T, Kollmann J, et al
    Identifying barriers to vaccination intention at walk-in vaccination facilities in deprived neighbourhoods: A cross-sectional survey.
    Vaccine. 2023 Sep 25:S0264-410X(23)01038-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  187. GOLOVKINA MI, Ertz SC, Lechnir SS, Hayney MS, et al
    Providing influenza vaccines at endoscopy visits increases influenza vaccine uptake.
    Vaccine. 2023 Sep 23:S0264-410X(23)01108-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  188. RAISER F, Davis M, Adelglass J, Cai MR, et al
    Immunogenicity and safety of NVX-CoV2373 as a booster: A phase 3 randomized clinical trial in adults.
    Vaccine. 2023;41:5965-5973.
    >> Share

  189. HAO F, Shao W
    Social network, political climate, income inequality, and Americans uptake of monovalent COVID-19 booster.
    Vaccine. 2023;41:6077-6082.
    >> Share

  190. NGAMCHALIEW P, Kaewkuea N, Nonthasorn N, Vonnasrichan T, et al
    Acceptance of COVID-19 vaccination and vaccine confidence levels in Thailand: A cross-sectional study.
    Vaccine. 2023 Sep 22:S0264-410X(23)01088-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  191. HOMAIRA N, He WQ, McRae J, Macartney K, et al
    Coverage and predictors of influenza and pertussis vaccination during pregnancy: a whole of population-based study.
    Vaccine. 2023 Sep 21:S0264-410X(23)01062-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  192. FU Y, Wu K, Wang Z, Yang H, et al
    Effectiveness of various COVID-19 vaccine regimens among 10.4 million patients from the National COVID Cohort Collaborative during Pre-Delta to Omicron periods - United States, 11 December 2020 to 30 June 2022.
    Vaccine. 2023 Sep 21:S0264-410X(23)01025-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  193. WILKINSON B, Patel KS, Smith K, Walker R, et al
    A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 vir
    Vaccine. 2023 Sep 20:S0264-410X(23)00871-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  194. ALHARBI HS
    Review: Factors influencing parents' decisions to vaccinate children against COVID-19.
    Vaccine. 2023 Sep 19:S0264-410X(23)01090-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  195. HAN C, Zhao ZZ, Chan P, Li F, et al
    A large survey on COVID-19 vaccination in patients with Parkinson's disease and healthy population.
    Vaccine. 2023 Sep 17:S0264-410X(23)01056-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  196. NELSON CB, Brady BL, Richards M, Lew CR, et al
    Optimal site of care for administration of extended half-life respiratory syncytial virus (RSV) antibodies to infants in the United States (US).
    Vaccine. 2023;41:5820-5824.
    >> Share

  197. SHAVER N, Katz M, Darko Asamoah G, Linkins LA, et al
    Protocol for a living evidence synthesis on variants of concern and COVID-19 vaccine effectiveness.
    Vaccine. 2023 Sep 15:S0264-410X(23)01065-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  198. SURYAWANSHI YR
    An overview of protein-based SARS-CoV-2 vaccines.
    Vaccine. 2023 Sep 10:S0264-410X(23)01067-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  199. POTT H, Andrew MK, Shaffelburg Z, Nichols MK, et al
    Vaccine Effectiveness of non-adjuvanted and adjuvanted trivalent inactivated influenza vaccines in the prevention of influenza-related hospitalization in older adults: A pooled analysis from the Serious Outcomes Surveillance (SOS) Network of the Canad
    Vaccine. 2023 Sep 9:S0264-410X(23)01026-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  200. YU J, Sreenivasan C, Sheng Z, Zhai SL, et al
    A recombinant chimeric influenza virus vaccine expressing the consensus H3 hemagglutinin elicits broad hemagglutination inhibition antibodies against divergent swine H3N2 influenza viruses.
    Vaccine. 2023 Sep 7:S0264-410X(23)01060-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  201. MONTEIRO HS, Lima Neto AS, Kahn R, Sousa GS, et al
    Impact of CoronaVac on Covid-19 outcomes of elderly adults in a large and socially unequal Brazilian city: A target trial emulation study.
    Vaccine. 2023;41:5742-5751.
    >> Share

  202. PATERNINA-CAICEDO A, Quevedo DS, Rios DS, Moyano D, et al
    Comparative effectiveness and duration of protection of ChAdOx1, CoronaVac, BNT162b2, mRNA-1273, and Ad26.COV2.S COVID-19 vaccines for symptomatic and hospitalized Mu, Delta, and Omicron: A test-negative case-control study.
    Vaccine. 2023 Sep 5:S0264-410X(23)01028-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  203. YUE PHR, Lau HPB, Ng SM, Chan LWC, et al
    When to be vaccinated? What to consider? Modelling decision-making and time preference for COVID-19 vaccine through a conjoint experiment.
    Vaccine. 2023 Sep 5:S0264-410X(23)01024-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  204. PHILLIPS A, Jiang Y, Walsh D, Andrews N, et al
    Background rates of adverse events of special interest for COVID-19 vaccines: A multinational Global Vaccine Data Network (GVDN) analysis.
    Vaccine. 2023 Sep 5:S0264-410X(23)01045-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  205. ALSAIF F, Twigg M, Scott S, Blyth A, et al
    A systematic review of barriers and enablers associated with uptake of influenza vaccine among care home staff.
    Vaccine. 2023 Sep 4:S0264-410X(23)01048-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  206. CLAESSENS T, Krouwer S, Vandebosch H, Poels K, et al
    Pathways to informed choices: The impact of freedom of choice and two-sided messages on psychological reactance and vaccination intentions among individuals who express concerns.
    Vaccine. 2023 Sep 3:S0264-410X(23)00948-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  207. WILLIS DE, Moore R, Andersen JA, Li J, et al
    Correlates of COVID-19 vaccine coverage in Arkansas: Results from a weighted random sample survey.
    Vaccine. 2023 Sep 1:S0264-410X(23)01039-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  208. PORRAS-RAMIREZ A, Sanchez-Paris R, Lopez-Devia W, Moreno-Perilla Z, et al
    Confirmed cases of COVID-19 after vaccination against COVID in health personnel in Bogota, Colombia.
    Vaccine. 2023 Sep 1:S0264-410X(23)00924-6. doi: 10.1016/j.vaccine.2023.
    >> Share

    August 2023
  209. SAKALA IG, Honda-Okubo Y, Petrovsky N
    Developmental and reproductive safety of Advax-CpG55.2 adjuvanted COVID-19 and influenza vaccines in mice.
    Vaccine. 2023 Aug 31:S0264-410X(23)01007-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  210. GRILLS LA, Wagner AL
    The impact of the COVID-19 pandemic on parental vaccine hesitancy: A cross-sectional survey.
    Vaccine. 2023 Aug 31:S0264-410X(23)00977-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  211. DUDLEY HM, O'Mara M, Auma A, Gong J, et al
    Rheumatoid arthritis and older age are associated with lower humoral and cellular immune response to primary series COVID-19 mRNA vaccine.
    Vaccine. 2023 Aug 31:S0264-410X(23)00965-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  212. REGAN AK, Fell DB, Wise LA, Vazquez-Benitez G, et al
    Challenges & opportunities for the epidemiological evaluation of the effects of COVID-19 vaccination on reproduction and pregnancy.
    Vaccine. 2023 Aug 31:S0264-410X(23)00964-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  213. PHIRIYASART F, Aimyong N, Jirapongsuwan A, Roseh N, et al
    COVID-19 vaccine hesitancy among older adult Thai Muslim people: A case-control study.
    Vaccine. 2023 Aug 27:S0264-410X(23)00994-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  214. YANG J, Li B, Yang D, Wu J, et al
    The immunogenicity of Alum+CpG adjuvant SARS-CoV-2 inactivated vaccine in mice.
    Vaccine. 2023 Aug 26:S0264-410X(23)01017-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  215. JANSSEN ERC, van Montfoort AZ, Hollman F, Lambers Heerspink FO, et al
    The prevalence and clinical course of shoulder injury related to vaccine administration (SIRVA) after COVID-19 vaccines in Dutch hospital workers.
    Vaccine. 2023 Aug 25:S0264-410X(23)00975-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  216. CHIBA S, Halfmann PJ, Iida S, Hirata Y, et al
    Recombinant spike protein vaccines coupled with adjuvants that have different modes of action induce protective immunity against SARS-CoV-2.
    Vaccine. 2023 Aug 25:S0264-410X(23)01008-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  217. CHEN IR, Wang GJ, Hsueh PR, Chou CH, et al
    Immune responses and safety of COVID-19 vaccination in atypical hemolytic uremic syndrome patients in Taiwan.
    Vaccine. 2023 Aug 25:S0264-410X(23)00952-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  218. WATERLOW NR, Procter SR, van Leeuwen E, Radhakrishnan S, et al
    The potential cost-effectiveness of next generation influenza vaccines in England and Wales: A modelling analysis.
    Vaccine. 2023 Aug 24:S0264-410X(23)00963-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  219. MOHAMMED IS, Widome R, Searle KM
    COVID-19 vaccine decision-making among Black women: A qualitative study.
    Vaccine. 2023 Aug 24:S0264-410X(23)00920-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  220. DENG L, Tapper K, Thosar D, Goeman E, et al
    Use of adrenaline to manage suspected anaphylaxis following COVID-19 vaccination: An Australian retrospective cohort study.
    Vaccine. 2023 Aug 24:S0264-410X(23)00956-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  221. GOULD S, Wrzesinski C, Stebbings R, Segal L, et al
    Report from an ICT 2022 workshop on toxicology for Covid19 vaccines: Industry, regulatory and CRO perspectives.
    Vaccine. 2023 Aug 24:S0264-410X(23)00972-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  222. STRUYF F, Hardt K, Van Rampelbergh R, Shukarev G, et al
    Thrombosis with thrombocytopenia syndrome: A database review of clinical trial and post-marketing experience with Ad26.COV2.S.
    Vaccine. 2023;41:5351-5359.
    >> Share

  223. SU Y, Guo Z, Gu X, Sun S, et al
    Influenza vaccine effectiveness against influenza A during the delayed 2022/23 epidemic in Shihezi, China.
    Vaccine. 2023 Aug 19:S0264-410X(23)00971-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  224. YAO T, Guo Y, Xu X, Zhang X, et al
    Predictors of immune persistence induced by two-dose BBIBP-CorV vaccine in high-risk occupational population.
    Vaccine. 2023 Aug 19:S0264-410X(23)00974-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  225. KENIGSBERG TA, Goddard K, Hanson KE, Lewis N, et al
    Simultaneous administration of mRNA COVID-19 bivalent booster and influenza vaccines.
    Vaccine. 2023 Aug 18:S0264-410X(23)00955-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  226. CHAIWONG W, Takheaw N, Pata S, Laopajon W, et al
    Neutralizing antibody and T-cell responses against SARS-CoV-2 variants by heterologous CoronaVac/ChAdOx-1 vaccination in elderly subjects with chronic obstructive pulmonary disease.
    Vaccine. 2023 Aug 18:S0264-410X(23)00966-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  227. PALACHE A, Billingsley JK, MacLaren K, Morgan L, et al
    Lessons learned from the COVID-19 pandemic for improved influenza control.
    Vaccine. 2023 Aug 17:S0264-410X(23)00960-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  228. MORRISON K, Cullen L, James AB, Chua V, et al
    Predictors of incomplete COVID-19 vaccine schedule among adults in Scotland: Two retrospective cohort analyses of the primary schedule and third dose.
    Vaccine. 2023 Aug 17:S0264-410X(23)00916-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  229. ZUR M, Shelef L, Glassberg E, Fink N, et al
    Are intelligent people more likely to get vaccinated? The association between COVID-19 vaccine adherence and cognitive profiles.
    Vaccine. 2023 Aug 15:S0264-410X(23)00951-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  230. SARNA M, Gebremedhin A, Richmond P, Levy A, et al
    Determining the true incidence of seasonal respiratory syncytial virus-confirmed hospitalizations in preterm and term infants in Western Australia.
    Vaccine. 2023;41:5216-5220.
    >> Share

  231. TOYAMA K, Eto T, Takazawa K, Shimizu S, et al
    DS-5670a, a novel mRNA-encapsulated lipid nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2: Results from a phase 2 clinical study.
    Vaccine. 2023 Aug 14:S0264-410X(23)00824-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  232. WITTAWATMONGKOL O, Bunjoungmanee P, Kosalaraksa P, Laoprasopwattana K, et al
    Immunogenicity and reactogenicity of fractional, heterologous primary COVID-19 vaccination schedules with BNT162b2 boosters in 5-11-year-old Thai children: A multicenter, prospective, double-blind, randomized control trial.
    Vaccine. 2023 Aug 14:S0264-410X(23)00953-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  233. BERTHELEMY C, Bouche P, Lamiral Z, Boivin JM, et al
    Parental acceptability of vaccinating young children against influenza and COVID-19.
    Vaccine. 2023 Aug 12:S0264-410X(23)00929-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  234. HONDA-OKUBO Y, Bart Tarbet E, Hurst BL, Petrovsky N, et al
    An Advax-CpG adjuvanted recombinant H5 hemagglutinin vaccine protects mice against lethal influenza infection.
    Vaccine. 2023 Aug 9:S0264-410X(23)00941-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  235. BAGLIVO F, Magri M, De Angelis L, Aprile V, et al
    Performance comparison between heterologous and homologous COVID19 vaccine schedules on Omicron variant incidence: A real-world retrospective cohort study in Southern Italy.
    Vaccine. 2023 Aug 9:S0264-410X(23)00886-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  236. MAC S, Shi S, Millson B, Tehrani A, et al
    Burden of illness associated with Respiratory Syncytial Virus (RSV)-related hospitalizations among adults in Ontario, Canada: A retrospective population-based study.
    Vaccine. 2023;41:5141-5149.
    >> Share

  237. CHICOYE A, Crepey P, Nguyen VH, Marquez-Pelaez S, et al
    Contributions of cost-effectiveness analyses (CEA) to influenza vaccination policy for older adults in Europe.
    Vaccine. 2023 Aug 5:S0264-410X(23)00919-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  238. SIMMS AJ, King KD, Tsui N, Edwards SA, et al
    COVID-19 vaccine behaviour among citizens of the Metis Nation of Ontario: A qualitative study.
    Vaccine. 2023 Aug 5:S0264-410X(23)00891-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  239. VERJOVSKY M, Barreto MP, Carmo I, Coutinho B, et al
    Political quarrel overshadows vaccination advocacy: How the vaccine debate on Brazilian Twitter was framed by anti-vaxxers during Bolsonaro administration.
    Vaccine. 2023 Aug 5:S0264-410X(23)00921-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  240. CAMPBELL J, Kaur A, Gamino D, Benoit E, et al
    Individual and structural determinants of COVID-19 vaccine uptake in a marginalized community in the United States.
    Vaccine. 2023 Aug 5:S0264-410X(23)00923-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  241. MOSCARA L, Venerito V, Martinelli A, Di Lorenzo A, et al
    Safety profile and SARS-CoV-2 breakthrough infections among HCWs receiving anti-SARS-CoV-2 and influenza vaccines simultaneously: an Italian observational study.
    Vaccine. 2023 Aug 4:S0264-410X(23)00874-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  242. XU S, Yu H, Cheng X, Wu J, et al
    Inactivated SARS-CoV-2 vaccination does not disturb the clinical course of Graves' disease: An observational cohort study.
    Vaccine. 2023 Aug 4:S0264-410X(23)00884-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  243. AUVIGNE V, Tamandjou Tchuem CR, Schaeffer J, Vaux S, et al
    Protection against symptomatic SARS-CoV-2 infection conferred by the Pfizer-BioNTech Original/BA.4-5 bivalent vaccine compared to the mRNA Original monovalent vaccines - A matched cohort study in France.
    Vaccine. 2023 Aug 2:S0264-410X(23)00917-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  244. MO J, Spackman E, Swayne DE
    Prediction of highly pathogenic avian influenza vaccine efficacy in chickens by comparison of in vitro and in vivo data: A meta-analysis and systematic review.
    Vaccine. 2023 Aug 1:S0264-410X(23)00922-2. doi: 10.1016/j.vaccine.2023.
    >> Share

    July 2023
  245. HONDA-OKUBO Y, Sakala IG, Andre G, Tarbet EB, et al
    An Advax-CpG55.2 adjuvanted recombinant hemagglutinin vaccine provides immunity against H7N9 influenza in adult and neonatal mice.
    Vaccine. 2023 Jul 31:S0264-410X(23)00892-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  246. LIU B, Stepien S, Qian J, Gidding H, et al
    Comparative effectiveness of four COVID-19 vaccines, BNT162b2 mRNA, mRNA-1273, ChAdOx1 nCov-19 and NVX-CoV2373 against SARS-CoV-2 B.1.1.529 (Omicron) infection.
    Vaccine. 2023 Jul 29:S0264-410X(23)00881-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  247. AMANI A, Njoh AA, Atuhebwe P, Ndoula S, et al
    Beyond the numbers: An in-depth look at Cameroon's fifth national COVID-19 vaccination campaign through geographical and gender lenses.
    Vaccine. 2023 Jul 29:S0264-410X(23)00905-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  248. GREEN-MCKENZIE J, Shofer FS, Kruse G, Momplaisir F, et al
    COVID-19 vaccine uptake before and after a vaccine mandate at a major academic hospital: Trends by race/ethnicity and level of patient contact.
    Vaccine. 2023 Jul 28:S0264-410X(23)00853-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  249. LAVENDER B, Hooker C, Frampton C, Williams M, et al
    Robust immunogenicity of a third BNT162b2 vaccination against SARS-CoV-2 Omicron variant in a naive New Zealand cohort.
    Vaccine. 2023 Jul 27:S0264-410X(23)00882-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  250. ROSA RG, Falavigna M, Manfio JL, de Araujo CLP, et al
    BNT162b2 mRNA COVID-19 against symptomatic Omicron infection following a mass vaccination campaign in southern Brazil: A prospective test-negative design study.
    Vaccine. 2023 Jul 26:S0264-410X(23)00869-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  251. KIM DH, Lee J, Youk S, Jeong JH, et al
    Intramuscular administration of recombinant Newcastle disease virus expressing SARS-CoV-2 spike protein protects hACE-2 TG mice against SARS-CoV-2 infection.
    Vaccine. 2023;41:4787-4797.
    >> Share

  252. TAMADA Y, Takeuchi K, Kusama T, Maeda M, et al
    Effectiveness of COVID-19 vaccines against infection in Japan: A test-negative study from the VENUS study.
    Vaccine. 2023 Jul 22:S0264-410X(23)00856-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  253. GHAZY RM, Ibrahim SA, Taha SHN, Elshabrawy A, et al
    Attitudes of parents towards influenza vaccine in the Eastern Mediterranean Region: A multilevel analysis.
    Vaccine. 2023 Jul 20:S0264-410X(23)00808-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  254. ARAUJO-CHAVERON L, Sicsic J, Moffroid H, Diaz Luevano C, et al
    Impact of a COVID-19 certificate requirement on vaccine uptake pattern and intention for future vaccination. A cross-sectional study among French adults.
    Vaccine. 2023 Jul 20:S0264-410X(23)00805-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  255. KIM YA, Mousavi K, Yazdi A, Zwierzyna M, et al
    Computational design of mRNA vaccines.
    Vaccine. 2023 Jul 20:S0264-410X(23)00836-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  256. KATHERINE YIH W, Daley MF, Duffy J, Fireman B, et al
    Safety signal identification for COVID-19 bivalent booster vaccination using tree-based scan statistics in the Vaccine Safety Datalink.
    Vaccine. 2023 Jul 19:S0264-410X(23)00823-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  257. PISL V, Vevera J
    COVID-19 vaccine uptake in mental healthcare users: Czech nationwide register study.
    Vaccine. 2023 Jul 19:S0264-410X(23)00840-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  258. ZIMMERMAN RK, Patricia Nowalk M, Dauer K, Clarke L, et al
    Vaccine effectiveness of recombinant and standard dose influenza vaccines against influenza related hospitalization using a retrospective test-negative design.
    Vaccine. 2023 Jul 18:S0264-410X(23)00741-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  259. SABAT I, Neumann-Bohme S, Barros PP, Torbica A, et al
    Vaccine hesitancy comes in waves: Longitudinal evidence on willingness to vaccinate against COVID-19 from seven European countries.
    Vaccine. 2023 Jul 15:S0264-410X(23)00829-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  260. MOROS A, Prenafeta A, Barreiro A, Perozo E, et al
    Immunogenicity and safety in pigs of PHH-1V, a SARS-CoV-2 RBD fusion heterodimer vaccine candidate.
    Vaccine. 2023 Jul 15:S0264-410X(23)00820-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  261. CLOUSTON SAP, Hanes DW, Link BG
    Social inequalities and the early provision and dispersal of COVID-19 vaccinations in the United States: A population trends study.
    Vaccine. 2023 Jul 15:S0264-410X(23)00833-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  262. TALOTTA R
    COVID-19 mRNA vaccines as hypothetical epigenetic players: Results from an in silico analysis, considerations and perspectives.
    Vaccine. 2023 Jul 13:S0264-410X(23)00819-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  263. ALABANZA C, Gavrilov V, Scott T, Yang RS, et al
    Quantitation of strain-specific hemagglutinin trimers in mosaic quadrivalent influenza nanoparticle vaccine by ELISA.
    Vaccine. 2023 Jul 12:S0264-410X(23)00821-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  264. BEYERS KCL, Rbeihat MNM, S Vasconcelos D, Pasmans D, et al
    Preclinical evaluation of performance, safety and usability of VAX-ID(R), a novel intradermal injection device.
    Vaccine. 2023;41:4609-4615.
    >> Share

  265. AGRAWAL P, Damania D, Cseh A, Grab J, et al
    Impact of COVID vaccine and comorbidities in patients receiving casirivimab-imdevimab monoclonal antibody during SARS-CoV-2 B.1.617.2 (Delta) surge: A real-world study.
    Vaccine. 2023 Jul 12:S0264-410X(23)00822-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  266. MINCHIN J, Harris GH, Baumann S, Smith ER, et al
    Exclusion of pregnant people from emergency vaccine clinical trials: A systematic review of clinical trial protocols and reporting from 2009 to 2019.
    Vaccine. 2023 Jul 11:S0264-410X(23)00776-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  267. WILLIS DE, Reece S, Gurel-Headley M, Selig JP, et al
    Social processes, practical issues, and COVID-19 vaccination among hesitant adults.
    Vaccine. 2023 Jul 7:S0264-410X(23)00809-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  268. FLEMING JA, Baral R, Higgins D, Khan S, et al
    Value profile for respiratory syncytial virus vaccines and monoclonal antibodies.
    Vaccine. 2023 Jul 6:S0264-410X(22)01212-9. doi: 10.1016/j.vaccine.2022.
    >> Share

  269. ZHANG X, Shen P, Liu J, Ji X, et al
    Evaluating the effectiveness and cost-effectiveness of free influenza vaccination policy for older adults in Yinzhou, China: Study protocol of a real-world analyses.
    Vaccine. 2023 Jul 5:S0264-410X(23)00790-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  270. WAGNER A, Juvalta S, Speranza C, Suggs LS, et al
    Let's talk about COVID-19 vaccination: Relevance of conversations about COVID-19 vaccination and information sources on vaccination intention in Switzerland.
    Vaccine. 2023 Jul 5:S0264-410X(23)00807-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  271. LE H, de Klerk N, Blyth CC, Gidding H, et al
    Non-specific benefit of seasonal influenza vaccine on respiratory syncytial virus-hospitalisations in children: An instrumental variable approach using population-based data.
    Vaccine. 2023 Jul 3:S0264-410X(23)00788-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  272. PATEL UC, Schultz T, Schmidt J
    Veteran influenza vaccination acceptance rates after completion of the COVID-19 vaccination series among historical influenza vaccine refusers.
    Vaccine. 2023 Jul 3:S0264-410X(23)00803-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  273. ROSHCHINA Y, Rozhkova K, Roshchin S
    Between nudges and mandates: The drivers of COVID-19 vaccination intentions and subsequent uptake in Russia.
    Vaccine. 2023 Jul 3:S0264-410X(23)00756-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  274. TUCKERMAN J, Kaufman J, Overmars I, Holland P, et al
    Barriers to COVID-19 vaccination of migrant populations: A qualitative interview study of immunisation providers in Victoria, Australia.
    Vaccine. 2023 Jul 3:S0264-410X(23)00804-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  275. TROGSTAD L, Laake I, Robertson AH, Mjaaland S, et al
    Heavy bleeding and other menstrual disturbances in young women after COVID-19 vaccination.
    Vaccine. 2023 Jul 3:S0264-410X(23)00801-0. doi: 10.1016/j.vaccine.2023.
    >> Share

    June 2023
  276. LIU Z, Pang C, Deng Y, Guo C, et al
    Humoral immune response following the inactivated quadrivalent influenza vaccination among HIV-infected and HIV-uninfected adults.
    Vaccine. 2023 Jun 30:S0264-410X(23)00616-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  277. SHINJOH M, Furuichi M, Tsuzuki S, Iqbal A, et al
    Effectiveness of inactivated influenza and COVID-19 vaccines in hospitalized children in 2022/23 season in Japan - The first season of co-circulation of influenza and COVID-19.
    Vaccine. 2023 Jun 30:S0264-410X(23)00785-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  278. LIU Y, Zhang A, Wang Y, Yang J, et al
    Immunogenicity and protective effects of recombinant bivalent COVID-19 vaccine in mice and rhesus macaques.
    Vaccine. 2023 Jun 30:S0264-410X(23)00789-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  279. KU JH, Sy LS, Qian L, Ackerson BK, et al
    Effectiveness of a fourth dose of mRNA-1273 against COVID-19 among older adults in the United States: Interim results from an observational cohort study.
    Vaccine. 2023;41:4212-4219.
    >> Share

  280. VAN DER BOOR SC, Schmitz-de Vries ETJ, Smits D, Scholl JHG, et al
    Spontaneously reported adverse events following COVID-19 basic and booster immunizations in the Netherlands.
    Vaccine. 2023;41:4319-4326.
    >> Share

  281. ALVES K, Plested JS, Galbiati S, Chau G, et al
    Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373.
    Vaccine. 2023;41:4280-4286.
    >> Share

  282. ISHIKAWA K, Nascimento MC, Asano M, Hirata H, et al
    One year safety and immunogenicity of AZD1222 (ChAdOx1 nCoV-19): Final analysis of a randomized, placebo-controlled phase 1/2 trial in Japan.
    Vaccine. 2023;41:4199-4205.
    >> Share

  283. LEE KS, Rader NA, Miller-Stump OA, Cooper M, et al
    Intranasal VLP-RBD vaccine adjuvanted with BECC470 confers immunity against Delta SARS-CoV-2 challenge in K18-hACE2-mice.
    Vaccine. 2023 Jun 28:S0264-410X(23)00783-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  284. SHENG Y, Li Z, Lin X, Ma Y, et al
    The position of Spy Tag/Catcher system in hepatitis B core protein particles affects the immunogenicity and stability of the synthetic vaccine.
    Vaccine. 2023 Jun 28:S0264-410X(23)00759-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  285. DOMNICH A, Orsi A, Ogliastro M, Trombetta CS, et al
    Influenza vaccine effectiveness in preventing hospital encounters for laboratory-confirmed infection among Italian adults, 2022/23 season.
    Vaccine. 2023 Jun 27:S0264-410X(23)00775-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  286. KIM S, Ko M, Heo Y, Lee YK, et al
    Safety surveillance of the NVX-CoV2373 COVID-19 vaccine among Koreans aged 18 years and over.
    Vaccine. 2023 Jun 27:S0264-410X(23)00780-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  287. BARRIENTOS M, Vasquez-Lavin F, Rosales C, Bratti L, et al
    Understanding the role of personal experiences and contextual variables in shaping risk reduction preferences.
    Vaccine. 2023;41:4092-4105.
    >> Share

  288. TORP HANSEN K, Kusk Povlsen F, Hammer Bech B, Nygaard Hansen S, et al
    Immediate adverse reactions following COVID-19 vaccination among 16-65-year-old Danish citizens.
    Vaccine. 2023 Jun 23:S0264-410X(23)00758-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  289. TURLEY CB, Tables L, Fuller T, Sanders LJ, et al
    Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trials.
    Vaccine. 2023 Jun 23:S0264-410X(23)00755-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  290. SALEH SN, McDonald SA, Basit MA, Kumar S, et al
    Public perception of COVID-19 vaccines through analysis of Twitter content and users.
    Vaccine. 2023 Jun 23:S0264-410X(23)00743-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  291. HOWARD MC
    Integrating the person-centered approach with the study of vaccine hesitancy: Applying latent profile analysis to identify vaccine hesitancy subpopulations and assess their relations with correlates and vaccination outcomes.
    Vaccine. 2023 Jun 23:S0264-410X(23)00742-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  292. CHAUDHARY A, Madhavan R, Babji S, Raju R, et al
    Characterization of immune responses to two and three doses of the adenoviral vectored vaccine ChAdOx1 nCov-19 and the whole virion inactivated vaccine BBV152 in a mix-and-match study in India.
    Vaccine. 2023 Jun 23:S0264-410X(23)00744-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  293. AUGUSTYNIAK A, Szymanski T, Porzucek F, Mieloch AA, et al
    A cohort study reveals different dynamics of SARS-CoV-2-specific antibody formation after Comirnaty and Vaxzevria vaccination.
    Vaccine. 2023 Jun 21:S0264-410X(23)00665-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  294. LUANGASANATIP N, Painter C, Pan-Ngum W, Saralamba S, et al
    How to model the impact of vaccines for policymaking when the characteristics are uncertain: A case study in Thailand prior to the vaccine rollout during the COVID-19 pandemic.
    Vaccine. 2023 Jun 20:S0264-410X(23)00740-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  295. CHEN X, Lin Y, Yue S, Yang Y, et al
    PD-1/PD-L1 blockade restores tumor-induced COVID-19 vaccine bluntness.
    Vaccine. 2023 Jun 20:S0264-410X(23)00737-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  296. EKIMOV A, Arunachalam AB, Blake T, Bodle J, et al
    Assessing the stability-indicating properties of alternative potency assays for inactivated influenza vaccine.
    Vaccine. 2023 Jun 19:S0264-410X(23)00726-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  297. HONDA-OKUBO Y, Li L, Andre G, Leong KH, et al
    An Advax-CpG55.2 adjuvanted recombinant spike protein vaccine protects cynomolgus macaques from a homologous SARS-CoV-2 virus challenge.
    Vaccine. 2023 Jun 19:S0264-410X(23)00748-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  298. UDA K, Okubo Y, Tsuge M, Tsukahara H, et al
    Impacts of routine varicella vaccination program and COVID-19 pandemic on varicella and herpes zoster incidence and health resource use among children in Japan.
    Vaccine. 2023 Jun 19:S0264-410X(23)00739-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  299. TZENG R, Huang FY, Lee J
    Compliance, procrastination and refusal: American COVID-19 vaccination trust and value orientation.
    Vaccine. 2023 Jun 19:S0264-410X(23)00745-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  300. MASOUD D, Pierz A, Rauh L, Cruz AK, et al
    Vaccine Trust Gauge: Mixed methods research to measure and understand vaccine trust.
    Vaccine. 2023 Jun 17:S0264-410X(23)00690-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  301. DOYON-PLOURDE P, Przepiorkowski J, Young K, Zhao L, et al
    Intraseasonal waning immunity of seasonal influenza vaccine - A systematic review and meta-analysis.
    Vaccine. 2023 Jun 16:S0264-410X(23)00713-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  302. DUNN DT, Gilson R, McCormack S, McCoy LE, et al
    Licenced doses of approved COVID-19 vaccines may not be optimal: A review of the early-phase, dose-finding trials.
    Vaccine. 2023 Jun 16:S0264-410X(23)00712-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  303. BISWAS RK, Afiaz A, Huq S, Farzana M, et al
    Public opinion on COVID-19 vaccine prioritization in Bangladesh: Who gets the vaccine and whom do you leave out?
    Vaccine. 2023 Jun 16:S0264-410X(23)00725-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  304. NISHIYAMA A, Adachi Y, Tonouchi K, Moriyama S, et al
    Post-fusion influenza vaccine adjuvanted with SA-2 confers heterologous protection via Th1-polarized, non-neutralizing antibody responses.
    Vaccine. 2023 Jun 15:S0264-410X(23)00685-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  305. PIGNATTI P, Ramirez GA, Russo M, Marraccini P, et al
    Hypersensitivity reactions to anti-SARS-CoV-2 vaccines: Basophil reactivity to excipients.
    Vaccine. 2023 Jun 15:S0264-410X(23)00714-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  306. MUANGNOICHAROEN S, Wiangcharoen R, Nanthapisal S, Kamolratakul S, et al
    Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial.
    Vaccine. 2023 Jun 15:S0264-410X(23)00718-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  307. KENIGSBERG TA, Hanson KE, Klein NP, Zerbo O, et al
    Safety of simultaneous vaccination with COVID-19 vaccines in the Vaccine Safety Datalink.
    Vaccine. 2023 Jun 15:S0264-410X(23)00717-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  308. PUTHANAKIT T, Chokephaibulkit K, Chaithongwongwatthana S, Bhat N, et al
    A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in pregnant women.
    Vaccine. 2023 Jun 15:S0264-410X(23)00657-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  309. SHOAIBI A, Lloyd PC, Wong HL, Clarke TC, et al
    Evaluation of potential adverse events following COVID-19 mRNA vaccination among adults aged 65 years and older: Two self-controlled studies in the U.S.
    Vaccine. 2023 Jun 14:S0264-410X(23)00682-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  310. CIEMINS EL, Gillen A, Tallam M
    RSV: A vaccine is coming, time to educate providers.
    Vaccine. 2023 Jun 14:S0264-410X(23)00695-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  311. SAADATIAN-ELAHI M, Henaff L, Elias C, Nunes MC, et al
    Patient influenza vaccination reduces the risk of hospital-acquired influenza: An incident test negative-case control study in Lyon university hospital, France (2004-2020).
    Vaccine. 2023 Jun 13:S0264-410X(23)00621-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  312. SALMANTON-GARCIA J, Wipfler P, Valle-Simon P, Merakou C, et al
    VACCELERATE Site Network: Real-time definition of clinical study capacity in Europe.
    Vaccine. 2023;41:3915-3922.
    >> Share

  313. WOO EJ, Gee J, Marquez P, Baggs J, et al
    Post-authorization safety surveillance of Ad.26.COV2.S vaccine: Reports to the Vaccine Adverse Event Reporting System and v-safe, February 2021-February 2022.
    Vaccine. 2023 Jun 13:S0264-410X(23)00687-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  314. MUNOZ FM, Posavad CM, Richardson BA, Badell ML, et al
    COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn.
    Vaccine. 2023 Jun 13:S0264-410X(23)00698-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  315. WATESKA AR, Nowalk MP, Lin CJ, Harrison LH, et al
    Cost-effectiveness of an in-development adult-formulated pneumococcal vaccine in older US adults.
    Vaccine. 2023 Jun 12:S0264-410X(23)00669-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  316. MA D, Tian S, Qin Q, Yu Y, et al
    Construction of an inhalable recombinant M2e-FP-expressing Bacillus subtilis spores-based vaccine and evaluation of its protection efficacy against influenza in a mouse model.
    Vaccine. 2023 Jun 10:S0264-410X(23)00655-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  317. MADRAN B, Kayi I, Beser A, Ergonul O, et al
    Uptake of COVID-19 vaccines among healthcare workers and the effect of nudging interventions: A mixed methods study.
    Vaccine. 2023 Jun 9:S0264-410X(23)00688-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  318. UI M, Hirama T, Akiba M, Honda M, et al
    Cellular and humoral immune responses after a third dose of SARS-CoV-2 mRNA vaccine in lung transplant recipients in Japan.
    Vaccine. 2023 Jun 9:S0264-410X(23)00663-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  319. MARTINEZ MR, Gao J, Wan H, Kang H, et al
    Inactivated influenza virions are a flexible vaccine platform for eliciting protective antibody responses against neuraminidase.
    Vaccine. 2023 Jun 8:S0264-410X(23)00629-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  320. NOGAREDA F, Gharpure R, Contreras M, Velandia M, et al
    Seasonal influenza vaccination in the Americas: Progress and challenges during the COVID-19 pandemic.
    Vaccine. 2023 Jun 8:S0264-410X(23)00689-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  321. DE GIER B, van Asten L, Boere TM, van Roon A, et al
    Effect of COVID-19 vaccination on mortality by COVID-19 and on mortality by other causes, the Netherlands, January 2021-January 2022.
    Vaccine. 2023 Jun 8:S0264-410X(23)00660-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  322. ROY A, Polazzi S, Ploin D, Gillet Y, et al
    The increasing age of respiratory syncytial virus-related hospitalisation during COVID-19 pandemic in Lyon was associated with reduced hospitalisation costs.
    Vaccine. 2023;41:3796-3800.
    >> Share

  323. SHAW RJ, Doyle AJ, Millen EA, Stowe J, et al
    Re-evaluation of the risk of venous thromboembolism after COVID-19 vaccination using haematological criteria.
    Vaccine. 2023 Jun 7:S0264-410X(23)00662-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  324. KATO H, Hozawa T, Fukushima W, Nobusawa E, et al
    Influenza vaccine viruses and the development of seasonal vaccines: A Japanese perspective.
    Vaccine. 2023 Jun 6:S0264-410X(23)00640-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  325. KIM DELUCA E, Gebremariam A, Rose A, Biggerstaff M, et al
    Cost-effectiveness of routine annual influenza vaccination by age and risk status.
    Vaccine. 2023 Jun 6:S0264-410X(23)00495-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  326. KIM WJ, Roberts CC, Song JY, Yoon JG, et al
    Immune response enhancement with GLS-5310 DNA primary vaccine against SARS-CoV-2 followed by administration of an mRNA vaccine heterologous boost.
    Vaccine. 2023 Jun 6:S0264-410X(23)00683-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  327. PELLETIER C, Labbe F, Bettinger JA, Curran J, et al
    From high hopes to disenchantment: A qualitative analysis of editorial cartoons on COVID-19 vaccines in Canadian newspapers.
    Vaccine. 2023 Jun 6:S0264-410X(23)00658-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  328. ELDER E, Bangalore Revanna C, Johansson C, Wallin RPA, et al
    Protective immunity induced by an inhaled SARS-CoV-2 subunit vaccine.
    Vaccine. 2023 Jun 6:S0264-410X(23)00684-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  329. MAKANUT S, Wangteeraprasert A, Jitpewngam W, Ngoenkam J, et al
    Immunological responses and adverse reactions of the heterologous second booster dose of BNT162b2 after two-dose CoronaVac for COVID-19 vaccination in healthcare workers of Faculty of Medicine, Naresuan University.
    Vaccine. 2023 Jun 5:S0264-410X(23)00666-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  330. WESSELINK AK, Lovett SM, Weinberg J, Geller RJ, et al
    COVID-19 vaccination and menstrual cycle characteristics: A prospective cohort study.
    Vaccine. 2023 Jun 5:S0264-410X(23)00681-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  331. KOZMA GT, Meszaros T, Berenyi P, Facsko R, et al
    Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: Evidence for immunogenicity of PEG.
    Vaccine. 2023 Jun 5:S0264-410X(23)00667-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  332. ERGUN T, Hosgoren Tekin S, Apti Sengun O, Akin Cakici O, et al
    Immunogenicity, efficacy, and safety of CoronaVac and Pfizer/BioNTech mRNA vaccines in patients with psoriasis receiving systemic therapies: A prospective cohort study.
    Vaccine. 2023 Jun 3:S0264-410X(23)00615-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  333. FEDDEMA JJ, Fernald KDS, Schikan HGCP, van de Burgwal LHM, et al
    Upscaling vaccine manufacturing capacity - Kkey bottlenecks and lessons learned.
    Vaccine. 2023 Jun 3:S0264-410X(23)00554-6. doi: 10.1016/j.vaccine.2023.
    >> Share

    May 2023
  334. WANG LJ, Tsai CS, Chou WJ, Li CJ, et al
    Medical outcomes of children with neurodevelopmental disorders after SARS-CoV-2 vaccination: A six-month follow-up study.
    Vaccine. 2023 May 29:S0264-410X(23)00628-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  335. ARROSPIDE A, Sagardui MG, Larizgoitia I, Iturralde A, et al
    Effectiveness of the booster dose of COVID-19 vaccine in the Basque Country during the sixth wave: A nationwide cohort study.
    Vaccine. 2023 May 29:S0264-410X(23)00622-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  336. HU S, Xiong C, Zhao Y, Yuan X, et al
    Vaccination, human mobility, and COVID-19 health outcomes: Empirical comparison before and during the outbreak of SARS-Cov-2 B.1.1.529 (Omicron) variant.
    Vaccine. 2023 May 29:S0264-410X(23)00617-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  337. MILLER ER, Moro PL, Shimabukuro TT, Carlock G, et al
    COVID-19 vaccine safety inquiries to the centers for disease control and prevention immunization safety office.
    Vaccine. 2023 May 24:S0264-410X(23)00613-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  338. HORI D, Keneda Y, Ozaki A, Tabuchi T, et al
    Sexual orientation was associated with intention to be vaccinated with a smallpox vaccine against mpox: A cross-sectional preliminary survey in Japan.
    Vaccine. 2023 May 24:S0264-410X(23)00611-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  339. NUGENT C, Abul Y, White EM, Shehadeh F, et al
    Second monovalent SARS-CoV-2 mRNA booster restores Omicron-specific neutralizing activity in both nursing home residents and health care workers.
    Vaccine. 2023;41:3403-3409.
    >> Share

  340. JOUDEH AI, Lutf AQ, Mahdi S, Tran G, et al
    Efficacy and safety of mRNA and AstraZeneca COVID-19 vaccines in patients with autoimmune rheumatic diseases: A systematic review.
    Vaccine. 2023 May 22:S0264-410X(23)00609-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  341. ALICANDRO G, Orena BS, Rosazza C, Cariani L, et al
    Humoral and cell-mediated immune responses to BNT162b2 vaccine against SARS-CoV-2 in people with cystic fibrosis.
    Vaccine. 2023 May 22:S0264-410X(23)00590-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  342. GHAZNAVI C, Eguchi A, Suu Lwin K, Yoneoka D, et al
    Estimating global changes in routine childhood vaccination coverage during the COVID-19 pandemic, 2020-2021.
    Vaccine. 2023 May 22:S0264-410X(23)00583-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  343. GUO BQ, Li HB, Yang LQ
    Incidence of myopericarditis after mRNA COVID-19 vaccination: A meta-analysis with focus on adolescents aged 12-17 years.
    Vaccine. 2023 May 22:S0264-410X(23)00610-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  344. BOLSEWICZ KT, Steffens MS, King C, Abdi I, et al
    A qualitative study on COVID-19 pandemic impacts on parental attitudes and intentions for routine adolescent vaccinations: The role of trust.
    Vaccine. 2023 May 22:S0264-410X(23)00586-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  345. EGER J, Kaplan LC, Sternberg H
    How to reduce vaccination hesitancy? The relevance of evidence and its communicator.
    Vaccine. 2023 May 22:S0264-410X(23)00298-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  346. EMBI PJ, Levy ME, Patel P, DeSilva MB, et al
    Effectiveness of COVID-19 vaccines at preventing emergency department or urgent care encounters and hospitalizations among immunocompromised adults: An observational study of real-world data across 10 US states from August-December 2021.
    Vaccine. 2023 May 22:S0264-410X(23)00588-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  347. BOING AF, Boing AC, Barberia L, Borges ME, et al
    Uncovering inequities in Covid-19 vaccine coverage for adults and elderly in Brazil: A multilevel study of 2021-2022 data.
    Vaccine. 2023 May 17:S0264-410X(23)00569-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  348. ZHOU ZH, Cortese MM, Fang JL, Wood R, et al
    Evaluation of association of anti-PEG antibodies with anaphylaxis after mRNA COVID-19 vaccination.
    Vaccine. 2023 May 16:S0264-410X(23)00568-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  349. BLACK SB, Chandler RE, Edwards KM, Sturkenboom MCJM, et al
    Assessing vaccine safety during a pandemic: Recent experience and lessons learned for the future.
    Vaccine. 2023 May 15:S0264-410X(23)00468-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  350. LIMAYE RJ, Singh P, Paul A, Fesshaye B, et al
    COVID-19 vaccine decision-making among pregnant and lactating women in Bangladesh.
    Vaccine. 2023 May 15:S0264-410X(23)00551-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  351. SURIE D, Bonnell LN, DeCuir J, Gaglani M, et al
    Comparison of mRNA vaccine effectiveness against COVID-19-associated hospitalization by vaccination source: Immunization information systems, electronic medical records, and self-report-IVY Network, February 1-August 31, 2022.
    Vaccine. 2023 May 15:S0264-410X(23)00567-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  352. GEORGE TK, Nair NP, Singh AK, Dilesh Kumar A, et al
    Development of a Choice-framework for Covid vaccines in India using a multi-criteria decision analysis approach.
    Vaccine. 2023 May 12:S0264-410X(23)00486-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  353. KEHAGIA E, Papakyriakopoulou P, Valsami G
    Advances in intranasal vaccine delivery: A promising non-invasive route of immunization.
    Vaccine. 2023 May 11:S0264-410X(23)00529-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  354. ROBERTS-MCCARTHY E, Buck PO, Smith-Ray RL, Van de Velde N, et al
    Factors associated with receipt of mRNA-1273 vaccine at a United States national retail pharmacy during the COVID-19 pandemic.
    Vaccine. 2023 May 11:S0264-410X(23)00383-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  355. LANGLETE P, Tesli M, Veneti L, Starrfelt J, et al
    Estimated vaccine effectiveness against SARS-CoV-2 Delta and Omicron infections among health care workers and the general adult population in Norway, August 2021 - January 2022.
    Vaccine. 2023 May 10:S0264-410X(23)00549-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  356. SMITH K, Hegazy K, Cai MR, McKnight I, et al
    Safety of the NVX-CoV2373 COVID-19 vaccine in randomized placebo-controlled clinical trials.
    Vaccine. 2023 May 10:S0264-410X(23)00543-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  357. VAN IERSEL SCJL, McDonald SA, de Gier B, Knol MJ, et al
    Number of COVID-19 hospitalisations averted by vaccination: Estimates for the Netherlands, January 6, 2021 through August 30, 2022.
    Vaccine. 2023 May 10:S0264-410X(23)00545-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  358. RUBIN THOMPSON LJ, Grubo M, Veller M, Badenhorst RH, et al
    Building global vaccine manufacturing capacity: Spotlight on Africa.
    Vaccine. 2023 May 10:S0264-410X(23)00527-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  359. CHIAVENNA C, Leone LP, Melegaro A, Rotesi T, et al
    Personal risk or societal benefit? Investigating adults' support for COVID-19 childhood vaccination.
    Vaccine. 2023 May 9:S0264-410X(23)00544-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  360. KURIYAMA K, Murakami K, Masuda T, Sugiura K, et al
    Immunogenicity and safety of a single booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Primary analysis report of a phase 3 open-label trial.
    Vaccine. 2023 May 8:S0264-410X(23)00519-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  361. SUTTON WJH, Branham PJ, Williamson YM, Cooper HC, et al
    Quantification of SARS-CoV-2 spike protein expression from mRNA vaccines using isotope dilution mass spectrometry.
    Vaccine. 2023 May 8:S0264-410X(23)00458-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  362. BORDALO FERREIRA F, Rafael MA, Coimbra L, Boavida N, et al
    Anti-tumor necrosis factor therapy is associated with attenuated humoral response to SARS-COV-2 vaccines in patients with inflammatory bowel disease.
    Vaccine. 2023 May 8:S0264-410X(23)00530-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  363. FITZ-PATRICK D, Young M, Yacisin K, McElwee K, et al
    Randomized trial to evaluate the safety, tolerability, and immunogenicity of a booster (third dose) of BNT162b2 COVID-19 vaccine coadministered with 20-valent pneumococcal conjugate vaccine in adults >/=65 years old.
    Vaccine. 2023 May 8:S0264-410X(23)00520-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  364. KPOZEHOUEN EB, Heywood AE, Menzies R, Seale H, et al
    Informing the design of a whole of life immunisation register for Australia.
    Vaccine. 2023;41:3011-3018.
    >> Share

  365. RODRIGUEZ DM, Major CG, Sanchez-Gonzalez L, Jones E, et al
    Dengue vaccine acceptability before and after the availability of COVID-19 vaccines in Puerto Rico.
    Vaccine. 2023 May 5:S0264-410X(23)00516-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  366. KU JH, Sy LS, Qian L, Ackerson BK, et al
    Vaccine effectiveness of the mRNA-1273 3-dose primary series against COVID-19 in an immunocompromised population: A prospective observational cohort study.
    Vaccine. 2023 May 3:S0264-410X(23)00498-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  367. FUKUNAGA R, Kaplan ZE, Rodriguez T, Hagan L, et al
    Attitudes towards COVID-19 vaccination among incarcerated persons in the Federal Bureau of Prisons, June-July 2021.
    Vaccine. 2023 May 2:S0264-410X(23)00512-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  368. LEFFERTS B, Bruden D, Plumb ID, Hodges E, et al
    Effectiveness of the COVID-19 vaccines on preventing symptomatic SARS-CoV-2 infections and hospitalizations in Southwestern Alaska, January-December 2021.
    Vaccine. 2023 May 1:S0264-410X(23)00496-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  369. MESINA FZ, Sapinoso FAD, De Castro JAV, Vaswani PPM, et al
    Hematologic adverse events reported after COVID-19 vaccination in the Philippines: A national database study.
    Vaccine. 2023 May 1:S0264-410X(23)00490-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  370. HUSSAINI L, Labberton AS, Winje BA, Kraft KB, et al
    COVID-19 vaccination rates among adolescents (12-17 years) by immigrant background and sociodemographic factors: A nationwide registry study in Norway.
    Vaccine. 2023 May 1:S0264-410X(23)00514-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  371. KUHLBRANDT C, McGowan CR, Stuart R, Grenfell P, et al
    COVID-19 vaccination decisions among Gypsy, Roma, and Traveller communities: A qualitative study moving beyond "vaccine hesitancy".
    Vaccine. 2023 May 1:S0264-410X(23)00515-7. doi: 10.1016/j.vaccine.2023.
    >> Share

    April 2023
  372. MARCHESE AM, Zhou X, Kinol J, Underwood E, et al
    NVX-CoV2373 vaccine efficacy against hospitalization: A post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trial.
    Vaccine. 2023 Apr 29:S0264-410X(23)00467-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  373. VANNI T, da Graca Salomao M, Viscondi JYK, Braga PE, et al
    A randomized, double-blind, non-inferiority trial comparing the immunogenicity and safety of two seasonal inactivated influenza vaccines in adults.
    Vaccine. 2023 Apr 28:S0264-410X(23)00464-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  374. KOEN AL, Izu A, Baillie V, Kwatra G, et al
    Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005).
    Vaccine. 2023 Apr 27:S0264-410X(23)00483-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  375. KIM C, Aminawung JA, Brinkley-Rubinstein L, Wang EA, et al
    COVID-19 vaccine deliberation in individuals directly impacted by incarceration.
    Vaccine. 2023 Apr 26:S0264-410X(23)00492-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  376. ALSUHEBANY N, Alowais SA, Aldairem A, Almohareb SN, et al
    Identifying gaps in vaccination perception after mandating the COVID-19 vaccine in Saudi Arabia.
    Vaccine. 2023 Apr 26:S0264-410X(23)00481-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  377. LU X, Masuda S, Horlad H, Katoh T, et al
    Safety and adverse effects of the coronavirus disease 2019 vaccine among the general Japanese adult population.
    Vaccine. 2023 Apr 26:S0264-410X(23)00469-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  378. KIM SJ, Kwon SL, Lee JY, Oh J, et al
    Why school is crucial to increase vaccination coverage for children: Evaluation of school vaccination check program in South Korea 2021-2022.
    Vaccine. 2023 Apr 25:S0264-410X(23)00430-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  379. JIANG M, Vaisanen E, Kolehmainen P, Huttunen M, et al
    COVID-19 adenovirus vector vaccine induces higher interferon and pro-inflammatory responses than mRNA vaccines in human PBMCs, macrophages and moDCs.
    Vaccine. 2023 Apr 25:S0264-410X(23)00463-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  380. WALTER D, Ophir Y, Ye H
    Conspiracies, misinformation and resistance to public health measures during COVID-19 in white nationalist online communication.
    Vaccine. 2023;41:2868-2877.
    >> Share

  381. TAMANDJOU C, Auvigne V, Schaeffer J, Vaux S, et al
    Effectiveness of second booster compared to first booster and protection conferred by previous SARS-CoV-2 infection against symptomatic Omicron BA.2 and BA.4/5 in France.
    Vaccine. 2023;41:2754-2760.
    >> Share

  382. MA L, Brecher M, Soufal A, Gaiotto T, et al
    Structural interrogation of a trimeric prefusion RSV fusion protein vaccine candidate by a camelid nanobody.
    Vaccine. 2023 Apr 19:S0264-410X(23)00413-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  383. BAO Y, He L, Miao B, Zhong Z, et al
    BBIBP-CorV vaccination accelerates anti-viral antibody responses in heterologous Omicron infection: A retrospective observation study in Shanghai.
    Vaccine. 2023 Apr 19:S0264-410X(23)00377-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  384. PILLSBURY A, Phillips A, Deng L, Quinn H, et al
    Background incidence rates of selected adverse events of special interest (AESI) to monitor the safety of COVID-19 vaccines.
    Vaccine. 2023 Apr 18:S0264-410X(23)00441-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  385. MAO Z, Li X, Dacosta-Urbieta A, Billard MN, et al
    Economic burden and health-related quality-of-life among infants with respiratory syncytial virus infection: A multi-country prospective cohort study in Europe.
    Vaccine. 2023;41:2707-2715.
    >> Share

  386. HOUTSMA C, Raines AM, Reggio A, Rushing LK, et al
    COVID-19 vaccine distribution: A high reliability organization approach.
    Vaccine. 2023 Apr 17:S0264-410X(23)00423-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  387. GORDON SF, Lam J, Vasquez JT, Cercone R, et al
    A tailored COVID-19 vaccination pathway for children 5-11 years in Victoria, Australia.
    Vaccine. 2023 Apr 17:S0264-410X(23)00424-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  388. LUDWIKOWSKA KM, Popiel A, Matkowska-Kocjan A, Biela M, et al
    COVID-19 mRNA BNT162b2 vaccine immunogenicity among children with a history of paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS-TS).
    Vaccine. 2023 Apr 14:S0264-410X(23)00427-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  389. FREITAG TL, Fagerlund R, Karam NL, Leppanen VM, et al
    Intranasal administration of adenoviral vaccines expressing SARS-CoV-2 spike protein improves vaccine immunity in mouse models.
    Vaccine. 2023 Apr 14:S0264-410X(23)00403-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  390. ANDRAUD M, Herve S, Gorin S, Barbier N, et al
    Evaluation of early single dose vaccination on swine influenza A virus transmission in piglets: From experimental data to mechanistic modelling.
    Vaccine. 2023 Apr 13:S0264-410X(23)00401-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  391. ESTEPHAN L, Lin YC, Lin YT, Chen YH, et al
    Safety and immunogenicity of homologous versus heterologous booster dose with AZD1222, mRNA-1273, or MVC-COV1901 SARS-CoV-2 vaccines in adults: An observer-blinded, multi-center, phase 2 randomized trial.
    Vaccine. 2023 Apr 12:S0264-410X(23)00421-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  392. UEMURA K, Ono S, Michihata N, Yamana H, et al
    Duration of influenza vaccine effectiveness in the elderly in Japan: A retrospective cohort study using large-scale population-based registry data.
    Vaccine. 2023 Apr 10:S0264-410X(23)00373-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  393. RATHORE APS, St John AL
    Promises and challenges of mucosal COVID-19 vaccines.
    Vaccine. 2023 Apr 10:S0264-410X(23)00396-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  394. HARRIS C, Cottrell S, Perry M, Meaden R, et al
    A pilot intervention to improve uptake and equality of childhood influenza vaccination in an area of Wales, through the introduction of a mixed delivery model including nursery school immunisation sessions.
    Vaccine. 2023 Apr 8:S0264-410X(23)00382-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  395. LEIGH HOBBS J, Paul LA, Buchan SA, Harris T, et al
    Methodological changes implemented over time to support accurate and timely COVID-19 vaccine coverage estimates: Ontario, Canada.
    Vaccine. 2023 Apr 7:S0264-410X(23)00389-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  396. HARRIS JN, Mauro CM, Morgan TL, de Roche A, et al
    Factors impacting parental uptake of COVID-19 vaccination for U.S. Children ages 5-17.
    Vaccine. 2023 Apr 7:S0264-410X(23)00384-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  397. ALMAHASIS SO, Fox B, Ha D, Qian J, et al
    Pharmacy-based immunization in rural USA during the COVID-19 pandemic: A survey of community pharmacists from five southeastern states.
    Vaccine. 2023;41:2503-2513.
    >> Share

  398. SMITS PD, Gratzl S, Simonov M, Nachimuthu SK, et al
    Risk of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities.
    Vaccine. 2023;41:2447-2455.
    >> Share

  399. GOLD MS, Amarasinghe A, Greenhawt M, Kelso JM, et al
    Anaphylaxis: Revision of the Brighton collaboration case definition.
    Vaccine. 2023;41:2605-2614.
    >> Share

  400. BURKHOLDER B, Wadood Z, Kassem AM, Ehrhardt D, et al
    The immediate impact of the COVID-19 pandemic on polio immunization and surveillance activities.
    Vaccine. 2023;41 Suppl 1:A2-A11.
    >> Share

  401. KALKOWSKA DA, Pallansch MA, Wassilak SGF, Cochi SL, et al
    Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response.
    Vaccine. 2023;41 Suppl 1:A136-A141.
    >> Share

  402. KALKOWSKA DA, Voorman A, Pallansch MA, Wassilak SGF, et al
    The impact of disruptions caused by the COVID-19 pandemic on global polio eradication.
    Vaccine. 2023;41 Suppl 1:A12-A18.
    >> Share

  403. PAYNE JR, Bose S, Kubiak RW, Nolen LD, et al
    Evaluation of mortality risk after COVID-19 vaccination, Utah 2021.
    Vaccine. 2023 Apr 5:S0264-410X(23)00380-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  404. BRAEYE T, Catteau L, Brondeel R, van Loenhout JAF, et al
    Vaccine effectiveness against transmission of alpha, delta and omicron SARS-COV-2-infection, Belgian contact tracing, 2021-2022.
    Vaccine. 2023 Apr 5:S0264-410X(23)00376-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  405. KIM H, Cho HK, Kang YM, Sagong M, et al
    Protective efficacy of a bivalent H5 influenza vaccine candidate against both clades 2.3.2.1 and 2.3.4.4 high pathogenic avian influenza viruses in SPF chickens.
    Vaccine. 2023 Apr 4:S0264-410X(23)00311-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  406. PRADA E, Langbecker A, Catalan-Matamoros D
    Public discourse and debate about vaccines in the midst of the covid-19 pandemic: A qualitative content analysis of Twitter.
    Vaccine. 2023 Apr 4:S0264-410X(23)00375-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  407. FRODLUND M, Nived P, Chatzidionysiou A, Sodergren A, et al
    The impact of immunomodulating treatment on the immunogenicity of COVID-19 vaccines in patients with immune-mediated inflammatory rheumatic diseases compared to healthy controls. A Swedish nationwide study (COVID19-REUMA).
    Vaccine. 2023 Apr 4:S0264-410X(23)00372-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  408. TOSHKOV D
    What accounts for the variation in COVID-19 vaccine hesitancy in Eastern, Southern and Western Europe?
    Vaccine. 2023 Apr 4:S0264-410X(23)00314-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  409. ALI Y, Piche-Renaud PP, Karimi-Shahrbabak E, Farrar DS, et al
    Pediatricians' perceptions, practices, and barriers regarding COVID-19 vaccine for children: A cross-sectional survey in Ontario, Canada.
    Vaccine. 2023 Apr 3:S0264-410X(23)00335-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  410. URQUIDI C, Santelices E, Lagomarcino AJ, Teresa Valenzuela M, et al
    The added effect of non-pharmaceutical interventions and lifestyle behaviors on vaccine effectiveness against severe COVID-19 in Chile: A matched case-double control study.
    Vaccine. 2023 Apr 3:S0264-410X(23)00354-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  411. MAQUILING A, Jeevakanthan A, Ho Mi Fane B
    The effect of vaccine mandate announcements on vaccine uptake in Canada: An interrupted time series analysis.
    Vaccine. 2023 Apr 3:S0264-410X(23)00334-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  412. CRIADO MF, Kassa A, Bertran K, Kwon JH, et al
    Efficacy of multivalent recombinant herpesvirus of turkey vaccines against high pathogenicity avian influenza, infectious bursal disease, and Newcastle disease viruses.
    Vaccine. 2023 Apr 1:S0264-410X(23)00349-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  413. LYTRAS T, Athanasiadou M, Demetriou A, Stylianou D, et al
    Lack of association between vaccination rates and excess mortality in Cyprus during the COVID-19 pandemic.
    Vaccine. 2023 Apr 1:S0264-410X(23)00316-X. doi: 10.1016/j.vaccine.2023.
    >> Share

    March 2023
  414. XU S, Zhang B, Yao J, Ruan W, et al
    A new H9 influenza virus mRNA vaccine elicits robust protective immunity against infection.
    Vaccine. 2023 Mar 31:S0264-410X(23)00343-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  415. DATAR RS, Fette LM, Hinkelman AN, Hammershaimb EA, et al
    Factors associated with COVID-19 vaccination during June-October 2021: A multi-site prospective study.
    Vaccine. 2023 Mar 31:S0264-410X(23)00352-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  416. HU Y, Wang Y, Shao T, Tang W, et al
    Safety and immunogenicity of heterologous ChAdOx1-nCoV19 and BNT162b2 vaccination: A meta-analysis of the heterologous COVID-19 vaccination outcomes.
    Vaccine. 2023 Mar 30:S0264-410X(23)00350-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  417. FUKUDA H, Maeda M, Murata F
    Development of a COVID-19 vaccine effectiveness and safety assessment system in Japan: The VENUS study.
    Vaccine. 2023 Mar 29:S0264-410X(23)00353-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  418. SU WJ, Arnold Chan K, Chuang JH, Wang TA, et al
    Acute reactions after a homologous primary COVID-19 vaccination series: Analysis of Taiwan V-Watch data.
    Vaccine. 2023 Mar 28:S0264-410X(23)00336-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  419. SANTI LAURINI G, Montanaro N, Broccoli M, Bonaldo G, et al
    Real-life safety profile of mRNA vaccines for COVID-19: An analysis of VAERS database.
    Vaccine. 2023 Mar 28:S0264-410X(23)00348-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  420. GIDENGIL CA, Parker AM, Markowitz LE, Gedlinske AM, et al
    Health care provider knowledge around shared clinical decision-making regarding HPV vaccination of adults aged 27-45 years in the United States.
    Vaccine. 2023 Mar 27:S0264-410X(23)00186-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  421. HU B, Yang W, Bouanchaud P, Chongo Y, et al
    Determinants of COVID-19 vaccine acceptance in Mozambique: The role of institutional trust.
    Vaccine. 2023 Mar 27:S0264-410X(23)00347-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  422. KANG SW, Park H, Yeun Kim J, Bae JY, et al
    Comparison of culture-competent virus shedding duration of SARS-CoV-2 Omicron variant in regard to vaccination status: A prospective cohort study.
    Vaccine. 2023 Mar 27:S0264-410X(23)00339-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  423. CESUR F, Atasever Z, Ozoran Y
    Impact of vitamin D3 supplementation on COVID-19 vaccine response and immunoglobulin G antibodies in deficient women: A randomized controlled trial.
    Vaccine. 2023 Mar 27:S0264-410X(23)00341-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  424. DUGOVICH AM, Cox TH, Weeda ER, Garner SS, et al
    First hepatitis B vaccine uptake in neonates prior to and during the COVID-19 pandemic.
    Vaccine. 2023 Mar 27:S0264-410X(23)00333-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  425. PANNUS P, Depickere S, Kemlin D, Georges D, et al
    Third dose of COVID-19 mRNA vaccine closes the gap in immune response between naive nursing home residents and healthy adults.
    Vaccine. 2023 Mar 27:S0264-410X(23)00340-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  426. CIAPPONI A, Berrueta M, P K Parker E, Bardach A, et al
    Safety of COVID-19 vaccines during pregnancy: A systematic review and meta-analysis.
    Vaccine. 2023 Mar 27:S0264-410X(23)00332-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  427. VAN KESSEL R, Forman R, Milstein R, Mastylak A, et al
    Divergent COVID-19 vaccine policies: Policy mapping of ten European countries.
    Vaccine. 2023 Mar 22:S0264-410X(23)00320-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  428. YANG J, Huo X, Jiang Q, Liao Y, et al
    Preclinical safety evaluation of intradermal SARS-CoV-2 inactivated vaccine (Vero cells) administration in macaques.
    Vaccine. 2023 Mar 21:S0264-410X(23)00317-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  429. PHOOLCHAROEN W, Shanmugaraj B, Khorattanakulchai N, Sunyakumthorn P, et al
    Preclinical evaluation of immunogenicity, efficacy and safety of a recombinant plant-based SARS-CoV-2 RBD vaccine formulated with 3M-052-Alum adjuvant.
    Vaccine. 2023 Mar 21:S0264-410X(23)00312-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  430. SATO R
    Vaccine hesitancy against COVID-19 vaccine over time in Nigeria.
    Vaccine. 2023 Mar 21:S0264-410X(23)00313-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  431. ATMAR RL, Bernstein DI, Winokur P, Frey SE, et al
    Safety and immunogenicity of Multimeric-001 (M-001) followed by seasonal quadrivalent inactivated influenza vaccine in young adults - A randomized clinical trial.
    Vaccine. 2023 Mar 18:S0264-410X(23)00285-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  432. SHEN AK, Browne S, Srivastava T, Kornides ML, et al
    Trusted messengers and trusted messages: The role for community-based organizations in promoting COVID-19 and routine immunizations.
    Vaccine. 2023;41:1994-2002.
    >> Share

  433. PEREZ MA, Hsiao HM, Chen X, Kunkel A, et al
    Serologic responses to COVID-19 vaccination in children with history of multisystem inflammatory syndrome (MIS-C).
    Vaccine. 2023 Mar 15:S0264-410X(23)00283-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  434. LIN JH, Huang YT, Yu JC, Chan KA, et al
    Mediation and instrumental variable analyses for vaccine-induced antibody titer against influenza B.
    Vaccine. 2023 Mar 14:S0264-410X(23)00261-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  435. LAMUDA PA, Azar A, Taylor BG, Balawajder EF, et al
    Latent class analysis of medical mistrust and COVID-19 vaccine hesitancy among adults in the United States just prior to FDA emergency use authorization.
    Vaccine. 2023 Mar 13:S0264-410X(23)00263-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  436. KELLY D, O'Donnell K, Marron L, Dwyer R, et al
    Immunocompromise among vaccinated versus unvaccinated COVID-19 cases admitted to critical care in Ireland, July to October 2021.
    Vaccine. 2023 Mar 13:S0264-410X(23)00258-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  437. KWAK HW, Park HJ, Jung SY, Oh EY, et al
    Recombinant measles virus encoding the spike protein of SARS-CoV-2 efficiently induces Th1 responses and neutralizing antibodies that block SARS-CoV-2 variants.
    Vaccine. 2023;41:1892-1901.
    >> Share

  438. LIU YC, Munoz FM, Izurieta HS, Tamborska AA, et al
    Anosmia: Brighton Collaboration case definition and guidelines for data collection, analysis, and presentation of immunization safety data.
    Vaccine. 2023;41:1902-1910.
    >> Share

  439. SRIVASTAV A, Lu PJ, Amaya A, Dever JA, et al
    Prevalence of influenza-specific vaccination hesitancy among adults in the United States, 2018.
    Vaccine. 2023 Mar 10:S0264-410X(23)00255-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  440. SANCHEZ L, Nakama T, Nagai H, Matsuoka O, et al
    Superior immunogenicity of high-dose quadrivalent inactivated influenza vaccine versus Standard-Dose vaccine in Japanese Adults >/= 60 years of age: Results from a phase III, randomized clinical trial.
    Vaccine. 2023 Mar 9:S0264-410X(23)00225-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  441. PLUMB ID, Fette LM, Tjaden AH, Feldstein L, et al
    Estimated COVID-19 vaccine effectiveness against seroconversion from SARS-CoV-2 Infection, March-October, 2021.
    Vaccine. 2023 Mar 9:S0264-410X(23)00253-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  442. IKEWAKI N, Kurosawa G, Levy GA, Preethy S, et al
    Antibody dependent disease enhancement (ADE) after COVID-19 vaccination and beta glucans as a safer strategy in management.
    Vaccine. 2023 Mar 8:S0264-410X(23)00252-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  443. HART RJ, Baumer-Mouradian S, Bone JN, Olson P, et al
    Factors associated with US caregivers' uptake of pediatric COVID-19 vaccine by race and ethnicity.
    Vaccine. 2023 Mar 6:S0264-410X(23)00242-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  444. BAEK YJ, Kim WJ, Ko JH, Lee YJ, et al
    A heterologous AZD1222 priming and BNT162b2 boosting regimen more efficiently elicits neutralizing antibodies, but not memory T cells, than the homologous BNT162b2 regimen.
    Vaccine. 2023;41:1694-1702.
    >> Share

  445. GRIGNOLIO CORSINI A, Zagarella RM, Adamo M, Caporale C, et al
    From COVID-19 vaccine candidates to compulsory vaccination: The attitudes of Italian citizens in the key 7-month of vaccination campaign.
    Vaccine. 2023 Mar 3:S0264-410X(23)00243-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  446. ESTEPHAN L, Liu LT, Lien CE, Smith ER, et al
    A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Medigen COVID-19 protein vaccine.
    Vaccine. 2023 Mar 3:S0264-410X(23)00245-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  447. XIE S, Monteiro K, Gjelsvik A
    The association between maternal influenza vaccination during pregnancy and adverse birth outcomes in the United States: Pregnancy risk Assessment Monitoring System (PRAMS).
    Vaccine. 2023 Mar 2:S0264-410X(23)00228-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  448. LUDWIKOWSKA KM, Popiel A, Matkowska-Kocjan A, Olbromski MJ, et al
    COVID-19 mRNA BNT162b2 vaccine safety and B-cell and T-cell reactogenicity among children with a history of paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS-TS) - preliminary study.
    Vaccine. 2023 Mar 2:S0264-410X(23)00227-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  449. HURSTAK EE, Paasche-Orlow MK, Hahn EA, Henault LE, et al
    The mediating effect of health literacy on COVID-19 vaccine confidence among a diverse sample of urban adults in Boston and Chicago.
    Vaccine. 2023 Mar 2:S0264-410X(23)00202-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  450. GOLDMAN RD, Hart RJ, Bone JN, Seiler M, et al
    Willingness to vaccinate children against COVID-19 declined during the pandemic.
    Vaccine. 2023 Mar 2:S0264-410X(23)00223-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  451. NA L, Banks S, Wang PP
    Racial and ethnic disparities in COVID-19 vaccine uptake: A mediation framework.
    Vaccine. 2023 Mar 1:S0264-410X(23)00241-4. doi: 10.1016/j.vaccine.2023.
    >> Share

    February 2023
  452. MALTEZOU HC, Hatziantoniou S, Theodoridou K, Vasileiou K, et al
    Anaphylaxis rates following mRNA COVID-19 vaccination in children and adolescents: Analysis of data reported to EudraVigilance.
    Vaccine. 2023 Feb 27:S0264-410X(23)00221-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  453. TAMANDJOU TCHUEM CR, Auvigne V, Vaux S, Montagnat C, et al
    Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France.
    Vaccine. 2023 Feb 27:S0264-410X(23)00216-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  454. O'KENNEDY MM, Abolnik C, Smith T, Motlou T, et al
    Immunogenicity of adjuvanted plant-produced SARS-CoV-2 Beta spike VLP vaccine in New Zealand white rabbits.
    Vaccine. 2023 Feb 27:S0264-410X(23)00185-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  455. ITAMOCHI M, Yazawa S, Inasaki N, Saga Y, et al
    Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort.
    Vaccine. 2023 Feb 27:S0264-410X(23)00222-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  456. GETANEH AM, Li X, Mao Z, Johannesen CK, et al
    Cost-effectiveness of monoclonal antibody and maternal immunization against respiratory syncytial virus (RSV) in infants: Evaluation for six European countries.
    Vaccine. 2023;41:1623-1631.
    >> Share

  457. FEITSMA EA, Janssen YF, Boersma HH, van Sleen Y, et al
    A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452.
    Vaccine. 2023 Feb 23:S0264-410X(23)00200-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  458. KABIR SULAIMAN S, Sale Musa M, Isma'il Tsiga-Ahmed F, Muhammad Dayyab F, et al
    COVID-19 vaccine hesitancy among people living with HIV in a low-resource setting: A multi-center study of prevalence, correlates and reasons.
    Vaccine. 2023 Feb 23:S0264-410X(23)00199-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  459. CANNON K, Cardona JF, Yacisin K, Thompson A, et al
    Safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine coadministered with quadrivalent influenza vaccine: A phase 3 randomized trial.
    Vaccine. 2023 Feb 22:S0264-410X(22)01459-1. doi: 10.1016/j.vaccine.2022.
    >> Share

  460. MOORE KA, Leighton T, Ostrowsky JT, Anderson CJ, et al
    A research and development (R&D) roadmap for broadly protective coronavirus vaccines: A pandemic preparedness strategy.
    Vaccine. 2023 Feb 21:S0264-410X(23)00167-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  461. ZHANG H, Chen L, Huang Z, Li D, et al
    The effects of parent's health literacy and health beliefs on vaccine hesitancy.
    Vaccine. 2023 Feb 21:S0264-410X(23)00161-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  462. HAMBURG M, Poland GA
    The time is now for committed and comprehensive action to attain more broadly protective coronavirus vaccines: The coronavirus vaccines R&D roadmap.
    Vaccine. 2023 Feb 21:S0264-410X(23)00196-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  463. MOTTA M, Callaghan T, Lunz-Trujillo K, Lockman A, et al
    Erroneous Consonance. How inaccurate beliefs about physician opinion influence COVID-19 vaccine hesitancy.
    Vaccine. 2023 Feb 20:S0264-410X(23)00195-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  464. USTYUGOVA IV, Pougatcheva S, Farrell T, Strugnell T, et al
    AF03 adjuvant improves anti-hemagglutinin and anti-neuraminidase immune responses induced by licensed seasonal quadrivalent influenza vaccines in mice.
    Vaccine. 2023 Feb 18:S0264-410X(23)00169-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  465. GEOGHEGAN S, Acosta F, Stephens LC, Gillan H, et al
    Maternity care provider acceptance of a future Group B Streptococcus vaccine - A qualitative study in three countries.
    Vaccine. 2023 Feb 18:S0264-410X(23)00172-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  466. FORD A, Hwang A, Mo AX, Baqar S, et al
    Meeting Summary: Global Vaccine and Immunization Research Forum, 2021.
    Vaccine. 2023 Feb 18:S0264-410X(23)00163-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  467. DUDLEY MZ, Gerber JE, Budigan Ni H, Blunt M, et al
    Vaccinomics: A scoping review.
    Vaccine. 2023 Feb 18:S0264-410X(23)00135-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  468. RANADE D, Jena R, Patil K, Dogar V, et al
    A novel high throughput plate-based method for 2-PE quantification in novel multidose vaccines (R21 malaria, Covishield and Covovax) and combination vaccines (Hexavalent).
    Vaccine. 2023 Feb 17:S0264-410X(23)00174-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  469. PARODI A, Martini M
    History of vaccine and immunization: Vaccine-hesitancy discussion in Germany in XIX century.
    Vaccine. 2023 Feb 17:S0264-410X(23)00164-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  470. MEYER C, Goffe L, Antonopoulou V, Graham F, et al
    Using the precaution adoption process model to understand decision-making about the COVID-19 booster vaccine in England.
    Vaccine. 2023 Feb 17:S0264-410X(23)00182-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  471. MORAIS A, Morais J, Felix M, Neto Z, et al
    Genetic and epidemiological description of an outbreak of circulating vaccine-derived polio-virus type 2 (cVDPV2) in Angola, 2019-2020.
    Vaccine. 2023 Feb 17:S0264-410X(23)00170-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  472. ZIMMERMANN BM, Paul KT, Araujo ER, Buyx A, et al
    The social and socio-political embeddedness of COVID-19 vaccination decision-making: A five-country qualitative interview study from Europe.
    Vaccine. 2023 Feb 16:S0264-410X(23)00139-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  473. BENEDICT KPOZEHOUEN E, Arrudsivah B, Raina Macintyre C
    Knowledge, attitudes and practices of health care workers in a cardiology department on influenza vaccination.
    Vaccine. 2023 Feb 15:S0264-410X(23)00112-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  474. CAMPMAN SL, van Rossem G, Boyd A, Coyer L, et al
    Intent to vaccinate against SARS-CoV-2 and its determinants across six ethnic groups living in Amsterdam, the Netherlands: A cross-sectional analysis of the HELIUS study.
    Vaccine. 2023 Feb 13:S0264-410X(23)00165-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  475. BARNES K, Faasse K, Colagiuri B
    The impact of side effect framing on COVID-19 booster vaccine intentions in an Australian sample.
    Vaccine. 2023 Feb 13:S0264-410X(23)00158-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  476. SAELEE R, Chandra Murthy N, Patel Murthy B, Zell E, et al
    Minority Health Social Vulnerability Index and COVID-19 vaccination coverage - The United States, December 14, 2020-January 31, 2022.
    Vaccine. 2023 Feb 13:S0264-410X(23)00157-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  477. WANKHEDE D, Grover S, Hofman P
    Determinants of humoral immune response to SARS-CoV-2 vaccines in solid cancer patients: A systematic review and meta-analysis.
    Vaccine. 2023 Feb 13:S0264-410X(23)00115-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  478. AFREH OK, Angwaawie P, Attivor E, Boateng LA, et al
    Examining confidence and hesitancy towards COVID-19 vaccines: A cross-sectional survey using in-person data collection in rural Ghana.
    Vaccine. 2023 Feb 13:S0264-410X(23)00159-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  479. FACCHIN G, Bella A, Del Manso M, Rota MC, et al
    Decline in reported measles cases in Italy in the COVID-19 era, January 2020 - July 2022: The need to prevent a resurgence upon lifting non-pharmaceutical pandemic measures.
    Vaccine. 2023;41:1286-1289.
    >> Share

  480. SELL H, Raj Paudel Y, Voaklander D, MacDonald SE, et al
    School immunization coverage in adolescents during the COVID-19 pandemic: A retrospective cohort study.
    Vaccine. 2023;41:1333-1341.
    >> Share

  481. DE VRIES M, Claassen L, Lambooij MS, Timen A, et al
    Did the temporary suspension of Vaxzveria vaccinations influence COVID-19 vaccination intentions, vaccination perceptions and trust in the vaccination campaign? A repeated survey study in the Netherlands.
    Vaccine. 2023 Feb 10:S0264-410X(23)00138-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  482. HOSAIN R, Aquino P, Baccarini C, Smolenov I, et al
    Six-month safety follow-up of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in adults: A phase 2/3, double-blind, randomized study.
    Vaccine. 2023 Feb 10:S0264-410X(23)00144-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  483. SHEN AK, Browne S, Srivastava T, Kornides ML, et al
    Persuading the "Movable Middle": Characteristics of effective messages to promote routine and COVID-19 vaccinations for adults and children - The impact of COVID-19 on beliefs and attitudes.
    Vaccine. 2023 Feb 9:S0264-410X(23)00141-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  484. SILVA VASCONCELOS G, da Conceicao Rodrigues Fernandes M, Cardoso Matsui T, Claudia Dos Santos Luciano M, et al
    Persistent SARS-COV-2 infection in vaccinated individual with three doses of COVID-19 vaccine.
    Vaccine. 2023 Feb 9:S0264-410X(23)00145-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  485. BUNTINX E, Brochado L, Borja-Tabora C, Yu CY, et al
    Immunogenicity of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in SARS-CoV-2-naive and exposed individuals in a phase 2/3, double-blind, randomized study.
    Vaccine. 2023 Feb 9:S0264-410X(23)00143-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  486. FEIKIN DR, Higdon MM, Andrews N, Collie S, et al
    Assessing COVID-19 vaccine effectiveness against Omicron subvariants: Report from a meeting of the World Health Organization.
    Vaccine. 2023 Feb 9:S0264-410X(23)00146-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  487. BUGHIN J, Cincera M, Peters K, Reykowska D, et al
    Make it or break it: On-time vaccination intent at the time of Covid-19.
    Vaccine. 2023 Feb 8:S0264-410X(23)00140-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  488. WATANABE A, Iwagami M, Yasuhara J, Takagi H, et al
    Protective effect of COVID-19 vaccination against long COVID syndrome: A systematic review and meta-analysis.
    Vaccine. 2023 Feb 8:S0264-410X(23)00134-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  489. FELL DB, Torok E, Sprague AE, Regan AK, et al
    Temporal trends and determinants of COVID-19 vaccine coverage and series initiation during pregnancy in Ontario, Canada, December 2020 to December 2021: A population-based retrospective cohort study.
    Vaccine. 2023 Feb 3:S0264-410X(23)00114-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  490. HASSAN RAZA S, Yousaf M, Zaman U, Waheed Khan S, et al
    Unlocking infodemics and mysteries in COVID-19 vaccine hesitancy: Nexus of conspiracy beliefs, digital informational support, psychological Well-being, and religious fatalism.
    Vaccine. 2023 Feb 3:S0264-410X(23)00079-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  491. LI R, Liu H, Fairley CK, Ong JJ, et al
    mRNA-based COVID-19 booster vaccination is highly effective and cost-effective in Australia.
    Vaccine. 2023 Feb 3:S0264-410X(23)00126-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  492. MALTEZOU HC, Basoulis D, Bonelis K, Gamaletsou MN, et al
    Effectiveness of full (booster) COVID-19 vaccination against severe outcomes and work absenteeism in hospitalized patients with COVID-19 during the Delta and Omicron waves in Greece.
    Vaccine. 2023 Feb 2:S0264-410X(23)00109-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  493. HAMADA H, Futamura M, Ito H, Yamamoto R, et al
    Association of a third vaccination with antibody levels and side reactions in essential workers: A prospective cohort study.
    Vaccine. 2023 Feb 1:S0264-410X(23)00082-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  494. JOHNSON R, Djaafara B, Haw D, Doohan P, et al
    The societal value of SARS-CoV-2 booster vaccination in Indonesia.
    Vaccine. 2023 Feb 1:S0264-410X(23)00110-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  495. ANDREJKO KL, Myers JF, Fukui N, Nelson L, et al
    Real-world uptake of COVID-19 vaccination among individuals expressing vaccine hesitancy: A registry-linkage study.
    Vaccine. 2023 Feb 1:S0264-410X(23)00108-1. doi: 10.1016/j.vaccine.2023.
    >> Share

    January 2023
  496. UWAMINO Y, Yokoyama T, Sato Y, Shibata A, et al
    Humoral and cellular immune response dynamics in Japanese healthcare workers up to six months after receiving a third dose of BNT162b2 monovalent vaccine.
    Vaccine. 2023 Jan 31:S0264-410X(23)00081-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  497. GRESSENS SB, Wiedemann A, Dechenaud M, Dupuis J, et al
    Anti-SARS-CoV-2 cellular response after 2 and 3 doses of BNT162b2 mRNA vaccine in lymphoma patients receiving anti-CD20 antibodies.
    Vaccine. 2023 Jan 30:S0264-410X(23)00095-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  498. MATTA MG, Pulido L, Herrera-Paz JJ, Picco JM, et al
    Influenza and pneumococcal vaccine prescription for adults during COVID-19 first wave in three regions of Argentina.
    Vaccine. 2023 Jan 27:S0264-410X(23)00088-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  499. RODRIGUEZ-APONTE SA, Dalvie NC, Wong TY, Johnston RS, et al
    Molecular engineering of a cryptic epitope in Spike RBD improves manufacturability and neutralizing breadth against SARS-CoV-2 variants.
    Vaccine. 2023;41:1108-1118.
    >> Share

  500. PARODI JB, Indavere A, Bobadilla Jacob P, Toledo GC, et al
    Impact of COVID-19 vaccination in post-COVID cardiac complications.
    Vaccine. 2023 Jan 27:S0264-410X(23)00084-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  501. HARBIN A, Laventhal N, Navin M
    Ethics of age de-escalation in pediatric vaccine trials: Attending to the case of COVID-19.
    Vaccine. 2023 Jan 27:S0264-410X(23)00087-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  502. KRAUSE NM, Beets B, Howell EL, Tosteson H, et al
    Collateral damage from debunking mRNA vaccine misinformation.
    Vaccine. 2023;41:922-929.
    >> Share

  503. RENNERT W, Hindiyeh M, Allahham M, Mercer LD, et al
    Introducing ROTAVAC(R) to the occupied Palestinian Territories: Impact on diarrhea incidence, rotavirus prevalence and genotype composition.
    Vaccine. 2023;41:945-954.
    >> Share

  504. KUZEL TG, Fu J, Anderson M, Stec M, et al
    Effects of a booster dose of BNT162b2 on spike-binding antibodies to SARS-CoV-2 Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-naive and previously-infected individuals.
    Vaccine. 2023;41:879-882.
    >> Share

  505. FAIZULOEV E, Gracheva A, Korchevaya E, Smirnova D, et al
    Cold-adapted SARS-CoV-2 variants with different temperature sensitivity exhibit an attenuated phenotype and confer protective immunity.
    Vaccine. 2023;41:892-902.
    >> Share

  506. MYERS TR, Marquez PL, Gee JM, Hause AM, et al
    The v-safe after vaccination health checker: Active vaccine safety monitoring during CDC's COVID-19 pandemic response.
    Vaccine. 2023 Jan 23:S0264-410X(22)01545-6. doi: 10.1016/j.vaccine.2022.
    >> Share

  507. VATCHARAVONGVAN P, Boonyanitchayakul N, Khampachuea P, Sinturong I, et al
    Health Belief Model and parents' acceptance of the Pfizer-BioNTech and Sinopharm COVID-19 vaccine for children aged 5-18 years Old: A national survey.
    Vaccine. 2023 Jan 23:S0264-410X(23)00050-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  508. TENG Y, Hanibuchi T, Machida M, Nakaya T, et al
    Psychological determinants of COVID-19 vaccine acceptance: A comparison between immigrants and the host population in Japan.
    Vaccine. 2023 Jan 23:S0264-410X(23)00056-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  509. ZOLOTAROVA T, Dussault C, Park H, Varsaneux O, et al
    Education increases COVID-19 vaccine uptake among people in Canadian federal prisons in a prospective randomized controlled trial: The EDUCATE study.
    Vaccine. 2023 Jan 23:S0264-410X(23)00061-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  510. GROSSMAN-GIRON A, Tzur Bitan D, Shemesh S, Mayer Y, et al
    COVID-19 vaccine hesitancy scale and its association with actual COVID-19 vaccine uptake in Israel.
    Vaccine. 2023 Jan 23:S0264-410X(23)00065-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  511. MALLAH SI, Alawadhi A, Jawad J, Wasif P, et al
    Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals.
    Vaccine. 2023 Jan 23:S0264-410X(23)00053-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  512. STRATHDEE SA, Abramovitz D, Vera CF, Artamonova I, et al
    Predictors of COVID-19 vaccine uptake among people who inject drugs.
    Vaccine. 2023 Jan 23:S0264-410X(23)00063-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  513. KRAMER C, Song M, Sufrin CB, Eber GB, et al
    COVID-19 vaccination hesitancy and uptake: Perspectives from people released from the Federal Bureau of Prisons.
    Vaccine. 2023 Jan 21:S0264-410X(23)00060-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  514. DARBY B, Alexander V, Murphy J
    SARS-CoV-2 vaccine breakthrough infections in Virginia, January 17, 2021 - June 30, 2021.
    Vaccine. 2023 Jan 20:S0264-410X(23)00062-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  515. BIANCHI FP, Stefanizzi P, Martinelli A, Brescia N, et al
    COVID-19 vaccination hesitancy in people affected by diabetes and strategies to increase vaccine compliance: A systematic narrative review and meta-analysis.
    Vaccine. 2023 Jan 20:S0264-410X(23)00058-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  516. DUDLEY MZ, Schuh HB, Shaw J, Rimal RN, et al
    COVID-19 vaccination among different types of US Healthcare Personnel.
    Vaccine. 2023 Jan 20:S0264-410X(23)00051-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  517. GHORBANI A, Ngunjiri JM, Edward C Abundo M, Pantin-Jackwood M, et al
    Development of in Ovo-Compatible NS1-truncated live attenuated influenza vaccines by modulation of hemagglutinin cleavage and polymerase Acidic X Frameshifting sites.
    Vaccine. 2023 Jan 18:S0264-410X(23)00029-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  518. MOINI A, Rabiei M, Pirjani R, Abiri A, et al
    COVID‑19 vaccine hesitancy among pregnant women and their reported reasons for vaccine refusal - A prospective study in Tehran, Iran.
    Vaccine. 2023 Jan 16:S0264-410X(23)00032-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  519. BEDSTON S, Lowthian E, Jarvis CI, Akbari A, et al
    COVID-19 booster vaccination uptake and infection breakthrough amongst health care workers in Wales: A national prospective cohort study.
    Vaccine. 2023 Jan 13:S0264-410X(23)00034-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  520. YANG H, Li Z, Zhang R, Guo S, et al
    Safety of primary immunization using inactivated SARS-CoV-2 vaccine (CoronaVac(R)) among population aged 3 years and older in a large-scale use: A multi-center open-label study in China.
    Vaccine. 2023 Jan 13:S0264-410X(23)00031-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  521. KALRA S, Kalra D, Grafova I, Rubin JS, et al
    Association of death or illness from COVID-19 among family and friends on vaccine uptake within four months of the Emergency Use Authorization. Findings from a national survey in the United States.
    Vaccine. 2023 Jan 13:S0264-410X(23)00035-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  522. KLUWER B, Margrethe Rydland K, Nybru Gleditsch R, Mamelund SE, et al
    Social and demographic patterns of influenza vaccination coverage in Norway, influenza seasons 2014/15 to 2020/21.
    Vaccine. 2023 Jan 11:S0264-410X(23)00013-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  523. ELLISON TJ, Talbott GC, Henderson DR
    Intradermal delivery of a quadrivalent cell-based seasonal influenza vaccine using an adjuvanted skin patch vaccination platform.
    Vaccine. 2023;41:304-314.
    >> Share

  524. ASLAM J, Khan FS, Talha Haris M, Hewadmal H, et al
    Prior immunization status of COVID-19 patients and disease severity: A multicenter retrospective cohort study assessing the different types of immunity.
    Vaccine. 2023;41:598-605.
    >> Share

  525. MOELLER-ARENDT M, van de Witte S, Nauta J, de Voogd H, et al
    Enhanced passive safety surveillance of Influvac(R) and Influvac(R) Tetra: Results from seven consecutive seasons.
    Vaccine. 2023;41:606-613.
    >> Share

  526. KEVIN YIN J, Harris RC, Loiacono MM, Chit A, et al
    Letter to editor regarding a review of MF59-adjuvanted influenza vaccine by Gartner et al.
    Vaccine. 2023 Jan 9:S0264-410X(22)01559-6. doi: 10.1016/j.vaccine.2022.
    >> Share

  527. MORO PL, Zhang B, Ennulat C, Harris M, et al
    Safety of co-administration of mRNA COVID-19 and seasonal inactivated influenza vaccines in the vaccine adverse event reporting system (VAERS) during July 1, 2021-June 30, 2022.
    Vaccine. 2023 Jan 9:S0264-410X(23)00016-6. doi: 10.1016/j.vaccine.2022.
    >> Share

  528. WHITEHEAD HS, French CE, Caldwell DM, Letley L, et al
    A systematic review of communication interventions for countering vaccine misinformation.
    Vaccine. 2023 Jan 9:S0264-410X(22)01593-6. doi: 10.1016/j.vaccine.2022.
    >> Share

  529. WAGNER AL, Moniz MH, Stout MJ, Townsel C, et al
    Experiences, risk perceptions, and COVID-19 vaccination outcomes among hospital workers.
    Vaccine. 2023 Jan 9:S0264-410X(23)00012-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  530. MENON I, Kang SM, Braz Gomes K, Uddin MN, et al
    Laser-assisted intradermal delivery of a microparticle vaccine for respiratory syncytial virus induces a robust immune response.
    Vaccine. 2023 Jan 9:S0264-410X(23)00002-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  531. CHAWANPAIBOON S, Anuwutnawin S, Kanjanapongporn A, Pooliam J, et al
    Breastfeeding women's attitudes towards and acceptance and rejection of COVID-19 vaccination: Implementation research.
    Vaccine. 2023 Jan 9:S0264-410X(23)00015-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  532. TULLOCH JSP, Lawrenson K, Gordon AL, Ghebrehewet S, et al
    COVID-19 vaccine hesitancy in care home staff: A survey of Liverpool care homes.
    Vaccine. 2023 Jan 9:S0264-410X(23)00009-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  533. LONG Z, He J, Shuai Q, Zhang K, et al
    Influenza vaccination-induced H3 stalk-reactive memory B-cell clone expansion.
    Vaccine. 2023 Jan 6:S0264-410X(22)01603-6. doi: 10.1016/j.vaccine.2022.
    >> Share

  534. EBRAHIMI N, Mazdak M, Shaygannejad V, Mirmosayyeb O, et al
    CNS demyelinating disease following inactivated or viral vector SARS-CoV-2 vaccines: A case series.
    Vaccine. 2023 Jan 6:S0264-410X(23)00004-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  535. JANG Y, Cho H, Chun J, Park K, et al
    Baculoviral COVID-19 Delta DNA vaccine cross-protects against SARS-CoV2 variants in K18-ACE2 transgenic mice.
    Vaccine. 2023 Jan 6:S0264-410X(22)01602-4. doi: 10.1016/j.vaccine.2022.
    >> Share

  536. TSUCHIYA Y, Tamura H, Fujii K, Numaguchi H, et al
    Safety, reactogenicity, and immunogenicity of Ad26.COV2.S: Results of a phase 1, randomized, double-blind, placebo-controlled COVID-19 vaccine trial in Japan.
    Vaccine. 2023 Jan 5:S0264-410X(23)00006-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  537. TORALES J, Cuenca-Torres O, Barrios L, Armoa-Garcia L, et al
    An evaluation of the safety and immunogenicity of MVC-COV1901: Results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled immunobridging study in Paraguay.
    Vaccine. 2023;41:109-118.
    >> Share

  538. MAERTZDORF KM, Rietman ML, Lambooij MS, Verschuren WMM, et al
    Willingness to get vaccinated against influenza, pneumococcal disease, pertussis, and herpes zoster - A pre-COVID-19 exploration among the older adult population.
    Vaccine. 2023 Jan 4:S0264-410X(23)00001-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  539. BAGGA S, Krishnan A, Dar L
    Revisiting live attenuated influenza vaccine efficacy among children in developing countries.
    Vaccine. 2023 Jan 3:S0264-410X(22)01594-8. doi: 10.1016/j.vaccine.2022.
    >> Share

  540. REGO RT, Kenney B, Ngugi AK, Espira L, et al
    COVID-19 vaccination refusal trends in Kenya over 2021.
    Vaccine. 2023 Jan 3:S0264-410X(22)01601-2. doi: 10.1016/j.vaccine.2022.
    >> Share

  541. SHOOK NJ, Oosterhoff B, Sevi B
    A longitudinal assessment of variability in COVID-19 vaccine hesitancy and psychosocial correlates in a national United States sample.
    Vaccine. 2023 Jan 2:S0264-410X(22)01600-0. doi: 10.1016/j.vaccine.2022.
    >> Share

  542. FORD JS, Rouleau SG, Wagner JL, Adams CB, et al
    Assessment of a COVID-19 vaccination protocol for unhoused patients in the emergency department.
    Vaccine. 2023 Jan 2:S0264-410X(22)01598-5. doi: 10.1016/j.vaccine.2022.
    >> Share

    December 2022
  543. GAMBLE A, Hastings TJ, Westrick SC, Smith M, et al
    COVID-19 booster vaccination in rural community pharmacies.
    Vaccine. 2022 Dec 26:S0264-410X(22)01576-6. doi: 10.1016/j.vaccine.2022.
    >> Share

  544. XIE Z, Hamadi HY, Mainous AG, Hong YR, et al
    Association of dual COVID-19 and seasonal influenza vaccination with COVID-19 infection and disease severity.
    Vaccine. 2022 Dec 23:S0264-410X(22)01568-7. doi: 10.1016/j.vaccine.2022.
    >> Share

  545. ANDREJKO KL, Myers JF, Openshaw J, Fukui N, et al
    Receipt of COVID-19 and seasonal influenza vaccines in California (USA) during the 2021-2022 influenza season.
    Vaccine. 2022 Dec 23:S0264-410X(22)01578-X. doi: 10.1016/j.vaccine.2022.
    >> Share

  546. SAIAG E, Alcalay Y, Marudi O, Orr-Urtreger A, et al
    Cellular and humoral immune response to the fourth Pfizer-BioNTech COVID-19 vaccine dose in individuals aged 60 years and older.
    Vaccine. 2022 Dec 21:S0264-410X(22)01560-2. doi: 10.1016/j.vaccine.2022.
    >> Share

  547. WAND O, Breslavsky A, Bar-Shai A, Levy C, et al
    One-year dynamics of antibody titers after three doses of SARS-CoV-2 BNT162b2 vaccine.
    Vaccine. 2022 Dec 21:S0264-410X(22)01567-5. doi: 10.1016/j.vaccine.2022.
    >> Share

  548. XU S, Huang R, Sy LS, Hong V, et al
    A safety study evaluating non-COVID-19 mortality risk following COVID-19 vaccination.
    Vaccine. 2022 Dec 20:S0264-410X(22)01561-4. doi: 10.1016/j.vaccine.2022.
    >> Share

  549. RANE MS, Robertson MM, Kulkarni SG, Frogel D, et al
    Effectiveness of Covid-19 vaccines against symptomatic and asymptomatic SARS-CoV-2 infections in an urgent care setting.
    Vaccine. 2022 Dec 20:S0264-410X(22)01564-X. doi: 10.1016/j.vaccine.2022.
    >> Share

  550. WILLIAMS KV, Moehling Geffel K, Alcorn JF, Patricia Nowalk M, et al
    Factors associated with humoral immune response in older adults who received egg-free influenza vaccine.
    Vaccine. 2022 Dec 19:S0264-410X(22)01566-3. doi: 10.1016/j.vaccine.2022.
    >> Share

  551. DUDLEY MZ, Barnett EE, Paulenich A, Omer SB, et al
    Characterization of parental intention to vaccinate elementary school aged children in the state of California.
    Vaccine. 2022 Dec 19:S0264-410X(22)01544-4. doi: 10.1016/j.vaccine.2022.
    >> Share

  552. BOISSON A, Morgan CE, Stover A, Ngimbi P, et al
    Changes in hepatitis B vaccine perception in response to the COVID-19 pandemic: Development of the Shift in vaccine confidence (SVC) survey tool.
    Vaccine. 2022 Dec 16:S0264-410X(22)01542-0. doi: 10.1016/j.vaccine.2022.
    >> Share

  553. YIH WK, Daley MF, Duffy J, Fireman B, et al
    A broad assessment of covid-19 vaccine safety using tree-based data-mining in the vaccine safety datalink.
    Vaccine. 2022 Dec 16:S0264-410X(22)01541-9. doi: 10.1016/j.vaccine.2022.
    >> Share

  554. SONOYAMA T, Iwata S, Shinkai M, Iwata-Yoshikawa N, et al
    Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults.
    Vaccine. 2022 Dec 16:S0264-410X(22)01540-7. doi: 10.1016/j.vaccine.2022.
    >> Share

  555. PAPAZACHARIOU A, Tsioutis C, Lytras T, Malikides O, et al
    The impact of seasonal influenza vaccination uptake on COVID-19 vaccination attitudes in a rural area in Greece.
    Vaccine. 2022 Dec 15:S0264-410X(22)01539-0. doi: 10.1016/j.vaccine.2022.
    >> Share

  556. VAUX S, Fonteneau L, Pefau M, Venier AG, et al
    Vaccination against influenza, measles, pertussis and varicella in workers in healthcare facilities in France: A national cross-sectional study in 2019.
    Vaccine. 2022 Dec 15:S0264-410X(22)01537-7. doi: 10.1016/j.vaccine.2022.
    >> Share

  557. CHEN L, Levine MZ, Zhou S, Bai T, et al
    Mild and asymptomatic influenza B virus infection among unvaccinated pregnant persons: Implication for effectiveness of non-pharmaceutical intervention and vaccination to prevent influenza.
    Vaccine. 2022 Dec 14:S0264-410X(22)01468-2. doi: 10.1016/j.vaccine.2022.
    >> Share

  558. OHNO M, Sagata M, Sekiya T, Nomura N, et al
    Assessing the pyrogenicity of whole influenza virus particle vaccine in cynomolgus macaques.
    Vaccine. 2022 Dec 14:S0264-410X(22)01534-1. doi: 10.1016/j.vaccine.2022.
    >> Share

  559. IBROCI E, Liu X, Lieb W, Jessel R, et al
    Impact of prenatal COVID-19 vaccination on delivery and neonatal outcomes: Results from a New York City cohort.
    Vaccine. 2022 Dec 14:S0264-410X(22)01226-9. doi: 10.1016/j.vaccine.2022.
    >> Share

  560. SAINI SJ, Carle AC, Forsyth AR, Chi DL, et al
    Association between caregiver opposition to topical fluoride and COVID-19 vaccines.
    Vaccine. 2022 Dec 14:S0264-410X(22)01532-8. doi: 10.1016/j.vaccine.2022.
    >> Share

  561. SALVATORE PP, Lee CC, Sleweon S, McCormick DW, et al
    Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, July-August 2021.
    Vaccine. 2022 Dec 13:S0264-410X(22)01458-X. doi: 10.1016/j.vaccine.2022.
    >> Share

  562. CHIBA S, Hatta M, Pattinson D, Yasuhara A, et al
    Ferret model to mimic the sequential exposure of humans to historical H3N2 influenza viruses.
    Vaccine. 2022 Dec 12:S0264-410X(22)01518-3. doi: 10.1016/j.vaccine.2022.
    >> Share

  563. CHO BH, Athar HM, Bates LG, Yarnoff BO, et al
    Patient flow time data of COVID-19 vaccination clinics in 23 sites, United States, April and May 2021.
    Vaccine. 2022 Dec 12:S0264-410X(22)01527-4. doi: 10.1016/j.vaccine.2022.
    >> Share

  564. TADDIO A, Ilersich ANT, Bucci L, McMurtry CM, et al
    Letting kids play their CARDs (Comfort, Ask, Relax, Distract) to help cope with needle-related fear and pain: Results from user testing.
    Vaccine. 2022;40:7667-7675.
    >> Share

  565. HALL PA, Meng G, Boudreau C, Hudson A, et al
    Social cognitive predictors of vaccination status, uptake and mitigation behaviors in the Canadian COVID-19 Experiences survey.
    Vaccine. 2022 Dec 12:S0264-410X(22)01526-2. doi: 10.1016/j.vaccine.2022.
    >> Share

  566. CUDDIHY MT, Berger WL, Cummings PL, Keith R, et al
    An organizational assessment of 101 Community-Based Adult Services centers to identify and address gaps in influenza vaccination among Medicare-Medicaid beneficiaries.
    Vaccine. 2022 Dec 10:S0264-410X(22)01490-6. doi: 10.1016/j.vaccine.2022.
    >> Share

  567. PEPIN S, Samson SI, Alvarez FP, Dupuy M, et al
    Corrigendum to "Impact of a quadrivalent inactivated influenza vaccine on influenza-associated complications and health care use in children aged 6 to 35 months: Analysis of data from a phase III trial in the northern and southern Hemispheres" [Vaccin
    Vaccine. 2022 Dec 9:S0264-410X(22)01483-9. doi: 10.1016/j.vaccine.2022.
    >> Share

  568. FERNANDES NEHAB M, Goncalves Camacho K, Teixeira Reis A, Junqueira-Marinho MF, et al
    Willingness of Brazilian caregivers in having their children and adolescents vaccinated against Covid-19.
    Vaccine. 2022 Dec 9:S0264-410X(22)01520-1. doi: 10.1016/j.vaccine.2022.
    >> Share

  569. ANDERSON-CHAVARRIA M, Turner J
    Searching for the 'Trigger': An ethnographic analysis of parental beliefs regarding autism causation and vaccination in Puerto Rico.
    Vaccine. 2022 Dec 7:S0264-410X(22)01488-8. doi: 10.1016/j.vaccine.2022.
    >> Share

  570. LATKIN C, Dayton L, Miller J, Eschliman E, et al
    Trusted information sources in the early months of the COVID-19 pandemic predict vaccination uptake over one year later.
    Vaccine. 2022 Dec 6:S0264-410X(22)01510-9. doi: 10.1016/j.vaccine.2022.
    >> Share

  571. SERISIER A, Beale S, Boukari Y, Hoskins S, et al
    A case-crossover study of the effect of vaccination on SARS-CoV-2 transmission relevant behaviours during a period of national lockdown in England and Wales.
    Vaccine. 2022 Dec 5:S0264-410X(22)01497-9. doi: 10.1016/j.vaccine.2022.
    >> Share

  572. IWAI-SAITO K, Sato K, Kondo K
    Associations of influenza and pneumococcal vaccinations with burdens of older family caregivers: The Japan Gerontological Evaluation study (JAGES) cross-sectional study.
    Vaccine. 2022 Dec 2:S0264-410X(22)01460-8. doi: 10.1016/j.vaccine.2022.
    >> Share

  573. CASPERSEN IH, Juvet LK, Feiring B, Laake I, et al
    Menstrual disturbances in 12- to 15-year-old girls after one dose of COVID-19 Comirnaty vaccine: Population-based cohort study in Norway.
    Vaccine. 2022 Dec 2:S0264-410X(22)01492-X. doi: 10.1016/j.vaccine.2022.
    >> Share

  574. STOLIAROFF-PEPIN A, Peine C, Herath T, Lachmann J, et al
    Effectiveness of vaccines in preventing hospitalization due to COVID-19: A multicenter hospital-based case-control study, Germany, June 2021 to January 2022.
    Vaccine. 2022 Dec 2:S0264-410X(22)01489-X. doi: 10.1016/j.vaccine.2022.
    >> Share

  575. AL-KASSAB-CORDOVA A, Silva-Perez C, Mendez-Guerra C, Sangster-Carrasco L, et al
    Inequalities in infant vaccination coverage during the COVID-19 pandemic: A population-based study in Peru.
    Vaccine. 2022 Dec 2:S0264-410X(22)01491-8. doi: 10.1016/j.vaccine.2022.
    >> Share

  576. INGRAM C, Roe M, Downey V, Phipps L, et al
    Exploring key informants' perceptions of Covid-19 vaccine hesitancy in a disadvantaged urban community in Ireland: Emergence of a '4Cs' model.
    Vaccine. 2022 Dec 2:S0264-410X(22)01496-7. doi: 10.1016/j.vaccine.2022.
    >> Share

  577. UTTEKAR S, MacDonald N, Orenstein WA, Danchin M, et al
    Empowering Health Workers to Build Public Trust in Vaccination: Experience from the International Pediatric Association's Online Vaccine Trust Course, 2020-2021.
    Vaccine. 2022 Dec 2:S0264-410X(22)01485-2. doi: 10.1016/j.vaccine.2022.
    >> Share

  578. BENDER FL, Rief W, Wilhelm M
    Really just a little prick? A meta-analysis on adverse events in placebo control groups of seasonal influenza vaccination RCTs.
    Vaccine. 2022 Dec 1:S0264-410X(22)01431-1. doi: 10.1016/j.vaccine.2022.
    >> Share

  579. WONG HL, Tworkoski E, Ke Zhou C, Hu M, et al
    Surveillance of COVID-19 vaccine safety among elderly persons aged 65 years and older.
    Vaccine. 2022 Dec 1:S0264-410X(22)01493-1. doi: 10.1016/j.vaccine.2022.
    >> Share

    November 2022
  580. SUN Y, Huang SK, Arlikatti S, Lindell MK, et al
    What attributes influence rural household's willingness to get vaccinated for COVID-19? Perspectives from six Chinese townships.
    Vaccine. 2022 Nov 29:S0264-410X(22)01487-6. doi: 10.1016/j.vaccine.2022.
    >> Share

  581. TANG S, Liu X, Jia Y, Chen H, et al
    Education level modifies parental hesitancy about COVID-19 vaccinations for their children.
    Vaccine. 2022 Nov 29:S0264-410X(22)01484-0. doi: 10.1016/j.vaccine.2022.
    >> Share

  582. CHRISTOU-ERGOS M, Wiley KE, Leask J
    Willingness to receive a vaccine is influenced by adverse events following immunisation experienced by others.
    Vaccine. 2022 Nov 26:S0264-410X(22)01447-5. doi: 10.1016/j.vaccine.2022.
    >> Share

  583. MICHELLE DRIEDGER S, Capurro G, Tustin J, Jardine CG, et al
    "I won't be a guinea pig": Rethinking public health communication and vaccine hesitancy in the context of COVID-19.
    Vaccine. 2022 Nov 25:S0264-410X(22)01469-4. doi: 10.1016/j.vaccine.2022.
    >> Share

  584. STOCKER A, Hoffmann J, Mause L, Neufeind J, et al
    What impact does the attitude toward COVID-19 vaccination have on physicians as vaccine providers? A cross sectional study from the German outpatient sector.
    Vaccine. 2022 Nov 25:S0264-410X(22)01466-9. doi: 10.1016/j.vaccine.2022.
    >> Share

  585. ZARZECZNA N, Bertlich T, Veckalov B, Rutjens BT, et al
    Spirituality is associated with Covid-19 vaccination scepticism.
    Vaccine. 2022 Nov 25:S0264-410X(22)01463-3. doi: 10.1016/j.vaccine.2022.
    >> Share

  586. RADER B, Chiang ME, Kriner DL, Weintraub RL, et al
    Persistent drop in confidence following US recommended pause of Ad26.COV2.S vaccine administration.
    Vaccine. 2022 Nov 25:S0264-410X(22)01448-7. doi: 10.1016/j.vaccine.2022.
    >> Share

  587. LIP A, Pateman M, Fullerton MM, Chen HM, et al
    Vaccine hesitancy educational tools for healthcare providers and trainees: A scoping review.
    Vaccine. 2022 Nov 24:S0264-410X(22)01225-7. doi: 10.1016/j.vaccine.2022.
    >> Share

  588. KATHERINE YIH W, Daley MF, Duffy J, Fireman B, et al
    Tree-based data mining for safety assessment of first COVID-19 booster doses in the Vaccine Safety Datalink.
    Vaccine. 2022 Nov 24:S0264-410X(22)01467-0. doi: 10.1016/j.vaccine.2022.
    >> Share

  589. HUMBLE RM, Scott SD, Dube E, Olson J, et al
    The impact of the COVID-19 pandemic on parents' perceptions and acceptance of routine childhood vaccination in Canada: A national longitudinal study.
    Vaccine. 2022 Nov 24:S0264-410X(22)01465-7. doi: 10.1016/j.vaccine.2022.
    >> Share

  590. TANAKA H, Mukai J, Kushibiki K, Mizushima S, et al
    Effect of the third dose of BNT162b2 COVID-19 mRNA vaccine on anti-SARS-CoV-2 antibody levels in healthcare workers.
    Vaccine. 2022 Nov 24:S0264-410X(22)01462-1. doi: 10.1016/j.vaccine.2022.
    >> Share

  591. CAETANO C, Morgado ML, Patricio P, Leite A, et al
    Measuring the impact of COVID-19 vaccination and immunity waning: A modelling study for Portugal.
    Vaccine. 2022;40:7115-7121.
    >> Share

  592. KAUFMANN J, DeVoe JE, Angier H, Moreno L, et al
    Association of parent influenza vaccination and early childhood vaccinations using linked electronic health record data.
    Vaccine. 2022;40:7097-7107.
    >> Share

  593. HASSAN YAM, Daud Ali M, Al-Eid RR, Al-Ghuraya FA, et al
    A retrospective evaluation of side-effects associated with the booster dose of Pfizer-BioNTech/BNT162b2 COVID-19 vaccine among females in Eastern Province, Saudi Arabia.
    Vaccine. 2022;40:7087-7096.
    >> Share

  594. FRANCO C, Herazo-Padilla N, Castaneda JA
    A queueing Network approach for capacity planning and patient Scheduling: A case study for the COVID-19 vaccination process in Colombia.
    Vaccine. 2022;40:7073-7086.
    >> Share

  595. HODGSON D, Koltai M, Krauer F, Flasche S, et al
    Optimal Respiratory Syncytial Virus intervention programmes using Nirsevimab in England and Wales.
    Vaccine. 2022;40:7151-7157.
    >> Share

  596. ZHOU W, Tang B, Bai Y, Shao Y, et al
    The resurgence risk of COVID-19 in China in the presence of immunity waning and ADE: A mathematical modelling study.
    Vaccine. 2022;40:7141-7150.
    >> Share

  597. WILLAME C, Dodd C, Duran CE, Elbers R, et al
    Background rates of 41 adverse events of special interest for COVID-19 vaccines in 10 European healthcare databases - an ACCESS cohort study.
    Vaccine. 2022 Nov 22:S0264-410X(22)01429-3. doi: 10.1016/j.vaccine.2022.
    >> Share

  598. OZDARENDELI A, Sezer Z, Pavel STI, Inal A, et al
    Safety and immunogenicity of an inactivated whole virion SARS-CoV-2 vaccine, TURKOVAC, in healthy adults: Interim results from randomised, double-blind, placebo-controlled phase 1 and 2 trials.
    Vaccine. 2022 Nov 22:S0264-410X(22)01380-9. doi: 10.1016/j.vaccine.2022.
    >> Share

  599. ELICABE RJ, Distel MN, Jofre BL, Leporati M, et al
    Assessing the long-stand antibody response induced by COVID-19 vaccines: A study in an educational cohort in San Luis, Argentina.
    Vaccine. 2022 Nov 21:S0264-410X(22)01416-5. doi: 10.1016/j.vaccine.2022.
    >> Share

  600. NIQUEUX E, Flodrops M, Allee C, Lebras MO, et al
    Evaluation of three hemagglutinin-based vaccines for the experimental control of a panzootic clade 2.3.4.4b A(H5N8) high pathogenicity avian influenza virus in mule ducks.
    Vaccine. 2022 Nov 18:S0264-410X(22)01398-6. doi: 10.1016/j.vaccine.2022.
    >> Share

  601. FEKETE M, Horvath A, Santa B, Tomisa G, et al
    COVID-19 vaccination coverage in patients with chronic obstructive pulmonary disease - A cross-sectional study in Hungary.
    Vaccine. 2022 Nov 18:S0264-410X(22)01415-3. doi: 10.1016/j.vaccine.2022.
    >> Share

  602. MCCORMICK DW, Hagan LM, Salvatore PP, Magleby R, et al
    SARS-CoV-2 viral shedding in vaccinated and unvaccinated persons: A case series.
    Vaccine. 2022 Nov 18:S0264-410X(22)01428-1. doi: 10.1016/j.vaccine.2022.
    >> Share

  603. KAHN AL, Steffen CA, Henaff L, MacDonald NE, et al
    COVID-19 vaccine policy development in a sample of 44 countries - Key findings from a December 2021 survey of National Immunization Technical Advisory Groups (NITAGs).
    Vaccine. 2022 Nov 17:S0264-410X(22)01427-X. doi: 10.1016/j.vaccine.2022.
    >> Share

  604. PANICKAN S, Bhatia S, Bhat S, Bhandari N, et al
    Reverse genetics based H5N2 vaccine provides clinical protection against H5N1, H5N8 and H9N2 avian influenza infection in chickens.
    Vaccine. 2022;40:6998-7008.
    >> Share

  605. ALFANO V, Ercolano S
    Your vaccine attitude determines your altitude. What are the determinants of attitudes toward vaccination?
    Vaccine. 2022;40:6987-6997.
    >> Share

  606. TURBYFILL C, Adams K, Tenforde MW, Murray NL, et al
    Comparison of test-negative and syndrome-negative controls in SARS-CoV-2 vaccine effectiveness evaluations for preventing COVID-19 hospitalizations in the United States.
    Vaccine. 2022;40:6979-6986.
    >> Share

  607. KULKARNI AV, Jaggaiahgari S, Iyengar S, Simhadri V, et al
    Poor immune response to coronavirus disease vaccines in decompensated cirrhosis patients and liver transplant recipients.
    Vaccine. 2022;40:6971-6978.
    >> Share

  608. HE H, Zhu Y, Jin M, Zhou Y, et al
    The decline in immunity and circulation of pertussis among Chinese population during the COVID-19 pandemic: A cross-sectional sero-epidemiological study.
    Vaccine. 2022;40:6956-6962.
    >> Share

  609. ATTWELL K, Rizzi M, Paul KT
    Consolidating a research agenda for vaccine mandates.
    Vaccine. 2022 Nov 14. pii: S0264-410X(22)01384.
    >> Share

  610. ZIMMERMAN T, Shiroma K, Fleischmann KR, Xie B, et al
    Misinformation and COVID-19 vaccine hesitancy.
    Vaccine. 2022 Nov 14:S0264-410X(22)01402-5. doi: 10.1016/j.vaccine.2022.
    >> Share

  611. VANWORMER JJ, Alicea G, Weichelt BP, Berg RL, et al
    COVID-19 vaccine coverage disparities in rural and farm children.
    Vaccine. 2022 Nov 14:S0264-410X(22)01403-7. doi: 10.1016/j.vaccine.2022.
    >> Share

  612. FABIANI M, Mateo-Urdiales A, Sacco C, Rota MC, et al
    Relative effectiveness of a 2nd booster dose of COVID-19 mRNA vaccine up to four months post administration in individuals aged 80 years or more in Italy: A retrospective matched cohort study.
    Vaccine. 2022 Nov 14:S0264-410X(22)01399-8. doi: 10.1016/j.vaccine.2022.
    >> Share

  613. MANANDHAR P, Wannemuehler K, Danovaro-Holliday MC, Nic Lochlainn L, et al
    Use of catch-up vaccinations in the second year of life (2YL) platform to close immunity gaps: A secondary DHS analysis in Pakistan, Philippines, and South Africa.
    Vaccine. 2022 Nov 14. pii: S0264-410X(22)01301.
    >> Share

  614. JACKSON ML, Phillips CH, Wellwood S, Kiniry E, et al
    Burden of medically attended influenza infection and cases averted by vaccination - United States, 2016/17 through 2018/19 influenza seasons.
    Vaccine. 2022 Nov 12. pii: S0264-410X(22)01397.
    >> Share

  615. KPOZEHOUEN EB, Tan T, Macintyre CR
    Uptake of influenza, pneumococcal and herpes zoster vaccines among people with heart failure and atrial fibrillation.
    Vaccine. 2022 Nov 12. pii: S0264-410X(22)01377.
    >> Share

  616. DE FIGUEIREDO A, Simas C, Larson HJ
    COVID-19 vaccine acceptance and its socio-demographic and emotional determinants: A multi-country cross-sectional study.
    Vaccine. 2022 Nov 10:S0264-410X(22)01310-X. doi: 10.1016/j.vaccine.2022.
    >> Share

  617. DENG T, Li T, Chen G, Zhu Y, et al
    Characterization and immunogenicity of SARS-CoV-2 spike proteins with varied glycosylation.
    Vaccine. 2022;40:6839-6848.
    >> Share

  618. REN H, Li H, Cao L, Wang Z, et al
    Intranasal immunization with HRSV prefusion F protein and CpG adjuvant elicits robust protective effects in mice.
    Vaccine. 2022;40:6830-6838.
    >> Share

  619. HASHIMOTO M, Aoe S, Kawazu Y, Seki NM, et al
    Homologous and heterologous booster vaccinations of S-268019-b, a recombinant S protein-based vaccine with a squalene-based adjuvant, enhance neutralization breadth against SARS-CoV-2 Omicron subvariants in cynomolgus macaques.
    Vaccine. 2022 Nov 8. pii: S0264-410X(22)01379.
    >> Share

  620. MOLL K, Lufkin B, Fingar KR, Ke Zhou C, et al
    Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019-2020.
    Vaccine. 2022 Nov 8:S0264-410X(22)01373-1. doi: 10.1016/j.vaccine.2022.
    >> Share

  621. TAKEUCHI Y, Iwagami M, Ono S, Michihata N, et al
    A post-marketing safety assessment of COVID-19 mRNA vaccination for serious adverse outcomes using administrative claims data linked with vaccination registry in a city of Japan.
    Vaccine. 2022 Nov 7. pii: S0264-410X(22)01370.
    >> Share

  622. HAO XB, Anand M, Wang TR, Rao AR, et al
    Reducing COVID vaccine hesitancy by inducing a comparative mindset.
    Vaccine. 2022 Nov 7. pii: S0264-410X(22)01359.
    >> Share

  623. GUERIN RJ, Naeim A, Baxter-King R, Okun AH, et al
    Parental intentions to vaccinate children against COVID-19: Findings from a U.S. National Survey.
    Vaccine. 2022 Nov 7:S0264-410X(22)01371-8. doi: 10.1016/j.vaccine.2022.
    >> Share

  624. BEALE S, Burns R, Braithwaite I, Byrne T, et al
    Occupation, Worker Vulnerability, and COVID-19 Vaccination Uptake: Analysis of the Virus Watch prospective cohort study.
    Vaccine. 2022 Nov 7. pii: S0264-410X(22)01362.
    >> Share

  625. SKAWRAN S, Schiesser H, Maurer A, Sartoretti T, et al
    Frequency and temporal evolution of COVID-19 vaccination rate among oncological patients undergoing 18F-FDG-PET.
    Vaccine. 2022 Nov 7. pii: S0264-410X(22)01376.
    >> Share

  626. WU YY, Zhang W
    Demographic disparities in COVID-19 vaccine hesitancy among U.S. adults: Analysis of household pulse survey data from Jul 21 to Oct 11 in 2021.
    Vaccine. 2022 Nov 7. pii: S0264-410X(22)01381.
    >> Share

  627. LOPEZ-DORIGA RUIZ P, Gunnes N, Michael Gran J, Karlstad O, et al
    Short-term safety of COVID-19 mRNA vaccines with respect to all-cause mortality in the older population in Norway.
    Vaccine. 2022 Nov 7. pii: S0264-410X(22)01367.
    >> Share

  628. OSOWICKI J, Morgan HJ, Harris A, Clothier HJ, et al
    Guillain-Barre syndrome temporally associated with COVID-19 vaccines in Victoria, Australia.
    Vaccine. 2022 Nov 7. pii: S0264-410X(22)01366.
    >> Share

  629. LEUNG J, Gray EB, Anderson TC, Sharkey SM, et al
    Recombinant zoster vaccine (RZV) second-dose series completion in adults aged 50-64 years in the United States.
    Vaccine. 2022 Nov 5. pii: S0264-410X(22)01328.
    >> Share

  630. MORSTEAD T, Zheng J, Sin NL, DeLongis A, et al
    Perceived threat and coping responses during the COVID-19 pandemic: Prospective associations with vaccine hesitancy.
    Vaccine. 2022 Nov 4. pii: S0264-410X(22)01363.
    >> Share

  631. MALDEN DE, Gee J, Glenn S, Li Z, et al
    Reactions following Pfizer-BioNTech COVID-19 mRNA vaccination and related healthcare encounters among 7,077 children aged 5-11 years within an integrated healthcare system.
    Vaccine. 2022 Nov 3. pii: S0264-410X(22)01361.
    >> Share

  632. TOMPKINS LK, Baggs J, Myers TR, Gee JM, et al
    Association between history of SARS-CoV-2 infection and severe systemic adverse events after mRNA COVID-19 vaccination among U.S. adults.
    Vaccine. 2022 Nov 1. pii: S0264-410X(22)01342.
    >> Share

  633. CHANG CT, Lim XJ, Chew CC, Rajan P, et al
    Preferences and willingness of accepting COVID-19 vaccine booster: Results from a middle-income country.
    Vaccine. 2022 Nov 1. pii: S0264-410X(22)01334.
    >> Share

  634. LUCINDE RK, Karia B, Ouma N, Amadi D, et al
    The impact of the COVID-19 pandemic on vaccine coverage in Kilifi, Kenya: A retrospective cohort study.
    Vaccine. 2022 Nov 1:S0264-410X(22)01345-7. doi: 10.1016/j.vaccine.2022.
    >> Share

    October 2022
  635. KUNASEKARAN M, Moa A, Hooshmand E, Trent M, et al
    Effectiveness estimates for enhanced trivalent influenza vaccines in an aged care summer outbreak.
    Vaccine. 2022 Oct 31. pii: S0264-410X(22)00766.
    >> Share

  636. KUNASEKARAN M, Poulos CJ, Chughtai AA, Heslop DJ, et al
    Factors associated with repeated influenza vaccine uptake among aged care staff in an Australian sample from 2017 to 2019.
    Vaccine. 2022 Oct 31. pii: S0264-410X(22)00981.
    >> Share

  637. CRUZ MC, Nascimento-Carvalho CM
    The early evolution of COVID-19 incidence and mortality among people aged under 80 years or 80 years and above after COVID-19 vaccine implementation in the state of Bahia, Brazil.
    Vaccine. 2022 Oct 31. pii: S0264-410X(22)01335.
    >> Share

  638. LIMAYE RJ, Paul A, Gur-Arie R, Zavala E, et al
    A socio-ecological exploration to identify factors influencing the COVID-19 vaccine decision-making process among pregnant and lactating women: Findings from Kenya.
    Vaccine. 2022 Oct 31. pii: S0264-410X(22)01331.
    >> Share

  639. CAPURRO G, Maier R, Tustin J, Jardine CG, et al
    "They're trying to bribe you and taking away your freedoms": COVID-19 vaccine hesitancy in communities with traditionally low vaccination rates.
    Vaccine. 2022 Oct 31. pii: S0264-410X(22)01338.
    >> Share

  640. SIANI A, Tranter A
    Is vaccine confidence an unexpected victim of the COVID-19 pandemic?
    Vaccine. 2022 Oct 31. pii: S0264-410X(22)01337.
    >> Share

  641. MARIE REINHART A, Tian Y, Lilly AE
    The role of trust in COVID-19 vaccine hesitancy and acceptance among Black and White Americans.
    Vaccine. 2022 Oct 31. pii: S0264-410X(22)01330.
    >> Share

  642. THULUVA S, Paradkar V, Gunneri S, Yerroju V, et al
    Safety, tolerability and immunogenicity of Biological E's CORBEVAX vaccine in children and adolescents: A prospective, randomised, double-blind, placebo controlled, phase-2/3 study.
    Vaccine. 2022 Oct 31. pii: S0264-410X(22)01308.
    >> Share

  643. HEYERDAHL LW, Dielen S, Dodion H, Van Riet C, et al
    Strategic silences, eroded trust: The impact of divergent COVID-19 vaccine sentiments on healthcare workers' relations with peers and patients.
    Vaccine. 2022 Oct 27. pii: S0264-410X(22)01306.
    >> Share

  644. SCHIFF J, Schmidt AR, Pham PK, Perez JB, et al
    Parental attitudes in the pediatric emergency department about the COVID-19 vaccine.
    Vaccine. 2022 Oct 26. pii: S0264-410X(22)01309.
    >> Share

  645. MALTEZOU HC, Ledda C, Gagneux-Brunon A, Botelho-Nevers E, et al
    Mandatory COVID-19 vaccination for healthcare personnel in the era of new SARS-CoV-2 variants.
    Vaccine. 2022 Oct 26. pii: S0264-410X(22)01313.
    >> Share

  646. MALTEZOU HC, Gamaletsou MN, Koukou DM, Giannouchos TV, et al
    Association between COVID-19 vaccination status, time elapsed since the last vaccine dose, morbidity, and absenteeism among healthcare personnel: A prospective, multicenter study.
    Vaccine. 2022 Oct 26. pii: S0264-410X(22)01304.
    >> Share

  647. PHOKSAWAT W, Nithichanon A, Lerdsamran H, Wongratanacheewin S, et al
    Phenotypic and functional changes of T cell subsets after CoronaVac vaccination.
    Vaccine. 2022 Oct 22. pii: S0264-410X(22)01265.
    >> Share

  648. MADEWELL ZJ, Chacon-Fuentes R, Badilla-Vargas X, Ramirez C, et al
    Knowledge, attitudes, and practices regarding seasonal influenza vaccination during pregnancy in Costa Rica: A mixed-methods study.
    Vaccine. 2022 Oct 21. pii: S0264-410X(22)01284.
    >> Share

  649. SUN R, Budhwani H
    Negative sentiments toward novel coronavirus (COVID-19) vaccines.
    Vaccine. 2022 Oct 21. pii: S0264-410X(22)01297.
    >> Share

  650. ARRIETA A, Garcia-Prado A, Sarmiento JP, Paz Castro C, et al
    Identifying early adopters of COVID-19 vaccines in Latin America.
    Vaccine. 2022 Oct 21. pii: S0264-410X(22)01294.
    >> Share

  651. LAI L, Rouphael N, Xu Y, Kabbani S, et al
    An Oil-in-Water adjuvant significantly increased influenza A/H7N9 split virus Vaccine-Induced circulating follicular helper T (cTFH) cells and antibody responses.
    Vaccine. 2022 Oct 20. pii: S0264-410X(22)01146.
    >> Share

  652. BLANCO S, Spinsanti L, Javier Aguilar J, Diaz A, et al
    Neutralizing response elicited by homologous and heterologous prime booster vaccination against ancestral SARS-CoV-2 B.1, P.1, C.37 and B.1.617.2 variants.
    Vaccine. 2022 Oct 20. pii: S0264-410X(22)01283.
    >> Share

  653. DUCLOS P, MacDonald NE, Dochez C, Thacker N, et al
    Report of the 2nd workshop of the International Collaboration on advanced vaccinology training.
    Vaccine. 2022 Oct 20. pii: S0264-410X(22)01222.
    >> Share

  654. SANTIBANEZ TA, Black CL, Vogt TM, Chatham-Stephens K, et al
    Where are children ages 5-17 years receiving their COVID-19 vaccinations? Variations over time and by sociodemographic characteristics, United States.
    Vaccine. 2022 Oct 20. pii: S0264-410X(22)01282.
    >> Share

  655. STONER MCD, Tweedy D, Comello MGL, Toval C, et al
    Using narratives to inform the development of a digital health intervention related to COVID-19 vaccination in Black young adults in Georgia, North Carolina and Alabama.
    Vaccine. 2022 Oct 20. pii: S0264-410X(22)01286.
    >> Share

  656. ZHONG VW, Li X, Ran J, Hu G, et al
    Vaccination, symptomatic infection and negative conversion of viral RNA by body mass index, diabetes, and age: An observational study.
    Vaccine. 2022 Oct 20. pii: S0264-410X(22)01262.
    >> Share

  657. HOSHI SL, Shono A, Seposo X, Okubo R, et al
    Cost-effectiveness analyses of 15- and 20-valent pneumococcal conjugate vaccines for Japanese elderly.
    Vaccine. 2022 Oct 20. pii: S0264-410X(22)01259.
    >> Share

  658. HALL PA, Meng G, Sakib MN, Quah ACK, et al
    Do the vaccinated perform less distancing, mask wearing and hand hygiene? A test of the risk compensation hypothesis in a representative sample during the COVID-19 pandemic.
    Vaccine. 2022 Oct 20. pii: S0264-410X(22)01289.
    >> Share

  659. GOLLAMUDI J, Sartain SE, Navaei AH, Aneja S, et al
    Thrombosis and thromboembolism: Brighton collaboration case definition and guidelines for data collection, analysis, and presentation of immunization safety data.
    Vaccine. 2022;40:6431-6444.
    >> Share

  660. LIAO SH, Chang WJ, Hsu CY, Ming-Fang Yen A, et al
    Evaluating correlates of protection for mix-match vaccine against COVID-19 VOCs with potential of evading immunity.
    Vaccine. 2022 Oct 17. pii: S0264-410X(22)01258.
    >> Share

  661. TAKAHASHI Y, Ishitsuka K, Sampei M, Okawa S, et al
    COVID-19 vaccine literacy and vaccine hesitancy among pregnant women and mothers of young children in Japan.
    Vaccine. 2022 Oct 17. pii: S0264-410X(22)01227.
    >> Share

  662. RHODES S, Smith N, Evans T, White R, et al
    Identifying COVID-19 optimal vaccine dose using mathematical immunostimulation/immunodynamic modelling.
    Vaccine. 2022 Oct 17. pii: S0264-410X(22)01260.
    >> Share

  663. CREISHER PS, Campbell AD, Perry JL, Roznik K, et al
    Influenza subtype-specific maternal antibodies protect offspring against infection but inhibit vaccine-induced immunity and protection in mice.
    Vaccine. 2022 Oct 14. pii: S0264-410X(22)01241.
    >> Share

  664. SAADE EA, Abul Y, McConeghy K, Edward Davidson H, et al
    High-dose influenza vaccines for the prevention of hospitalization due to cardiovascular events in older adults in the nursing home: Post-hoc analysis of a cluster-randomized trial.
    Vaccine. 2022 Oct 13. pii: S0264-410X(22)01215.
    >> Share

  665. HUDSON A, Hall PA, Hitchman SC, Meng G, et al
    Cognitive predictors of COVID-19 mitigation behaviors in vaccinated and unvaccinated general population members.
    Vaccine. 2022 Oct 13. pii: S0264-410X(22)01242.
    >> Share

  666. LIU S, Yang G, Li M, Sun F, et al
    Transcutaneous immunization via dissolving microneedles protects mice from lethal influenza H7N9 virus challenge.
    Vaccine. 2022 Oct 12. pii: S0264-410X(22)01102.
    >> Share

  667. VOGELSANG EM, Polonijo AN
    Scarier than the flu shot? : The social determinants of shingles and influenza vaccinations among U.S. older adults.
    Vaccine. 2022 Oct 8. pii: S0264-410X(22)01183.
    >> Share

  668. CHEN JY, Hsieh SM, Hwang SJ, Liu CS, et al
    Immunogenicity and safety of high-dose quadrivalent influenza vaccine in older adults in Taiwan: A phase III, randomized, multi-center study.
    Vaccine. 2022 Oct 7. pii: S0264-410X(22)01200.
    >> Share

  669. ELHARAKE JA, Omer SB, Schwartz JL
    Country immunization policies for refugees across 20 low-middle income and 20 high-income countries.
    Vaccine. 2022;40:6017-6022.
    >> Share

  670. EKTARE V, Lang J, Choi Y, Finelli L, et al
    The clinical impact of multiple prevention strategies for respiratory syncytial virus infections in infants and high-risk toddlers in the United States.
    Vaccine. 2022;40:6064-6073.
    >> Share

  671. MARLOWE E, Pranikoff S, Borsheim B, Salafian K, et al
    Pilot study to determine effect of an altruism intervention focusing on herd immunity to enhance influenza vaccination rates.
    Vaccine. 2022 Oct 6. pii: S0264-410X(22)01194.
    >> Share

  672. PAGUIO JA, Ojikutu BO, Alfonso PG, Yao JS, et al
    Association of culturally competent care with influenza vaccination coverage in the United States.
    Vaccine. 2022 Oct 5. pii: S0264-410X(22)01065.
    >> Share

  673. CHUGHTAI AA, Mohammed S, Al Ariqi L, McCarron M, et al
    Development of a road map to scale up the uptake and utilization of influenza vaccine in 22 countries of Eastern Mediterranean Region.
    Vaccine. 2022 Oct 5. pii: S0264-410X(22)01159.
    >> Share

  674. BYRNE A, Thompson LA, Filipp SL, Ryan K, et al
    COVID-19 vaccine perceptions and hesitancy amongst parents of school-aged children during the pediatric vaccine rollout.
    Vaccine. 2022 Oct 5. pii: S0264-410X(22)01221.
    >> Share

  675. VAN EWIJK CE, Hazelhorst EI, Hahne SJM, Knol MJ, et al
    COVID-19 outbreak in an elderly care home: Very low vaccine effectiveness and late impact of booster vaccination campaign.
    Vaccine. 2022 Oct 4. pii: S0264-410X(22)01213.
    >> Share

  676. CHAO CR, Xu L, Cannizzaro N, Bronstein D, et al
    Trends in HPV vaccine administration and HPV vaccine coverage in children by race/ethnicity and socioeconomic status during the COVID-19 pandemic in an integrated health care system in California.
    Vaccine. 2022 Oct 3. pii: S0264-410X(22)01195.
    >> Share

  677. AL-SHAIKH A, Mahmoud RI, Boukerdenna H, Muthu N, et al
    Counselling of non-communicable diseases' patients for COVID-19 vaccine uptake in Jordan: Evaluating the intervention.
    Vaccine. 2022 Oct 3. pii: S0264-410X(22)01214.
    >> Share

  678. FERREIRA LS, de Almeida GB, Borges ME, Simon LM, et al
    Modelling optimal vaccination strategies against COVID-19 in a context of Gamma variant predominance in Brazil.
    Vaccine. 2022 Oct 3. pii: S0264-410X(22)01216.
    >> Share

  679. ODIO CD, Katzelnick LC
    'Mix and Match' vaccination: Is dengue next?
    Vaccine. 2022 Oct 1. pii: S0264-410X(22)01101.
    >> Share

    September 2022
  680. WILLIAMS E, Colson J, Valiathan R, Carreno JM, et al
    Permissive omicron breakthrough infections in individuals with binding or neutralizing antibodies to ancestral SARS-CoV-2.
    Vaccine. 2022;40:5868-5872.
    >> Share

  681. SPETZ M, Lundberg L, Nwaru C, Li H, et al
    An intersectional analysis of sociodemographic disparities in Covid-19 vaccination: A nationwide register-based study in Sweden.
    Vaccine. 2022 Sep 28. pii: S0264-410X(22)01186.
    >> Share

  682. HATHAWAY CA, Siegel EM, Gonzalez BD, Oswald LB, et al
    Individual-level factors associated with COVID-19 vaccine acceptance among U.S. patients with cancer.
    Vaccine. 2022 Sep 28. pii: S0264-410X(22)01184.
    >> Share

  683. MARCHESE AM, Beyhaghi H, Orenstein WA
    With established safe and effective use, protein vaccines offer another choice against COVID-19.
    Vaccine. 2022 Sep 28. pii: S0264-410X(22)01185.
    >> Share

  684. SILVA-VALENCIA J, Soto-Becerra P, Escobar-Agreda S, Fernandez-Navarro M, et al
    Relative vaccine effectiveness of the booster dose of COVID-19 vaccine for preventing death in individuals with a primary regimen based on the BBIBP-CorV, ChAdOx1-S, or BNT162b2 vaccines during the Omicron wave in Peru: A nested case-control study usi
    Vaccine. 2022 Sep 28. pii: S0264-410X(22)01189.
    >> Share

  685. TRAKARNVANICH T, Ngamvichchukorn T, Phumisantiphong U, Pholtawornkulchai K, et al
    Immune response after COVID-19 vaccination among patients with chronic kidney disease and kidney transplant.
    Vaccine. 2022 Sep 28. pii: S0264-410X(22)01187.
    >> Share

  686. CERVANTES-TORRES J, Rosales-Mendoza S, Cabello C, Montero L, et al
    Towards the development of an epitope-focused vaccine for SARS-CoV-2.
    Vaccine. 2022 Sep 27. pii: S0264-410X(22)01168.
    >> Share

  687. LLOYD PC, Hu M, Wong HL, Shoaibi A, et al
    Near real-time surveillance of safety outcomes in US COVID-19 vaccine recipients aged 12 to 64 years.
    Vaccine. 2022 Sep 27. pii: S0264-410X(22)01167.
    >> Share

  688. ZHU H, Li X, Ren X, Chen H, et al
    Improving cross-protection against influenza virus in mice using a nanoparticle vaccine of mini-HA.
    Vaccine. 2022 Sep 26. pii: S0264-410X(22)01165.
    >> Share

  689. OHTA M, Kambayashi Y, Mita H, Kuroda T, et al
    Protective efficacy of a reverse genetics-derived inactivated vaccine against equine influenza virus in horses.
    Vaccine. 2022 Sep 26. pii: S0264-410X(22)01155.
    >> Share

  690. TOLSTRUP WESTER C, Lybecker Scheel-Hincke L, Bovil T, Andersen-Ranberg K, et al
    Prayer frequency and COVID-19 vaccine hesitancy among older adults in Europe.
    Vaccine. 2022 Sep 26. pii: S0264-410X(22)01153.
    >> Share

  691. GATES DM, Cohen SA, Orr K, Caffrey AR, et al
    Pediatric influenza vaccination rates lower than previous estimates in the United States.
    Vaccine. 2022 Sep 24. pii: S0264-410X(22)01162.
    >> Share

  692. MOHAMMED AH, Hassan BAR, Wayyes AM, Gadhban AQ, et al
    Parental health beliefs, intention, and strategies about covid-19 vaccine for their children: A cross-sectional analysis from five Arab countries in the Middle East.
    Vaccine. 2022 Sep 23. pii: S0264-410X(22)01161.
    >> Share

  693. MUES KE, Kirk B, Patel DA, Gelman A, et al
    Real-world comparative effectiveness of mRNA-1273 and BNT162b2 vaccines among immunocompromised adults identified in administrative claims data in the United States.
    Vaccine. 2022 Sep 23. pii: S0264-410X(22)01120.
    >> Share

  694. RUCKSTUHL L, Czock A, Haile SR, Lang P, et al
    Influence of cantonal health policy frameworks & activities on the influenza vaccination rate in patients with non-communicable diseases in Switzerland.
    Vaccine. 2022 Sep 22. pii: S0264-410X(22)01148.
    >> Share

  695. ROMER D, Winneg KM, Jamieson PE, Brensinger C, et al
    Misinformation about vaccine safety and uptake of COVID-19 vaccines among adults and 5-11-year-olds in the United States.
    Vaccine. 2022 Sep 22. pii: S0264-410X(22)01154.
    >> Share

  696. LIU B, Gidding H, Stepien S, Cretikos M, et al
    Relative effectiveness of COVID-19 vaccination with 3 compared to 2 doses against SARS-CoV-2 B.1.1.529 (Omicron) among an Australian population with low prior rates of SARS-CoV-2 infection.
    Vaccine. 2022 Sep 21. pii: S0264-410X(22)01126.
    >> Share

  697. KIEFER MK, Mehl R, Rood KM, Germann K, et al
    Association between social vulnerability and COVID-19 vaccination hesitancy and vaccination in pregnant and postpartum individuals.
    Vaccine. 2022 Sep 21. pii: S0264-410X(22)01152.
    >> Share

  698. SHAPIRO JR, Privor-Dumm L, Rosser EN, Leng SX, et al
    The intersection of gender and race in older adults' decision to receive COVID-19 vaccines.
    Vaccine. 2022 Sep 20:S0264-410X(22)01151-3. doi: 10.1016/j.vaccine.2022.
    >> Share

  699. GRAAF A, Petric PP, Sehl-Ewert J, Henritzi D, et al
    Cold-passaged isolates and bat-swine influenza a chimeric viruses as modified live-attenuated vaccines against influenza a viruses in pigs.
    Vaccine. 2022 Sep 19. pii: S0264-410X(22)01108.
    >> Share

  700. NTZIORA F, Georgia Kostaki E, Karapanou A, Mylona M, et al
    Protection of vaccination versus hybrid immunity against infection with COVID-19 Omicron variants among Health-Care Workers.
    Vaccine. 2022 Sep 19. pii: S0264-410X(22)01150.
    >> Share

  701. CARRENO JM, Singh G, Tcheou J, Srivastava K, et al
    mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations.
    Vaccine. 2022 Sep 14. pii: S0264-410X(22)01003.
    >> Share

  702. FRANKENTHAL D, Zatlawi M, Karni-Efrati Z, Keinan-Boker L, et al
    COVID-19 vaccine hesitancy among Israeli adults before and after vaccines' availability: A cross-sectional national survey.
    Vaccine. 2022 Sep 14. pii: S0264-410X(22)01078.
    >> Share

  703. CREVECOEUR J, Hens N, Neyens T, Lariviere Y, et al
    Change in COVID19 outbreak pattern following vaccination in long-term care facilities in Flanders, Belgium.
    Vaccine. 2022 Sep 14. pii: S0264-410X(22)01124.
    >> Share

  704. OSEI I, Sarwar G, Hossain I, Sonko K, et al
    Attendance and vaccination at immunization clinics in rural Gambia before and during the COVID-19 pandemic.
    Vaccine. 2022 Sep 13. pii: S0264-410X(22)01125.
    >> Share

  705. DAY ME, Klein M, Sucharew H, Carol Burkhardt M, et al
    Declining influenza vaccination rates in an underserved pediatric primary care center during the COVID-19 pandemic.
    Vaccine. 2022 Sep 12. pii: S0264-410X(22)01121.
    >> Share

  706. ZACE D, La Gatta E, Petrella L, Di Pietro ML, et al
    The impact of COVID-19 vaccines on fertility-A systematic review and meta-analysis.
    Vaccine. 2022 Sep 12. pii: S0264-410X(22)01118.
    >> Share

  707. FRIEDMAN-KLABANOFF DJ, Tjaden AH, Santacatterina M, Munawar I, et al
    Vaccine-induced seroconversion in participants in the North Carolina COVID-19 community Research Partnership.
    Vaccine. 2022 Sep 12. pii: S0264-410X(22)01116.
    >> Share

  708. MONFARED IG
    The connection between COVID-19 vaccine abundance, vaccination coverage, and public trust in government across the globe.
    Vaccine. 2022 Sep 12. pii: S0264-410X(22)01107.
    >> Share

  709. NAEIM A, Guerin RJ, Baxter-King R, Okun AH, et al
    Strategies to increase the intention to get vaccinated against COVID-19: Findings from a nationally representative survey of US adults, October 2020 to October 2021.
    Vaccine. 2022 Sep 12. pii: S0264-410X(22)01117.
    >> Share

  710. ISHIGURO C, Mimura W, Murata F, Fukuda H, et al
    Development and application of a Japanese vaccine database for comparative assessments in the post-authorization phase: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study.
    Vaccine. 2022 Sep 9. pii: S0264-410X(22)01077.
    >> Share

  711. TEPEROWSKI MONRAD J, Quaade S, Powell-Jackson T
    Supply, then demand? Health expenditure, political leanings, cost obstacles to care, and vaccine hesitancy predict state-level COVID-19 vaccination rates.
    Vaccine. 2022 Sep 8. pii: S0264-410X(22)01041.
    >> Share

  712. CEANNT R, Vallieres F, Burns H, Murphy J, et al
    Covid-19 vaccine hesitancy and resistance amongst parents of children under 18 years of age in Ireland.
    Vaccine. 2022 Sep 7. pii: S0264-410X(22)01082.
    >> Share

  713. MOK CC, Chan KL, Tse SM
    Hesitancy for SARS-CoV-2 vaccines and post-vaccination flares in patients with systemic lupus erythematosus.
    Vaccine. 2022 Sep 6. pii: S0264-410X(22)01067.
    >> Share

  714. LUBIS TA, Gunardi H, Herqutanto, Soedjatmiko S, et al
    Educational videos to address vaccine hesitancy in childhood immunization.
    Vaccine. 2022 Sep 6. pii: S0264-410X(22)01035.
    >> Share

  715. HABERSAAT KB, Narayan S, Malue Nielsen S, Scherzer M, et al
    How health workers can make a difference in the public COVID-19 vaccination response.
    Vaccine. 2022 Sep 6. pii: S0264-410X(22)01081.
    >> Share

  716. PERRIER Q, Lupo J, Gerster T, Augier C, et al
    SARS-CoV-2 anti-spike antibodies after a fourth dose of COVID-19 vaccine in adult solid-organ transplant recipients.
    Vaccine. 2022 Sep 6. pii: S0264-410X(22)01064.
    >> Share

  717. BOLSEWICZ KT, Steffens MS, Karpish L, Bullivant B, et al
    "Every interaction you have ...should be an opportunity to discuss and offer influenza vaccination". Health service perspectives on influenza vaccination promotion and delivery to Aboriginal families living in New South Wales, Australia.
    Vaccine. 2022 Sep 1. pii: S0264-410X(22)01047.
    >> Share

    August 2022
  718. HRIN ML, Emmerich VK, Ip EH, Feldman SR, et al
    Development and validation of a COVID-19 vaccine hesitancy scale for adults in the United States.
    Vaccine. 2022 Aug 31. pii: S0264-410X(22)01052.
    >> Share

  719. FRAIMAN J, Erviti J, Jones M, Greenland S, et al
    Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults.
    Vaccine. 2022 Aug 30. pii: S0264-410X(22)01028.
    >> Share

  720. JACOBSON M, Chang TY, Shah M, Pramanik R, et al
    Can financial incentives and other nudges increase COVID-19 vaccinations among the vaccine hesitant? A randomized trial.
    Vaccine. 2022 Aug 30. pii: S0264-410X(22)01050.
    >> Share

  721. SARKAR P, Chandrasekaran V, Gunasekaran D, Chinnakali P, et al
    COVID-19 vaccine hesitancy among health care worker-parents (HCWP) in Puducherry, India and its implications on their children: A cross sectional descriptive study.
    Vaccine. 2022 Aug 29. pii: S0264-410X(22)01040.
    >> Share

  722. CAO X, Zai J, Zhao Q, Xie L, et al
    Intranasal immunization with recombinant Vaccinia virus encoding trimeric SARS-CoV-2 spike receptor-binding domain induces neutralizing antibody.
    Vaccine. 2022 Aug 29. pii: S0264-410X(22)01044.
    >> Share

  723. SANCHEZ-SAEZ F, Peiro S, Cuenca L, Vanaclocha H, et al
    Side effects during the week after first dose vaccination with four Covid-19 vaccines. Results of the ProVaVac Survey Study with 13,837 people in Spain.
    Vaccine. 2022 Aug 29. pii: S0264-410X(22)01007.
    >> Share

  724. DOYON-PLOURDE P, Fortin E, Quach C
    Evaluation of the 2018-2019 vaccine effectiveness against medically attended influenza-like illness using medical records and claims data.
    Vaccine. 2022 Aug 27. pii: S0264-410X(22)00976.
    >> Share

  725. CHUAN VOO T, Savulescu J, Schaefer O, Ho Zhi Ling A, et al
    COVID-19 differentiated measures for unvaccinated individuals: The need for clear goals and strong justifications.
    Vaccine. 2022;40:5333-5337.
    >> Share

  726. PIDIYAR V, Kumraj G, Ahmed K, Ahmed S, et al
    COVID-19 management landscape: A need for an affordable platform to manufacture safe and efficacious biotherapeutics and prophylactics for the developing countries.
    Vaccine. 2022;40:5302-5312.
    >> Share

  727. ROSHCHINA Y, Roshchin S, Rozhkova K
    Determinants of COVID-19 vaccine hesitancy and resistance in Russia.
    Vaccine. 2022 Aug 26. pii: S0264-410X(22)01032.
    >> Share

  728. TERESA VIETRI M, D'Elia G, Caliendo G, Passariello L, et al
    Antibody levels after BNT162b2 vaccine booster and SARS-CoV-2 Omicron infection.
    Vaccine. 2022 Aug 26. pii: S0264-410X(22)01034.
    >> Share

  729. HEMMI T, Ainai A, Hashiguchi T, Tobiume M, et al
    Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology.
    Vaccine. 2022 Aug 26. pii: S0264-410X(22)01038.
    >> Share

  730. KIKUT A, Clark D, Jesch E, Hornik R, et al
    Strengthened belief in vaccine effectiveness predicted increased COVID-19 vaccination intention and behaviour: Results from a nationally representative longitudinal survey of U.S. adults from July 2020 to April/May 2021.
    Vaccine. 2022 Aug 26. pii: S0264-410X(22)01036.
    >> Share

  731. OKUYAMA M, Morino S, Tanaka K, Nakamura-Miwa H, et al
    Vasovagal reactions after COVID-19 vaccination in Japan.
    Vaccine. 2022 Aug 25. pii: S0264-410X(22)01046.
    >> Share

  732. LIM AH, Ab Rahman N, Ong SM, Paraja J, et al
    Evaluation of BNT162b2 vaccine effectiveness in Malaysia: test negative case-control study.
    Vaccine. 2022 Aug 24. pii: S0264-410X(22)01005.
    >> Share

  733. WILLIS GA, Bloomfield L, Berry M, Bulsara C, et al
    The impact of a vaccine mandate and the COVID-19 pandemic on influenza vaccination uptake in Western Australian health care students.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)01026.
    >> Share

  734. JAFFRY M, Mostafa F, Mandava K, Rosario S, et al
    No significant increase in Guillain-Barre syndrome after COVID-19 vaccination in adults: A vaccine adverse event reporting system study.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)01025.
    >> Share

  735. MARRON L, Ferenczi A, O'Brien KM, Cotter S, et al
    Views on COVID-19 vaccination of young children in Ireland, results from a cross-sectional survey of parents.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)01013.
    >> Share

  736. STIVANELLO E, Beghelli C, Cardoni F, Giansante C, et al
    Short-term mortality following COVID-19 vaccination in Bologna, Italy: a one-year study.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)01029.
    >> Share

  737. WANG X, Deng Y, Zhao L, Wang L, et al
    Safety, immunogenicity, and immune persistence of two inactivated COVID-19 vaccines replacement vaccination in China: An observational cohort study.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)01030.
    >> Share

  738. KANOKUDOM S, Assawakosri S, Suntronwong N, Chansaenroj J, et al
    Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)01011.
    >> Share

  739. DOCHEZ C, Duclos P, MacDonald N, Steffen C, et al
    Advanced vaccinology training globally: Update and impact of the COVID-19 crisis.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)01006.
    >> Share

  740. KURASHIMA K, Numano T, Yoshino A, Osawa A, et al
    Antibody titers among healthcare workers for coronavirus disease 2019 at 6 months after BNT162b2 vaccination.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)01027.
    >> Share

  741. TOAPANTA-YANCHAPAXI L, Chiquete E, Avila-Rojo E, Lopez-Yanez S, et al
    Humoral response to different SARS-CoV-2 vaccines in orthotopic liver transplant recipients.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)01012.
    >> Share

  742. CLEMENS SAC, Fortaleza CMCB, Crowe M, Pollard A, et al
    Safety of the Fiocruz ChAdOx COVID-19 vaccine used in a mass vaccination campaign in Botucatu, Brazil.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)01010.
    >> Share

  743. MIHIGO RM, Okeibunor JC, Karmal F, O'Malley H, et al
    The Addis Declaration on Immunization: A binding reminder of the political support needed to achieve universal immunization in Africa.
    Vaccine. 2022;40:5126-5130.
    >> Share

  744. PSARIDI L, Maltezou HC, Simonidou S, Lialliou I, et al
    Neutralizing antibody responses in healthcare personnel after three doses of mRNA BNT162b2 vaccine and association with baseline characteristics and past SARS-CoV-2 infection.
    Vaccine. 2022 Aug 19. pii: S0264-410X(22)01008.
    >> Share

  745. STOECKEL F, Stockli S, Phillips J, Lyons B, et al
    Stamping the vaccine passport? Public support for lifting COVID-19 related restrictions for vaccinated citizens in France, Germany, and Sweden.
    Vaccine. 2022 Aug 18. pii: S0264-410X(22)00965.
    >> Share

  746. LAFFAN MA, Rees S, Yadavalli M, Ferstenberg LB, et al
    Thrombosis with thrombocytopenia after AZD1222 (ChAdOx1 nCov-19) vaccination: Case characteristics and associations.
    Vaccine. 2022 Aug 18. pii: S0264-410X(22)00964.
    >> Share

  747. AMANI A, Ngo Bama S, Dia M, Nguefack Lekelem S, et al
    Challenges, best practices, and lessons learned from oral cholera mass vaccination campaign in urban Cameroon during the COVID-19 era.
    Vaccine. 2022 Aug 18. pii: S0264-410X(22)01004.
    >> Share

  748. WYMORE BRAND M, Anderson TK, Kitikoon P, Brian Kimble J, et al
    Bivalent hemagglutinin and neuraminidase influenza replicon particle vaccines protect pigs against influenza a virus without causing vaccine associated enhanced respiratory disease.
    Vaccine. 2022 Aug 17. pii: S0264-410X(22)00937.
    >> Share

  749. LINNANDER E, Ineza L, Mupeta Bobo P, Bechtold K, et al
    Improving management of vaccine supply chains: A multi-methods evaluation of vSTEP in Zambia.
    Vaccine. 2022 Aug 17. pii: S0264-410X(22)00914.
    >> Share

  750. MATSUURA T, Fukushima W, Nakagama Y, Kido Y, et al
    Kinetics of anti-SARS-CoV-2 antibody titer in healthy adults up to 6 months after BNT162b2 vaccination measured by two immunoassays: A prospective cohort study in Japan.
    Vaccine. 2022 Aug 15. pii: S0264-410X(22)00984.
    >> Share

  751. ALKETBI LMB, Al Hosani F, Al Memari S, Al Mazrouei S, et al
    Parents' views on the acceptability of a COVID-19 vaccine for their children: A cross-sectional study in Abu Dhabi-United Arab Emirates.
    Vaccine. 2022 Aug 15. pii: S0264-410X(22)00954.
    >> Share

  752. CASEROTTI M, Gavaruzzi T, Girardi P, Sellaro R, et al
    People's perspectives about COVID-19 vaccination certificate: Findings from a representative Italian sample.
    Vaccine. 2022 Aug 15. pii: S0264-410X(22)00980.
    >> Share

  753. ELLIOTT CBP, Chambers CS
    A historical analysis of vaccine mandates in the United States military and its application to the COVID-19 vaccine mandate.
    Vaccine. 2022 Aug 15. pii: S0264-410X(22)00982.
    >> Share

  754. VISKUPIC F, Wiltse DL, Badahdah A
    Reminders of existing vaccine mandates increase support for a COVID-19 vaccine mandate: Evidence from a survey experiment.
    Vaccine. 2022 Aug 15. pii: S0264-410X(22)00978.
    >> Share

  755. OMER SB, O'Leary ST, Bednarczyk RA, Ellingson MK, et al
    Multi-tiered intervention to increase maternal immunization coverage: A randomized, controlled trial.
    Vaccine. 2022;40:4955-4963.
    >> Share

  756. SCHMIDTKE KA, Skrybant M, Kudrna L, Russell S, et al
    A workshop to co-design messages that may increase uptake of vaccines: A case study.
    Vaccine. 2022 Aug 12. pii: S0264-410X(22)00951.
    >> Share

  757. PROUT A, Rustandi RR, Tubbs C, Winters MA, et al
    Functional profiling of Covid 19 vaccine candidate by flow virometry.
    Vaccine. 2022 Aug 9. pii: S0264-410X(22)00963.
    >> Share

  758. PERROUD JM, Soldano S, Avancena ALV, Wagner A, et al
    Adult vaccination uptake strategies in low- and middle-income countries: A systematic review.
    Vaccine. 2022 Aug 8. pii: S0264-410X(22)00952.
    >> Share

  759. HU S, Xiong C, Li Q, Wang Z, et al
    COVID-19 vaccine hesitancy cannot fully explain disparities in vaccination coverage across the contiguous United States.
    Vaccine. 2022 Aug 8. pii: S0264-410X(22)00947.
    >> Share

  760. DE SWART RL, de Leeuw OS, Oreshkova N, Gerhards NM, et al
    Intranasal administration of a live-attenuated recombinant newcastle disease virus expressing the SARS-CoV-2 Spike protein induces high neutralizing antibody levels and protects from experimental challenge infection in hamsters.
    Vaccine. 2022;40:4676-4681.
    >> Share

  761. ESTRELA M, Magalhaes Silva T, Roque V, Rebelo Gomes E, et al
    Unravelling the drivers behind COVID-19 vaccination hesitancy and refusal among teachers: A nationwide study.
    Vaccine. 2022 Aug 5. pii: S0264-410X(22)00955.
    >> Share

  762. YEO J, Furr Gudmundsen C, Fazel S, Corrigan A, et al
    A behavior change model to address caregiver hesitancy around COVID-19 vaccination in pediatrics.
    Vaccine. 2022 Aug 5. pii: S0264-410X(22)00949.
    >> Share

  763. ULRICH AK, Pankratz GK, Bohn B, Yendell S, et al
    COVID-19 vaccine confidence and reasons for vaccination among health care workers and household members.
    Vaccine. 2022 Aug 5. pii: S0264-410X(22)00956.
    >> Share

  764. SQUIRE JD, Joshi AY
    Response to mRNA COVID-19 vaccination in three XLA patients.
    Vaccine. 2022 Aug 3. pii: S0264-410X(22)00941.
    >> Share

  765. SNYDER J, Goldenberg M, Crooks VA, Katz R, et al
    Crowdfunding narratives and the valuation of vaccines for COVID-19.
    Vaccine. 2022 Aug 3. pii: S0264-410X(22)00946.
    >> Share

  766. CIMA MJ, McCormick D, Porter A 3rd, Zohoori N, et al
    COVID-19 vaccine uptake among Arkansas public K-12 school teachers and staff.
    Vaccine. 2022 Aug 2. pii: S0264-410X(22)00942.
    >> Share

  767. BAUMER-MOURADIAN SH, Hart RJ, Bone JN, Seiler M, et al
    Should COVID-19 vaccines be mandated in schools? - an international caregiver perspective.
    Vaccine. 2022 Aug 1. pii: S0264-410X(22)00921.
    >> Share

  768. KORODI M, Horvath I, Rakosi K, Jenei Z, et al
    Longitudinal determination of BNT162b2 vaccine induced strongly binding SARS-CoV-2 IgG antibodies in a cohort of Romanian healthcare workers.
    Vaccine. 2022 Aug 1. pii: S0264-410X(22)00936.
    >> Share

    July 2022
  769. SHINKAI M, Sonoyama T, Kamitani A, Shibata RY, et al
    Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study.
    Vaccine. 2022;40:4328-4333.
    >> Share

  770. SADOFF J, Le Gars M, Brandenburg B, Cardenas V, et al
    Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials.
    Vaccine. 2022;40:4403-4411.
    >> Share

  771. NOWALK MP, D'Agostino H, Dauer K, Stiegler M, et al
    Estimating the burden of adult hospitalized RSV infection including special populations.
    Vaccine. 2022;40:4121-4127.
    >> Share

  772. SALMANTON-GARCIA J, Stewart FA, Heringer S, Koniordou M, et al
    VACCELERATE Volunteer Registry: A European study participant database to facilitate clinical trial enrolment.
    Vaccine. 2022;40:4090-4097.
    >> Share

  773. CHEN H, Huang Z, Chang S, Hu M, et al
    Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV) coadministered with quadrivalent split-virion inactivated influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in China: A multicentre, non-inferiorit
    Vaccine. 2022 Jul 29. pii: S0264-410X(22)00919.
    >> Share

  774. ROSE O, Erzkamp S, Schobel W, Grajeda M, et al
    COVID-19 vaccinations in German pharmacies: A survey on patient and provider satisfaction.
    Vaccine. 2022 Jul 28. pii: S0264-410X(22)00925.
    >> Share

  775. RAMMAURO F, Carrion F, Olivero-Deibe N, Flo M, et al
    Humoral immune response characterization of heterologous prime-boost vaccination with CoronaVac and BNT162b2.
    Vaccine. 2022 Jul 27. pii: S0264-410X(22)00911.
    >> Share

  776. SHENYU W, Xiaoqian D, Bo C, Xuan D, et al
    Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine (CoronaVac) co-administered with an inactivated quadrivalent influenza vaccine: A randomized, open-label, controlled study in healthy adults aged 18 to 59 years in China.
    Vaccine. 2022 Jul 26. pii: S0264-410X(22)00908.
    >> Share

  777. KRAUSE PR, Arora N, Dowling W, Munoz-Fontela C, et al
    Making more COVID-19 vaccines available to address global needs: Considerations and a framework for their evaluation.
    Vaccine. 2022 Jul 26. pii: S0264-410X(22)00916.
    >> Share

  778. MCMILLAN CLD, Amarilla AA, Modhiran N, Choo JJY, et al
    Skin-patch delivered subunit vaccine induces broadly neutralising antibodies against SARS-CoV-2 variants of concern.
    Vaccine. 2022 Jul 18. pii: S0264-410X(22)00888.
    >> Share

  779. DUGORD C, Franc C
    Trajectories and individual determinants of repeated seasonal flu vaccination use over the long term using data from the French E3N cohort.
    Vaccine. 2022 Jul 18. pii: S0264-410X(22)00855.
    >> Share

  780. SETHY G, Chisema M, Sharma L, Joshi K, et al
    COVID-19 vaccine express strategy in Malawi: An effort to reach the un-reach.
    Vaccine. 2022 Jul 18. pii: S0264-410X(22)00887.
    >> Share

  781. MIMURA W, Ishiguro C, Fukuda H
    Influenza vaccine effectiveness against hospitalization during the 2018/2019 season among older persons aged>/=75years in Japan: The LIFE-VENUS Study.
    Vaccine. 2022 Jul 15. pii: S0264-410X(22)00852.
    >> Share

  782. VASUDEVAN L, Bruening R, Hung A, Woolson S, et al
    COVID-19 vaccination intention and activation among health care system employees: A mixed methods study.
    Vaccine. 2022 Jul 13. pii: S0264-410X(22)00884.
    >> Share

  783. PRIDDY FH, Williams M, Carson S, Lavender B, et al
    Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults.
    Vaccine. 2022 Jul 12. pii: S0264-410X(22)00885.
    >> Share

  784. ORTQVIST AK, Dahlqwist E, Magnus MC, Ljung R, et al
    COVID-19 vaccination in pregnant women in Sweden and Norway.
    Vaccine. 2022 Jul 12. pii: S0264-410X(22)00859.
    >> Share

  785. GODDARD K, Lewis N, Fireman B, Weintraub E, et al
    Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination.
    Vaccine. 2022 Jul 12. pii: S0264-410X(22)00860.
    >> Share

  786. CUFFEL A, Maylin S, Le Buanec H, Delaugerre C, et al
    Humoral and cellular responses to SARS-CoV-2 BNT162b2 vaccination in allogeneic hematopoietic stem cell transplantation recipients.
    Vaccine. 2022 Jul 11. pii: S0264-410X(22)00857.
    >> Share

  787. PADRON-REGALADO E, Medina-Rivero E
    Perspectives for licensing vaccines in Mexico.
    Vaccine. 2022 Jul 11. pii: S0264-410X(22)00854.
    >> Share

  788. WYPLOSZ B, Fernandes J, Sultan A, Roche N, et al
    Pneumococcal and influenza vaccination coverage among at-risk adults: A 5-year French national observational study.
    Vaccine. 2022 Jul 7. pii: S0264-410X(22)00841.
    >> Share

  789. ZHANG Y, Wang Y, Jia C, Li G, et al
    Immunogenicity and safety of an egg culture-based quadrivalent inactivated non-adjuvanted subunit influenza vaccine in subjects >/=3 years: A randomized, multicenter, double-blind, active-controlled phase III, non-inferiority trial.
    Vaccine. 2022 Jul 7. pii: S0264-410X(22)00846.
    >> Share

  790. CHADWICK C, Friede M, Moen A, Nannei C, et al
    Technology transfer programme for influenza vaccines - Lessons from the past to inform the future.
    Vaccine. 2022 Jul 6. pii: S0264-410X(22)00826.
    >> Share

  791. XIRIDOU M, Adam P, Meiberg A, Visser M, et al
    The impact of the COVID-19 pandemic on hepatitis B virus vaccination and transmission among men who have sex with men: A mathematical modelling study.
    Vaccine. 2022 Jul 4. pii: S0264-410X(22)00847.
    >> Share

  792. MCCORMICK DW, Konkle SL, Magleby R, Chakrabarti AK, et al
    SARS-CoV-2 infection risk among vaccinated and unvaccinated household members during the Alpha variant surge - Denver, Colorado, and San Diego, California, January-April 2021.
    Vaccine. 2022 Jul 4. pii: S0264-410X(22)00835.
    >> Share

  793. HOU Z, Guo J, Lai X, Zhang H, et al
    Influenza vaccination hesitancy and its determinants among elderly in China: A national cross-sectional study.
    Vaccine. 2022 Jul 1. pii: S0264-410X(22)00832.
    >> Share

  794. BARRALL AL, Hoff NA, Nkamba DM, Musene K, et al
    Hesitancy to receive the novel coronavirus vaccine and potential influences on vaccination among a cohort of healthcare workers in the Democratic Republic of the Congo.
    Vaccine. 2022 Jul 1. pii: S0264-410X(22)00842.
    >> Share

  795. SKIRROW H, Barnett S, Bell S, Mounier-Jack S, et al
    Women's views and experiences of accessing pertussis vaccination in pregnancy and infant vaccinations during the COVID-19 pandemic: A multi-methods study in the UK.
    Vaccine. 2022 Jul 1. pii: S0264-410X(22)00845.
    >> Share

    June 2022
  796. HILLS T, Paterson A, Woodward R, Middleton F, et al
    The effect of needle length and skin to deltoid muscle distance in adults receiving an mRNA COVID-19 vaccine.
    Vaccine. 2022 Jun 29. pii: S0264-410X(22)00839.
    >> Share

  797. WONG SC, Chan VW, Lam GKM, Yuen LL, et al
    The impact of personal coaching on influenza vaccination among healthcare workers before and during COVID-19 pandemic.
    Vaccine. 2022 Jun 27. pii: S0264-410X(22)00836.
    >> Share

  798. MEDEIROS MZ, Soares PF, Fialho BC, Gauss L, et al
    Vaccine innovation model: A technology transfer perspective in pandemic contexts.
    Vaccine. 2022 Jun 27. pii: S0264-410X(22)00823.
    >> Share

  799. LEE JT, Sean Hu S, Zhou T, Bonner KE, et al
    Employer requirements and COVID-19 vaccination and attitudes among healthcare personnel in the U.S.: Findings from National Immunization Survey Adult COVID Module, August - September 2021.
    Vaccine. 2022 Jun 27. pii: S0264-410X(22)00838.
    >> Share

  800. MOGHNIEH R, Abdallah D, Sayegh MH, Rahman Bizri A, et al
    Response to letter to the editor: Immunophenotyping of SARS-CoV-2 and vaccine design.
    Vaccine. 2022;40:3987-3988.
    >> Share

  801. CIMOLAI N
    Immunophenotyping of SARS-CoV-2 and vaccine design.
    Vaccine. 2022;40:3985-3986.
    >> Share

  802. STRAUS W, Rubin H
    COVID-19 vaccine safety monitoring in low and middle income countries - Time for a bold new approach.
    Vaccine. 2022 Jun 24. pii: S0264-410X(22)00822.
    >> Share

  803. SEYRAN M
    Artificial intelligence and clinical data suggest the T cell-mediated SARS-CoV-2 nonstructural protein intranasal vaccines for global COVID-19 immunity.
    Vaccine. 2022 Jun 24. pii: S0264-410X(22)00821.
    >> Share

  804. SHIVJI R, Conocchia R, Korakianiti E, Jekerle V, et al
    Considerations for the chemistry, manufacturing and Controls (CMC) - quality package for COVID-19 vaccines- interim lessons learnt by the European medicines Agency (EMA).
    Vaccine. 2022 Jun 24. pii: S0264-410X(22)00827.
    >> Share

  805. WILSON B, Mukundan Geetha K
    Nanomedicine to deliver biological macromolecules for treating COVID-19.
    Vaccine. 2022;40:3931-3941.
    >> Share

  806. CARTANYA-HUESO A, Martinez-Sanchez JM, Carlos Martin-Sanchez J, Lidon-Moyano C, et al
    Relationship between double COVID-19 vaccine uptake and trust in effectiveness and safety of vaccination in general in 23 Member states of the European Union: an ecological study.
    Vaccine. 2022 Jun 23. pii: S0264-410X(22)00820.
    >> Share

  807. AL-MUSTAPHA AI, Okechukwu O, Olayinka A, Muhammed OR, et al
    A national survey of COVID-19 vaccine acceptance in Nigeria.
    Vaccine. 2022 Jun 23. pii: S0264-410X(22)00818.
    >> Share

  808. LOHMANN S, Albarracin D
    Trust in the public health system as a source of information on vaccination matters most when environments are supportive.
    Vaccine. 2022 Jun 23. pii: S0264-410X(22)00759.
    >> Share

  809. RONZANI P, Panizza F, Martini C, Savadori L, et al
    Countering vaccine hesitancy through medical expert endorsement.
    Vaccine. 2022 Jun 21. pii: S0264-410X(22)00780.
    >> Share

  810. KORVES C, Izurieta HS, Smith J, Zwain GM, et al
    Relative effectiveness of booster vs. 2-dose mRNA Covid-19 vaccination in the Veterans Health Administration: Self-controlled risk interval analysis.
    Vaccine. 2022 Jun 21. pii: S0264-410X(22)00816.
    >> Share

  811. DIONATO FAV, Jalalizadeh M, Buosi K, Visacri MB, et al
    BCG vaccine safety in COVID-19 convalescent adults: BATTLE a randomized controlled trial.
    Vaccine. 2022 Jun 20. pii: S0264-410X(22)00803.
    >> Share

  812. ATWELL JE, Lutz CS, Sparrow EG, Feikin DR, et al
    Biological factors that may impair transplacental transfer of RSV antibodies: Implications for maternal immunization policy and research priorities for low- and middle-income countries.
    Vaccine. 2022 Jun 17. pii: S0264-410X(22)00783.
    >> Share

  813. CANADAY LM, Resnick JD, Liu H, Powell H, et al
    HA and M2 sequences alter the replication of 2013-16 H1 live attenuated influenza vaccine infection in human nasal epithelial cell cultures.
    Vaccine. 2022 Jun 16. pii: S0264-410X(22)00733.
    >> Share

  814. UWAMINO Y, Kurafuji T, Takato K, Sakai A, et al
    Dynamics of antibody titers and cellular immunity among Japanese healthcare workers during the 6 months after receiving two doses of BNT162b2 mRNA vaccine.
    Vaccine. 2022 Jun 16. pii: S0264-410X(22)00763.
    >> Share

  815. MOUTA NUNES DE OLIVEIRA P, Mendes-de-Almeida DP, Bertollo Gomes Porto V, Crespo Cordeiro C, et al
    Vaccine-induced immune thrombotic thrombocytopenia after COVID-19 vaccination: Description of a series of 39 cases in Brazil.
    Vaccine. 2022 Jun 16. pii: S0264-410X(22)00761.
    >> Share

  816. REICHERZ F, Golding L, Lavoie PM, Abu-Raya B, et al
    Decay of anti-Bordetella pertussis antibodies in women of childbearing age following COVID-19 non-pharmaceutical measures.
    Vaccine. 2022;40:3746-3751.
    >> Share

  817. FREW PM, Gonzalez-Casanova I, Otieno NA, Malik FA, et al
    Development of effective messages to promote maternal immunization in Kenya.
    Vaccine. 2022;40:3761-3770.
    >> Share

  818. BRAUNFELD JB, Carson HN, Williams SR, Schwartz LM, et al
    Clinical endpoints to inform vaccine policy: A systematic review of outcome measures from pediatric influenza vaccine efficacy trials.
    Vaccine. 2022 Jun 15. pii: S0264-410X(22)00778.
    >> Share

  819. GAMBRELL A, Sundaram M, Bednarczyk RA
    Estimating the number of US children susceptible to measles resulting from COVID-19-related vaccination coverage declines.
    Vaccine. 2022 Jun 15. pii: S0264-410X(22)00782.
    >> Share

  820. CHUNG JR, Kim SS, Flannery B, Smith ME, et al
    Vaccine-associated attenuation of subjective severity among outpatients with influenza.
    Vaccine. 2022 Jun 14. pii: S0264-410X(22)00767.
    >> Share

  821. FOLEGATTI PM, Jenkin D, Morris S, Gilbert S, et al
    Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment.
    Vaccine. 2022 Jun 14. pii: S0264-410X(22)00755.
    >> Share

  822. HERNANDEZ LM, Sumathy K, Sahastrabuddhe S, Excler JL, et al
    A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for an inactivated viral vaccine against Chikungunya virus.
    Vaccine. 2022 Jun 14. pii: S0264-410X(22)00753.
    >> Share

  823. RAZZAGHI H, Yankey D, Vashist K, Lu PJ, et al
    COVID-19 vaccination coverage and intent among women aged 18-49 years by pregnancy status, United States, April-November 2021.
    Vaccine. 2022 Jun 13. pii: S0264-410X(22)00779.
    >> Share

  824. PHATARPHEKAR A, Vidyadhar Reddy GEC, Gokhale A, Karanam G, et al
    RelCoVax(R), a two antigen subunit protein vaccine candidate against SARS-CoV-2 induces strong immune responses in mice.
    Vaccine. 2022 Jun 13. pii: S0264-410X(22)00775.
    >> Share

  825. WIEMKEN TL, Salas J, Hoft DF, Jacobs C, et al
    In response to: JVAC-D-21-02863, detection of a potential error in the results of the manuscript, dementia risk following influenza vaccination in a large veteran cohort, that could call into question the main conclusion.
    Vaccine. 2022;40:3529.
    >> Share

  826. VUICHARD-GYSIN D, Schoenenberger A
    Detection of a potential error in the results of the manuscript "Dementia risk following influenza vaccination in a large veteran cohort" that could eventually call into question the main conclusion.
    Vaccine. 2022;40:3528.
    >> Share

  827. SCHENK J, Abrams S, Litzroth A, Cornelissen L, et al
    Identifying immunity gaps for measles using Belgian serial serology data.
    Vaccine. 2022;40:3676-3683.
    >> Share

  828. POLLET J, Strych U, Chen WH, Versteeg L, et al
    Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern.
    Vaccine. 2022;40:3655-3663.
    >> Share

  829. EVANS S, Holt D, Weil-Olivier C, Finnegan G, et al
    Building population and health system resilience: Using lessons learned during the COVID pandemic to implement life-course immunisation policy.
    Vaccine. 2022;40:3511-3513.
    >> Share

  830. WILLIAMS E, Craig K, Chiu C, Davies H, et al
    Ethics review of COVID-19 human challenge studies: A joint HRA/WHO workshop.
    Vaccine. 2022;40:3484-3489.
    >> Share

  831. SPARROW E, Adetifa I, Chaiyakunapruk N, Cherian T, et al
    WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key considerations for global use.
    Vaccine. 2022;40:3506-3510.
    >> Share

  832. EVANS B, Jombart T
    Worldwide routine immunisation coverage regressed during the first year of the COVID-19 pandemic.
    Vaccine. 2022;40:3531-3535.
    >> Share

  833. KUNASEKARAN MP, Chughtai AA, Heslop DJ, Poulos CJ, et al
    Influenza cases in nine aged care facilities in Sydney, Australia over a three-year surveillance period, 2018-2020.
    Vaccine. 2022 Jun 9. pii: S0264-410X(22)00476.
    >> Share

  834. HALME J, Syrjanen RK, Baum U, Palmu AA, et al
    Effectiveness of trivalent influenza vaccines against hospitalizations due to laboratory-confirmed influenza a in the elderly: Comparison of test-negative design with register-based designs.
    Vaccine. 2022 Jun 9. pii: S0264-410X(22)00716.
    >> Share

  835. ZHAO FJ, Liu LT, Wang Z, Wang NX, et al
    Development and immunogenicity evaluation of porcine deltacoronavirus inactivated vaccine with different adjuvants in mice.
    Vaccine. 2022 Jun 9. pii: S0264-410X(22)00721.
    >> Share

  836. LEAV B, Straus W, White P, Leav A, et al
    A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273).
    Vaccine. 2022 Jun 9. pii: S0264-410X(22)00752.
    >> Share

  837. KOBAYASHI T, Nishina Y, Tomoi H, Harada K, et al
    Corowa-kun: A messenger app chatbot delivers COVID-19 vaccine information, Japan 2021.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00754.
    >> Share

  838. LIN K, Liu M, Bao L, Lv Q, et al
    Safety and protective capability of an inactivated SARS-CoV-2 vaccine on pregnancy, lactation and the growth of offspring in hACE2 mice.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00765.
    >> Share

  839. ZHANG H, Li Y, Peng S, Jiang Y, et al
    The effect of health literacy on COVID-19 vaccine hesitancy among community population in China: The moderating role of stress.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00762.
    >> Share

  840. DIAZ-MENENDEZ M, de la Calle-Prieto F, Montejano R, Arsuaga M, et al
    Clinical characteristics and outcome of hospitalized elderly patients with COVID- 19 after vaccine failure.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00751.
    >> Share

  841. NIESSEN FA, Knol MJ, Hahne SJM, Bonten MJM, et al
    Vaccine effectiveness against COVID-19 related hospital admission in the Netherlands: A test-negative case-control study.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00758.
    >> Share

  842. BASS JR, Poland GA
    Shoulder injury related to vaccine administration (SIRVA) after COVID-19 vaccination.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00750.
    >> Share

  843. WYNBERG E, Han AX, Boyd A, van Willigen HDG, et al
    The effect of SARS-CoV-2 vaccination on post-acute sequelae of COVID-19 (PASC): A prospective cohort study.
    Vaccine. 2022 Jun 7. pii: S0264-410X(22)00748.
    >> Share

  844. WALKER JL, Schultze A, Tazare J, Tamborska A, et al
    Safety of COVID-19 vaccination and acute neurological events: A self-controlled case series in England using the OpenSAFELY platform.
    Vaccine. 2022 Jun 7. pii: S0264-410X(22)00757.
    >> Share

  845. FLYNN JA, Weber T, Cejas PJ, Cox KS, et al
    Characterization of humoral and cell-mediated immunity induced by mRNA vaccines expressing influenza hemagglutinin stem and nucleoprotein in mice and nonhuman primates.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00382.
    >> Share

  846. HASHIMOTO M, Nagata N, Homma T, Maeda H, et al
    Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00718.
    >> Share

  847. EUGENIA-TOLEDO-ROMANI M, Verdecia-Sanchez L, Rodriguez-Gonzalez M, Rodriguez-Noda L, et al
    Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00717.
    >> Share

  848. DAYTON L, Miller J, Strickland J, Davey-Rothwell M, et al
    A socio-ecological perspective on parents' intentions to vaccinate their children against COVID-19.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00736.
    >> Share

  849. EL-SHESHENY R, El Taweel A, Gomaa MR, Roshdy WH, et al
    Induced humoral immunity of different types of vaccines against most common variants of SARS-CoV-2 in Egypt prior to Omicron outbreak.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00734.
    >> Share

  850. SHANMUGARAJ B, Khorattanakulchai N, Panapitakkul C, Malla A, et al
    Preclinical evaluation of a plant-derived SARS-CoV-2 subunit vaccine: Protective efficacy, immunogenicity, safety, and toxicity.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00735.
    >> Share

  851. WATANABE A, Nishida S, Burcu T, Shibahara T, et al
    Safety and immunogenicity of a quadrivalent seasonal influenza vaccine adjuvanted with hydroxypropyl-beta-cyclodextrin: A phase 1 clinical trial.
    Vaccine. 2022 Jun 4. pii: S0264-410X(22)00677.
    >> Share

  852. AB RAHMAN N, Lim MT, Lee FY, Lee SC, et al
    Risk of serious adverse events after the BNT162b2, CoronaVac, and ChAdOx1 vaccines in Malaysia: A self-controlled case series study.
    Vaccine. 2022 Jun 3. pii: S0264-410X(22)00700.
    >> Share

  853. STEAD M, Ford A, Eadie D, Biggs H, et al
    A "step too far" or "perfect sense"? A qualitative study of British adults' views on mandating COVID-19 vaccination and vaccine passports.
    Vaccine. 2022 Jun 3. pii: S0264-410X(22)00696.
    >> Share

    May 2022
  854. TOOR J, Li X, Jit M, Trotter CL, et al
    COVID-19 impact on routine immunisations for vaccine-preventable diseases: Projecting the effect of different routes to recovery.
    Vaccine. 2022 May 30. pii: S0264-410X(22)00698.
    >> Share

  855. WOO EJ, Dimova RB
    Thrombocytopenia after Ad.26.COV2.S COVID-19 vaccine: Reports to the vaccine adverse event reporting system.
    Vaccine. 2022 May 30. pii: S0264-410X(22)00704.
    >> Share

  856. MERRICK E, Weissman JP, Patel SJ
    Utilizing Google trends to monitor coronavirus vaccine interest and hesitancies.
    Vaccine. 2022 May 30. pii: S0264-410X(22)00699.
    >> Share

  857. FISHMAN J, Salmon MK, Scheitrum D, Aleks Schaefer K, et al
    Comparative effectiveness of mandates and financial policies targeting COVID-19 vaccine hesitancy: A randomized, controlled survey experiment.
    Vaccine. 2022 May 30. pii: S0264-410X(22)00702.
    >> Share

  858. SHIOHARA M, Suzuki S, Shichinohe S, Ishigaki H, et al
    Inactivated whole influenza virus particle vaccines induce neutralizing antibodies with an increase in immunoglobulin gene subclones of B-lymphocytes in cynomolgus macaques.
    Vaccine. 2022 May 28. pii: S0264-410X(22)00640.
    >> Share

  859. SHAPIRO BEN DAVID S, Mizrahi B, Rahamim-Cohen D, Supino-Rosin L, et al
    Robust antibody response after a third BNT162b2 vaccine compared to the second among immunocompromised and healthy individuals, a prospective longitudinal cohort study.
    Vaccine. 2022 May 28. pii: S0264-410X(22)00668.
    >> Share

  860. LAI X, Li M, Hou Z, Guo J, et al
    Factors associated with caregivers' hesitancy to vaccinate children against influenza: A cross-sectional survey in China.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00606.
    >> Share

  861. PATEL KM, Shafiq M, Malik AA, Cobanoglu A, et al
    Relationship between the use of nonpharmaceutical interventions and COVID-19 vaccination among U.S. child care providers: A prospective cohort study.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00680.
    >> Share

  862. SOEGIARTO G, Wulandari L, Purnomosari D, Dhia Fahmita K, et al
    Hypertension is associated with antibody response and breakthrough infection in health care workers following vaccination with inactivated SARS-CoV-2.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00676.
    >> Share

  863. DUBE C, Paris-Robidas S, Andreani G, Gutzeit C, et al
    Broad neutralization against SARS-CoV-2 variants induced by ancestral and B.1.351 AS03-Adjuvanted recombinant Plant-Derived Virus-Like particle vaccines.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00641.
    >> Share

  864. MOSS P, Berenbaum F, Curigliano G, Grupper A, et al
    Benefit-risk evaluation of COVID-19 vaccination in special population groups of interest.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00682.
    >> Share

  865. HALSTEAD IN, McKay RT, Lewis GJ
    COVID-19 and seasonal flu vaccination hesitancy: Links to personality and general intelligence in a large, UK cohort.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00678.
    >> Share

  866. DUBE E, Gagnon D, MacDonald N
    Between persuasion and compulsion: The case of COVID-19 vaccination in Canada.
    Vaccine. 2022 May 25. pii: S0264-410X(22)00670.
    >> Share

  867. ABRAHAM N, Spruin S, Rossi T, Fireman B, et al
    Myocarditis and/or pericarditis risk after mRNA COVID-19 vaccination: A Canadian head to head comparison of BNT162b2 and mRNA-1273 vaccines.
    Vaccine. 2022 May 25. pii: S0264-410X(22)00667.
    >> Share

  868. BECK E, Biundo E, Devlin N, Doherty TM, et al
    Capturing the value of vaccination within health technology assessment and health economics: Literature review and novel conceptual framework.
    Vaccine. 2022 May 23. pii: S0264-410X(22)00490.
    >> Share

  869. FOO D, Sarna M, Pereira G, Moore HC, et al
    Maternal influenza vaccination and child mortality: Longitudinal, population-based linked cohort study.
    Vaccine. 2022 May 20. pii: S0264-410X(22)00614.
    >> Share

  870. KITCHEN M, Leierer G, Kistner O, Wodal W, et al
    High seroprotection rates and geometric mean titre increases after repeated annual influenza vaccinations in a cohort of HIV-infected adults in Austria.
    Vaccine. 2022 May 20. pii: S0264-410X(22)00575.
    >> Share

  871. MCELFISH PA, Selig JP, Scott AJ, Rowland B, et al
    Associations between 5-year influenza vaccination and sociodemographic factors and healthcare access among Arkansans.
    Vaccine. 2022 May 20. pii: S0264-410X(22)00615.
    >> Share

  872. SZANYI J, Wilson T, Scott N, Blakely T, et al
    A log-odds system for waning and boosting of COVID-19 vaccine effectiveness.
    Vaccine. 2022 May 20. pii: S0264-410X(22)00634.
    >> Share

  873. CARSON B, Isaacs J, Carilli T
    Jabbing together? The complementarity between social capital, formal public health rules, and COVID-19 vaccine rates in the United States.
    Vaccine. 2022 May 19. pii: S0264-410X(22)00612.
    >> Share

  874. STEELFISHER GK, Caporello H, McIntosh R, Muhammad Safdar R, et al
    Preventing erosion of oral polio vaccine acceptance: A role for vaccinator visits and social norms.
    Vaccine. 2022 May 19. pii: S0264-410X(22)00567.
    >> Share

  875. SIQUEIRA PG, Duarte HO, Moura MDC
    Risk-based cost-benefit analysis of alternative vaccines against COVID-19 in Brazil: Coronavac vs. Astrazeneca vs. Pfizer.
    Vaccine. 2022 May 19. pii: S0264-410X(22)00633.
    >> Share

  876. SALO-TUOMINEN K, Teros-Jaakkola T, Toivonen L, Ollila H, et al
    Parental socioeconomic and psychological determinants of the 2009 pandemic influenza A(H1N1) vaccine uptake in children.
    Vaccine. 2022 May 17. pii: S0264-410X(22)00582.
    >> Share

  877. ROBERTSON DA, Mohr KS, Barjakova M, Lunn PD, et al
    Experimental pre-tests of public health communications on the COVID-19 vaccine: A null finding for medical endorsement, risk and altruism.
    Vaccine. 2022 May 16. pii: S0264-410X(22)00613.
    >> Share

  878. TSAI SY, Yeh TY, Chiu NC, Huang CT, et al
    National safety surveillance of quadrivalent recombinant influenza vaccine in Taiwan during NH 20/21.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00588.
    >> Share

  879. IWATA S, Sonoyama T, Kamitani A, Shibata R, et al
    Phase 1/2 clinical trial of COVID-19 vaccine in Japanese participants: A report of interim findings.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00494.
    >> Share

  880. ALYA WA, Maraqa B, Nazzal Z, Odeh M, et al
    COVID-19 vaccine uptake and its associated factors among Palestinian healthcare workers: Expectations beaten by reality.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00610.
    >> Share

  881. KUMAR SURI R, Hayman B, Prasad SD, Makhoana M, et al
    Vaccines: New challenges, new paradigms, new opportunities: Report of the 22nd DCVMN Annual General Meeting.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00576.
    >> Share

  882. DUC DANG A, Dinh Vu T, Hai Vu H, Thanh Ta V, et al
    Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00526.
    >> Share

  883. RUSKIN AC, Rice S, O'Connor M, Ruskin KJ, et al
    Effects of vaccination status in the United States on willingness to undergo surgery during a pandemic: A prospective survey study.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00583.
    >> Share

  884. MANCARELLA M, Natarelli F, Bertolini C, Zagari A, et al
    Catch-up vaccination campaign in children between 6 and 8 years old during COVID-19 pandemic: The experience in a COVID hub in Milan, Italy.
    Vaccine. 2022 May 12. pii: S0264-410X(22)00573.
    >> Share

  885. CHONG-VALBUENA A, De-Jesus-Maria I, Agurto-Ramirez A, Puchades-Gimeno F, et al
    Safety of Pfizer-BioNTech vaccine in a cohort of healthcare providers: Differences between naive and previously infected by SARS-CoV-2.
    Vaccine. 2022 May 12. pii: S0264-410X(22)00586.
    >> Share

  886. TEASDALE CA, Ratzan S, Stuart Lathan H, Rauh L, et al
    Acceptability of COVID-19 vaccine mandates among New York City parents, November 2021.
    Vaccine. 2022 May 11. pii: S0264-410X(22)00580.
    >> Share

  887. GUPTA C, Sachdeva A, Khamar J, Bu C, et al
    Effectiveness of the influenza vaccine at reducing adverse events in patients with heart failure: A systematic review and meta-analysis.
    Vaccine. 2022 May 10. pii: S0264-410X(22)00468.
    >> Share

  888. KITRO A, Sirikul W, Thongkum W, Soponpong S, et al
    Dynamic of anti-spike receptor binding domain (RBD) levels and short-term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers.
    Vaccine. 2022;40:2915-2924.
    >> Share

  889. PERUMAL N, Steffen A, Ullrich A, Siedler A, et al
    Impact of COVID-19 immunisation on COVID-19 incidence, hospitalisations, and deaths by age group in Germany from December 2020 to October 2021.
    Vaccine. 2022;40:2910-2914.
    >> Share

  890. YI S, Choe YJ, Lim DS, Lee HR, et al
    Impact of national Covid-19 vaccination Campaign, South Korea.
    Vaccine. 2022 May 8. pii: S0264-410X(22)00572.
    >> Share

  891. BIFULCO M, Di Zazzo E, Pisanti S, Martini M, et al
    The nineteenth-century experience of the kingdom of the two Sicilies on mandatory vaccination: An Italian phenomenon?
    Vaccine. 2022 May 6. pii: S0264-410X(22)00492.
    >> Share

  892. LUMBRERAS ARETA M, Valiton A, Diana A, Morales M, et al
    Flu and pertussis vaccination during pregnancy in Geneva during the COVID-19 pandemic: A multicentric, prospective, survey-based study.
    Vaccine. 2022 May 6. pii: S0264-410X(22)00533.
    >> Share

  893. YU Y, Ma YL, Luo S, Wang S, et al
    Prevalence and factors of influenza vaccination during the COVID-19 pandemic among university students in China.
    Vaccine. 2022 May 5. pii: S0264-410X(22)00532.
    >> Share

  894. BELLIZZI S, Panu Napodano CM, Pinto S, Pichierri G, et al
    COVID-19 and seasonal influenza: The potential 2021-22 "Twindemic".
    Vaccine. 2022 May 5. pii: S0264-410X(22)00531.
    >> Share

  895. GASTEIGER N, Gasteiger C, Vedhara K, Broadbent E, et al
    Characteristics associated with the willingness to receive a COVID-19 vaccine and an exploration of the general public's perceptions: A mixed-methods approach.
    Vaccine. 2022 May 5. pii: S0264-410X(22)00547.
    >> Share

  896. NAULT L, Marchitto L, Goyette G, Tremblay-Sher D, et al
    Covid-19 vaccine immunogenicity in people living with HIV-1.
    Vaccine. 2022 May 5. pii: S0264-410X(22)00543.
    >> Share

  897. REES F, Geiger M, Lilleholt L, Zettler I, et al
    Measuring parents' readiness to vaccinate themselves and their children against COVID-19.
    Vaccine. 2022 May 5. pii: S0264-410X(22)00549.
    >> Share

  898. LEIGH JP, Moss SJ, White TM, Picchio CA, et al
    Factors affecting COVID-19 vaccine hesitancy among healthcare providers in 23 countries.
    Vaccine. 2022 May 5. pii: S0264-410X(22)00545.
    >> Share

  899. LIU W, Lien YH, Lee PI, Chan TC, et al
    Impact of prior infection and repeated vaccination on post-vaccination antibody titers of the influenza A(H1N1)pdm09 strain in Taiwan schoolchildren: Implications for public health.
    Vaccine. 2022 May 4. pii: S0264-410X(22)00358.
    >> Share

  900. PERSSON U, Olofsson S, Althin R, Palmborg A, et al
    Acceptance and application of a broad population health perspective when evaluating vaccine.
    Vaccine. 2022 May 4. pii: S0264-410X(22)00425.
    >> Share

  901. BOSE AS, Rai P, Gupta BP, Pradhan R, et al
    Nepal measles outbreak response immunization during COVID-19: A risk-based intervention strategy.
    Vaccine. 2022;40:2884-2893.
    >> Share

  902. BOTHUN LS, Feeder SE, Poland GA
    Readability of COVID-19 vaccine information for the general public.
    Vaccine. 2022 May 3. pii: S0264-410X(22)00546.
    >> Share

  903. NANTANEE R, Aikphaibul P, Jaru-Ampornpan P, Sodsai P, et al
    Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac.
    Vaccine. 2022 May 2. pii: S0264-410X(22)00521.
    >> Share

  904. FEIKIN DR, Abu-Raddad LJ, Andrews N, Davies MA, et al
    Assessing vaccine effectiveness against severe COVID-19 disease caused by omicron variant. Report from a meeting of the World Health Organization.
    Vaccine. 2022 May 2. pii: S0264-410X(22)00523.
    >> Share

    April 2022
  905. MASUDA T, Murakami K, Sugiura K, Sakui S, et al
    Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial.
    Vaccine. 2022 Apr 29. pii: S0264-410X(22)00463.
    >> Share

  906. HUSSAIN B, Latif A, Timmons S, Nkhoma K, et al
    Overcoming COVID-19 vaccine hesitancy among ethnic minorities: A systematic review of UK studies.
    Vaccine. 2022 Apr 28. pii: S0264-410X(22)00446.
    >> Share

  907. NASREEN S, Calzavara A, Buchan SA, Thampi N, et al
    Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance.
    Vaccine. 2022 Apr 27. pii: S0264-410X(22)00520.
    >> Share

  908. DEMIR E, Dheir H, Safak S, Serra Artan A, et al
    Differences in clinical outcomes of COVID-19 among vaccinated and unvaccinated kidney transplant recipients.
    Vaccine. 2022 Apr 27. pii: S0264-410X(22)00519.
    >> Share

  909. KULCZYCKI A, Shewchuk R
    Back to Basics: A general approach to improving Covid and adult immunization delivery focused on Pharmacy-Based immunization services.
    Vaccine. 2022;40:2647-2649.
    >> Share

  910. MARKOVITZ NH, Strome AL, Patel PK
    Commentary: "The vaccine Selfie" and its influence on COVID-19 vaccine acceptance.
    Vaccine. 2022 Apr 26. pii: S0264-410X(22)00503.
    >> Share

  911. KRUPP K, Galea J, Madhivanan P, Gerald L, et al
    Conversational artificial intelligence: A new approach for increasing influenza vaccination rates in children with asthma?
    Vaccine. 2022 Apr 25. pii: S0264-410X(22)00496.
    >> Share

  912. MCCOSKER LK, El-Heneidy A, Seale H, Ware RS, et al
    Strategies to improve vaccination rates in people who are homeless: A systematic review.
    Vaccine. 2022 Apr 25. pii: S0264-410X(22)00436.
    >> Share

  913. BEYER WEP, Palache AM, Boulfich M, Osterhaus ADME, et al
    Clinical relevance of increased antibody titres in older adults upon vaccination with squalene-adjuvanted versus non-adjuvanted influenza vaccines.
    Vaccine. 2022 Apr 23. pii: S0264-410X(22)00489.
    >> Share

  914. STRECKENBACH B, Baldt J, Heidler F, Frahm N, et al
    General vaccination willingness and current vaccination status in relation to clinical and psychological variables in patients with multiple sclerosis.
    Vaccine. 2022 Apr 23. pii: S0264-410X(22)00428.
    >> Share

  915. SALO H, Lehtonen T, Auranen K, Baum U, et al
    Predictors of hospitalisation and death due to SARS-CoV-2 infection in Finland: A population-based register study with implications to vaccinations.
    Vaccine. 2022 Apr 22. pii: S0264-410X(22)00495.
    >> Share

  916. TAMANG ST, Dorji T
    COVID-19 vaccinations in Bhutan - Mix-and-Match to Boosters: An experience.
    Vaccine. 2022 Apr 22. pii: S0264-410X(22)00499.
    >> Share

  917. ANTONOPOULOU T, Athanassakis I
    SARS-CoV-2 immunogenicity: Is S protein the best target for vaccination?
    Vaccine. 2022 Apr 22. pii: S0264-410X(22)00501.
    >> Share

  918. SHEA LL, Becker A, Lee BK, Miller KK, et al
    Self-reported COVID-19 vaccination acceptance and hesitancy among autistic adults.
    Vaccine. 2022 Apr 22. pii: S0264-410X(22)00500.
    >> Share

  919. ORTIZ JR, Spearman PW, Goepfert PA, Cross K, et al
    Safety and immunogenicity of monovalent H7N9 influenza vaccine with AS03 adjuvant given sequentially or simultaneously with a seasonal influenza vaccine: A randomized clinical trial.
    Vaccine. 2022 Apr 21. pii: S0264-410X(22)00366.
    >> Share

  920. CAN G, Acar HC, Aydin SN, Balkan II, et al
    Waning effectiveness of CoronaVac in real life: A retrospective cohort study in health care workers.
    Vaccine. 2022;40:2574-2579.
    >> Share

  921. GARTNER BC, Weinke T, Wahle K, Kwetkat A, et al
    Importance and value of adjuvanted influenza vaccine in the care of older adults from a European perspective - A systematic review of recently published literature on real-world data.
    Vaccine. 2022 Apr 19. pii: S0264-410X(22)00440.
    >> Share

  922. SINGH BK, Walker J, Paul P, Reddy S, et al
    De-escalation of asymptomatic testing and potential of future COVID-19 outbreaks in US nursing homes amidst rising community vaccination coverage: A modeling study.
    Vaccine. 2022 Apr 18. pii: S0264-410X(22)00467.
    >> Share

  923. LI L, Honda-Okubo Y, Baldwin J, Bowen R, et al
    Covax-19/Spikogen(R) vaccine based on recombinant spike protein extracellular domain with Advax-CpG55.2 adjuvant provides single dose protection against SARS-CoV-2 infection in hamsters.
    Vaccine. 2022 Apr 18. pii: S0264-410X(22)00469.
    >> Share

  924. WANLAPAKORN N, Suntronwong N, Phowatthanasathian H, Yorsaeng R, et al
    Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: Real-world data.
    Vaccine. 2022 Apr 18. pii: S0264-410X(22)00471.
    >> Share

  925. SAADE A, Cha L, Tadie E, Jurado B, et al
    Delay between COVID-19 complete vaccination and SARS-CoV-2 infection among healthcare workers.
    Vaccine. 2022 Apr 18. pii: S0264-410X(22)00473.
    >> Share

  926. CHRISSIAN AA, Oyoyo UE, Patel P, Lawrence Beeson W, et al
    Impact of COVID-19 vaccine-associated side effects on health care worker absenteeism and future booster vaccination.
    Vaccine. 2022 Apr 18. pii: S0264-410X(22)00474.
    >> Share

  927. XU S, Hong V, Sy LS, Glenn SC, et al
    Changes in incidence rates of outcomes of interest in vaccine safety studies during the COVID-19 pandemic.
    Vaccine. 2022 Apr 18. pii: S0264-410X(22)00464.
    >> Share

  928. MACINTYRE CR, Heslop DJ, Nguyen P, Adam D, et al
    Pacific Eclipse - A tabletop exercise on smallpox pandemic response.
    Vaccine. 2022;40:2478-2483.
    >> Share

  929. BRAEYE T, Catteau L, Brondeel R, van Loenhout JAF, et al
    Vaccine effectiveness against onward transmission of SARS-CoV2-infection by variant of concern and time since vaccination, Belgian contact tracing, 2021.
    Vaccine. 2022 Apr 12. pii: S0264-410X(22)00441.
    >> Share

  930. FENOLLAR F, Thomas L, Raoult D, Gautret P, et al
    Screening for SARS-CoV-2 antibodies to save vaccine doses.
    Vaccine. 2022 Apr 12. pii: S0264-410X(22)00444.
    >> Share

  931. MORO PL, Olson CK, Clark E, Marquez P, et al
    Post-authorization surveillance of adverse events following COVID-19 vaccines in pregnant persons in the vaccine adverse event reporting system (VAERS), December 2020 - October 2021.
    Vaccine. 2022 Apr 12. pii: S0264-410X(22)00447.
    >> Share

  932. YAN Y, Naito T, Tabe Y, Ito K, et al
    Increased delta variant SARS-CoV-2 infections in a highly vaccinated medical center in Japan.
    Vaccine. 2022 Apr 12. pii: S0264-410X(22)00445.
    >> Share

  933. SHINJOH M, Furuichi M, Kobayashi H, Yamaguchi Y, et al
    Trends in effectiveness of inactivated influenza vaccine in children by age groups in seven seasons immediately before the COVID-19 era.
    Vaccine. 2022 Apr 11. pii: S0264-410X(22)00449.
    >> Share

  934. CEYLAN ME, Onen Unsalver B, Donmez A, Kaya Yertutanol FD, et al
    A case of myocarditis and isolated hypopotassemia after Biontech-Pfizer vaccine for Covid-19.
    Vaccine. 2022 Apr 11. pii: S0264-410X(22)00432.
    >> Share

  935. LJUNG R, Feychting M, Burstrom B, Moller J, et al
    Differences by region of birth in SARS-CoV-2 vaccine coverage and positive SARS-CoV-2 test among 400 000 healthcare workers and the general population in Sweden.
    Vaccine. 2022 Apr 11. pii: S0264-410X(22)00431.
    >> Share

  936. BENINGER P
    Need for a contingency dimension when planning vaccine development in a pandemic environment.
    Vaccine. 2022 Apr 11. pii: S0264-410X(22)00401.
    >> Share

  937. ZHU XM, Yan W, Sun J, Liu L, et al
    Patterns and influencing factors of COVID-19 vaccination willingness among college students in China.
    Vaccine. 2022 Apr 11. pii: S0264-410X(22)00433.
    >> Share

  938. SPRINGER S, Kaatz M, Zieger M
    Evaluation of weekly COVID-19 vaccination and case data supports negative correlation between incidence and vaccination in German federal states and cities during 4th wave.
    Vaccine. 2022 Apr 11. pii: S0264-410X(22)00430.
    >> Share

  939. PARK SJ, Kang YM, Cho HK, Kim DY, et al
    Corrigendum to 'Cross-protective efficacy of inactivated whole influenza vaccines against Korean Y280 and Y439 lineage H9N2 viruses in mice' [Vaccine 39 (2021) 6213-6220].
    Vaccine. 2022 Apr 9. pii: S0264-410X(22)00221.
    >> Share

  940. AINSLIE KEC, Riley S
    Is annual vaccination best? A modelling study of influenza vaccination strategies in children.
    Vaccine. 2022 Apr 8. pii: S0264-410X(22)00384.
    >> Share

  941. MAYFIELD HJ, Lau CL, Sinclair JE, Brown SJ, et al
    Designing an evidence-based Bayesian network for estimating the risk versus benefits of AstraZeneca COVID-19 vaccine.
    Vaccine. 2022 Apr 8. pii: S0264-410X(22)00418.
    >> Share

  942. BELDA F, Mora O, Lopez Martinez M, Torres N, et al
    Seroconversion panels demonstrate anti-SARS-CoV-2 antibody development after administration of the mRNA-1273 vaccine.
    Vaccine. 2022 Apr 8. pii: S0264-410X(22)00419.
    >> Share

  943. ERFANI P, Sandoval RS, Rich KM, Ojo A, et al
    Ask Me Anything": Lessons learned in implementing a COVID-19 vaccine information initiative in Massachusetts jails.
    Vaccine. 2022 Apr 8. pii: S0264-410X(22)00439.
    >> Share

  944. KENIGSBERG TA, Hause AM, McNeil MM, Nelson JC, et al
    Dashboard development for near real-time visualization of COVID-19 vaccine safety surveillance data in the vaccine safety datalink.
    Vaccine. 2022 Apr 8. pii: S0264-410X(22)00426.
    >> Share

  945. LINKINS LA, Iorio A, Little J, Lavis J, et al
    Extended reporting guidance for vaccine effectiveness studies for variants of concern for COVID-19.
    Vaccine. 2022 Apr 7. pii: S0264-410X(22)00422.
    >> Share

  946. DE-LOS-RIOS-PINTO A, Fernandez-Guzman D, Soriano-Moreno DR, Sangster-Carrasco L, et al
    Factors associated with the intention to participate in COVID-19 vaccine clinical trials: A cross-sectional study in Peru.
    Vaccine. 2022 Apr 7. pii: S0264-410X(22)00421.
    >> Share

  947. SHAH S, Gui H, Chua PEY, Tan JB, et al
    Factors associated with COVID-19 vaccination intent in Singapore, Australia and Hong Kong.
    Vaccine. 2022 Apr 5. pii: S0264-410X(22)00381.
    >> Share

  948. WALTERS JN, Schouest B, Patel A, Reuschel EL, et al
    Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates.
    Vaccine. 2022 Apr 4. pii: S0264-410X(22)00368.
    >> Share

  949. HASSAN PM, Ali T, Saber E, Asghar A, et al
    Potency, toxicity and protection evaluation of PastoCoAd candidate vaccines: Novel preclinical mix and match rAd5 S, rAd5 RBD-N and SOBERANA dimeric-RBD protein.
    Vaccine. 2022 Apr 4. pii: S0264-410X(22)00385.
    >> Share

  950. MA C, Sun W, Tang T, Jia M, et al
    Effectiveness of adenovirus type 5 vectored and inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the B.1.617.2 (Delta) variant: Evidence from an outbreak in Yunnan, China, 2021.
    Vaccine. 2022 Apr 1. pii: S0264-410X(22)00386.
    >> Share

  951. SUGHAYER MA, Souan L, Abu Alhowr MM, Al Rimawi D, et al
    Comparison of the effectiveness and duration of anti-RBD SARS-CoV-2 IgG antibody response between different types of vaccines: Implications for vaccine strategies.
    Vaccine. 2022 Apr 1. pii: S0264-410X(22)00387.
    >> Share

  952. FRISE R, Baillon L, Zhou J, Kugathasan R, et al
    A self-amplifying RNA vaccine protects against SARS-CoV-2 (D614G) and Alpha variant of concern (B.1.1.7) in a transmission-challenge hamster model.
    Vaccine. 2022 Apr 1. pii: S0264-410X(22)00383.
    >> Share

    March 2022
  953. VANDOORN E, Parys A, Chepkwony S, Chiers K, et al
    Efficacy of the NS1-truncated live attenuated influenza virus vaccine for swine against infection with viruses of major North American and European H3N2 lineages.
    Vaccine. 2022 Mar 30. pii: S0264-410X(22)00362.
    >> Share

  954. MCRAE J, Blyth CC, Cheng AC, Quinn HE, et al
    Preventing severe influenza in Australian infants: Maternal influenza vaccine effectiveness in the PAEDS-FluCAN networks using the test-negative design.
    Vaccine. 2022 Mar 29. pii: S0264-410X(22)00353.
    >> Share

  955. LI K, Yu T, Seabury SA, Dor A, et al
    Trends and disparities in the utilization of influenza vaccines among commercially insured US adults during the COVID-19 pandemic.
    Vaccine. 2022 Mar 29. pii: S0264-410X(22)00370.
    >> Share

  956. KATO H, Miyakawa K, Ohtake N, Yamaoka Y, et al
    Vaccine-induced humoral response against SARS-CoV-2 dramatically declined but cellular immunity possibly remained at 6 months post BNT162b2 vaccination.
    Vaccine. 2022 Mar 29. pii: S0264-410X(22)00369.
    >> Share

  957. ISITT C, Sjoholm D, Hergens MP, Granath F, et al
    The early impact of vaccination against SARS-CoV-2 in Region Stockholm, Sweden.
    Vaccine. 2022 Mar 29. pii: S0264-410X(22)00372.
    >> Share

  958. FUNK PR, Yogurtcu ON, Forshee RA, Anderson SA, et al
    Benefit-risk assessment of COVID-19 vaccine, mRNA (Comirnaty) for age 16-29 years.
    Vaccine. 2022 Mar 28. pii: S0264-410X(22)00329.
    >> Share

  959. JUDDOO V, Juddoo S, Megarbane B
    Erythema nodosum triggered by BNT162b2 mRNA COVID-19 vaccine.
    Vaccine. 2022 Mar 28. pii: S0264-410X(22)00363.
    >> Share

  960. WELLS K, Moore KL, Bednarczyk R
    Supporting immunization programs to address COVID-19 vaccine hesitancy: Recommendations for national and community-based stakeholders.
    Vaccine. 2022 Mar 28. pii: S0264-410X(22)00339.
    >> Share

  961. SIMMONS LA, Whipps MDM, Phipps JE, Satish NS, et al
    Understanding COVID-19 vaccine uptake during pregnancy: 'Hesitance', knowledge, and evidence-based decision-making.
    Vaccine. 2022 Mar 25. pii: S0264-410X(22)00355.
    >> Share

  962. FARAH W, Breeher L, Shah V, Hainy C, et al
    Disparities in COVID-19 vaccine uptake among health care workers.
    Vaccine. 2022 Mar 25. pii: S0264-410X(22)00356.
    >> Share

  963. NANTHAPISAL S, Puthanakit T, Jaru-Ampornpan P, Nantanee R, et al
    A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines.
    Vaccine. 2022 Mar 24. pii: S0264-410X(22)00336.
    >> Share

  964. ABDEL-QADER DH, Hazza Alkhatatbeh I, Hayajneh W, Annab H, et al
    IgA nephropathy in a pediatric patient after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine.
    Vaccine. 2022 Mar 23. pii: S0264-410X(22)00265.
    >> Share

  965. MALTEZOU HC, Medic S, Cassimos DC, Effraimidou E, et al
    Decreasing routine vaccination rates in children in the COVID-19 era.
    Vaccine. 2022 Mar 22. pii: S0264-410X(22)00333.
    >> Share

  966. FANO V, Crielesi A, Coviello E, Fabiani M, et al
    Effectiveness of the Comirnaty and the Vaxzevria vaccines in preventing SARS-CoV-2 infection among residents in Lazio region (Italy).
    Vaccine. 2022 Mar 22. pii: S0264-410X(22)00208.
    >> Share

  967. SNIDER CJ, Boualam L, Tallis G, Takashima Y, et al
    Concurrent outbreaks of circulating vaccine-derived poliovirus types 1 and 2 affecting the Republic of the Philippines and Malaysia, 2019-2021.
    Vaccine. 2022 Mar 22. pii: S0264-410X(22)00145.
    >> Share

  968. FERDINANDS JM, Patel M
    Influence of disease attenuation on relative influenza vaccine effectiveness by vaccine type.
    Vaccine. 2022 Mar 21. pii: S0264-410X(22)00274.
    >> Share

  969. YUEN WLP, Loh SYJ, Wang DB
    SIRVA (Shoulder Injury Related to Vaccine Administration) following mRNA COVID-19 Vaccination: Case discussion and literature review.
    Vaccine. 2022 Mar 21. pii: S0264-410X(22)00337.
    >> Share

  970. JIAN-BIN L, Lau EYH, Chan DKC
    Why do Hong Kong parents have low intention to vaccinate their children against COVID-19? testing health belief model and theory of planned behavior in a large-scale survey.
    Vaccine. 2022 Mar 21. pii: S0264-410X(22)00340.
    >> Share

  971. PI-ESTOPINAN F, Perez MT, Fraga A, Bergado G, et al
    A cell-based ELISA as surrogate of virus neutralization assay for RBD SARS-CoV-2 specific antibodies.
    Vaccine. 2022;40:1958-1967.
    >> Share

  972. ESPOSITO S, Nauta J, Lapini G, Montomoli E, et al
    Efficacy and safety of a quadrivalent influenza vaccine in children aged 6-35 months: A global, multiseasonal, controlled, randomized Phase III study.
    Vaccine. 2022 Mar 18. pii: S0264-410X(22)00263.
    >> Share

  973. BILGIN H, Marku M, Yilmaz SS, Karahasan Yagci A, et al
    The effect of immunization with inactivated SARS-CoV-2 vaccine (CoronaVac) and/or SARS-CoV-2 infection on antibody levels, plasmablasts, long-lived-plasma-cells, and IFN-gamma release by natural killer cells.
    Vaccine. 2022 Mar 18. pii: S0264-410X(22)00264.
    >> Share

  974. CALLAGHAN T, Washburn D, Goidel K, Nuzhath T, et al
    Imperfect messengers? An analysis of vaccine confidence among primary care physicians.
    Vaccine. 2022 Mar 18. pii: S0264-410X(22)00302.
    >> Share

  975. JI C, Piche-Renaud PP, Apajee J, Stephenson E, et al
    Impact of the COVID-19 pandemic on routine immunization coverage in children under 2 years old in Ontario, Canada: A retrospective cohort study.
    Vaccine. 2022;40:1790-1798.
    >> Share

  976. CAMARA J, Gonzalez-Diaz A, Barrabeig I, Fernandez-Huerta M, et al
    SARS-CoV-2 outbreak in a nursing home after vaccination with BNT162b2: A role for the quantification of circulating antibodies.
    Vaccine. 2022 Mar 15. pii: S0264-410X(22)00303.
    >> Share

  977. ROTOLO B, Dube E, Vivion M, MacDonald SE, et al
    Hesitancy towards COVID-19 vaccines on social media in Canada.
    Vaccine. 2022 Mar 15. pii: S0264-410X(22)00301.
    >> Share

  978. MOSCARDINO U, Musso P, Inguglia C, Ceccon C, et al
    Sociodemographic and psychological correlates of COVID-19 vaccine hesitancy and resistance in the young adult population in Italy.
    Vaccine. 2022 Mar 14. pii: S0264-410X(22)00293.
    >> Share

  979. VAN DEN HOOGEN LL, Smits G, van Hagen CCE, Wong D, et al
    Seropositivity to Nucleoprotein to detect mild and asymptomatic SARS-CoV-2 infections: A complementary tool to detect breakthrough infections after COVID-19 vaccination?
    Vaccine. 2022 Mar 9. pii: S0264-410X(22)00272.
    >> Share

  980. THOMAS CM, Searle K, Galvan A, Liebman AK, et al
    Healthcare worker perspectives on COVID-19 vaccines: Implications for increasing vaccine acceptance among healthcare workers and patients.
    Vaccine. 2022 Mar 9. pii: S0264-410X(22)00276.
    >> Share

  981. YUEN VWH
    Political attitudes and efficacy of health expert communication on the support for COVID-19 vaccination program: Findings from a survey in Hong Kong.
    Vaccine. 2022 Mar 7. pii: S0264-410X(22)00261.
    >> Share

  982. BANSAL P, Raj A, Mani Shukla D, Sunder N, et al
    COVID-19 vaccine preferences in India.
    Vaccine. 2022 Mar 7. pii: S0264-410X(22)00241.
    >> Share

  983. MASCHERINI M, Nivakoski S
    Social media use and vaccine hesitancy in the European Union.
    Vaccine. 2022 Mar 3. pii: S0264-410X(22)00206.
    >> Share

  984. KLUMPP M, Monfared IG, Vollmer S
    Public opinion on global distribution of COVID-19 vaccines: Evidence from two nationally representative surveys in Germany and the United States.
    Vaccine. 2022 Mar 3. pii: S0264-410X(22)00259.
    >> Share

  985. COULAUD PJ, Ablona A, Bolduc N, Fast D, et al
    COVID-19 vaccine intention among young adults: Comparative results from a cross-sectional study in Canada and France.
    Vaccine. 2022 Mar 3. pii: S0264-410X(22)00260.
    >> Share

  986. ROBERTSON LJ, Price R, Moore JS, Curry G, et al
    IgG antibody production and persistence to 6 months following SARS-CoV-2 vaccination: A Northern Ireland observational study.
    Vaccine. 2022 Mar 3. pii: S0264-410X(22)00262.
    >> Share

  987. YU M, Yao X, Liu G, Wu J, et al
    Barriers and facilitators to uptake and promotion of influenza vaccination among health care workers in the community in Beijing, China: A qualitative study.
    Vaccine. 2022 Mar 2. pii: S0264-410X(22)00207.
    >> Share

  988. POINTON L, Howe AS, Hobbs M, Paynter J, et al
    Evidence of suboptimal maternal vaccination coverage in pregnant New Zealand women and increasing inequity over time: A nationwide retrospective cohort study.
    Vaccine. 2022 Mar 2. pii: S0264-410X(22)00243.
    >> Share

  989. KREPS SE, Kriner DL
    How do COVID-19 vaccine mandates affect attitudes toward the vaccine and participation in mandate-affected activities? Evidence from the United States.
    Vaccine. 2022 Mar 2. pii: S0264-410X(22)00258.
    >> Share

  990. LAI FTT, Leung MTY, Chan EWW, Huang L, et al
    Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): A prospective cohort study with intensive monitoring.
    Vaccine. 2022;40:1390-1396.
    >> Share

  991. LILLVIS DF, Miller CR, Kuo DZ
    Pediatric primary care immunization policies in New York State.
    Vaccine. 2022;40:1458-1463.
    >> Share

  992. MOURA C, Truche P, Sousa Salgado L, Meireles T, et al
    The impact of COVID-19 on routine pediatric vaccination delivery in Brazil.
    Vaccine. 2022 Mar 1. pii: S0264-410X(22)00242.
    >> Share

    February 2022
  993. SINGH JA, Kochhar S, Wolff J, Atuire C, et al
    WHO guidance on COVID-19 vaccine trial designs in the context of authorized COVID-19 vaccines and expanding global access: Ethical considerations.
    Vaccine. 2022 Feb 28. pii: S0264-410X(22)00175.
    >> Share

  994. MCANDREW T, Cambeiro J, Besiroglu T
    Aggregating human judgment probabilistic predictions of the safety, efficacy, and timing of a COVID-19 vaccine.
    Vaccine. 2022 Feb 28. pii: S0264-410X(22)00200.
    >> Share

  995. SALIOU P, Duteil Q, Plotkin SA, Gentilini M, et al
    The scourge of vaccine falsification.
    Vaccine. 2022 Feb 26. pii: S0264-410X(22)00119.
    >> Share

  996. MULLER KE, Dohos D, Sipos Z, Kiss S, et al
    Immune response to influenza and pneumococcal vaccines in adults with inflammatory bowel disease: A systematic review and meta-analysis of 1429 patients.
    Vaccine. 2022 Feb 25. pii: S0264-410X(22)00163.
    >> Share

  997. KAGEYAMA T, Tanaka S, Etori K, Hattori K, et al
    Immunological features that associate with the strength of antibody responses to BNT162b2 mRNA vaccine against SARS-CoV-2.
    Vaccine. 2022 Feb 25. pii: S0264-410X(22)00192.
    >> Share

  998. MCGOLDRICK M, Gastineau T, Wilkinson D, Campa C, et al
    How to accelerate the supply of vaccines to all populations worldwide? Part II: Initial industry lessons learned and detailed technical reflections leveraging the COVID-19 situation.
    Vaccine. 2022;40:1223-1230.
    >> Share

  999. MCGOLDRICK M, Gastineau T, Wilkinson D, Campa C, et al
    How to accelerate the supply of vaccines to all populations worldwide? Part I: Initial industry lessons learned and practical overarching proposals leveraging the COVID-19 situation.
    Vaccine. 2022;40:1215-1222.
    >> Share

  1000. HAO F, Shao W
    Understanding the influence of political orientation, social network, and economic recovery on COVID-19 vaccine uptake among Americans.
    Vaccine. 2022 Feb 22. pii: S0264-410X(22)00219.
    >> Share

  1001. ABBATECOLA AM, Incalzi RA, Malara A, Palmieri A, et al
    Monitoring COVID-19 vaccine use in Italian long term care centers: The GeroCovid VAX study.
    Vaccine. 2022 Feb 22. pii: S0264-410X(22)00217.
    >> Share

  1002. EL-HENEIDY A, Grimwood K, Lambert SB, Sarna M, et al
    Association between vaccination status, symptom identification and healthcare use: Implications for test negative design observational studies.
    Vaccine. 2022 Feb 22. pii: S0264-410X(22)00198.
    >> Share

  1003. TAWINPRAI K, Siripongboonsitti T, Porntharukchareon T, Wittayasak K, et al
    Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial
    Vaccine. 2022 Feb 21. pii: S0264-410X(22)00143.
    >> Share

  1004. ISMAIL ALHOSANI F, Eduardo Stanciole A, Aden B, Timoshkin A, et al
    Impact of the Sinopharm's BBIBP-CorV vaccine in preventing hospital admissions and death in infected vaccinees: Results from a retrospective study in the emirate of Abu Dhabi, United Arab Emirates (UAE).
    Vaccine. 2022 Feb 19. pii: S0264-410X(22)00174.
    >> Share

  1005. WINTER T, Riordan BC, Scarf D, Jose PE, et al
    Conspiracy beliefs and distrust of science predicts reluctance of vaccine uptake of politically right-wing citizens.
    Vaccine. 2022 Feb 18. pii: S0264-410X(22)00074.
    >> Share

  1006. SCHMALING KB
    Couples and COVID-19 vaccination: Frequency and reasons for discordance.
    Vaccine. 2022 Feb 18. pii: S0264-410X(22)00202.
    >> Share

  1007. MERKLEY E, Loewen PJ
    The correlates and dynamics of COVID-19 vaccine-specific hesitancy.
    Vaccine. 2022 Feb 17. pii: S0264-410X(22)00168.
    >> Share

  1008. KASSTAN B, Mounier-Jack S, Letley L, Gaskell KM, et al
    Localising vaccination services: Qualitative insights on public health and minority group collaborations to co-deliver coronavirus vaccines.
    Vaccine. 2022 Feb 17. pii: S0264-410X(22)00201.
    >> Share

  1009. LAZO L, Bequet-Romero M, Lemos G, Musacchio A, et al
    A recombinant SARS-CoV-2 receptor-binding domain expressed in an engineered fungal strain of Thermothelomyces heterothallica induces a functional immune response in mice.
    Vaccine. 2022;40:1162-1169.
    >> Share

  1010. JOG P, Memon IA, Thisyakorn U, Hozbor D, et al
    Pertussis in Asia: Recent country-specific data and recommendations.
    Vaccine. 2022;40:1170-1179.
    >> Share

  1011. STEFANIZZI P, Larocca AMV, Martinelli A, Soldano S, et al
    Immune response to one dose of BNT162b2 mRNA Covid-19 vaccine followed by SARS-CoV-2 infection: An Italian prospective observational study.
    Vaccine. 2022 Feb 16. pii: S0264-410X(22)00124.
    >> Share

  1012. KALASKA B, Miklosz J, Swieton J, Jakimczuk A, et al
    The effect of ChAdOx1 nCov-19 vaccine on arterial thrombosis development and platelet aggregation in female rats.
    Vaccine. 2022 Feb 16. pii: S0264-410X(22)00173.
    >> Share

  1013. SALEH OA, Halperin O
    Influenza virus vaccine compliance among pregnant women during the COVID-19 pandemic (pre-vaccine era) in Israel and future intention to uptake BNT162b2 mRNA COVID-19 vaccine.
    Vaccine. 2022 Feb 15. pii: S0264-410X(22)00160.
    >> Share

  1014. QUITIAN LM, Rodriguez-Martinez CE, Sossa-Briceno MP, Cortes JA, et al
    Disease burden and vaccination priorities in Colombia.
    Vaccine. 2022 Feb 15. pii: S0264-410X(22)00029.
    >> Share

  1015. AMMETER T, Lang P, Czock A
    Overview of the influenza vaccination activities and legal frameworks in 26 Swiss cantons during the influenza season 2019/20.
    Vaccine. 2022 Feb 14. pii: S0264-410X(22)00132.
    >> Share

  1016. GAFFNEY KK, Jana Broadhurst M, Brett-Major DM
    Mumps to COVID-19: Vaccinated persons remain vulnerable when community uptake is low.
    Vaccine. 2022 Feb 14. pii: S0264-410X(22)00193.
    >> Share

  1017. CHAN IL, Mowson R, Alonso JP, Roberti J, et al
    Promoting immunization equity in Latin America and the Caribbean: Case studies, lessons learned, and their implication for COVID-19 vaccine equity.
    Vaccine. 2022 Feb 14. pii: S0264-410X(22)00197.
    >> Share

  1018. MUCHIRI SK, Muthee R, Kiarie H, Sitienei J, et al
    Unmet need for COVID-19 vaccination coverage in Kenya.
    Vaccine. 2022 Feb 14. pii: S0264-410X(22)00167.
    >> Share

  1019. UWAMINO Y, Yokoyama T, Shimura T, Nishimura T, et al
    The effect of the E484K mutation of SARS-CoV-2 on the neutralizing activity of antibodies from BNT162b2 vaccinated individuals.
    Vaccine. 2022 Feb 14. pii: S0264-410X(22)00191.
    >> Share

  1020. YAMAMOTO S, Fukunaga A, Tanaka A, Takeuchi JS, et al
    Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine.
    Vaccine. 2022 Feb 14. pii: S0264-410X(22)00196.
    >> Share

  1021. TANI N, Chong Y, Kurata Y, Gondo K, et al
    Relation of fever intensity and antipyretic use with specific antibody response after two doses of the BNT162b2 mRNA vaccine.
    Vaccine. 2022 Feb 14. pii: S0264-410X(22)00158.
    >> Share

  1022. GAO F, An C, Bian L, Wang Y, et al
    Establishment of the first Chinese national standard for protein subunit SARS-CoV-2 vaccine.
    Vaccine. 2022 Feb 14. pii: S0264-410X(22)00194.
    >> Share

  1023. CHRYSI P, Stella M, Marios K, Despo C, et al
    Exploring vaccination coverage and attitudes of health care workers towards influenza vaccine in Cyprus.
    Vaccine. 2022 Feb 12. pii: S0264-410X(22)00141.
    >> Share

  1024. TIBBELS NJ, Dosso A, Fordham C, Benie W, et al
    "On the last day of the last month, I will go": A qualitative exploration of COVID-19 vaccine confidence among Ivoirian adults.
    Vaccine. 2022 Feb 11. pii: S0264-410X(22)00166.
    >> Share

  1025. HELLER O, Chun Y, Shlomo Y, Gewirtz-Meydan A, et al
    Public perceptions and the willingness to get vaccinated against COVID-19: Lessons from Israel.
    Vaccine. 2022 Feb 11. pii: S0264-410X(22)00165.
    >> Share

  1026. DIETRICH LG, Luthy A, Lucas Ramanathan P, Baldesberger N, et al
    Healthcare professional and professional stakeholders' perspectives on vaccine mandates in Switzerland: A mixed-methods study.
    Vaccine. 2022 Feb 11. pii: S0264-410X(22)00007.
    >> Share

  1027. ABHILASH KPP, Mathiyalagan P, Krishnaraj VRK, Selvan S, et al
    Impact of prior vaccination with Covishield(TM) and Covaxin(R) on mortality among symptomatic COVID-19 patients during the second wave of the pandemic in South India during April and May 2021: a cohort study.
    Vaccine. 2022 Feb 10. pii: S0264-410X(22)00157.
    >> Share

  1028. DREYER N, Reynolds MW, Albert L, Brinkley E, et al
    How frequent are acute reactions to COVID-19 vaccination and who is at risk?
    Vaccine. 2022 Feb 9. pii: S0264-410X(22)00103.
    >> Share

  1029. PRAMOD S, Govindan D, Ramasubramani P, Kar SS, et al
    Effectiveness of Covishield vaccine in preventing Covid-19 - A test-negative case-control study.
    Vaccine. 2022 Feb 9. pii: S0264-410X(22)00138.
    >> Share

  1030. MASUDA T, Murakami K, Sugiura K, Sakui S, et al
    A phase 1/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: An interim report.
    Vaccine. 2022 Feb 8. pii: S0264-410X(22)00164.
    >> Share

  1031. PEREZ-RODRIGUEZ S, de la Caridad Rodriguez-Gonzalez M, Ochoa-Azze R, Climent-Ruiz Y, et al
    A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity.
    Vaccine. 2022 Feb 8. pii: S0264-410X(22)00161.
    >> Share

  1032. WALKER B, Anderson A, Stoecker C, Shao Y, et al
    COVID-19 and Routine Childhood and Adolescent Immunizations: Evidence from Louisiana Medicaid.
    Vaccine. 2022;40:837-840.
    >> Share

  1033. DOMNICH A, Orsi A, Sticchi L, Panatto D, et al
    Effect of the 2020/21 season influenza vaccine on SARS-CoV-2 infection in a cohort of Italian healthcare workers.
    Vaccine. 2022 Feb 7. pii: S0264-410X(22)00137.
    >> Share

  1034. CRUVINEL E, P Richter K, S Scheuermann T, M Machado N, et al
    The impact of COVID-19 on income and employment and willingness to become vaccinated among African Americans enrolled in a smoking cessation randomized trial.
    Vaccine. 2022 Feb 7. pii: S0264-410X(22)00120.
    >> Share

  1035. MEWHIRTER J, Sagir M, Sanders R
    Towards a predictive model of COVID-19 vaccine hesitancy among American adults.
    Vaccine. 2022 Feb 7. pii: S0264-410X(22)00134.
    >> Share

  1036. BELLOS I, Karageorgiou V, Viskin D
    Myocarditis following mRNA Covid-19 vaccination: A pooled analysis.
    Vaccine. 2022 Feb 7. pii: S0264-410X(22)00140.
    >> Share

  1037. WONODI C, Obi-Jeff C, Adewumi F, Keluo-Udeke SC, et al
    Conspiracy theories and misinformation about COVID-19 in Nigeria: Implications for vaccine demand generation communications.
    Vaccine. 2022 Feb 7. pii: S0264-410X(22)00126.
    >> Share

  1038. WALKER J, Paul P, Dooling K, Oliver S, et al
    Modeling strategies for the allocation of SARS-CoV-2 vaccines in the United States.
    Vaccine. 2022 Feb 7. pii: S0264-410X(22)00136.
    >> Share

  1039. SPRENGHOLZ P, Korn L, Eitze S, Felgendreff L, et al
    Attitude toward a mandatory COVID-19 vaccination policy and its determinants: Evidence from serial cross-sectional surveys conducted throughout the pandemic in Germany.
    Vaccine. 2022 Feb 7. pii: S0264-410X(22)00130.
    >> Share

  1040. NONVIGNON J, Owusu R, Asare B, Adjagba A, et al
    Estimating the cost of COVID-19 vaccine deployment and introduction in Ghana using the CVIC tool.
    Vaccine. 2022 Feb 4. pii: S0264-410X(22)00070.
    >> Share

  1041. AKGUN O, Kayaalp GK, Demirkan FG, Cakmak F, et al
    Exploring the attitudes, concerns, and knowledge regarding COVID-19 vaccine by the parents of children with rheumatic disease: Cross-sectional online survey.
    Vaccine. 2022 Feb 4. pii: S0264-410X(22)00117.
    >> Share

  1042. GORSE GJ, Grimes S, Buck H, Mulla H, et al
    MAS-1, a novel water-in-oil adjuvant/delivery system, with reduced seasonal influenza vaccine hemagglutinin dose may enhance potency, durability and cross-reactivity of antibody responses in the elderly.
    Vaccine. 2022 Feb 3. pii: S0264-410X(22)00059.
    >> Share

  1043. GORSE GJ, Grimes S, Buck H, Mulla H, et al
    A phase 1 dose-sparing, randomized clinical trial of seasonal trivalent inactivated influenza vaccine combined with MAS-1, a novel water-in-oil adjuvant/delivery system.
    Vaccine. 2022 Feb 3. pii: S0264-410X(22)00058.
    >> Share

  1044. OLIANI F, Savoia A, Gallo G, Tiwana N, et al
    Italy's rollout of COVID-19 vaccinations: The crucial contribution of the first experimental mass vaccination site in Lombardy.
    Vaccine. 2022 Feb 3. pii: S0264-410X(22)00115.
    >> Share

  1045. IRVING SA, Groom HC, Dandamudi P, Daley MF, et al
    A decade of data: Adolescent vaccination in the vaccine safety datalink, 2007 through 2016.
    Vaccine. 2022 Feb 3. pii: S0264-410X(22)00091.
    >> Share

  1046. ELLITHORPE ME, Alade F, Adams RB, Nowak GJ, et al
    Looking ahead: Caregivers' COVID-19 vaccination intention for children 5 years old and younger using the health belief model.
    Vaccine. 2022 Feb 1. pii: S0264-410X(22)00097.
    >> Share

  1047. HEYERDAHL LW, Vray M, Lana B, Tvardik N, et al
    Conditionality of COVID-19 vaccine acceptance in European countries.
    Vaccine. 2022 Feb 1. pii: S0264-410X(22)00099.
    >> Share

  1048. SHAW J, Anderson KB, Fabi RE, Thompson CA, et al
    COVID-19 vaccination intention and behavior in a large, diverse, U.S. refugee population.
    Vaccine. 2022 Feb 1. pii: S0264-410X(22)00100.
    >> Share

  1049. YOUSAF M, Hassan Raza S, Mahmood N, Core R, et al
    Immunity debt or vaccination crisis? A multi-method evidence on vaccine acceptance and media framing for emerging COVID-19 variants.
    Vaccine. 2022 Feb 1. pii: S0264-410X(22)00101.
    >> Share

    January 2022
  1050. SANDMANN FG, van Leeuwen E, Bernard-Stoecklin S, Casado I, et al
    Health and economic impact of seasonal influenza mass vaccination strategies in European settings: A mathematical modelling and cost-effectiveness analysis.
    Vaccine. 2022 Jan 31. pii: S0264-410X(22)00039.
    >> Share

  1051. JANSSEN YF, Feitsma EA, Boersma HH, Alleva DG, et al
    Phase I interim results of a phase I/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452.
    Vaccine. 2022 Jan 31. pii: S0264-410X(22)00077.
    >> Share

  1052. PAGET J, Danielle Iuliano A, Taylor RJ, Simonsen L, et al
    Estimates of mortality associated with seasonal influenza for the European Union from the GLaMOR project.
    Vaccine. 2022 Jan 28. pii: S0264-410X(21)01561.
    >> Share

  1053. DING H, Huang J, Ngai CH, Sun Q, et al
    The cost-effectiveness of starting 23-valent pneumococcal polysaccharide vaccine and influenza vaccination at 50 vs. 65 years: A comparative modelling study.
    Vaccine. 2022 Jan 28. pii: S0264-410X(22)00057.
    >> Share

  1054. KALNIN KV, Plitnik T, Kishko M, Huang D, et al
    Pan-SARS neutralizing responses after third boost vaccination in non-human primate immunogenicity model.
    Vaccine. 2022 Jan 28. pii: S0264-410X(22)00045.
    >> Share

  1055. JAFFE AE, Graupensperger S, Blayney JA, Duckworth JC, et al
    The role of perceived social norms in college student vaccine hesitancy: Implications for COVID-19 prevention strategies.
    Vaccine. 2022 Jan 26. pii: S0264-410X(22)00073.
    >> Share

  1056. BLUNCK BN, Aideyan L, Ye X, Avadhanula V, et al
    Antibody responses of healthy adults to the p27 peptide of respiratory syncytial virus fusion protein.
    Vaccine. 2022;40:536-543.
    >> Share

  1057. TANGUAY M, Boutin M, Laumaea A, Salaciak M, et al
    B-cell cytopenia and time to last B-cell-depleting therapy predict response to SARS-COV-2 vaccines in patients with lymphoproliferative disorders.
    Vaccine. 2022 Jan 24. pii: S0264-410X(22)00071.
    >> Share

  1058. TRENT MJ, Salmon DA, MacIntyre CR
    Predictors of pneumococcal vaccination among Australian adults at high risk of pneumococcal disease.
    Vaccine. 2022 Jan 22. pii: S0264-410X(22)00026.
    >> Share

  1059. STEBBINGS R, Armour G, Pettis V, Goodman J, et al
    AZD1222 (ChAdOx1 nCov-19): A Single-Dose biodistribution study in mice.
    Vaccine. 2022;40:192-195.
    >> Share

  1060. LIAO Q, Cowling BJ, Xiao J, Yuan J, et al
    Priming with social benefit information of vaccination to increase acceptance of COVID-19 vaccines.
    Vaccine. 2022 Jan 20. pii: S0264-410X(22)00055.
    >> Share

  1061. LIU F, Feng C, Xu S, Wu Q, et al
    An AAV vaccine targeting the RBD of the SARS-CoV-2 S protein induces effective neutralizing antibody titers in mice and canines.
    Vaccine. 2022 Jan 20. pii: S0264-410X(22)00054.
    >> Share

  1062. ZHU D, Lv M, Bai Y, Wu J, et al
    Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in Beijing: A modeling analysis.
    Vaccine. 2022 Jan 19. pii: S0264-410X(22)00024.
    >> Share

  1063. LI LL, Zheng C, La J, Do NV, et al
    Impact of prior SARS-CoV-2 infection on incidence of hospitalization and adverse events following mRNA SARS-CoV-2 vaccination: A nationwide, retrospective cohort study.
    Vaccine. 2022 Jan 19. pii: S0264-410X(22)00051.
    >> Share

  1064. PITCOVSKI J, Gruzdev N, Abzach A, Katz C, et al
    Oral subunit SARS-CoV-2 vaccine induces systemic neutralizing IgG, IgA and cellular immune responses and can boost neutralizing antibody responses primed by an injected vaccine.
    Vaccine. 2022 Jan 19. pii: S0264-410X(22)00050.
    >> Share

  1065. PASSARETTI CL, Priem JS, Agner TG, McCurdy L, et al
    Reducing the rates of household transmission: The impact of COVID-19 vaccination in healthcare workers with a known household exposure.
    Vaccine. 2022 Jan 19. pii: S0264-410X(22)00044.
    >> Share

  1066. ROLFES L, Harmark L, Kant A, van Balveren L, et al
    COVID-19 vaccine reactogenicity - A cohort event monitoring study in the Netherlands using patient reported outcomes.
    Vaccine. 2022 Jan 17. pii: S0264-410X(22)00028.
    >> Share

  1067. BEDSTON S, Akbari A, Jarvis CI, Lowthian E, et al
    COVID-19 vaccine uptake, effectiveness, and waning in 82,959 health care workers: A national prospective cohort study in Wales.
    Vaccine. 2022 Jan 15. pii: S0264-410X(21)01535.
    >> Share

  1068. MOYO P, Bosco E, Bardenheier BH, Rivera-Hernandez M, et al
    Variation in influenza vaccine assessment, receipt, and refusal by the concentration of Medicare Advantage enrollees in U.S. nursing homes.
    Vaccine. 2022 Jan 13. pii: S0264-410X(21)01688.
    >> Share

  1069. WONG WHS, Leung D, Chua GT, Duque JSR, et al
    Adolescents' attitudes to the COVID-19 vaccination.
    Vaccine. 2022 Jan 12. pii: S0264-410X(22)00025.
    >> Share

  1070. WOO EJ, Moro PL
    Postmarketing safety surveillance of high-dose quadrivalent influenza vaccine: Reports to the Vaccine Adverse Event Reporting System.
    Vaccine. 2022 Jan 11. pii: S0264-410X(22)00001.
    >> Share

  1071. SHIMIZU S, Tanaka R, Itoh E, Maekawa-Matsuura M, et al
    Performance and usability evaluation of novel intradermal injection device Immucise and reanalysis of intradermal administration trials of influenza vaccine for the elderly.
    Vaccine. 2022 Jan 11. pii: S0264-410X(21)01669.
    >> Share

  1072. BLYTH DM, Liang Z, Williams M, Murray CK, et al
    Immune interference revisited: Impact of live-attenuated influenza vaccine prior to yellow fever vaccination.
    Vaccine. 2022 Jan 11. pii: S0264-410X(21)01637.
    >> Share

  1073. DANIEL CL, Williams J, Legg R, McGowen C, et al
    Factors associated with COVID-19 vaccination intentions among adults in the deep South.
    Vaccine. 2022 Jan 10. pii: S0264-410X(21)01667.
    >> Share

  1074. PENG KW, Carey T, Lech P, Vandergaast R, et al
    Boosting of SARS-CoV-2 immunity in nonhuman primates using an oral rhabdoviral vaccine.
    Vaccine. 2022 Jan 10. pii: S0264-410X(21)01671.
    >> Share

  1075. OMER I, Rosenberg A, Sefty H, Pando R, et al
    Lineage-matched versus mismatched influenza B vaccine effectiveness following seasons of marginal influenza B circulation.
    Vaccine. 2022 Jan 8. pii: S0264-410X(21)01664.
    >> Share

  1076. FOO D, Sarna M, Pereira G, Moore HC, et al
    Longitudinal, population-based cohort study of prenatal influenza vaccination and influenza infection in childhood.
    Vaccine. 2022 Jan 7. pii: S0264-410X(21)01556.
    >> Share

  1077. UWAMINO Y, Kurafuji T, Sato Y, Tomita Y, et al
    Young age, female sex, and presence of systemic adverse reactions are associated with high post-vaccination antibody titer after two doses of BNT162b2 mRNA SARS-CoV-2 vaccination: An observational study of 646 Japanese healthcare workers and universit
    Vaccine. 2022 Jan 7. pii: S0264-410X(22)00002.
    >> Share

  1078. HSIAO A, Hansen J, Nunley KV, Lewis N, et al
    Safety of recombinant quadrivalent influenza vaccine compared to inactivated influenza vaccine in Chinese adults: An observational study.
    Vaccine. 2022 Jan 6. pii: S0264-410X(21)01641.
    >> Share

  1079. EUSER S, Kroese FM, Derks M, de Bruin M, et al
    Understanding COVID-19 vaccination willingness among youth: A survey study in the Netherlands.
    Vaccine. 2022 Jan 5. pii: S0264-410X(21)01670.
    >> Share

  1080. THOMAS S, Durrheim D, Islam F, Higgins H, et al
    Improved childhood immunization coverage using the World Health Organization's Tailoring Immunization Programmes guide (TIP) in a regional centre in Australia.
    Vaccine. 2022;40:18-20.
    >> Share

  1081. KUJAWSKI SA, Yao L, Wang HE, Carias C, et al
    Impact of the COVID-19 pandemic on pediatric and adolescent vaccinations and well child visits in the United States: A database analysis.
    Vaccine. 2022 Jan 1. pii: S0264-410X(21)01672.
    >> Share

    December 2021
  1082. GROOM HC, Crane B, Naleway AL, Weintraub E, et al
    Monitoring vaccine safety using the vaccine safety Datalink: Assessing capacity to integrate data from Immunization Information systems.
    Vaccine. 2021 Dec 31. pii: S0264-410X(21)01656.
    >> Share

  1083. PASCHALL AV, Ozdilek A, Briner SL, Brindley MA, et al
    Modulation of immunosuppressant drug treatment to improve SARS-CoV-2 vaccine efficacy in mice.
    Vaccine. 2021 Dec 31. pii: S0264-410X(21)01666.
    >> Share

  1084. SAELAND E, van der Fits L, Bolder R, Heemskerk-van der Meer M, et al
    Immunogenicity and protective efficacy of adenoviral and subunit RSV vaccines based on stabilized prefusion F protein in pre-clinical models.
    Vaccine. 2021 Dec 29. pii: S0264-410X(21)01651.
    >> Share

  1085. SHUKLA S, Fressin F, Un M, Coetzer H, et al
    Optimizing vaccine distribution via mobile clinics: a case study on COVID-19 vaccine distribution to long-term care facilities.
    Vaccine. 2021 Dec 27. pii: S0264-410X(21)01657.
    >> Share

  1086. RIBEIRO SP, De Moura Mattaraia VG, Almeida RR, Valentine EJG, et al
    A promiscuous T cell epitope-based HIV vaccine providing redundant population coverage of the HLA class II elicits broad, polyfunctional T cell responses in nonhuman primates.
    Vaccine. 2021 Dec 24. pii: S0264-410X(21)01550.
    >> Share

  1087. JUNE CHOE Y, Yi S, Hwang I, Kim J, et al
    Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents.
    Vaccine. 2021 Dec 24. pii: S0264-410X(21)01654.
    >> Share

  1088. THOMAS SJ, Perez JL, Lockhart SP, Hariharan S, et al
    Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial.
    Vaccine. 2021 Dec 24. pii: S0264-410X(21)01652.
    >> Share

  1089. KIM HJ, Yun HJ, Kim J, Kym S, et al
    Antibody response to second dose of the BNT162b2 mRNA vaccine in the first 12 weeks in South Korea: A prospective longitudinal study.
    Vaccine. 2021 Dec 22. pii: S0264-410X(21)01620.
    >> Share

  1090. ROMAIN-SCELLE N, Elias C, Vanhems P
    COVID-19 vaccine is correlated with favourable epidemiological indicators in the Auvergne-Rhone-Alpes region (France): An ecological study.
    Vaccine. 2021 Dec 22. pii: S0264-410X(21)01644.
    >> Share

  1091. MANOMAIPIBOON A, Phumisantiphong U, Maneerit J, Chalearmchai Y, et al
    Immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 with 12-dose vials: An interim analysis.
    Vaccine. 2021 Dec 22. pii: S0264-410X(21)01632.
    >> Share

  1092. TADAKUMA K, Maruyama T, Mori K, Fujiki N, et al
    Effectiveness of seasonal influenza vaccine in adult Japanese workers, 2017-2020.
    Vaccine. 2021 Dec 21. pii: S0264-410X(21)01624.
    >> Share

  1093. WILLIAMS KV, Zhai B, Alcorn JF, Patricia Nowalk M, et al
    A randomized controlled trial of antibody response to 2019-20 cell-based inactivated and egg-based live attenuated influenza vaccines in children and young adults.
    Vaccine. 2021 Dec 21. pii: S0264-410X(21)01643.
    >> Share

  1094. PETERSEN MB, Jorgensen F, Lindholt MF
    Did the European suspension of the AstraZeneca vaccine decrease vaccine acceptance during the COVID-19 pandemic?
    Vaccine. 2021 Dec 21. pii: S0264-410X(21)01631.
    >> Share

  1095. SHAPIRO GK, Gottfredson N, Leask J, Wiley K, et al
    COVID-19 and missed or delayed vaccination in 26 middle- and high-income countries: An observational survey.
    Vaccine. 2021 Dec 21. pii: S0264-410X(21)01649.
    >> Share

  1096. BLANCO S, Salome Konigheim B, Diaz A, Spinsanti L, et al
    Evaluation of the Gam-COVID-Vac and vaccine-induced neutralizing response against SARS-CoV-2 lineage P.1 variant in an Argentinean cohort.
    Vaccine. 2021 Dec 20. pii: S0264-410X(21)01634.
    >> Share

  1097. POUKKA E, Baum U, Palmu AA, Lehtonen TO, et al
    Cohort study of Covid-19 vaccine effectiveness among healthcare workers in Finland, December 2020 - October 2021.
    Vaccine. 2021 Dec 18. pii: S0264-410X(21)01640.
    >> Share

  1098. HERRING WL, Zhang Y, Shinde V, Stoddard J, et al
    Clinical and economic outcomes associated with respiratory syncytial virus vaccination in older adults in the United States.
    Vaccine. 2021 Dec 18. pii: S0264-410X(21)01609.
    >> Share

  1099. CHUNG NH, Chen YC, Yang SJ, Lin YC, et al
    Induction of Th1 and Th2 in the protection against SARS-CoV-2 through mucosal delivery of an adenovirus vaccine expressing an engineered spike protein.
    Vaccine. 2021 Dec 17. pii: S0264-410X(21)01635.
    >> Share

  1100. CARLSON SJ, McKenzie L, Roberts L, Blyth CC, et al
    Does a major change to a COVID-19 vaccine program alter vaccine intention? A qualitative investigation.
    Vaccine. 2021 Dec 16. pii: S0264-410X(21)01629.
    >> Share

  1101. GOLDBLATT D, Fiore-Gartland A, Johnson M, Hunt A, et al
    Towards a population-based threshold of protection for COVID-19 vaccines.
    Vaccine. 2021 Dec 15. pii: S0264-410X(21)01615.
    >> Share

  1102. YU Y, Jia W, Lau MMC, Lau JTF, et al
    Levels and factors derived from the Health Action Process Approach of behavioral intentions to take up COVID-19 vaccination: A random population-based study.
    Vaccine. 2021 Dec 15. pii: S0264-410X(21)01628.
    >> Share

  1103. CHEN X, Wang H
    On the rise of the new B.1.1.529 variant: Five dimensions of access to a COVID-19 vaccine.
    Vaccine. 2021 Dec 14. pii: S0264-410X(21)01596.
    >> Share

  1104. ALMOHAYA AM, Alsubie H, Alqarni B, Alzayad B, et al
    Acute unsolicited adverse events following BNT162b2 vaccine in Saudi Arabia, a real-world data.
    Vaccine. 2021 Dec 13. pii: S0264-410X(21)01610.
    >> Share

  1105. BOTTON J, Dray-Spira R, Baricault B, Drouin J, et al
    Reduced risk of severe COVID-19 in more than 1.4 million elderly people aged 75 years and older vaccinated with mRNA-based vaccines.
    Vaccine. 2021 Dec 11. pii: S0264-410X(21)01617.
    >> Share

  1106. LUTRICK K, Groom H, Fowlkes AL, Groover KD, et al
    COVID-19 vaccine perceptions and uptake in a national prospective cohort of essential workers.
    Vaccine. 2021 Dec 11. pii: S0264-410X(21)01593.
    >> Share

  1107. HSIEH YL, Rak S, SteelFisher GK, Bauhoff S, et al
    Effect of the suspension of the J&J COVID-19 vaccine on vaccine hesitancy in the United States.
    Vaccine. 2021 Dec 11. pii: S0264-410X(21)01559.
    >> Share

  1108. OLIVEIRA-SILVA J, Reis T, Lopes C, Batista-Silva R, et al
    Humoral response to the SARS-CoV-2 BNT162b2 mRNA vaccine: Real-world data from a large cohort of healthcare workers.
    Vaccine. 2021 Dec 11. pii: S0264-410X(21)01621.
    >> Share

  1109. ZHAO AR, Bishai DM
    Public health spending, primary care, and perceived risk promoted vaccination against H1N1.
    Vaccine. 2021 Dec 10. pii: S0264-410X(21)01538.
    >> Share

  1110. KATZ MA, Harlev EB, Chazan B, Chowers M, et al
    Early effectiveness of BNT162b2 Covid-19 vaccine in preventing SARS-CoV-2 infection in healthcare personnel in six Israeli hospitals (CoVEHPI).
    Vaccine. 2021 Dec 10. pii: S0264-410X(21)01580.
    >> Share

  1111. KADKHODA K
    Post RNA-based COVID vaccines myocarditis: Proposed mechanisms.
    Vaccine. 2021 Dec 9. pii: S0264-410X(21)01594.
    >> Share

  1112. ZHAO H, Li Y, Wang Z
    Adverse event of Sinovac Coronavirus vaccine: Deafness.
    Vaccine. 2021 Dec 9. pii: S0264-410X(21)01576.
    >> Share

  1113. PEPIN J, Labbe AC, Carignan A, Parent ME, et al
    Does BCG provide long-term protection against SARS-CoV-2 infection? A case-control study in Quebec, Canada.
    Vaccine. 2021;39:7300-7307.
    >> Share

  1114. HOOK SA, Hansen AP, Niesobecki SA, Meek JI, et al
    Evaluating public acceptability of a potential Lyme disease vaccine using a population-based, cross-sectional survey in high incidence areas of the United States.
    Vaccine. 2021 Dec 8. pii: S0264-410X(21)01540.
    >> Share

  1115. LENNON RP, Block R Jr, Schneider EC, Zephrin L, et al
    Underserved population acceptance of combination influenza-COVID-19 booster vaccines.
    Vaccine. 2021 Dec 7. pii: S0264-410X(21)01597.
    >> Share

  1116. SULIS G, Basta NE, Wolfson C, Kirkland SA, et al
    Influenza vaccination uptake among Canadian adults before and during the COVID-19 pandemic: An analysis of the Canadian Longitudinal study on Aging (CLSA).
    Vaccine. 2021 Dec 4. pii: S0264-410X(21)01579.
    >> Share

  1117. RAW RK, Rees J, Kelly CA, Wroe C, et al
    Prior COVID-19 infection is associated with increased Adverse Events (AEs) after the first, but not the second, dose of the BNT162b2/Pfizer vaccine.
    Vaccine. 2021 Dec 4. pii: S0264-410X(21)01577.
    >> Share

  1118. BRONSTEIN MV, Kummerfeld E, MacDonald A 3rd, Vinogradov S, et al
    Willingness to vaccinate against SARS-CoV-2: The role of reasoning biases and conspiracist ideation.
    Vaccine. 2021 Dec 4. pii: S0264-410X(21)01553.
    >> Share

  1119. NGUYEN AT, Arnold BF, Kennedy CJ, Mishra K, et al
    Evaluation of a city-wide school-located influenza vaccination program in Oakland, California with respect to race and ethnicity: A matched cohort study.
    Vaccine. 2021 Dec 3. pii: S0264-410X(21)01547.
    >> Share

  1120. HILL R
    COVID-19 from a polio perspective.
    Vaccine. 2021;39:7117-7118.
    >> Share

  1121. IZAK M, Stoyanov E, Dezuraev K, Shinar E, et al
    Correlation of Anti-SARS-CoV-2 S1-specificIgG antibody levels and adverse events following vaccination with BNT162b2 mRNA COVID-19 vaccine in healthcare workers.
    Vaccine. 2021 Dec 3. pii: S0264-410X(21)01557.
    >> Share

  1122. HERZBERG J, Vollmer T, Fischer B, Becher H, et al
    SARS-CoV-2-antibody response in health care workers after vaccination or natural infection in a longitudinal observational study.
    Vaccine. 2021 Dec 3. pii: S0264-410X(21)01555.
    >> Share

  1123. YORSAENG R, Suntronwong N, Phowatthanasathian H, Assawakosri S, et al
    Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults.
    Vaccine. 2021 Dec 3. pii: S0264-410X(21)01560.
    >> Share

  1124. HELLE F, Moyet J, Demey B, Francois C, et al
    Humoral anti-SARS-CoV-2 immune response after two doses of Comirnaty vaccine in nursing home residents by previous infection status.
    Vaccine. 2021 Dec 3. pii: S0264-410X(21)01558.
    >> Share

  1125. VALCKX S, Crevecoeur J, Verelst F, Vranckx M, et al
    Individual factors influencing COVID-19 vaccine acceptance in between and during pandemic waves (July-December 2020).
    Vaccine. 2021 Dec 1. pii: S0264-410X(21)01414.
    >> Share

    November 2021
  1126. ATTWELL K, Rizzi M, McKenzie L, Carlson SJ, et al
    COVID-19 vaccine Mandates: An Australian attitudinal study.
    Vaccine. 2021 Nov 30. pii: S0264-410X(21)01530.
    >> Share

  1127. SUGISHITA Y, Sugawara T
    Effectiveness and cost-effectiveness of influenza vaccination for elderly people.
    Vaccine. 2021 Nov 29. pii: S0264-410X(21)01257.
    >> Share

  1128. CASTRO F, Pascale JM, Slocum Hewitt I, Calvo A, et al
    Mass vaccination campaign during the 2016 influenza outbreak in Panama: Challenges and implications for COVID-19 vaccination efforts.
    Vaccine. 2021 Nov 27. pii: S0264-410X(21)01504.
    >> Share

  1129. SCHMITZ M, Luminet O, Klein O, Morbee S, et al
    Predicting vaccine uptake during COVID-19 crisis: A motivational approach.
    Vaccine. 2021 Nov 27. pii: S0264-410X(21)01542.
    >> Share

  1130. MALTEZOU HC, Anastassopoulou C, Hatziantoniou S, Poland GA, et al
    Anaphylaxis rates associated with COVID-19 vaccines are comparable to those of other vaccines.
    Vaccine. 2021 Nov 27. pii: S0264-410X(21)01539.
    >> Share

  1131. GULPINAR G, Uzun MB
    Examining community pharmacists' intention to provide pharmacist-driven vaccination services: A structural equation modelling.
    Vaccine. 2021 Nov 26. pii: S0264-410X(21)01499.
    >> Share

  1132. ROBERTSON JS, Loizides U, Adisa A, Lopez de la Rica Manjavacas A, et al
    International Nonproprietary Names (INN) for novel vaccine substances: A matter of safety.
    Vaccine. 2021 Nov 26. pii: S0264-410X(21)01528.
    >> Share

  1133. BUCHMAN TG, Simpson SQ, Sciarretta KL, Finne KP, et al
    Seasonal influenza vaccination is associated with reduced risk of death among Medicare beneficiaries().
    Vaccine. 2021 Nov 23. pii: S0264-410X(21)01461.
    >> Share

  1134. LENTZEN MP, Huebenthal V, Kaiser R, Kreppel M, et al
    A retrospective analysis of social media posts pertaining to COVID-19 vaccination side effects.
    Vaccine. 2021 Nov 22. pii: S0264-410X(21)01526.
    >> Share

  1135. DINC HO, Saltoglu N, Can G, Balkan II, et al
    Inactive SARS-CoV-2 vaccine generates high antibody responses in healthcare workers with and without prior infection.
    Vaccine. 2021 Nov 22. pii: S0264-410X(21)01507.
    >> Share

  1136. LIN C, Tu P, Terry TC
    Moving the needle on racial disparity: COVID-19 vaccine trust and hesitancy.
    Vaccine. 2021 Nov 20. pii: S0264-410X(21)01444.
    >> Share

  1137. MUSCATELLO DJ, Nazareno AL, Turner RM, Newall AT, et al
    Influenza-associated mortality in Australia, 2010 through 2019: High modelled estimates in 2017.
    Vaccine. 2021 Nov 19. pii: S0264-410X(21)01464.
    >> Share

  1138. CHEN T, Dai M, Xia S
    Perceived facilitators and barriers to intentions of receiving the COVID-19 vaccines among elderly Chinese adults.
    Vaccine. 2021 Nov 19. pii: S0264-410X(21)01484.
    >> Share

  1139. CAMBON L, Schwarzinger M, Alla F
    Increasing acceptance of a vaccination program for coronavirus disease 2019 in France: A challenge for one of the world's most vaccine-hesitant countries.
    Vaccine. 2021 Nov 19. pii: S0264-410X(21)01467.
    >> Share

  1140. ORTEGA-SANCHEZ IR, Mott JA, Kittikraisak W, Khanthamaly V, et al
    Cost-effectiveness of seasonal influenza vaccination in pregnant women, healthcare workers and adults >= 60 years of age in Lao People's Democratic Republic.
    Vaccine. 2021 Nov 18. pii: S0264-410X(21)01445.
    >> Share

  1141. IRVING SA, Ball SW, Booth SM, Regan AK, et al
    A multi-country investigation of influenza vaccine coverage in pregnant individuals, 2010-2016.
    Vaccine. 2021 Nov 18. pii: S0264-410X(21)01463.
    >> Share

  1142. NGUYEN KH, Anneser E, Toppo A, Allen JD, et al
    Disparities in national and state estimates of COVID-19 vaccination receipt and intent to vaccinate by race/ethnicity, income, and age group among adults >/= 18 years, United States.
    Vaccine. 2021 Nov 18. pii: S0264-410X(21)01485.
    >> Share

  1143. BELLIZZI S, Aidyralieva C, Al-Shaikh A, Muthu N, et al
    Inclusiveness of prisons in COVID-19 vaccination deployment: Evidence from Jordan.
    Vaccine. 2021 Nov 18. pii: S0264-410X(21)01468.
    >> Share

  1144. KITRO A, Sirikul W, Piankusol C, Rirermsoonthorn P, et al
    Acceptance, attitude, and factors affecting the intention to accept COVID-19 vaccine among Thai people and expatriates living in Thailand.
    Vaccine. 2021 Nov 17. pii: S0264-410X(21)01476.
    >> Share

  1145. VOSS G, Jacquet JM, Tornieporth N, Kampmann B, et al
    Meeting report: CEPI consultation on accelerating access to novel vaccines against emerging infectious diseases for pregnant and lactating women, London, 12-13 February 2020.
    Vaccine. 2021 Nov 16. pii: S0264-410X(21)01382.
    >> Share

  1146. BRAKEL KA, Binjawadagi B, French-Kim K, Watts M, et al
    Coexpression of respiratory syncytial virus (RSV) fusion (F) protein and attachment glycoprotein (G) in a vesicular stomatitis virus (VSV) vector system provides synergistic effects against RSV infection in a cotton rat model.
    Vaccine. 2021;39:6817-6828.
    >> Share

  1147. MURPHY RP, Taaffe C, Ahern E, McMahon G, et al
    A meta-analysis of influenza vaccination following correspondence: Considerations for COVID-19.
    Vaccine. 2021 Nov 15. pii: S0264-410X(21)01470.
    >> Share

  1148. ROGERS JH, Cox SN, Hughes JP, Link AC, et al
    Trends in COVID-19 vaccination intent and factors associated with deliberation and reluctance among adult homeless shelter residents and staff, 1 November 2020 to 28 February 2021 - King County, Washington.
    Vaccine. 2021 Nov 15. pii: S0264-410X(21)01471.
    >> Share

  1149. SILAS J, Jones A, Weiss-Cohen L, Ayton P, et al
    The seductive allure of technical language and its effect on covid-19 vaccine beliefs and intentions.
    Vaccine. 2021 Nov 15. pii: S0264-410X(21)01472.
    >> Share

  1150. ROSENTHAL S, Cummings CL
    Influence of rapid COVID-19 vaccine development on vaccine hesitancy.
    Vaccine. 2021 Nov 13. pii: S0264-410X(21)01448.
    >> Share

  1151. VIZCARRA P, Haemmerle J, Velasco H, Velasco T, et al
    BNT162b2 mRNA COVID-19 vaccine Reactogenicity: The key role of immunity.
    Vaccine. 2021 Nov 11. pii: S0264-410X(21)01417.
    >> Share

  1152. CHHABRIA S, Stanford FC
    A long shot: The importance of needle length in vaccinating patients with obesity against COVID-19.
    Vaccine. 2021 Nov 11. pii: S0264-410X(21)01442.
    >> Share

  1153. MCLEAN HQ, Levine MZ, King JP, Flannery B, et al
    Serologic response to sequential vaccination with enhanced influenza vaccines: Open label randomized trial among adults aged 65-74 years.
    Vaccine. 2021 Nov 10. pii: S0264-410X(21)01415.
    >> Share

  1154. RODRIGUES CMC, Plotkin SA
    The influence of interval between doses on response to vaccines.
    Vaccine. 2021 Nov 10. pii: S0264-410X(21)01381.
    >> Share

  1155. WU K, Choi A, Koch M, Elbashir S, et al
    Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice.
    Vaccine. 2021 Nov 8. pii: S0264-410X(21)01435.
    >> Share

  1156. MCKINNON B, Quach C, Dube E, Tuong Nguyen C, et al
    Social inequalities in COVID-19 vaccine acceptance and uptake for children and adolescents in Montreal, Canada.
    Vaccine. 2021 Nov 8. pii: S0264-410X(21)01426.
    >> Share

  1157. SHARUN K, Tiwari R, Saied AA, Dhama K, et al
    SARS-CoV-2 vaccine for domestic and captive animals: An effort to counter COVID-19 pandemic at the human-animal interface.
    Vaccine. 2021 Nov 6. pii: S0264-410X(21)01386.
    >> Share

  1158. GOODE JR, Cook P, Cuttino S, Gatewood SBS, et al
    Early experience with COVID-19 vaccine in a Federally-Qualified Healthcare Center for the homeless.
    Vaccine. 2021 Nov 6. pii: S0264-410X(21)01388.
    >> Share

  1159. DE HAAS TDJ, Yeung KHT, Hutubessy R, van der Putten IM, et al
    Programme costs for introducing age/gestation-based universal influenza vaccine schedules for young children and pregnant women in Hong Kong.
    Vaccine. 2021;39:6762-6780.
    >> Share

  1160. LAU CL, Mayfield HJ, Sinclair JE, Brown SJ, et al
    Risk-benefit analysis of the AstraZeneca COVID-19 vaccine in Australia using a Bayesian network modelling framework.
    Vaccine. 2021 Nov 4. pii: S0264-410X(21)01428.
    >> Share

  1161. SANZ-ROJO S, Jimenez-Garcia R, Lopez-de-Andres A, de Miguel-Diez J, et al
    Influenza vaccination uptake among high-risk target groups and health care workers in Spain and change from 2017 to 2020.
    Vaccine. 2021 Nov 3. pii: S0264-410X(21)01392.
    >> Share

  1162. RIBERA-CANO A, Dupont M, Houze-Cerfon CH, Houze-Cerfon V, et al
    Evaluation of a prototype decontamination mobile unit (UMDEO) for COVID-19 vaccination: A cross-sectional survey in France.
    Vaccine. 2021 Nov 3. pii: S0264-410X(21)01429.
    >> Share

  1163. MALTEZOU HC
    Vaccination of healthcare personnel in the COVID-19 era: A call for actions.
    Vaccine. 2021 Nov 2. pii: S0264-410X(21)01427.
    >> Share

  1164. CASSONE A, Cauda R
    Multicomponent vaccines to fight SARS-CoV-2 variants of concern.
    Vaccine. 2021 Nov 1. pii: S0264-410X(21)01402.
    >> Share

  1165. WAGNER A, Jasinska J, Tomosel E, Zielinski CC, et al
    Absent antibody production following COVID19 vaccination with mRNA in patients under immunosuppressive treatments.
    Vaccine. 2021 Nov 1. pii: S0264-410X(21)01401.
    >> Share

    October 2021
  1166. KHOURY J, Najjar-Debbiny R, Hanna A, Jabbour A, et al
    COVID-19 vaccine - Long term immune decline and breakthrough infections.
    Vaccine. 2021 Oct 30. pii: S0264-410X(21)01370.
    >> Share

  1167. LIU H, Zhou C, An J, Song Y, et al
    Development of recombinant COVID-19 vaccine based on CHO-produced, prefusion spike trimer and alum/CpG adjuvants.
    Vaccine. 2021 Oct 30. pii: S0264-410X(21)01399.
    >> Share

  1168. MALTEZOU HC, Panagopoulos P, Sourri F, Giannouchos TV, et al
    COVID-19 vaccination significantly reduces morbidity and absenteeism among healthcare personnel: A prospective multicenter study.
    Vaccine. 2021 Oct 30. pii: S0264-410X(21)01387.
    >> Share

  1169. GORDON SF, Clothier HJ, Morgan H, Buttery JP, et al
    Immune thrombocytopenia following immunisation with Vaxzevria ChadOx1-S (AstraZeneca) vaccine, Victoria, Australia.
    Vaccine. 2021 Oct 29. pii: S0264-410X(21)01350.
    >> Share

  1170. GARCIA-GRIMSHAW M, Ceballos-Liceaga SE, Michel-Chavez A, Garcia-Alanis M, et al
    Transient sensory symptoms among first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine: A case-control study.
    Vaccine. 2021 Oct 29. pii: S0264-410X(21)01391.
    >> Share

  1171. MAZUR A, Benitez S, Chuffart-Finsterwald S, La Rotta R, et al
    COVAX no fault compensation program for COVID-19 vaccine injuries in 92 low and middle income countries.
    Vaccine. 2021 Oct 28. pii: S0264-410X(21)01380.
    >> Share

  1172. MARTIN S, Vanderslott S
    "Any idea how fast 'It's just a mask!' can turn into 'It's just a vaccine!'": From mask mandates to vaccine mandates during the COVID-19 pandemic.
    Vaccine. 2021 Oct 28. pii: S0264-410X(21)01351.
    >> Share

  1173. NOWALK MP, D'Agostino HEA, Zimmerman RK, Saul SG, et al
    Agreement among sources of adult influenza vaccination in the age of immunization information systems.
    Vaccine. 2021 Oct 26. pii: S0264-410X(21)01372.
    >> Share

  1174. CHANTHAVANICH P, Versage E, Van Twuijver E, Hohenboken M, et al
    Antibody responses against heterologous A/H5N1 strains for an MF59-adjuvanted cell culture-derived A/H5N1 (aH5N1c) influenza vaccine in healthy pediatric subjects.
    Vaccine. 2021 Oct 25. pii: S0264-410X(21)01317.
    >> Share

  1175. OLANIPEKUN T, Abe T, Effoe V, Westney G, et al
    Changes in COVID-19 vaccine acceptance rate among recovered critically Ill patients: A 12-month follow-up study.
    Vaccine. 2021 Oct 25. pii: S0264-410X(21)01324.
    >> Share

  1176. LOEB M, Russell ML, Kelly-Stradiotto C, Fuller N, et al
    Adjuvanted trivalent influenza vaccine versus quadrivalent inactivated influenza vaccine in Hutterite Children: A randomized clinical trial.
    Vaccine. 2021 Oct 23. pii: S0264-410X(21)01355.
    >> Share

  1177. SHACHOR-MEYOUHAS Y, Hussein K, Szwarcwort-Cohen M, Weissman A, et al
    Single BNT162b2 vaccine dose produces seroconversion in under 60 s cohort.
    Vaccine. 2021 Oct 23. pii: S0264-410X(21)01327.
    >> Share

  1178. TRAN VN, Nguyen HA, Le TTA, Truong TT, et al
    Factors influencing adverse events following immunization with AZD1222 in Vietnamese adults during first half of 2021.
    Vaccine. 2021;39:6485-6491.
    >> Share

  1179. ANDRADE G
    Covid-19 vaccine hesitancy, conspiracist beliefs, paranoid ideation and perceived ethnic discrimination in a sample of University students in Venezuela.
    Vaccine. 2021 Oct 22. pii: S0264-410X(21)01371.
    >> Share

  1180. MAKOVITZKI A, Lerer E, Kafri Y, Adar Y, et al
    Evaluation of a downstream process for the recovery and concentration of a Cell-Culture-Derived rVSV-Spike COVID-19 vaccine candidate.
    Vaccine. 2021 Oct 22. pii: S0264-410X(21)01376.
    >> Share

  1181. FAN S, Li D, Zhao H, Yu L, et al
    Ameliorated immunity elicited by intradermal inoculation in individuals vaccinated with inactivated SARS-CoV-2 vaccine.
    Vaccine. 2021 Oct 22. pii: S0264-410X(21)01375.
    >> Share

  1182. JAMES EK, Bokemper SE, Gerber AS, Omer SB, et al
    Persuasive messaging to increase COVID-19 vaccine uptake intentions.
    Vaccine. 2021 Oct 22. pii: S0264-410X(21)01368.
    >> Share

  1183. WANG J, Wagner AL, Chen Y, Jaime E, et al
    Would COVID-19 vaccination willingness increase if mobile technologies prohibit unvaccinated individuals from public spaces? A nationwide discrete choice experiment from China.
    Vaccine. 2021 Oct 22. pii: S0264-410X(21)01340.
    >> Share

  1184. DANG TKNS, Rivero Cabrera R, Yeung KHT, van der Putten IM, et al
    Feasibility of age- and gestation-based routine universal influenza vaccines schedules for children aged 6 months - 2 years and pregnant women.
    Vaccine. 2021 Oct 18. pii: S0264-410X(21)01291.
    >> Share

  1185. CHEN AT, Stacey HD, Marzok A, Singh P, et al
    Effect of inactivated influenza vaccination on human coronavirus infection: Secondary analysis of a randomized trial in Hutterite colonies.
    Vaccine. 2021 Oct 18. pii: S0264-410X(21)01341.
    >> Share

  1186. KIM D, Pekgun P, Yildirim I, Keskinocak P, et al
    Resource allocation for different types of vaccines against COVID-19: Tradeoffs and synergies between efficacy and reach.
    Vaccine. 2021 Oct 18. pii: S0264-410X(21)01346.
    >> Share

  1187. CHAPIN-BARDALES J, Myers T, Gee J, Shay DK, et al
    Reactogenicity within 2 weeks after mRNA COVID-19 vaccines: Findings from the CDC v-safe surveillance system.
    Vaccine. 2021 Oct 16. pii: S0264-410X(21)01339.
    >> Share

  1188. ALI SAHRAIAN M, Ghadiri F, Azimi A, Naser Moghadasi A, et al
    Adverse events reported by Iranian patients with multiple sclerosis after the first dose of Sinopharm BBIBP-CorV.
    Vaccine. 2021;39:6347-6350.
    >> Share

  1189. YAMAMOTO N, Takahashi Y, Hayashi S
    Legal and regulatory processes for Japan's COVID-19 immunization program.
    Vaccine. 2021;39:6449-6450.
    >> Share

  1190. AYAZ S, Dibben O, Chapman D
    Presence of defective viral genes in H1N1 live attenuated influenza vaccine strains is not associated with reduced human cell fitness or vaccine effectiveness.
    Vaccine. 2021 Oct 15. pii: S0264-410X(21)01320.
    >> Share

  1191. MOGHNIEH R, Mekdashi R, El-Hassan S, Abdallah D, et al
    Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with homologous BNT162b2 vaccination: Results of a pilot prospective cohort study from Lebanon.
    Vaccine. 2021 Oct 13. pii: S0264-410X(21)01314.
    >> Share

  1192. MCNAY LA, Arnoczy G, Martell M, Mock P, et al
    Community-based hospitals: New partners for government-sponsored clinical research during public health emergencies.
    Vaccine. 2021;39:6183-6185.
    >> Share

  1193. HART P, Farrar J
    The influenza vaccines roadmap - A better future through improved influenza vaccines.
    Vaccine. 2021 Oct 8. pii: S0264-410X(21)01286.
    >> Share

  1194. MOTTELSON A, Vandeweerdt C, Atchapero M, Luong T, et al
    A self-administered virtual reality intervention increases COVID-19 vaccination intention.
    Vaccine. 2021 Oct 8. pii: S0264-410X(21)01311.
    >> Share

  1195. BYRNE T, Patel P, Shrotri M, Beale S, et al
    Trends, patterns and psychological influences on COVID-19 vaccination intention: Findings from a large prospective community cohort study in England and Wales (Virus Watch).
    Vaccine. 2021 Oct 8. pii: S0264-410X(21)01281.
    >> Share

  1196. HUMBLE RM, Sell H, Dube E, MacDonald NE, et al
    Canadian parents' perceptions of COVID-19 vaccination and intention to vaccinate their children: Results from a cross-sectional national survey.
    Vaccine. 2021 Oct 8. pii: S0264-410X(21)01309.
    >> Share

  1197. MULLER-PEBODY B, Sinnathamby MA, Warburton F, Rooney G, et al
    Impact of the childhood influenza vaccine programme on antibiotic prescribing rates in primary care in England.
    Vaccine. 2021 Oct 6. pii: S0264-410X(21)01284.
    >> Share

  1198. REIDENBERG BE, Hirsch K, Costello CM, Russo M, et al
    Drive through COVID19 vaccination for developmentally disabled persons.
    Vaccine. 2021 Oct 6. pii: S0264-410X(21)01279.
    >> Share

  1199. ALLEVA DG, Delpero AR, Scully MM, Murikipudi S, et al
    Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452.
    Vaccine. 2021 Oct 5. pii: S0264-410X(21)01294.
    >> Share

  1200. LAZAROS G, Anastassopoulou C, Hatziantoniou S, Kalos T, et al
    A case series of acute pericarditis following COVID-19 vaccination in the context of recent reports from Europe and the United States.
    Vaccine. 2021 Oct 5. pii: S0264-410X(21)01295.
    >> Share

  1201. CORCORAN KE, Scheitle CP, DiGregorio BD
    Christian nationalism and COVID-19 vaccine hesitancy and uptake.
    Vaccine. 2021 Oct 2. pii: S0264-410X(21)01289.
    >> Share

  1202. PALLIKKUTH S, Williams E, Pahwa R, Hoffer M, et al
    Association of Flu specific and SARS-CoV-2 specific CD4 T cell responses in SARS-CoV-2 infected asymptomatic heath care workers.
    Vaccine. 2021;39:6019-6024.
    >> Share

  1203. BOZORGI A, Fahimnia B
    Micro array patch (MAP) for the delivery of thermostable vaccines in Australia: A cost/benefit analysis.
    Vaccine. 2021;39:6166-6173.
    >> Share

  1204. BOZORGI A, Fahimnia B
    Transforming the vaccine supply chain in Australia: Opportunities and challenges.
    Vaccine. 2021;39:6157-6165.
    >> Share

    September 2021
  1205. ROMANO CJ, Hall C, Khodr ZG, Bukowinski AT, et al
    History of pandemic H1N1-containing influenza vaccination and risk for spontaneous abortion and birth defects.
    Vaccine. 2021 Sep 28. pii: S0264-410X(21)01171.
    >> Share

  1206. FRANCIS-OLIVIERO F, Bozoki S, Micsik A, Kieny MP, et al
    Research priorities to increase vaccination coverage in Europe (EU joint action on vaccination).
    Vaccine. 2021 Sep 28. pii: S0264-410X(21)01224.
    >> Share

  1207. YACOUB MR, Cucca V, Asperti C, Ramirez GA, et al
    Efficacy of a rational algorithm to assess allergy risk in patients receiving the BNT162b2 vaccine.
    Vaccine. 2021 Sep 28. pii: S0264-410X(21)01239.
    >> Share

  1208. VIEIRA REZENDE RP, Braz AS, Guimaraes MFB, Ribeiro SLE, et al
    Characteristics associated with COVID-19 vaccine hesitancy: A nationwide survey of 1000 patients with immune-mediated inflammatory diseases.
    Vaccine. 2021 Sep 25. pii: S0264-410X(21)01260.
    >> Share

  1209. BLEICHER I, Kadour-Peero E, Sagi-Dain L, Sagi S, et al
    Early exploration of COVID-19 vaccination safety and effectiveness during pregnancy: interim descriptive data from a prospective observational study.
    Vaccine. 2021 Sep 25. pii: S0264-410X(21)01234.
    >> Share

  1210. SHEVZOV-ZEBRUN N, Caplan A
    Parental consent for vaccination of minors against COVID-19.
    Vaccine. 2021 Sep 25. pii: S0264-410X(21)01250.
    >> Share

  1211. FISHER KA, Nguyen N, Crawford S, Fouayzi H, et al
    Preferences for COVID-19 vaccination information and location: Associations with vaccine hesitancy, race and ethnicity.
    Vaccine. 2021 Sep 25. pii: S0264-410X(21)01261.
    >> Share

  1212. MOLODECKY NA, Jafari H, Safdar RM, Ahmed JA, et al
    Modelling the spread of serotype-2 vaccine derived-poliovirus outbreak in Pakistan and Afghanistan to inform outbreak control strategies in the context of the COVID-19 pandemic.
    Vaccine. 2021 Sep 25. pii: S0264-410X(21)01228.
    >> Share

  1213. LAW JLM, Logan M, Joyce MA, Landi A, et al
    SARS-COV-2 recombinant Receptor-Binding-Domain (RBD) induces neutralizing antibodies against variant strains of SARS-CoV-2 and SARS-CoV-1.
    Vaccine. 2021;39:5769-5779.
    >> Share

  1214. LI L, Honda-Okubo Y, Huang Y, Jang H, et al
    Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection.
    Vaccine. 2021;39:5940-5953.
    >> Share

  1215. FADLYANA E, Rusmil K, Tarigan R, Rahmadi AR, et al
    A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia.
    Vaccine. 2021 Sep 24. pii: S0264-410X(21)01255.
    >> Share

  1216. SINGH AK, Phatak SR, Singh R, Bhattacharjee K, et al
    Antibody response after first and second-dose of ChAdOx1-nCOV (Covishield(TM)(R)) and BBV-152 (Covaxin(TM)(R)) among health care workers in India: The final results of cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study.
    Vaccine. 2021 Sep 24. pii: S0264-410X(21)01258.
    >> Share

  1217. MOORE KA, Ostrowsky JT, Kraigsley AM, Mehr AJ, et al
    A Research and Development (R&D) roadmap for influenza vaccines: Looking toward the future.
    Vaccine. 2021 Sep 23. pii: S0264-410X(21)01028.
    >> Share

  1218. PARK SJ, Kang YM, Cho HK, Kim DY, et al
    Cross-protective efficacy of inactivated whole influenza vaccines against Korean Y280 and Y439 lineage H9N2 viruses in mice.
    Vaccine. 2021 Sep 20. pii: S0264-410X(21)01207.
    >> Share

  1219. MANSUY JM, Sagna AS, Laurent M, Izopet J, et al
    COVID-19 diagnosis in a Senegalese company: A model for COVID-19 vaccination?
    Vaccine. 2021 Sep 17. pii: S0264-410X(21)01227.
    >> Share

  1220. RAINA MACINTYRE C, Costantino V, Chanmugam A
    The use of face masks during vaccine roll-out in New YorkCity and impact on epidemic control.
    Vaccine. 2021 Sep 16. pii: S0264-410X(21)01164.
    >> Share

  1221. MOSINA L, Kulper-Schiek W, Jacques-Carroll L, Earnshaw A, et al
    Supporting National Immunization Technical Advisory Groups in the WHO European Region in developing national COVID-19 vaccination recommendations through online communication platform.
    Vaccine. 2021 Sep 16. pii: S0264-410X(21)01225.
    >> Share

  1222. SELL H, Assi A, Driedger SM, Dube E, et al
    Continuity of routine immunization programs in Canada during the COVID-19 pandemic.
    Vaccine. 2021;39:5532-5537.
    >> Share

  1223. SULIMAN S, Pelzer PT, Shaku M, Rozot V, et al
    Meeting report: Virtual Global Forum on Tuberculosis Vaccines, 20-22 April 2021.
    Vaccine. 2021 Sep 15. pii: S0264-410X(21)01154.
    >> Share

  1224. LIU D, Leung K, Jit M, Wu JT, et al
    Cost-effectiveness of strategies for preventing paediatric lower respiratory infections associated with respiratory syncytial virus in eight Chinese cities.
    Vaccine. 2021;39:5490-5498.
    >> Share

  1225. KOHL-HECKL WK, Schroter M, Dobos G, Cramer H, et al
    Complementary medicine use and flu vaccination - A nationally representative survey of US adults.
    Vaccine. 2021;39:5635-5640.
    >> Share

  1226. KIM DY, Kang YM, Cho HK, Park SJ, et al
    Development of a recombinant H9N2 influenza vaccine candidate against the Y280 lineage field virus and its protective efficacy.
    Vaccine. 2021 Sep 14. pii: S0264-410X(21)01149.
    >> Share

  1227. VAN HOOSTE WLC
    Influenza vaccination at the workplace.
    Vaccine. 2021 Sep 14. pii: S0264-410X(21)01188.
    >> Share

  1228. BENJAMIN-CHUNG J, Arnold BF, Mishra K, Kennedy CJ, et al
    City-wide school-located influenza vaccination: A retrospective cohort study.
    Vaccine. 2021 Sep 14. pii: S0264-410X(21)01161.
    >> Share

  1229. PALACHE A, Rockman S, Taylor B, Akcay M, et al
    Vaccine complacency and dose distribution inequities limit the benefits of seasonal influenza vaccination, despite a positive trend in use.
    Vaccine. 2021 Sep 11. pii: S0264-410X(21)01157.
    >> Share

  1230. THOMPSON MG, Soto G, Perez A, Newes-Adeyim G, et al
    Influenza vaccine effectiveness within prospective cohorts of healthcare personnel in Israel and Peru 2016-2019.
    Vaccine. 2021 Sep 8. pii: S0264-410X(21)00982.
    >> Share

  1231. PERRY M, Akbari A, Cottrell S, Gravenor MB, et al
    Inequalities in coverage of COVID-19 vaccination: A population register based cross-sectional study in Wales, UK.
    Vaccine. 2021 Sep 8. pii: S0264-410X(21)01198.
    >> Share

  1232. JOGI P, Soeorg H, Ingerainen D, Soots M, et al
    Prevalence of SARS-CoV-2 IgG antibodies and their association with clinical symptoms of COVID-19 in Estonia (KoroSero-EST-1 study).
    Vaccine. 2021;39:5376-5384.
    >> Share

  1233. WAINSTOCK T, Yoles I, Sergienko R, Sheiner E, et al
    Prenatal maternal COVID-19 vaccination and pregnancy outcomes.
    Vaccine. 2021 Sep 7. pii: S0264-410X(21)01191.
    >> Share

  1234. MOORE DCBC, Nehab MF, Camacho KG, Reis AT, et al
    Low COVID-19 vaccine hesitancy in Brazil.
    Vaccine. 2021 Sep 7. pii: S0264-410X(21)01192.
    >> Share

  1235. EBERHARDT J, Ling J
    Predicting COVID-19 vaccination intention using protection motivation theory and conspiracy beliefs.
    Vaccine. 2021 Sep 7. pii: S0264-410X(21)01189.
    >> Share

  1236. SULIMAN DM, Nawaz FA, Mohanan P, Modber MAKA, et al
    UAE efforts in promoting COVID-19 vaccination and building vaccine confidence.
    Vaccine. 2021 Sep 7. pii: S0264-410X(21)01194.
    >> Share

  1237. JACOBI CJ, Vaidyanathan B
    Racial differences in anticipated COVID-19 vaccine acceptance among religious populations in the US.
    Vaccine. 2021 Sep 7. pii: S0264-410X(21)01184.
    >> Share

  1238. SCHLEISS MR, John CC, Permar SR
    Children are the key to the Endgame: A case for routine pediatric COVID vaccination.
    Vaccine. 2021;39:5333-5336.
    >> Share

  1239. LEVIN D, Shimon G, Fadlon-Derai M, Gershovitz L, et al
    Myocarditis following COVID-19 vaccination - A case series.
    Vaccine. 2021 Sep 4. pii: S0264-410X(21)01172.
    >> Share

  1240. ZHOU Z, Zhang X, Li Q, Fu L, et al
    Unmethylated CpG motif-containing genomic DNA fragments of bacillus calmette-guerin improves immune response towards a DNA vaccine for COVID-19.
    Vaccine. 2021 Sep 3. pii: S0264-410X(21)01165.
    >> Share

  1241. ALI A, Dwyer D, Wu Q, Wang Q, et al
    Characterization of humoral response to COVID mRNA vaccines in multiple sclerosis patients on disease modifying therapies.
    Vaccine. 2021 Sep 2. pii: S0264-410X(21)01126.
    >> Share

  1242. DRUEDAHL LC, Minssen T, Price WN
    Collaboration in times of crisis: A study on COVID-19 vaccine R&D partnerships.
    Vaccine. 2021 Sep 2. pii: S0264-410X(21)01163.
    >> Share

  1243. BARRY M, Temsah MH, Aljamaan F, Saddik B, et al
    COVID-19 vaccine uptake among healthcare workers in the fourth country to authorize BNT162b2 during the first month of rollout.
    Vaccine. 2021 Sep 1. pii: S0264-410X(21)01131.
    >> Share

    August 2021
  1244. PRIVOR-DUMM LA, Poland GA, Barratt J, Durrheim DN, et al
    A global agenda for older adult immunization in the COVID-19 era: A roadmap for action.
    Vaccine. 2021;39:5240-5250.
    >> Share

  1245. CANTARELLI P, Belle N, Quattrone F
    Nudging influenza vaccination among health care workers.
    Vaccine. 2021 Aug 31. pii: S0264-410X(21)01073.
    >> Share

  1246. TROGSTAD L, Robertson AH, Mjaaland S, Magnus P, et al
    Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: Large population-based cohort study.
    Vaccine. 2021 Aug 31. pii: S0264-410X(21)01103.
    >> Share

  1247. ALBANI VVL, Loria J, Massad E, Zubelli JP, et al
    The impact of COVID-19 vaccination delay: A data-driven modeling analysis for Chicago and New York City.
    Vaccine. 2021 Aug 31. pii: S0264-410X(21)01158.
    >> Share

  1248. DRISCOLL AJ, Ortiz JR, Hartert TV, Riddell CA, et al
    Recalibrating public health expectations of respiratory syncytial virus lower respiratory tract illness prevention on chronic respiratory disease.
    Vaccine. 2021;39:5257-5258.
    >> Share

  1249. BROSH-NISSIMOV T, Sorek N, Yeshayahu M, Zherebovich I, et al
    Oropharyngeal shedding of herpesviruses before and after BNT162b2 mRNA vaccination against COVID-19.
    Vaccine. 2021 Aug 30. pii: S0264-410X(21)01148.
    >> Share

  1250. O'LORCAIN P, Cotter S, Walsh C
    Influenza vaccine uptake among healthcare workers and residents in public health care facilities in Ireland over nine influenza seasons (2011-2012 to 2019-2020).
    Vaccine. 2021 Aug 27. pii: S0264-410X(21)00987.
    >> Share

  1251. XU X, Rodgers MD, Guo WG
    A hub-and-spoke design for ultra-cold COVID-19 vaccine distribution.
    Vaccine. 2021 Aug 25. pii: S0264-410X(21)01117.
    >> Share

  1252. HARPAZ R
    COVID-19 vaccine safety monitoring: Might differential healthcare seeking introduce detection bias into rates of medical events and cause false safety signals?
    Vaccine. 2021 Aug 25. pii: S0264-410X(21)00712.
    >> Share

  1253. ROTENBERG S, Downer MB, Cooper J
    Making COVID-19 vaccinations accessible for people with disabilities.
    Vaccine. 2021 Aug 24. pii: S0264-410X(21)01110.
    >> Share

  1254. PIERCE-RUIZ C, Santana WI, Sutton WJH, Fischler DA, et al
    Quantification of SARS-CoV-2 spike and nucleocapsid proteins using isotope dilution tandem mass spectrometry.
    Vaccine. 2021;39:5106-5115.
    >> Share

  1255. WIEMKEN TL, Salas J, Hoft DF, Jacobs C, et al
    Dementia risk following influenza vaccination in a large veteran cohort running head: Influenza vaccination and dementia.
    Vaccine. 2021 Aug 19. pii: S0264-410X(21)01079.
    >> Share

  1256. BRAEYE T, Cornelissen L, Catteau L, Haarhuis F, et al
    Vaccine effectiveness against infection and onwards transmission of COVID-19: Analysis of Belgian contact tracing data, January-June 2021.
    Vaccine. 2021 Aug 19. pii: S0264-410X(21)01108.
    >> Share

  1257. DUDLEY MZ, Bernier R, Brewer J, Salmon DA, et al
    Walking the Tightrope: Reevaluating science communication in the era of COVID-19 vaccines.
    Vaccine. 2021 Aug 19. pii: S0264-410X(21)01070.
    >> Share

  1258. PENG HK, Dombkowski KJ, Freed GL, Creary SE, et al
    Influenza immunization coverage of children with sickle cell disease.
    Vaccine. 2021 Aug 17. pii: S0264-410X(21)01072.
    >> Share

  1259. LIU S, Liu J
    Public attitudes toward COVID-19 vaccines on English-language Twitter: A sentiment analysis.
    Vaccine. 2021 Aug 17. pii: S0264-410X(21)01106.
    >> Share

  1260. LAUFER RS, Driscoll AJ, Baral R, Buchwald AG, et al
    Cost-effectiveness of infant respiratory syncytial virus preventive interventions in Mali: A modeling study to inform policy and investment decisions.
    Vaccine. 2021;39:5037-5045.
    >> Share

  1261. HAGAN LM, Dusseau C, Crockett M, Rodriguez T, et al
    COVID-19 vaccination in the Federal Bureau of Prisons, December 2020-April 2021.
    Vaccine. 2021 Aug 14. pii: S0264-410X(21)01078.
    >> Share

  1262. LAIGLE V, Postma MJ, Pavlovic M, Cadeddu C, et al
    Vaccine market access pathways in the EU27 and the United Kingdom-analysis and recommendations for improvements.
    Vaccine. 2021 Aug 14. pii: S0264-410X(21)00918.
    >> Share

  1263. CIAPPONI A, Bardach A, Mazzoni A, Alconada T, et al
    Safety of components and platforms of COVID-19 vaccines considered for use in pregnancy: A rapid review.
    Vaccine. 2021 Aug 13. pii: S0264-410X(21)01067.
    >> Share

  1264. PALLADINO G, Ferrari A, Music N, Settembre EC, et al
    Improved immunologic responses to heterologous influenza strains in children with low preexisting antibody response vaccinated with MF59-adjuvanted influenza vaccine.
    Vaccine. 2021 Aug 12. pii: S0264-410X(21)01041.
    >> Share

  1265. STINSON JA, Boopathy AV, Cieslewicz BM, Zhang Y, et al
    Enhancing influenza vaccine immunogenicity and efficacy through infection mimicry using silk microneedles.
    Vaccine. 2021 Aug 11. pii: S0264-410X(21)00957.
    >> Share

  1266. GRUPEL D, Gazit S, Schreiber L, Nadler V, et al
    Kinetics of SARS-CoV-2 anti-S IgG after BNT162b2 vaccination.
    Vaccine. 2021 Aug 11. pii: S0264-410X(21)01045.
    >> Share

  1267. KANJI JN, Bailey A, Fenton J, Ling SH, et al
    Detection of SARS-CoV-2 antibodies formed in response to the BNT162b2 and mRNA-1237 mRNA vaccine by commercial antibody tests.
    Vaccine. 2021 Aug 11. pii: S0264-410X(21)01042.
    >> Share

  1268. OKAMURA S, Ebina H
    Could live attenuated vaccines better control COVID-19?
    Vaccine. 2021 Aug 11. pii: S0264-410X(21)01038.
    >> Share

  1269. RIZK JG, Barr CE, Rizk Y, Lewin JC, et al
    The next frontier in vaccine safety and VAERS: Lessons from COVID-19 and ten recommendations for action.
    Vaccine. 2021 Aug 10. pii: S0264-410X(21)01006.
    >> Share

  1270. PETRIE JG, Fligiel H, Lamerato L, Martin ET, et al
    Agreement between state registry, health record, and self-report of influenza vaccination.
    Vaccine. 2021 Aug 9. pii: S0264-410X(21)00995.
    >> Share

  1271. LYTLE KL, Collins SP, Feldstein LR, Baughman AH, et al
    Influenza vaccine acceptance and hesitancy among adults hospitalized with severe acute respiratory illnesses, United States 2019-2020.
    Vaccine. 2021 Aug 7. pii: S0264-410X(21)00948.
    >> Share

  1272. YOSHIKAWA T
    Implementing vaccination policies based upon scientific evidence in Japan.
    Vaccine. 2021 Aug 7. pii: S0264-410X(21)00968.
    >> Share

  1273. PHILLIPS A, Carlson S, Danchin M, Beard F, et al
    From program suspension to the pandemic: A qualitative examination of Australia's vaccine pharmacovigilance system over 10 years.
    Vaccine. 2021 Aug 7. pii: S0264-410X(21)00950.
    >> Share

  1274. FENG J, Li Q
    How to ensure vaccine safety: An evaluation of China's vaccine regulation system.
    Vaccine. 2021 Aug 6. pii: S0264-410X(21)00986.
    >> Share

  1275. TAYLOR SC, Hurst B, Martiszus I, Hausman MS, et al
    Semi-quantitative, high throughput analysis of SARS-CoV-2 neutralizing antibodies: Measuring the level and duration of immune response antibodies post infection/vaccination.
    Vaccine. 2021 Aug 6. pii: S0264-410X(21)01013.
    >> Share

  1276. D'SOUZA MP, Palin AC, Calder T, Golding H, et al
    Mind the gap from research laboratory to clinic: Challenges and opportunities for next-generation assays in human diseases.
    Vaccine. 2021 Aug 5. pii: S0264-410X(21)00964.
    >> Share

  1277. FRIEDENSOHN L, Zur M, Timofeyev M, Burshtein S, et al
    Sub-cutaneous Pfizer/BioNTech COVID-19 vaccine administration results in seroconversion among young adults.
    Vaccine. 2021 Aug 5. pii: S0264-410X(21)01010.
    >> Share

  1278. DODD RH, Pickles K, Cvejic E, Cornell S, et al
    Perceived public health threat a key factor for willingness to get the COVID-19 vaccine in Australia.
    Vaccine. 2021 Aug 5. pii: S0264-410X(21)01008.
    >> Share

  1279. HAUPT RE, Harberts EM, Kitz RJ, Strohmeier S, et al
    Novel TLR4 adjuvant elicits protection against homologous and heterologous Influenza A infection.
    Vaccine. 2021 Aug 3. pii: S0264-410X(21)00847.
    >> Share

  1280. SAKALA IG, Honda-Okubo Y, Li L, Baldwin J, et al
    A M2 protein-based universal influenza vaccine containing Advax-SM adjuvant provides newborn protection via maternal or neonatal immunization.
    Vaccine. 2021 Aug 3. pii: S0264-410X(21)00914.
    >> Share

  1281. HAYMAN B, Dennehy M
    Developing-country vaccine manufacturers' technical capabilities can make a difference in global immunization.
    Vaccine. 2021 Aug 3. pii: S0264-410X(21)00922.
    >> Share

    July 2021
  1282. REDONDO E, Drago G, Lopez-Belmonte JL, Guillen JM, et al
    Cost-utility analysis of influenza vaccination in a population aged 65 years or older in Spain with a high-dose vaccine versus an adjuvanted vaccine.
    Vaccine. 2021 Jul 31. pii: S0264-410X(21)00926.
    >> Share

  1283. KONTOPOULOU K, Ainatzoglou A, Nakas CT, Ifantidou A, et al
    Second dose of the BNT162b2 mRNA vaccine: Value of timely administration but questionable necessity among the seropositive.
    Vaccine. 2021 Jul 31. pii: S0264-410X(21)00958.
    >> Share

  1284. SIDDIQUI A, Ahmed A, Tanveer M, Saqlain M, et al
    An overview of procurement, pricing, and uptake of COVID-19 vaccines in Pakistan.
    Vaccine. 2021 Jul 31. pii: S0264-410X(21)00965.
    >> Share

  1285. MAHAJAN A, Kaur J, Sidana C, Shivam S, et al
    Geo-prioritization framework for COVID-19 vaccine allocation in India.
    Vaccine. 2021 Jul 31. pii: S0264-410X(21)00989.
    >> Share

  1286. RAGHUNANDAN R, Higgins D, Hosken N
    RSV neutralization assays - Use in immune response assessment.
    Vaccine. 2021;39:4591-4597.
    >> Share

  1287. DIACO M, Yin K, Seet B, Samson S, et al
    Author response to a Letter to the Editor on "Introductory paper: High dose influenza vaccine".
    Vaccine. 2021 Jul 28. pii: S0264-410X(21)00917.
    >> Share

  1288. YU VG, Lasco G, David CC
    Fear, mistrust, and vaccine hesitancy: Narratives of the dengue vaccine controversy in the Philippines.
    Vaccine. 2021 Jul 27. pii: S0264-410X(21)00929.
    >> Share

  1289. GEORGIADIS GP, Georgiadis MC
    Optimal planning of the COVID-19 vaccine supply chain.
    Vaccine. 2021 Jul 27. pii: S0264-410X(21)00961.
    >> Share

  1290. RAJAN S, Akhtar N, Sharma S, Chakrabarti D, et al
    COVID-19 vaccination for cancer patients: Evidence, priority, and practice.
    Vaccine. 2021 Jul 24. pii: S0264-410X(21)00956.
    >> Share

  1291. MICHOS A, Tatsi EB, Filippatos F, Dellis C, et al
    Association of total and neutralizing SARS-CoV-2 spike -receptor binding domain antibodies with epidemiological and clinical characteristics after immunization with the 1(st) and 2(nd) doses of the BNT162b2 vaccine.
    Vaccine. 2021 Jul 24. pii: S0264-410X(21)00960.
    >> Share

  1292. CALLAHAN AG, Coleman-Cowger VH, Schulkin J, Power ML, et al
    Racial disparities in influenza immunization during pregnancy in the United States: A narrative review of the evidence for disparities and potential interventions.
    Vaccine. 2021 Jul 23. pii: S0264-410X(21)00905.
    >> Share

  1293. BURKE PF, Masters D, Massey G
    Enablers and barriers to COVID-19 vaccine uptake: An international study of perceptions and intentions.
    Vaccine. 2021 Jul 23. pii: S0264-410X(21)00947.
    >> Share

  1294. TEASDALE CA, Borrell LN, Shen Y, Kimball S, et al
    Parental plans to vaccinate children for COVID-19 in New York city.
    Vaccine. 2021 Jul 23. pii: S0264-410X(21)00949.
    >> Share

  1295. SUNDARAM M, Nasreen S, Calzavara A, He S, et al
    Background rates of all-cause mortality, hospitalizations, and emergency department visits among nursing home residents in Ontario, Canada to inform COVID-19 vaccine safety assessments.
    Vaccine. 2021 Jul 23. pii: S0264-410X(21)00951.
    >> Share

  1296. SCHEIBLHOFER S, Drothler S, Braun W, Braun R, et al
    Laser-facilitated epicutaneous immunization of mice with SARS-CoV-2 spike protein induces antibodies inhibiting spike/ACE2 binding.
    Vaccine. 2021;39:4399-4403.
    >> Share

  1297. ARIAS-FERNANDEZ L, San-Roman Montero J, Gil-Prieto R, Walter S, et al
    Burden of pneumonia in patients with viral and bacterial coinfection in Spain during six consecutive influenza seasons, from 2009-10 to 2014-15.
    Vaccine. 2021 Jul 22. pii: S0264-410X(21)00912.
    >> Share

  1298. HERVE PL, Dhelft V, Zuniga A, Ghasparian A, et al
    Epicutaneous immunization using synthetic virus-like particles efficiently boosts protective immunity to respiratory syncytial virus.
    Vaccine. 2021;39:4555-4563.
    >> Share

  1299. MATHIVATHANAN K
    Will COVID-19 vaccine equity be possible in India?
    Vaccine. 2021 Jul 22. pii: S0264-410X(21)00927.
    >> Share

  1300. TISSOT N, Brunel AS, Bozon F, Rosolen B, et al
    Patients with history of covid-19 had more side effects after the first dose of covid-19 vaccine.
    Vaccine. 2021 Jul 22. pii: S0264-410X(21)00925.
    >> Share

  1301. CHUA H, Kwan MYW, Chan ELY, Wong JSC, et al
    Influenza vaccine effectiveness against influenza-associated hospitalization in children in Hong Kong, 2010-2020.
    Vaccine. 2021 Jul 20. pii: S0264-410X(21)00873.
    >> Share

  1302. INGROLE RSJ, Tao W, Joshi G, Gill HS, et al
    M2e conjugated gold nanoparticle influenza vaccine displays thermal stability at elevated temperatures and confers protection to ferrets.
    Vaccine. 2021 Jul 20. pii: S0264-410X(21)00909.
    >> Share

  1303. PAUL E, Brown GW, Kalk A, Ridde V, et al
    Playing vaccine roulette: Why the current strategy of staking everything on Covid-19 vaccines is a high-stakes wager.
    Vaccine. 2021 Jul 20. pii: S0264-410X(21)00923.
    >> Share

  1304. HANLY M, Churches T, Fitzgerald O, MacIntyre CR, et al
    Vaccinating Australia: How long will it take?
    Vaccine. 2021 Jul 17. pii: S0264-410X(21)00865.
    >> Share

  1305. FLUCKIGER AC, Ontsouka B, Bozic J, Diress A, et al
    An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits highly potent immunity.
    Vaccine. 2021 Jul 16. pii: S0264-410X(21)00911.
    >> Share

  1306. INSERRA F, Tajer C, Antonietti L, Mariani J, et al
    Vitamin D supplementation: An alternative to enhance the effectiveness of vaccines against SARS-CoV-2?
    Vaccine. 2021 Jul 16. pii: S0264-410X(21)00908.
    >> Share

  1307. JAIN R, Chopra A, Falezan C, Patel M, et al
    COVID-19 related immunization disruptions in Rajasthan, India: A retrospective observational study.
    Vaccine. 2021;39:4343-4350.
    >> Share

  1308. PICHE-RENAUD PP, Ji C, Farrar DS, Friedman JN, et al
    Impact of the COVID-19 pandemic on the provision of routine childhood immunizations in Ontario, Canada.
    Vaccine. 2021;39:4373-4382.
    >> Share

  1309. MOGAJI E
    Marketing the COVID-19 vaccine and the implications for public health.
    Vaccine. 2021 Jul 13. pii: S0264-410X(21)00874.
    >> Share

  1310. HAYMAN B, Suri R, Prasad SD
    COVID-19 vaccine capacity: Challenges and mitigation - The DCVMN perspective.
    Vaccine. 2021 Jul 13. pii: S0264-410X(21)00866.
    >> Share

  1311. LAZAROS G, Klein AL, Hatziantoniou S, Tsioufis C, et al
    The Novel Platform of mRNA COVID-19 Vaccines and Myocarditis: Clues into the Potential Underlying Mechanism.
    Vaccine. 2021 Jul 13. pii: S0264-410X(21)00875.
    >> Share

  1312. CLARKE M, Goodchild LM, Evans S, Giles LC, et al
    Body mass index and vaccine responses following influenza vaccination during pregnancy.
    Vaccine. 2021 Jul 12. pii: S0264-410X(21)00826.
    >> Share

  1313. MACINTYRE CR, Veness B, Berger D, Hamad N, et al
    Thrombosis with Thrombocytopenia Syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination - A risk-benefit analysis for people < 60 years in Australia.
    Vaccine. 2021 Jul 10. pii: S0264-410X(21)00872.
    >> Share

  1314. MATEO-URDIALES A, Del Manso M, Andrianou X, Spuri M, et al
    Initial impact of SARS-Cov-2 vaccination on healthcare workers in Italy- Update on the 28th of March 2021.
    Vaccine. 2021 Jul 7. pii: S0264-410X(21)00862.
    >> Share

  1315. BELLIER L, Petitjean A, Sarazu T, Tresierra J, et al
    Cost-effectiveness analysis of switching from a trivalent to a quadrivalent inactivated influenza vaccine in the Peruvian immunisation programme.
    Vaccine. 2021;39:4144-4152.
    >> Share

  1316. LO CY, Misplon JA, Li X, Price GE, et al
    Universal influenza vaccine based on conserved antigens provides long-term durability of immune responses and durable broad protection against diverse challenge virus strains in mice.
    Vaccine. 2021 Jul 2. pii: S0264-410X(21)00833.
    >> Share

  1317. RAHAMIMOV N, Baturov V, Shani A, Ben Zoor I, et al
    Inadequate deltoid muscle penetration and concerns of improper COVID mRNA vaccine administration can be avoided by injection technique modification.
    Vaccine. 2021 Jul 2. pii: S0264-410X(21)00843.
    >> Share

    June 2021
  1318. HINES AM, Murphy N, Mullin C, Barillas J, et al
    Henoch-Schonlein purpura presenting post COVID-19 vaccination.
    Vaccine. 2021 Jun 30. pii: S0264-410X(21)00841.
    >> Share

  1319. YOUSSEF Y, Chmaisse A, Boutros C, Chamseddine S, et al
    The burden of Respiratory Syncytial Virus (RSV) infection in the Middle East and North Africa (MENA) region across age groups: A systematic review.
    Vaccine. 2021;39:3803-3813.
    >> Share

  1320. AL-SHAIKH A, Muthu N, Aidyralieva C, Profili MC, et al
    COVID-19 vaccine roll-out in middle-income countries: Lessons learned from the Jordan experience.
    Vaccine. 2021 Jun 29. pii: S0264-410X(21)00840.
    >> Share

  1321. BANKS C, Portnoy A, Moi F, Boonstoppel L, et al
    Cost of vaccine delivery strategies in low- and middle-income countries during the COVID-19 pandemic.
    Vaccine. 2021 Jun 29. pii: S0264-410X(21)00838.
    >> Share

  1322. FUJIMOTO AB, Keskinocak P, Yildirim I
    Significance of SARS-CoV-2 specific antibody testing during COVID-19 vaccine allocation.
    Vaccine. 2021 Jun 26. pii: S0264-410X(21)00828.
    >> Share

  1323. MYLES IA, Vinciguerra JS, Premus RT
    Specialist confirmed allergic reactions to COVID-19 mRNA vaccines at a mass vaccination site.
    Vaccine. 2021 Jun 25. pii: S0264-410X(21)00811.
    >> Share

  1324. GUAN L, Yu Y, Wu X, Nie J, et al
    The first Chinese national standards for SARS-CoV-2 neutralizing antibody.
    Vaccine. 2021;39:3724-3730.
    >> Share

  1325. DESAI AP, Desai AP, Loomis GJ
    Relationship between pre-existing allergies and anaphylactic reactions post mRNA COVID-19 vaccine administration.
    Vaccine. 2021 Jun 23. pii: S0264-410X(21)00808.
    >> Share

  1326. BALDOLLI A, Michon J, Appia F, Galimard C, et al
    Tolerance of BNT162b2 mRNA COVI-19 vaccine in patients with a medical history of COVID-19 disease: A case control study.
    Vaccine. 2021 Jun 23. pii: S0264-410X(21)00804.
    >> Share

  1327. GOOCH KE, Smith TRF, Salguero FJ, Fotheringham SA, et al
    One or two dose regimen of the SARS-CoV-2 synthetic DNA vaccine INO-4800 protects against respiratory tract disease burden in nonhuman primate challenge model.
    Vaccine. 2021 Jun 23. pii: S0264-410X(21)00807.
    >> Share

  1328. TRENT M, Seale H, Chughtai AA, Salmon D, et al
    Trust in government, intention to vaccinate and COVID-19 vaccine hesitancy: A comparative survey of five large cities in the United States, United Kingdom, and Australia.
    Vaccine. 2021 Jun 23. pii: S0264-410X(21)00798.
    >> Share

  1329. CHEN IH, Ahorsu DK, Ko NY, Yen CF, et al
    Adapting the Motors of Influenza Vaccination Acceptance Scale into the Motors of COVID-19 Vaccination Acceptance Scale: Psychometric evaluation among mainland Chinese university students.
    Vaccine. 2021 Jun 22. pii: S0264-410X(21)00794.
    >> Share

  1330. LUNDBERG L, Bygdell M, Stukat von Feilitzen G, Woxenius S, et al
    Recent MMR vaccination in health care workers and Covid-19: A test negative case-control study.
    Vaccine. 2021 Jun 22. pii: S0264-410X(21)00795.
    >> Share

  1331. SMITH KJ, Wateska AR, Nowalk MP, Lin CJ, et al
    Should older adult pneumococcal vaccination recommendations change due to decreased vaccination in children during the pandemic? A cost-effectiveness analysis.
    Vaccine. 2021 Jun 21. pii: S0264-410X(21)00773.
    >> Share

  1332. FOGEL B, Schaefer EW, Hicks SD
    Early influenza vaccination rates decline in children during the COVID-19 pandemic.
    Vaccine. 2021 Jun 17. pii: S0264-410X(21)00777.
    >> Share

  1333. BROWN CC, Young SG, Pro GC
    COVID-19 vaccination rates vary by community vulnerability: A county-level analysis.
    Vaccine. 2021 Jun 17. pii: S0264-410X(21)00774.
    >> Share

  1334. BIFULCO M, Pisanti S, Fusco I
    Lessons from the 1656 Neapolitan Plague: Something to learn for the current coronavirus Pandemic?
    Vaccine. 2021;39:3641-3643.
    >> Share

  1335. JETHWA H, Wong R, Abraham S
    Covid-19 vaccine trials: Ethnic diversity and immunogenicity.
    Vaccine. 2021;39:3541-3543.
    >> Share

  1336. PRASAD N, Read JM, Jewell C, Waite B, et al
    Modelling the impact of respiratory syncytial virus (RSV) vaccine and immunoprophylaxis strategies in New Zealand.
    Vaccine. 2021 Jun 16. pii: S0264-410X(21)00708.
    >> Share

  1337. ZIMMERMAN RK
    Helping patients with ethical concerns about COVID-19 vaccines in light of fetal cell lines used in some COVID-19 vaccines.
    Vaccine. 2021 Jun 15. pii: S0264-410X(21)00763.
    >> Share

  1338. POLAND GA, Ovsyannikova IG, Kennedy RB
    The need for broadly protective COVID-19 vaccines: Beyond S-only approaches.
    Vaccine. 2021 Jun 14. pii: S0264-410X(21)00764.
    >> Share

  1339. IVANOV V, Oomens AGP, Papin JF, Staats R, et al
    Intranasal and intrapulmonary vaccination with an M protein-deficient respiratory syncytial virus (RSV) vaccine improves clinical signs and reduces viral replication in infant baboons after an RSV challenge infection.
    Vaccine. 2021 Jun 14. pii: S0264-410X(21)00737.
    >> Share

  1340. FERRARI D, Di Resta C, Tomaiuolo R, Sabetta E, et al
    Long-term antibody persistence and exceptional vaccination response on previously SARS-CoV-2 infected subjects.
    Vaccine. 2021 Jun 12. pii: S0264-410X(21)00756.
    >> Share

  1341. LIPSITCH M, Kahn R
    Interpreting vaccine efficacy trial results for infection and transmission.
    Vaccine. 2021 Jun 12. pii: S0264-410X(21)00735.
    >> Share

  1342. MCFADDEN K, Heywood A, Dyda A, Kaufman J, et al
    Minimising missed opportunities to promote and deliver immunization services to middle and older age adults: Can hospital-based programs be a solution?
    Vaccine. 2021;39:3467-3472.
    >> Share

  1343. BEAU RENEER Z, Abreu RB, Jamal US, Corn MR, et al
    Seasonal influenza vaccination does not effectively expand H2 cross-reactive antibodies in humans.
    Vaccine. 2021 Jun 11. pii: S0264-410X(21)00659.
    >> Share

  1344. HSIA J, Zhao G, Lu PJ, Town M, et al
    Estimating bias from internet non-use for a hybrid web vaccination survey - 2013-2017 Behavioral Risk Factor Surveillance System.
    Vaccine. 2021 Jun 11. pii: S0264-410X(21)00675.
    >> Share

  1345. ODITA CI, Conan A, Smith-Antony M, Battice J, et al
    Non-specific effects of rabies vaccine on the incidence of self-reported common infectious disease episodes: A randomized controlled trial.
    Vaccine. 2021 Jun 11. pii: S0264-410X(21)00719.
    >> Share

  1346. LUTZ CS, Biggerstaff M, Rolfes MA, Lafond KE, et al
    Estimating the number of averted illnesses and deaths as a result of vaccination against an influenza pandemic in nine low- and middle-income countries.
    Vaccine. 2021 Jun 9. pii: S0264-410X(21)00557.
    >> Share

  1347. GUNTUKU SC, Buttenheim AM, Sherman G, Merchant RM, et al
    Twitter discourse reveals geographical and temporal variation in concerns about COVID-19 vaccines in the United States.
    Vaccine. 2021 Jun 9. pii: S0264-410X(21)00738.
    >> Share

  1348. IKILEZI G, Bachmeier SD, Cogswell IE, Maddison ER, et al
    Tracking government spending on immunization: The joint reporting forms, national health accounts, comprehensive multi-year plans and co-financing data.
    Vaccine. 2021;39:3410-3418.
    >> Share

  1349. NUZHATH T, Ajayi KV, Fan Q, Hotez P, et al
    Childhood immunization during the COVID-19 pandemic in Texas.
    Vaccine. 2021;39:3333-3337.
    >> Share

  1350. SILVEIRA MF, Tonial CT, Goretti K Maranhao A, Teixeira AMS, et al
    Missed childhood immunizations during the COVID-19 pandemic in Brazil: Analyses of routine statistics and of a national household survey.
    Vaccine. 2021;39:3404-3409.
    >> Share

  1351. JENSEN A, A F Simoes E, Bohn Christiansen C, Graff Stensballe L, et al
    Respiratory syncytial virus and influenza hospitalizations in Danish children 2010-2016.
    Vaccine. 2021 Jun 8. pii: S0264-410X(21)00705.
    >> Share

  1352. HOEHL S, Ciesek S, Graf J, Wicker S, et al
    A new group at increased risk of a SARS-CoV-2 infection emerges: The recently vaccinated.
    Vaccine. 2021 Jun 8. pii: S0264-410X(21)00736.
    >> Share

  1353. ANDAYI F, Emukule GO, Osoro E, Ndegwa LK, et al
    Knowledge and attitude of Kenyan healthcare workers towards pandemic influenza disease and vaccination: 9 years after the last influenza pandemic.
    Vaccine. 2021 Jun 7. pii: S0264-410X(21)00643.
    >> Share

  1354. RAZ A, Keshet Y, Popper-Giveon A, Karkabi MS, et al
    One size does not fit all: Lessons from Israel's Covid-19 vaccination drive and hesitancy.
    Vaccine. 2021 Jun 5. pii: S0264-410X(21)00714.
    >> Share

  1355. DAL-RE R, Launay O
    Public trust on regulatory decisions: The European Medicines Agency and the AstraZeneca COVID-19 vaccine label.
    Vaccine. 2021 Jun 4. pii: S0264-410X(21)00703.
    >> Share

  1356. STUURMAN AL, Biccler J, Carmona A, Descamps A, et al
    Brand-specific influenza vaccine effectiveness estimates during 2019/20 season in Europe - Results from the DRIVE EU study platform.
    Vaccine. 2021 Jun 3. pii: S0264-410X(21)00654.
    >> Share

  1357. GATES A, Rahman S, Sim S, Pillay J, et al
    Health inequities related to vaccination: An evidence map of potentially influential factors and systematic review of interventions.
    Vaccine. 2021 Jun 3. pii: S0264-410X(21)00640.
    >> Share

  1358. FERDINANDS JM, Thompson MG, Blanton L, Spencer S, et al
    Does influenza vaccination attenuate the severity of breakthrough infections? A narrative review and recommendations for further research.
    Vaccine. 2021 Jun 2. pii: S0264-410X(21)00562.
    >> Share

  1359. SHINGAI M, Nomura N, Sekiya T, Ohno M, et al
    Potent priming by inactivated whole influenza virus particle vaccines is linked to viral RNA uptake into antigen presenting cells.
    Vaccine. 2021 Jun 2. pii: S0264-410X(21)00660.
    >> Share

  1360. LASKY T, McMahon AW, Hua W, Forshee R, et al
    Methodologic approaches in studies using real-world data (RWD) to measure pediatric safety and effectiveness of vaccines administered to pregnant women: A scoping review.
    Vaccine. 2021 Jun 2. pii: S0264-410X(21)00666.
    >> Share

  1361. WANG Y, Zhang Y, Wu H, Huang L, et al
    Safety and immunogenicity of a quadrivalent inactivated subunit non-adjuvanted influenza vaccine: A randomized, double-blind, active-controlled phase 1 clinical trial.
    Vaccine. 2021 Jun 1. pii: S0264-410X(21)00665.
    >> Share

  1362. DEY A, Chozhavel Rajanathan TM, Chandra H, Pericherla HPR, et al
    Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV-2 in animal models.
    Vaccine. 2021 Jun 1. pii: S0264-410X(21)00706.
    >> Share

  1363. PATEL MK, Bergeri I, Bresee JS, Cowling BJ, et al
    Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization.
    Vaccine. 2021 Jun 1. pii: S0264-410X(21)00707.
    >> Share

    May 2021
  1364. ZIPFEL CM, Colizza V, Bansal S
    The missing season: The impacts of the COVID-19 pandemic on influenza.
    Vaccine. 2021 May 30. pii: S0264-410X(21)00635.
    >> Share

  1365. LEWIS NS, Banyard AC, Essen S, Whittard E, et al
    Antigenic evolution of contemporary clade 2.3.4.4 HPAI H5 influenza A viruses and impact on vaccine use for mitigation and control.
    Vaccine. 2021 May 29. pii: S0264-410X(21)00655.
    >> Share

  1366. BARDENHEIER BH, Gravenstein S, Blackman C, Gutman R, et al
    Adverse events following mRNA SARS-CoV-2 vaccination among U.S. nursing home residents.
    Vaccine. 2021 May 28. pii: S0264-410X(21)00683.
    >> Share

  1367. ABU MOUCH S, Roguin A, Hellou E, Ishai A, et al
    Myocarditis following COVID-19 mRNA vaccination.
    Vaccine. 2021 May 28. pii: S0264-410X(21)00682.
    >> Share

  1368. GURWITZ D
    COVID-19 vaccine hesitancy: Lessons from Israel.
    Vaccine. 2021 May 27. pii: S0264-410X(21)00680.
    >> Share

  1369. KESSELS R, Luyten J, Tubeuf S
    Willingness to get vaccinated against Covid-19 and attitudes toward vaccination in general.
    Vaccine. 2021 May 26. pii: S0264-410X(21)00664.
    >> Share

  1370. VANHEMS P
    A breath of humanity in the era of Covid-19 vaccine.
    Vaccine. 2021 May 24. pii: S0264-410X(21)00638.
    >> Share

  1371. EARLE KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, et al
    Evidence for antibody as a protective correlate for COVID-19 vaccines.
    Vaccine. 2021 May 24. pii: S0264-410X(21)00658.
    >> Share

  1372. SAM IC, Ahmad Jaafar N, Wong LP, Nathan AM, et al
    Socioeconomic costs of children <5 years hospitalised with acute respiratory infections in Kuala Lumpur, Malaysia.
    Vaccine. 2021;39:2983-2988.
    >> Share

  1373. VOGEL TP, Top KA, Karatzios C, Hilmers DC, et al
    Multisystem inflammatory syndrome in children and adults (MIS-C/A): Case definition & guidelines for data collection, analysis, and presentation of immunization safety data.
    Vaccine. 2021;39:3037-3049.
    >> Share

  1374. SERAZIN NA, Edem B, Williams SR, Ortiz JR, et al
    Acute respiratory distress syndrome (ARDS) as an adverse event following immunization: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data.
    Vaccine. 2021;39:3028-3036.
    >> Share

  1375. AIZAWA Y, Katsuta T, Sakiyama H, Tanaka-Taya K, et al
    Changes in childhood vaccination during the coronavirus disease 2019 pandemic in Japan.
    Vaccine. 2021 May 21. pii: S0264-410X(21)00636.
    >> Share

  1376. NICHOLLS LAB, Gallant AJ, Cogan N, Rasmussen S, et al
    Older adults' vaccine hesitancy: Psychosocial factors associated with influenza, pneumococcal, and shingles vaccine uptake.
    Vaccine. 2021 May 19. pii: S0264-410X(21)00544.
    >> Share

  1377. KIM S, Williams TC, Viboud C, Campbell H, et al
    RSV genomic diversity and the development of a globally effective RSV intervention.
    Vaccine. 2021;39:2811-2820.
    >> Share

  1378. NAG K, Chandra Baray J, Rahman Khan M, Mahmud A, et al
    An mRNA-based vaccine candidate against SARS-CoV-2 elicits stable immuno-response with single dose.
    Vaccine. 2021 May 18. pii: S0264-410X(21)00607.
    >> Share

  1379. LUK TT, Zhao S, Wu Y, Wong JY, et al
    Prevalence and determinants of SARS-CoV-2 vaccine hesitancy in Hong Kong: A population-based survey.
    Vaccine. 2021 May 18. pii: S0264-410X(21)00608.
    >> Share

  1380. CHAN YW, Wong ML, Kwok FY, Au AK, et al
    The effect of seasonal influenza vaccine on medically-attended influenza and non-influenza respiratory viruses infections at primary care level, Hong Kong SAR, 2017/18 to 2019/20.
    Vaccine. 2021 May 17. pii: S0264-410X(21)00541.
    >> Share

  1381. GUBERNOT D, Jazwa A, Niu M, Baumblatt J, et al
    U.S. Population-Based background incidence rates of medical conditions for use in safety assessment of COVID-19 vaccines.
    Vaccine. 2021 May 14. pii: S0264-410X(21)00578.
    >> Share

  1382. WOOD RM, Murch BJ, Moss SJ, Tyler JMB, et al
    Operational research for the safe and effective design of COVID-19 mass vaccination centres.
    Vaccine. 2021 May 14. pii: S0264-410X(21)00588.
    >> Share

  1383. CHUNG JR, Flannery B, Kim SS, Gaglani M, et al
    Sample size considerations for mid-season estimates from a large influenza vaccine effectiveness network in the United States.
    Vaccine. 2021 May 13. pii: S0264-410X(21)00555.
    >> Share

  1384. KIM TH, Choi JH, Park SH, Yoo JH, et al
    Safety and immunogenicity of a seasonal quadrivalent influenza vaccine (GC3110A) in healthy participants aged >/= 65 years.
    Vaccine. 2021 May 12. pii: S0264-410X(21)00551.
    >> Share

  1385. KRAIGSLEY AM, Moore KA, Bolster A, Peters M, et al
    Barriers and activities to implementing or expanding influenza vaccination programs in low- and middle-income countries: A global survey.
    Vaccine. 2021 May 12. pii: S0264-410X(21)00502.
    >> Share

  1386. AFIFI TO, Salmon S, Taillieu T, Stewart-Tufescu A, et al
    Older adolescents and young adults willingness to receive the COVID-19 vaccine: Implications for informing public health strategies.
    Vaccine. 2021 May 12. pii: S0264-410X(21)00590.
    >> Share

  1387. LONGCHAMPS C, Ducarroz S, Crouzet L, Vignier N, et al
    COVID-19 vaccine hesitancy among persons living in homeless shelters in France.
    Vaccine. 2021 May 12. pii: S0264-410X(21)00563.
    >> Share

  1388. LEUNG VKY, Fox A, Carolan LA, Aban M, et al
    Impact of prior vaccination on antibody response and influenza-like illness among Australian healthcare workers after influenza vaccination in 2016.
    Vaccine. 2021 May 10. pii: S0264-410X(21)00483.
    >> Share

  1389. POWELL H, Liu H, Pekosz A
    Changes in sialic acid binding associated with egg adaptation decrease live attenuated influenza virus replication in human nasal epithelial cell cultures.
    Vaccine. 2021 May 10. pii: S0264-410X(21)00535.
    >> Share

  1390. PASTORINO R, Villani L, La Milia DI, Ieraci R, et al
    Influenza and pneumococcal vaccinations are not associated to COVID-19 outcomes among patients admitted to a university hospital.
    Vaccine. 2021 May 9. pii: S0264-410X(21)00566.
    >> Share

  1391. HUANG JM, Wang SY, Lai MR, Tseng YK, et al
    Development of a respiratory syncytial virus vaccine using human hepatitis B core-based virus-like particles to induce mucosal immunity.
    Vaccine. 2021 May 7. pii: S0264-410X(21)00485.
    >> Share

  1392. CORREIA R, Meneses L, Richheimer C, Alves PM, et al
    Improved storage of influenza HA-VLPs using a trehalose-glycerol natural deep eutectic solvent system.
    Vaccine. 2021 May 6. pii: S0264-410X(21)00480.
    >> Share

  1393. SOMIYA M, Mine S, Yasukawa K, Ikeda S, et al
    Sex differences in the incidence of anaphylaxis to LNP-mRNA COVID-19 vaccines.
    Vaccine. 2021 May 6. pii: S0264-410X(21)00548.
    >> Share

    April 2021
  1394. EYAL N, Gerhard T, Strom BL
    Strengthening and accelerating SARS-CoV-2 vaccine safety surveillance through registered pre-approval rollout after challenge tests.
    Vaccine. 2021 Apr 30. pii: S0264-410X(21)00526.
    >> Share

  1395. WELSH KJ, Baumblatt J, Chege W, Goud R, et al
    Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS).
    Vaccine. 2021 Apr 30. pii: S0264-410X(21)00524.
    >> Share

  1396. KINI A, Morgan R, Kuo H, Shea P, et al
    Differences and disparities in seasonal influenza vaccine, acceptance, adverse reactions, and coverage by age, sex, gender, and race.
    Vaccine. 2021 Apr 28. pii: S0264-410X(21)00448.
    >> Share

  1397. SAITOH A, Okabe N
    Changes and remaining challenges for the Japanese immunization program: Closing the vaccine gap.
    Vaccine. 2021 Apr 27. pii: S0264-410X(21)00460.
    >> Share

  1398. KWON JH, Criado MF, Killmaster L, Ali MZ, et al
    Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh.
    Vaccine. 2021 Apr 25. pii: S0264-410X(21)00459.
    >> Share

  1399. KREPS SE, Kriner DL
    Factors influencing Covid-19 vaccine acceptance across subgroups in the United States: Evidence from a conjoint experiment.
    Vaccine. 2021 Apr 24. pii: S0264-410X(21)00503.
    >> Share

  1400. MACINTYRE CR, Costantino V, Trent M
    Modelling of COVID-19 vaccination strategies and herd immunity, in scenarios of limited and full vaccine supply in NSW, Australia.
    Vaccine. 2021 Apr 24. pii: S0264-410X(21)00501.
    >> Share

  1401. OLATUNJI EA, Ogunsola AS, Khodakarami N, Callaghan T, et al
    Who receives influenza vaccinations at the Pharmacy? An analysis of the Texas Behavioral Risk Factor Surveillance System.
    Vaccine. 2021 Apr 22. pii: S0264-410X(21)00451.
    >> Share

  1402. DADARI I, Higgins-Steele A, Sharkey A, Charlet D, et al
    Pro-equity immunization and health systems strengthening strategies in select Gavi-supported countries.
    Vaccine. 2021;39:2434-2444.
    >> Share

  1403. WANG C, Han B, Zhao T, Liu H, et al
    Vaccination willingness, vaccine hesitancy, and estimated coverage at the first round of COVID-19 vaccination in China: A national cross-sectional study.
    Vaccine. 2021 Apr 13. pii: S0264-410X(21)00455.
    >> Share

  1404. LEVIN Y, Balakirski NM, Caraco Y, Ben-Ami E, et al
    Ethics and execution of developing a 2nd wave COVID vaccine - Our interim phase I/II VSV-SARS-CoV2 vaccine experience.
    Vaccine. 2021 Apr 13. pii: S0264-410X(21)00452.
    >> Share

  1405. HAMILTON RA, Krockow EM, Vekria P
    Attitudes towards influenza and uptake of the flu vaccine: A survey of pharmacy staff working in English hospitals.
    Vaccine. 2021 Apr 9. pii: S0264-410X(21)00407.
    >> Share

  1406. PU J, Yu Q, Yin Z, Zhang Y, et al
    The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18-59 years: A phase I randomized, double-blinded, controlled trial.
    Vaccine. 2021 Apr 9. pii: S0264-410X(21)00431.
    >> Share

  1407. POLUEKTOV Y, George M, Daftarian P, Delcommenne MC, et al
    Assessment of SARS-CoV-2 specific CD4(+) and CD8 (+) T cell responses using MHC class I and II tetramers.
    Vaccine. 2021;39:2110-2116.
    >> Share

  1408. HOGAN AB, Winskill P, Watson OJ, Walker PGT, et al
    Within-country age-based prioritisation, global allocation, and public health impact of a vaccine against SARS-CoV-2: A mathematical modelling analysis.
    Vaccine. 2021 Apr 8. pii: S0264-410X(21)00427.
    >> Share

  1409. PAGLIUSI S, Hayman B, Jarrett S
    Vaccines for a healthy future: 21st DCVMN Annual General Meeting 2020 report.
    Vaccine. 2021 Apr 7. pii: S0264-410X(21)00293.
    >> Share

  1410. DANIELS V, Saxena K, Roberts C, Kothari S, et al
    Impact of reduced human papillomavirus vaccination coverage rates due to COVID-19 in the United States: A model based analysis.
    Vaccine. 2021 Apr 6. pii: S0264-410X(21)00428.
    >> Share

  1411. GRAMACHO WG, Turgeon M
    When politics collides with public health: COVID-19 vaccine country of origin and vaccination acceptance in Brazil.
    Vaccine. 2021 Apr 6. pii: S0264-410X(21)00396.
    >> Share

  1412. HATZIANTONIOU S, Maltezou HC, Tsakris A, Poland GA, et al
    Anaphylactic reactions to mRNA COVID-19 vaccines: A call for further study.
    Vaccine. 2021 Apr 6. pii: S0264-410X(21)00377.
    >> Share

    March 2021
  1413. PELTON SI, Divino V, Postma MJ, Shah D, et al
    A retrospective cohort study assessing relative effectiveness of adjuvanted versus high-dose trivalent influenza vaccines among older adults in the United States during the 2018-19 influenza season.
    Vaccine. 2021 Mar 30. pii: S0264-410X(21)00347.
    >> Share

  1414. GUR-ARIE R, Katz MA, Hirsch A, Greenberg D, et al
    "You Have to Die Not to Come to Work": A Mixed Methods Study of Attitudes and Behaviors regarding Presenteeism, Absenteeism and Influenza Vaccination among Healthcare Personnel with Respiratory Illness in Israel, 2016-2019.
    Vaccine. 2021 Mar 29. pii: S0264-410X(21)00361.
    >> Share

  1415. KUTER BJ, Offit PA, Poland GA
    The development of COVID-19 vaccines in the United States: Why and how so fast?
    Vaccine. 2021 Mar 26. pii: S0264-410X(21)00383.
    >> Share

  1416. RUSSO AG, Decarli A, Valsecchi MG
    Strategy to identify priority groups for COVID-19 vaccination: A population based cohort study.
    Vaccine. 2021 Mar 26. pii: S0264-410X(21)00382.
    >> Share

  1417. GKENTZI D, Aggelopoulos K, Karatza A, Sinopidis X, et al
    Influenza vaccination among caregivers and household contacts of children with asthma.
    Vaccine. 2021 Mar 25. pii: S0264-410X(21)00325.
    >> Share

  1418. SALMON DA, Dudley MZ, Brewer J, Kan L, et al
    COVID-19 vaccination attitudes, values and intentions among United States adults prior to emergency use authorization.
    Vaccine. 2021 Mar 24. pii: S0264-410X(21)00315.
    >> Share

  1419. ROSA SS, Prazeres DMF, Azevedo AM, Marques MPC, et al
    mRNA vaccines manufacturing: Challenges and bottlenecks.
    Vaccine. 2021 Mar 23. pii: S0264-410X(21)00319.
    >> Share

  1420. HAEDER SF
    Joining the herd? U.S. public opinion and vaccination requirements across educational settings during the COVID-19 pandemic.
    Vaccine. 2021 Mar 23. pii: S0264-410X(21)00348.
    >> Share

  1421. KOCHHAR S, Dube E, Graham J, Jee Y, et al
    COVID-19 vaccine safety questions and answers for healthcare providers (CONSIDER).
    Vaccine. 2021 Mar 22. pii: S0264-410X(21)00364.
    >> Share

  1422. ZHANG Y, Li D, Zhao H, Wang L, et al
    The role of multiple SARS-CoV-2 viral antigens in a vaccine-induced integrated immune response.
    Vaccine. 2021 Mar 22. pii: S0264-410X(21)00371.
    >> Share

  1423. ANTONELLI INCALZI R, Trevisan C, Del Signore S, Volpato S, et al
    Are vaccines against COVID-19 tailored to the most vulnerable people?
    Vaccine. 2021 Mar 22. pii: S0264-410X(21)00370.
    >> Share

  1424. ANGELIS A, Darrow J
    Safeguarding evidence-based decision making in the FDA for COVID-19 vaccines.
    Vaccine. 2021 Mar 22. pii: S0264-410X(21)00346.
    >> Share

  1425. KENDAL A
    Safety monitoring of COVID-19 vaccines - Lessons learned from the 1976 national influenza immunization program about detecting rare vaccine-related severe adverse events in emergency mass-vaccination programs.
    Vaccine. 2021 Mar 20. pii: S0264-410X(21)00283.
    >> Share

  1426. CHEN D, Ye Z, Pi Z, Mizukami S, et al
    Cost-effectiveness of dual influenza and pneumococcal vaccination among the elderly in Shenzhen, China.
    Vaccine. 2021 Mar 20. pii: S0264-410X(21)00324.
    >> Share

  1427. VILCHES TN, Zhang K, Van Exan R, Langley JM, et al
    Projecting the impact of a two-dose COVID-19 vaccination campaign in Ontario, Canada.
    Vaccine. 2021 Mar 20. pii: S0264-410X(21)00362.
    >> Share

  1428. CAMBOU MC, Copeland TP, Nielsen-Saines K, Macinko J, et al
    Insurance status predicts self-reported influenza vaccine coverage among pregnant women in the United States: A cross-sectional analysis of the National Health Interview Study Data from 2012 to 2018.
    Vaccine. 2021 Mar 17. pii: S0264-410X(21)00294.
    >> Share

  1429. GRAUPENSPERGER S PHD, Abdallah DA, Lee CM
    Social norms and vaccine uptake: College students' COVID vaccination intentions, attitudes, and estimated peer norms and comparisons with influenza vaccine.
    Vaccine. 2021 Mar 17. pii: S0264-410X(21)00286.
    >> Share

  1430. SZIGETI R, Kellermayer R
    Natural unblinding of BCG vaccination trials.
    Vaccine. 2021 Mar 17. pii: S0264-410X(21)00320.
    >> Share

  1431. ALLINGTON D, McAndrew S, Moxham-Hall VL, Duffy B, et al
    Media usage predicts intention to be vaccinated against SARS-CoV-2 in the US and the UK.
    Vaccine. 2021 Mar 16. pii: S0264-410X(21)00234.
    >> Share

  1432. CHOI UY, Kim KH, Lee KY, Kim JH, et al
    Active-controlled phase III study of an egg-cultivated quadrivalent inactivated split-virion influenza vaccine (GC3110A) in healthy Korean children aged 6-35 months.
    Vaccine. 2021 Mar 15. pii: S0264-410X(21)00273.
    >> Share

  1433. NET P, Colrat F, Nascimento Costa M, Bianic F, et al
    Estimating public health and economic benefits along 10 years of Fluzone(R) High Dose in the United States.
    Vaccine. 2021;39 Suppl 1:A56-A69.
    >> Share

  1434. BUTTERY JP
    Developing standard safety outcomes for COVID-19 vaccines.
    Vaccine. 2021 Mar 12. pii: S0264-410X(21)00272.
    >> Share

  1435. LEE J, Li Y, Li Y, Cino-Ozuna AG, et al
    Bat influenza vectored NS1-truncated live vaccine protects pigs against heterologous virus challenge.
    Vaccine. 2021 Mar 11. pii: S0264-410X(21)00268.
    >> Share

  1436. BERTRAN K, Kassa A, Criado MF, Nunez IA, et al
    Efficacy of recombinant Marek's disease virus vectored vaccines with computationally optimized broadly reactive antigen (COBRA) hemagglutinin insert against genetically diverse H5 high pathogenicity avian influenza viruses.
    Vaccine. 2021 Mar 11. pii: S0264-410X(21)00266.
    >> Share

  1437. EBAMA MS, Chu SY, Azziz-Baumgartner E, Lafond KE, et al
    Ancillary benefits of seasonal influenza vaccination in middle-income countries.
    Vaccine. 2021 Mar 10. pii: S0264-410X(21)00228.
    >> Share

  1438. LATKIN C, Dayton LA, Yi G, Konstantopoulos A, et al
    COVID-19 vaccine intentions in the United States, a social-ecological framework.
    Vaccine. 2021 Mar 10. pii: S0264-410X(21)00238.
    >> Share

  1439. REPERANT LA, Osterhaus ADME
    COVID-19 vaccination and critical care capacity: Perilous months ahead.
    Vaccine. 2021 Mar 10. pii: S0264-410X(21)00316.
    >> Share

  1440. WENTZELL E, Racila AM
    The social experience of participation in a COVID-19 vaccine trial: Subjects' motivations, others' concerns, and insights for vaccine promotion.
    Vaccine. 2021 Mar 10. pii: S0264-410X(21)00317.
    >> Share

  1441. GUIDRY JPD, Perrin PB, Laestadius LI, Vraga EK, et al
    U.S. public support for COVID-19 vaccine donation to low- and middle-income countries during the COVID-19 pandemic.
    Vaccine. 2021 Mar 9. pii: S0264-410X(21)00306.
    >> Share

  1442. SADARANGANI M, Abu Raya B, Conway JM, Iyaniwura SA, et al
    Importance of COVID-19 vaccine efficacy in older age groups.
    Vaccine. 2021 Mar 8. pii: S0264-410X(21)00288.
    >> Share

  1443. KISZEWSKI AE, Cleary EG, Jackson MJ, Ledley FD, et al
    NIH funding for vaccine readiness before the COVID-19 pandemic.
    Vaccine. 2021 Mar 8. pii: S0264-410X(21)00290.
    >> Share

  1444. PULLAN S, Dey M
    Vaccine hesitancy and anti-vaccination in the time of COVID-19: A Google Trends analysis.
    Vaccine. 2021 Mar 6. pii: S0264-410X(21)00287.
    >> Share

  1445. BLACK SB, Law B, Chen RT, Dekker CL, et al
    The critical role of background rates of possible adverse events in the assessment of COVID-19 vaccine safety.
    Vaccine. 2021 Mar 6. pii: S0264-410X(21)00284.
    >> Share

  1446. GASPAR EB, De Gaspari E
    Avidity assay to test functionality of anti-SARS-Cov-2 antibodies.
    Vaccine. 2021;39:1473-1475.
    >> Share

  1447. YOKOMICHI H, Kojima R, Horiuchi S, Ooka T, et al
    Effectiveness of influenza vaccination in infants and toddlers with and without prior infection history: The Japan Environment and Children's Study.
    Vaccine. 2021 Mar 5. pii: S0264-410X(21)00224.
    >> Share

  1448. DU Y, Xu Y, Feng J, Hu L, et al
    Intranasal administration of a recombinant RBD vaccine induced protective immunity against SARS-CoV-2 in mouse.
    Vaccine. 2021 Mar 5. pii: S0264-410X(21)00274.
    >> Share

  1449. KUO H, Shapiro JR, Dhakal S, Morgan R, et al
    Sex-specific effects of age and body mass index on antibody responses to seasonal influenza vaccines in healthcare workers.
    Vaccine. 2021 Mar 4. pii: S0264-410X(21)00227.
    >> Share

  1450. WOO EJ, Moro PL
    Postmarketing safety surveillance of quadrivalent recombinant influenza vaccine: Reports to the vaccine adverse event reporting system.
    Vaccine. 2021 Mar 4. pii: S0264-410X(21)00232.
    >> Share

  1451. STURM L, Kasting ML, Head KJ, Hartsock JA, et al
    Influenza vaccination in the time of COVID-19: A national U.S. survey of adults.
    Vaccine. 2021 Mar 4. pii: S0264-410X(21)00271.
    >> Share

  1452. HELMKAMP LJ, Szilagyi PG, Zimet G, Saville AW, et al
    A validated modification of the vaccine hesitancy scale for childhood, influenza and HPV vaccines.
    Vaccine. 2021 Mar 3. pii: S0264-410X(21)00206.
    >> Share

  1453. FELL DB, Dimitris MC, Hutcheon JA, Ortiz JR, et al
    Guidance for design and analysis of observational studies of fetal and newborn outcomes following COVID-19 vaccination during pregnancy.
    Vaccine. 2021 Mar 2. pii: S0264-410X(21)00261.
    >> Share

    February 2021
  1454. WANG J, Lyu Y, Zhang H, Jing R, et al
    Willingness to pay and financing preferences for COVID-19 vaccination in China.
    Vaccine. 2021 Feb 27. pii: S0264-410X(21)00240.
    >> Share

  1455. SHEN M, Zu J, Fairley CK, Pagan JA, et al
    Projected COVID-19 epidemic in the United States in the context of the effectiveness of a potential vaccine and implications for social distancing and face mask use.
    Vaccine. 2021 Feb 27. pii: S0264-410X(21)00236.
    >> Share

  1456. SANDBRINK JB, Koblentz GD
    Biosecurity risks associated with vaccine platform technologies.
    Vaccine. 2021 Feb 25. pii: S0264-410X(21)00171.
    >> Share

  1457. SELL TK, Gastfriend D, Watson M, Watson C, et al
    Building the global vaccine manufacturing capacity needed to respond to pandemics.
    Vaccine. 2021 Feb 24. pii: S0264-410X(21)00165.
    >> Share

  1458. MUNOZ FM, Cramer JP, Dekker CL, Dudley MZ, et al
    Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data.
    Vaccine. 2021 Feb 23. pii: S0264-410X(21)00094.
    >> Share

  1459. VERELST F, Beutels P, Hens N, Willem L, et al
    Workplace influenza vaccination to reduce employee absenteeism: An economic analysis from the employers' perspective.
    Vaccine. 2021 Feb 22. pii: S0264-410X(21)00168.
    >> Share

  1460. SU QD, Zou YN, Yi Y, Shen LP, et al
    Recombinant SARS-CoV-2 RBD with a built in T helper epitope induces strong neutralization antibody response.
    Vaccine. 2021;39:1241-1247.
    >> Share

  1461. BLUNCK BN, Aideyan L, Ye X, Avadhanula V, et al
    A prospective surveillance study on the kinetics of the humoral immune response to the respiratory syncytial virus fusion protein in adults in Houston, Texas.
    Vaccine. 2021;39:1248-1256.
    >> Share

  1462. ELSENPETER HMS
    How COVID exposed the hypocrisy within me.
    Vaccine. 2021;39:1178-1179.
    >> Share

  1463. ORTIZ JR, Robertson J, Hsu JS, Yu SL, et al
    The potential effects of deploying SARS-Cov-2 vaccines on cold storage capacity and immunization workload in countries of the WHO African Region.
    Vaccine. 2021 Feb 19. pii: S0264-410X(21)00204.
    >> Share

  1464. CHANG LJ, Anderson EJ, Jeanfreau R, He Y, et al
    Safety and immunogenicity of high doses of quadrivalent influenza vaccine in children 6months through<18years of age: A randomized controlled phase II dose-finding trial.
    Vaccine. 2021 Feb 18. pii: S0264-410X(21)00162.
    >> Share

  1465. KUTER BJ, Browne S, Momplaisir FM, Feemster KA, et al
    Perspectives on the receipt of a COVID-19 vaccine: A survey of employees in two large hospitals in Philadelphia.
    Vaccine. 2021 Feb 16. pii: S0264-410X(21)00185.
    >> Share

  1466. WU MJ, Chung JR, Kim SS, Jackson ML, et al
    Influenza vaccination coverage among persons seeking outpatient medical care for acute respiratory illness in five states in the United States, 2011-2012 through 2018-2019.
    Vaccine. 2021 Feb 15. pii: S0264-410X(21)00106.
    >> Share

  1467. GURWITZ D
    Ethical tradeoffs in SARS-CoV-2 vaccine development: Assuring fair availability for low-income countries.
    Vaccine. 2021;39:1027.
    >> Share

  1468. RID A, Shah SK, Miller FG, Danis M, et al
    Ethical trade-offs in vaccine development and distribution-Response to Gurwitz.
    Vaccine. 2021;39:1028-1029.
    >> Share

  1469. WARD BJ, Seguin A, Couillard J, Trepanier S, et al
    Phase III: Randomized observer-blind trial to evaluate lot-to-lot consistency of a new plant-derived quadrivalent virus like particle influenza vaccine in adults 18-49 years of age.
    Vaccine. 2021 Feb 10. pii: S0264-410X(21)00004.
    >> Share

  1470. POLAND CM, Matthews AKS, Poland GA
    Improving COVID-19 vaccine acceptance: Including insights from human decision-making under conditions of uncertainty and human-centered design.
    Vaccine. 2021 Feb 10. pii: S0264-410X(21)00154.
    >> Share

  1471. BRUCE-STASKAL PJ, Woods RM, Borisov OV, Massare MJ, et al
    Corrigendum to "Hemagglutinin from multiple divergent influenza A and B viruses bind to a distinct branched, sialylated poly-LacNAc glycan by surface plasmon resonance" [Vaccine 38(43) (2020) 6757-6765].
    Vaccine. 2021 Feb 9. pii: S0264-410X(21)00105.
    >> Share

  1472. CHU L, McPhee R, Huang W, Bennett H, et al
    A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine.
    Vaccine. 2021 Feb 9. pii: S0264-410X(21)00153.
    >> Share

  1473. ROBINSON E, Jones A, Lesser I, Daly M, et al
    International estimates of intended uptake and refusal of COVID-19 vaccines: A rapid systematic review and meta-analysis of large nationally representative samples.
    Vaccine. 2021 Feb 6. pii: S0264-410X(21)00140.
    >> Share

  1474. KUMAR N, Bhartiya S, Singh T
    Duration of anti-SARS-CoV-2 antibodies much shorter in India.
    Vaccine. 2021;39:886-888.
    >> Share

  1475. DIACO M, Chang LJ, Seet B, Robertson CA, et al
    Introductory paper: High dose influenza vaccine.
    Vaccine. 2021 Feb 3. pii: S0264-410X(20)31147.
    >> Share

  1476. WILCK MB, Jin Xu Z, Stek JE, Goveia MG, et al
    Protective immune responses against Haemophilus influenza type B elicited by a fully-liquid DTaP-IPV-Hib-HepB vaccine (VAXELIS).
    Vaccine. 2021 Feb 1. pii: S0264-410X(21)00073.
    >> Share

    January 2021
  1477. AXELSEN PH, Poland GA
    Vaccines, masks, distancing and credibility: An urgent warning for pandemic management.
    Vaccine. 2021 Jan 31. pii: S0264-410X(21)00079.
    >> Share

  1478. COLRAT F, Thommes E, Largeron N, Alvarez FP, et al
    Economic evaluation of high-dose inactivated influenza vaccine in adults aged >/=65 years: A systematic literature review.
    Vaccine. 2021 Jan 29. pii: S0264-410X(20)31603.
    >> Share

  1479. HAMPTON LM, Aggarwal R, Evans SJW, Law B, et al
    General determination of causation between Covid-19 vaccines and possible adverse events.
    Vaccine. 2021 Jan 29. pii: S0264-410X(21)00096.
    >> Share

  1480. BERMAN L, Riedel M
    Coping with COVID.
    Vaccine. 2021;39:777-778.
    >> Share

  1481. KIM SH, Paldurai A, Xiao S, Collins PL, et al
    Retraction notice to "Modified Newcastle disease virus vectors expressing the H5 hemagglutinin induce enhanced protection against highly pathogenic H5N1 avian influenza virus in chickens" [Vaccine 32(35) (2014) 4428-4435].
    Vaccine. 2021;39:775.
    >> Share

  1482. WANG Y, Chen L, Cheng F, Biggerstaff M, et al
    Economic burden of influenza illness among children under 5 years in Suzhou, China: Report from the cost surveys during 2011/12 to 2016/17 influenza seasons.
    Vaccine. 2021 Jan 22. pii: S0264-410X(20)31672.
    >> Share

  1483. OKOLI GN, Racovitan F, Abdulwahid T, Righolt CH, et al
    Variable seasonal influenza vaccine effectiveness across geographical regions, age groups and levels of vaccine antigenic similarity with circulating virus strains: A systematic review and meta-analysis of the evidence from test-negative design studie
    Vaccine. 2021 Jan 22. pii: S0264-410X(21)00048.
    >> Share

  1484. BHUIYAN MU, Stiboy E, Hassan MZ, Chan M, et al
    Epidemiology of COVID-19 infection in young children under five years: A systematic review and meta-analysis.
    Vaccine. 2021;39:667-677.
    >> Share

  1485. JAMROZIK E, Littler K, Bull S, Emerson C, et al
    Key criteria for the ethical acceptability of COVID-19 human challenge studies: Report of a WHO Working Group.
    Vaccine. 2021;39:633-640.
    >> Share

  1486. BALASUBRAMANI GK, Zimmerman RK, Eng H, Lyons J, et al
    Comparison of local influenza vaccine effectiveness using two methods.
    Vaccine. 2021 Jan 20. pii: S0264-410X(21)00017.
    >> Share

  1487. DAL-RE R
    US FDA erratic approach to placebo-controlled trials after issuing an emergency use authorization for a COVID-19 vaccine.
    Vaccine. 2021 Jan 20. pii: S0264-410X(21)00077.
    >> Share

  1488. POLAND EG, McGuire DK, Ratishvili T, Poland GA, et al
    The economics of global COVID vaccine administration during a pandemic - Why continue skin alcohol preparation as a costly but ineffective practice?
    Vaccine. 2021 Jan 20. pii: S0264-410X(20)31694.
    >> Share

  1489. WINOKUR P, El Sahly HM, Mulligan MJ, Frey SE, et al
    Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older.
    Vaccine. 2021 Jan 20. pii: S0264-410X(20)31504.
    >> Share

  1490. CAO L, Lou J, Zhao S, Chan RWY, et al
    In silico prediction of influenza vaccine effectiveness by sequence analysis.
    Vaccine. 2021 Jan 19. pii: S0264-410X(21)00006.
    >> Share

  1491. REEMERS S, Verstegen I, Basten S, Hubers W, et al
    A broad spectrum HVT-H5 avian influenza vector vaccine which induces a rapid onset of immunity.
    Vaccine. 2021 Jan 19. pii: S0264-410X(21)00022.
    >> Share

  1492. FATOBA AJ, Maharaj L, Adeleke VT, Okpeku M, et al
    Immunoinformatics prediction of overlapping CD8(+) T-cell, IFN-gamma and IL-4 inducer CD4(+) T-cell and linear B-cell epitopes based vaccines against COVID-19 (SARS-CoV-2).
    Vaccine. 2021 Jan 18. pii: S0264-410X(21)00003.
    >> Share

  1493. SCOTT EM, Stein R, Brown MF, Hershberger J, et al
    Vaccination patterns of the northeast Ohio Amish revisited.
    Vaccine. 2021 Jan 18. pii: S0264-410X(21)00026.
    >> Share

  1494. WHITAKER JA, Parikh SA, Shanafelt TD, Kay NE, et al
    The humoral immune response to high-dose influenza vaccine in persons with monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL).
    Vaccine. 2021 Jan 15. pii: S0264-410X(21)00001.
    >> Share

  1495. GUALANO MR, Corradi A, Voglino G, Catozzi D, et al
    Healthcare Workers' (HCWs) attitudes towards mandatory influenza vaccination: A systematic review and meta-analysis.
    Vaccine. 2021 Jan 12. pii: S0264-410X(20)31655.
    >> Share

  1496. AKMATOV MK, Holstiege J, Steffen A, Batzing J, et al
    Utilization of influenza vaccination among chronically ill individuals in Germany: A nationwide claims-based analysis.
    Vaccine. 2021 Jan 12. pii: S0264-410X(20)31693.
    >> Share

  1497. BURGER AE, Reither EN, Mamelund SE, Lim S, et al
    Black-white disparities in 2009 H1N1 vaccination among adults in the United States: A cautionary tale for the COVID-19 pandemic.
    Vaccine. 2021 Jan 11. pii: S0264-410X(20)31666.
    >> Share

  1498. WIEMKEN TL, Rutschman AS
    Development of vaccines for influenza disease: Opportunity costs of the COVID-19 pandemic.
    Vaccine. 2021 Jan 9. pii: S0264-410X(21)00018.
    >> Share

  1499. SINGH J, Malik D, Raina A
    Immuno-informatics approach for B-cell and T-cell epitope based peptide vaccine design against novel COVID-19 virus.
    Vaccine. 2021 Jan 9. pii: S0264-410X(21)00015.
    >> Share

  1500. RUIZ JB, Bell RA
    Predictors of intention to vaccinate against COVID-19: Results of a nationwide survey.
    Vaccine. 2021 Jan 9. pii: S0264-410X(21)00014.
    >> Share

  1501. BEIGI RH, Krubiner C, Jamieson DJ, Lyerly AD, et al
    The need for inclusion of pregnant women in COVID-19 vaccine trials.
    Vaccine. 2021 Jan 8. pii: S0264-410X(20)31671.
    >> Share

  1502. GOLD MS, Lincoln G, Cashman P, Braunack-Mayer A, et al
    Efficacy of m-Health for the detection of adverse events following immunization - The stimulated telephone assisted rapid safety surveillance (STARSS) randomised control trial.
    Vaccine. 2021;39:332-342.
    >> Share

  1503. CALDERA F, Mercer M, Samson SI, Pitt JM, et al
    Influenza vaccination in immunocompromised populations: Strategies to improve immunogenicity.
    Vaccine. 2021 Jan 7. pii: S0264-410X(20)31490.
    >> Share

  1504. WILLIAMS J, Degeling C, McVernon J, Dawson A, et al
    How should we conduct pandemic vaccination?
    Vaccine. 2021 Jan 7. pii: S0264-410X(20)31639.
    >> Share

  1505. KELSO JM
    Anaphylactic reactions to novel mRNA SARS-CoV-2/COVID-19 vaccines.
    Vaccine. 2021 Jan 6. pii: S0264-410X(20)31696.
    >> Share

  1506. KOHLI M, Maschio M, Becker D, Weinstein MC, et al
    The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness modeling to inform vaccination prioritization.
    Vaccine. 2021 Jan 6. pii: S0264-410X(20)31690.
    >> Share

  1507. MIDDELDORP M, van Lier A, van der Maas N, Veldhuijzen I, et al
    Short term impact of the COVID-19 pandemic on incidence of vaccine preventable diseases and participation in routine infant vaccinations in the Netherlands in the period March-September 2020.
    Vaccine. 2021 Jan 6. pii: S0264-410X(20)31692.
    >> Share

  1508. WONG MCS, Wong ELY, Huang J, Cheung AWL, et al
    Acceptance of the COVID-19 vaccine based on the health belief model: A population-based survey in Hong Kong.
    Vaccine. 2021 Jan 6. pii: S0264-410X(20)31695.
    >> Share

  1509. SU JR, McNeil MM, Welsh KJ, Marquez PL, et al
    Myopericarditis after vaccination, Vaccine Adverse Event Reporting System (VAERS), 1990-2018.
    Vaccine. 2021 Jan 6. pii: S0264-410X(20)31614.
    >> Share

  1510. GODINOT LD, Sicsic J, Lachatre M, Bouvet E, et al
    Quantifying preferences around vaccination against frequent, mild disease with risk for vulnerable persons: A discrete choice experiment among French hospital health care workers.
    Vaccine. 2021 Jan 5. pii: S0264-410X(20)31637.
    >> Share

    December 2020
  1511. JIANG X, Shang X, Lin J, Zhao Y, et al
    Impacts of free vaccination policy and associated factors on influenza vaccination behavior of the elderly in China: A quasi-experimental study.
    Vaccine. 2020 Dec 31. pii: S0264-410X(20)31608.
    >> Share

  1512. DAMJANOVSKA S, Smith C, Sayin I, Burant CJ, et al
    Adjuvant effect of type I interferon induced by many but not all commercial influenza vaccines.
    Vaccine. 2020 Dec 31. pii: S0264-410X(20)31631.
    >> Share

  1513. ZHONG Y, Clapham HE, Aishworiya R, Chua YX, et al
    Childhood vaccinations: Hidden impact of COVID-19 on children in Singapore.
    Vaccine. 2020 Dec 26. pii: S0264-410X(20)31634.
    >> Share

  1514. MORO PL, Marquez P
    Reports of cell-based influenza vaccine administered during pregnancy in the Vaccine Adverse Event Reporting System (VAERS), 2013-2020.
    Vaccine. 2020 Dec 24. pii: S0264-410X(20)31613.
    >> Share

  1515. THANGARAJAH D, Malo JA, Field E, Andrews R, et al
    Effectiveness of quadrivalent influenza vaccination in the first year of a funded childhood program in Queensland, Australia, 2018.
    Vaccine. 2020 Dec 23. pii: S0264-410X(20)31579.
    >> Share

  1516. MCFADDEN K, Seale H
    A review of hospital-based interventions to improve inpatient influenza vaccination uptake for high-risk adults.
    Vaccine. 2020 Dec 21. pii: S0264-410X(20)31610.
    >> Share

  1517. SCHMIT T, Kuntz M, Patel D, Nadeem Khan M, et al
    Anti-capsular immunity to Streptococcus pneumoniae serotype 22F prevents bacterial transmission in murine colonization and influenza virus co-infection models.
    Vaccine. 2020 Dec 18. pii: S0264-410X(20)31558.
    >> Share

  1518. SPARROW E, Wood JG, Chadwick C, Newall AT, et al
    Global production capacity of seasonal and pandemic influenza vaccines in 2019.
    Vaccine. 2020 Dec 16. pii: S0264-410X(20)31585.
    >> Share

  1519. FULVINI AA, Tuteja A, Le J, Pokorny BA, et al
    HA1 (Hemagglutinin) quantitation for influenza A H1N1 and H3N2 high yield reassortant vaccine candidate seed viruses by RP-UPLC.
    Vaccine. 2020 Dec 16. pii: S0264-410X(20)31563.
    >> Share

  1520. BORRIELLO A, Master D, Pellegrini A, Rose JM, et al
    Preferences for a COVID-19 vaccine in Australia.
    Vaccine. 2020 Dec 16. pii: S0264-410X(20)31599.
    >> Share

  1521. BOKEMPER SE, Huber GA, Gerber AS, James EK, et al
    Timing of COVID-19 vaccine approval and endorsement by public figures.
    Vaccine. 2020 Dec 16. pii: S0264-410X(20)31616.
    >> Share

  1522. SANFTENBERG L, Kuehne F, Anraad C, Jung-Sievers C, et al
    Assessing the impact of shared decision making processes on influenza vaccination rates in adult patients in outpatient care: A systematic review and meta-analysis.
    Vaccine. 2020 Dec 14. pii: S0264-410X(20)31581.
    >> Share

  1523. BROOCKMAN D, Kalla J, Guerrero A, Budolfson M, et al
    Broad cross-national public support for accelerated COVID-19 vaccine trial designs.
    Vaccine. 2020 Dec 14. pii: S0264-410X(20)31555.
    >> Share

  1524. BRAVO-GRANDE JL, Asuncion Blanco-Gonzalez M, de la Torre-Robles JM, Asmat-Inostrosa MP, et al
    Vaccination adjuvated against hepatitis B in Spanish National Healthcare System (SNS) workers typed as non-responders to conventional vaccines.
    Vaccine. 2020 Dec 14. pii: S0264-410X(20)31571.
    >> Share

  1525. SARINHO E, Goudouris E, Sole D
    BCG vaccine: Worrying proposal for COVID-19.
    Vaccine. 2020 Dec 13. pii: S0264-410X(20)31593.
    >> Share

  1526. DEGELING C, Williams J, Carter SM, Moss R, et al
    Priority allocation of pandemic influenza vaccines in Australia - Recommendations of 3 community juries.
    Vaccine. 2020 Dec 11. pii: S0264-410X(20)31577.
    >> Share

  1527. RASTEGAR M, Tavana M, Meraj A, Mina H, et al
    An inventory-location optimization model for equitable influenza vaccine distribution in developing countries during the COVID-19 pandemic.
    Vaccine. 2020 Dec 9. pii: S0264-410X(20)31589.
    >> Share

  1528. HOLM MR, Poland GA
    Critical aspects of packaging, storage, preparation, and administration of mRNA and adenovirus-vectored COVID-19 vaccines for optimal efficacy.
    Vaccine. 2020 Dec 9. pii: S0264-410X(20)31584.
    >> Share

  1529. CARIAS C, Pawaskar M, Nyaku M, Conway JH, et al
    Potential impact of COVID-19 pandemic on vaccination coverage in children: A case study of measles-containing vaccine administration in the United States (US).
    Vaccine. 2020 Dec 9. pii: S0264-410X(20)31557.
    >> Share

  1530. DHAKAL S, Deshpande S, McMahon M, Strohmeier S, et al
    Female-biased effects of aging on a chimeric hemagglutinin stalk-based universal influenza virus vaccine in mice.
    Vaccine. 2020 Dec 5. pii: S0264-410X(20)31510.
    >> Share

  1531. LENG A, Maitland E, Wang S, Nicholas S, et al
    Individual preferences for COVID-19 vaccination in China.
    Vaccine. 2020 Dec 5. pii: S0264-410X(20)31576.
    >> Share

  1532. GHIGA I, Richardson S, Alvarez AMR, Kato M, et al
    PIPDeploy: Development and implementation of a gamified table top simulation exercise to strengthen national pandemic vaccine preparedness and readiness.
    Vaccine. 2020 Dec 5. pii: S0264-410X(20)31500.
    >> Share

  1533. WENZEL NS, Atkins KE, van Leeuwen E, Halloran ME, et al
    Cost-effectiveness of live-attenuated influenza vaccination among school-age children.
    Vaccine. 2020 Dec 4. pii: S0264-410X(20)31282.
    >> Share

  1534. MAYKIN MM, Heuser C, Feltovich H
    Pregnant people deserve the protection offered by SARS-CoV-2 vaccines.
    Vaccine. 2020 Dec 4. pii: S0264-410X(20)31572.
    >> Share

  1535. BOTHUN LS
    COVID-19: The worst date to the senior dance.
    Vaccine. 2020;38:8066-8067.
    >> Share

    November 2020
  1536. EDOKA I, Kohli-Lynch C, Fraser H, Hofman K, et al
    A cost-effectiveness analysis of South Africa's seasonal influenza vaccination programme.
    Vaccine. 2020 Nov 30. pii: S0264-410X(20)31468.
    >> Share

  1537. HAVERI A, Ikonen N, Savolainen-Kopra C, Julkunen I, et al
    Long-lasting heterologous antibody responses after sequential vaccination with A/Indonesia/5/2005 and A/Vietnam/1203/2004 pre-pandemic influenza A(H5N1) virus vaccines.
    Vaccine. 2020 Nov 24. pii: S0264-410X(20)31494.
    >> Share

  1538. VANDER STICHELE RH, Hay C, Fladvad M, Sturkenboom MCJM, et al
    How to ensure we can track and trace global use of COVID-19 vaccines?
    Vaccine. 2020 Nov 24. pii: S0264-410X(20)31508.
    >> Share

  1539. KITANO T, Aoki H
    A model for the incremental burden of invasive Haemophilus influenzae type b due to a decline of childhood vaccination during the COVID-19 outbreak: A dynamic transmission model in Japan.
    Vaccine. 2020 Nov 24. pii: S0264-410X(20)31506.
    >> Share

  1540. URA T, Yamashita A, Mizuki N, Okuda K, et al
    New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
    Vaccine. 2020 Nov 24. pii: S0264-410X(20)31507.
    >> Share

  1541. KITTIKRAISAK W, Phadungkiatwatana P, Ditsungnoen D, Kaoiean S, et al
    Comparison of influenza antibody titers among women who were vaccinated in the 2(nd) and the 3(rd) trimesters of pregnancy.
    Vaccine. 2020 Nov 23. pii: S0264-410X(20)31472.
    >> Share

  1542. DRORI Y, Pando R, Sefty H, Rosenberg A, et al
    Influenza vaccine effectiveness against laboratory-confirmed influenza in a vaccine-mismatched influenza B-dominant season.
    Vaccine. 2020 Nov 23. pii: S0264-410X(20)31394.
    >> Share

  1543. GANGULY M, Yeolekar L, Tyagi P, Sagar U, et al
    Evaluation of manufacturing feasibility and safety of an MDCK cell-based live attenuated influenza vaccine (LAIV) platform.
    Vaccine. 2020 Nov 20. pii: S0264-410X(20)31424.
    >> Share

  1544. TUCKERMAN JL, Kaufman J, Danchin M, Marshall HS, et al
    Influenza vaccination: A qualitative study of practice level barriers from medical practitioners caring for children with special risk medical conditions.
    Vaccine. 2020;38:7806-7814.
    >> Share

  1545. GARCIA LY, Cerda AA
    Acceptance of a COVID-19 vaccine: A multifactorial consideration.
    Vaccine. 2020;38:7587.
    >> Share

  1546. GRAFFIGNA G, Palamenghi L, Barello S, Stefania B, et al
    "Cultivating" acceptance of a COVID-19 vaccination program: Lessons from Italy.
    Vaccine. 2020;38:7585-7586.
    >> Share

  1547. COUDEVILLE L, Gomez GB, Jollivet O, Harris RC, et al
    Exploring uncertainty and risk in the accelerated response to a COVID-19 vaccine: Perspective from the pharmaceutical industry.
    Vaccine. 2020;38:7588-7595.
    >> Share

  1548. ZHANG W, Gao J, Chen L, Tian J, et al
    Estimated influenza illnesses and hospitalizations averted by influenza vaccination among children aged 6-59 months in Suzhou, China, 2011/12 to 2015/16 influenza seasons.
    Vaccine. 2020 Nov 8. pii: S0264-410X(20)31389.
    >> Share

  1549. CHIU SS, Chua H, Kwan MYW, Chan ELY, et al
    Influenza vaccination effectiveness in preventing influenza hospitalization in children, Hong Kong, winter 2019/20.
    Vaccine. 2020 Nov 6. pii: S0264-410X(20)31401.
    >> Share

  1550. SARASTY O, Carpio CE, Hudson D, Guerrero-Ochoa PA, et al
    The demand for a COVID-19 vaccine in Ecuador.
    Vaccine. 2020 Nov 6. pii: S0264-410X(20)31439.
    >> Share

  1551. KESKE S, Mutters NT, Tsioutis C, Ergonul O, et al
    Influenza vaccination among infection control teams: A EUCIC survey prior to COVID-19 pandemic.
    Vaccine. 2020 Nov 5. pii: S0264-410X(20)31427.
    >> Share

  1552. CHEN WH, Tao X, Agrawal AS, Algaissi A, et al
    Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement.
    Vaccine. 2020;38:7533-7541.
    >> Share

    October 2020
  1553. VESIKARI T, Ramsey K, Pitisuttithum P, Capeding R, et al
    Repeated exposure to an MF-59 adjuvanted quadrivalent subunit influenza vaccine (aQIV) in children: Results of two revaccination studies.
    Vaccine. 2020 Oct 30. pii: S0264-410X(20)31330.
    >> Share

  1554. BONANNI P, Angelillo IF, Villani A, Biasci P, et al
    Maintain and increase vaccination coverage in children, adolescents, adults and elderly people: Let's avoid adding epidemics to the pandemic: Appeal from the Board of the Vaccination Calendar for Life in Italy: Maintain and increase coverage also by r
    Vaccine. 2020 Oct 30. pii: S0264-410X(20)31318.
    >> Share

  1555. CARCELEN AC, Vilajeliu A, Malik F, Gilman RH, et al
    Perceptions and attitudes towards vaccination during pregnancy in a peri urban area of Lima, Peru.
    Vaccine. 2020 Oct 30. pii: S0264-410X(20)31325.
    >> Share

  1556. LIU B, Shi P, Wang T, Zhao Y, et al
    Recombinant H7 hemagglutinin expressed in glycoengineered Pichia pastoris forms nanoparticles that protect mice from challenge with H7N9 influenza virus.
    Vaccine. 2020 Oct 29. pii: S0264-410X(20)31370.
    >> Share

  1557. SCHNEIKART G, Tavarini S, Sammicheli C, Torricelli G, et al
    The respiratory syncytial virus fusion protein-specific B cell receptor repertoire reshaped by post-fusion subunit vaccination.
    Vaccine. 2020 Oct 29. pii: S0264-410X(20)31371.
    >> Share

  1558. SCHOCH-SPANA M, Brunson EK, Long R, Ruth A, et al
    The public's role in COVID-19 vaccination: Human-centered recommendations to enhance pandemic vaccine awareness, access, and acceptance in the United States.
    Vaccine. 2020 Oct 29. pii: S0264-410X(20)31368.
    >> Share

  1559. LIU X, Drelich A, Li W, Chen C, et al
    Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice.
    Vaccine. 2020;38:7205-7212.
    >> Share

  1560. GUEBRE-XABIER M, Patel N, Tian JH, Zhou B, et al
    NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge.
    Vaccine. 2020 Oct 23. pii: S0264-410X(20)31373.
    >> Share

  1561. CHANDIR S, Siddiqi DA, Mehmood M, Setayesh H, et al
    Impact of COVID-19 pandemic response on uptake of routine immunizations in Sindh, Pakistan: An analysis of provincial electronic immunization registry data.
    Vaccine. 2020;38:7146-7155.
    >> Share

  1562. RUSCIO BA, Hotez P
    Expanding global and national influenza vaccine systems to match the COVID-19 pandemic response.
    Vaccine. 2020 Oct 21. pii: S0264-410X(20)31364.
    >> Share

  1563. BELL S, Clarke R, Mounier-Jack S, Walker JL, et al
    Parents' and guardians' views on the acceptability of a future COVID-19 vaccine: A multi-methods study in England.
    Vaccine. 2020 Oct 19. pii: S0264-410X(20)31321.
    >> Share

  1564. ZHAI Y, Santibanez TA, Kahn KE, Srivastav A, et al
    Rural, urban, and suburban differences in influenza vaccination coverage among children.
    Vaccine. 2020 Oct 15. pii: S0264-410X(20)31324.
    >> Share

  1565. GARCIA PJ, George PE, Romero C, Soto G, et al
    "The flu... is a little more complicated than a cold": Knowledge, beliefs, and practices related to influenza and influenza vaccination among at-risk populations and health professionals in Peru.
    Vaccine. 2020 Oct 15. pii: S0264-410X(20)31236.
    >> Share

  1566. VERGKIZI S, Nikolakakis I
    Bacillus Calmette-Guerin (BCG) vaccine generates immunoregulatory cells in the cervical lymph nodes in guinea pigs injected intra dermally.
    Vaccine. 2020 Oct 15. pii: S0264-410X(20)31284.
    >> Share

  1567. MALTEZOU HC, Theodoridou K, Tseroni M, Raftopoulos V, et al
    Influenza vaccination policies for health workers in low-income and middle-income countries: A cross-sectional survey, January-March 2020.
    Vaccine. 2020 Oct 12. pii: S0264-410X(20)31276.
    >> Share

  1568. MO Y, Zeng J, Xiao C, Zhang, et al
    Effectiveness and safety of pneumococcal vaccines used alone or combined with influenza vaccination in dialysis patients: A systematic review and meta-analysis.
    Vaccine. 2020 Oct 12. pii: S0264-410X(20)31262.
    >> Share

  1569. GOLDMAN RD, Yan TD, Seiler M, Parra Cotanda C, et al
    Caregiver willingness to vaccinate their children against COVID-19: Cross sectional survey.
    Vaccine. 2020 Oct 10. pii: S0264-410X(20)31317.
    >> Share

  1570. SAFAVI A, Kefayat A, Mahdevar E, Abiri A, et al
    Exploring the out of sight antigens of SARS-CoV-2 to design a candidate multi-epitope vaccine by utilizing immunoinformatics approaches.
    Vaccine. 2020 Oct 9. pii: S0264-410X(20)31307.
    >> Share

  1571. RONCATI L, Vadala M, Corazzari V, Palmieri B, et al
    COVID-19 vaccine and boosted immunity: Nothing ad interim to do?
    Vaccine. 2020 Oct 9. pii: S0264-410X(20)31303.
    >> Share

  1572. SINGH JA
    COVID-19 vaccine trials: Duty of care and standard of prevention considerations.
    Vaccine. 2020 Oct 9. pii: S0264-410X(20)31302.
    >> Share

  1573. MACIAS AE, McElhaney JE, Chaves SS, Nealon J, et al
    The disease burden of influenza beyond respiratory illness.
    Vaccine. 2020 Oct 8. pii: S0264-410X(20)31209.
    >> Share

  1574. GUILFOYLE K, Major D, Skeldon S, James H, et al
    Protective efficacy of a polyvalent influenza A DNA vaccine against both homologous (H1N1pdm09) and heterologous (H5N1) challenge in the ferret model.
    Vaccine. 2020 Oct 6. pii: S0264-410X(20)31233.
    >> Share

  1575. LEE JKH, Lam GKL, Shin T, Samson SI, et al
    Efficacy and effectiveness of high-dose influenza vaccine in older adults by circulating strain and antigenic match: An updated systematic review and meta-analysis.
    Vaccine. 2020 Oct 6. pii: S0264-410X(20)31146.
    >> Share

  1576. WOLF J, Hansen R, Hassis K, Lapps W, et al
    The impact of export regulations on recombinant viral vaccine development for emerging infectious diseases.
    Vaccine. 2020 Oct 5. pii: S0264-410X(20)31228.
    >> Share

  1577. CUSTERS J, Kim D, Leyssen M, Gurwith M, et al
    Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment.
    Vaccine. 2020 Oct 3. pii: S0264-410X(20)31160.
    >> Share

  1578. HOSHI SL, Shono A, Seposo X, Okubo I, et al
    Cost-effectiveness analysis of influenza vaccination during pregnancy in Japan.
    Vaccine. 2020 Oct 2. pii: S0264-410X(20)31180.
    >> Share

  1579. NIANG M, Deming ME, Goudiaby D, Diop OM, et al
    Immunogenicity of seasonal inactivated influenza and inactivated polio vaccines among children in Senegal: Results from a cluster-randomized trial.
    Vaccine. 2020 Oct 1. pii: S0264-410X(20)31230.
    >> Share

    September 2020
  1580. TEMPIA S, Moyes J, Cohen AL, Walaza S, et al
    Influenza economic burden among potential target risk groups for immunization in South Africa, 2013-2015.
    Vaccine. 2020 Sep 23. pii: S0264-410X(20)31193.
    >> Share

  1581. DETOC M, Bruel S, Frappe P, Tardy B, et al
    Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemic.
    Vaccine. 2020 Sep 17. pii: S0264-410X(20)31201.
    >> Share

  1582. DEAN NE, Pastore Y Piontti A, Madewell ZJ, Cummings DAT, et al
    Ensemble forecast modeling for the design of COVID-19 vaccine efficacy trials.
    Vaccine. 2020 Sep 15. pii: S0264-410X(20)31191.
    >> Share

  1583. WANG K, Wong ELY, Ho KF, Cheung AWL, et al
    Intention of nurses to accept coronavirus disease 2019 vaccination and change of intention to accept seasonal influenza vaccination during the coronavirus disease 2019 pandemic: A cross-sectional survey.
    Vaccine. 2020 Sep 10. pii: S0264-410X(20)31175.
    >> Share

    August 2020
  1584. TOMITA Y, Sato R, Ikeda T, Sakagami T, et al
    BCG vaccine may generate cross-reactive T cells against SARS-CoV-2: In silico analyses and a hypothesis.
    Vaccine. 2020 Aug 20. pii: S0264-410X(20)31086.
    >> Share

  1585. REITER PL, Pennell ML, Katz ML
    Acceptability of a COVID-19 vaccine among adults in the United States: How many people would get vaccinated?
    Vaccine. 2020 Aug 20. pii: S0264-410X(20)31084.
    >> Share

  1586. GALILI U
    Amplifying immunogenicity of prospective Covid-19 vaccines by glycoengineering the coronavirus glycan-shield to present alpha-gal epitopes.
    Vaccine. 2020 Aug 19. pii: S0264-410X(20)31073.
    >> Share

  1587. GRADY C, Shah S, Miller F, Danis M, et al
    So much at stake: Ethical tradeoffs in accelerating SARSCoV-2 vaccine development.
    Vaccine. 2020 Aug 11. pii: S0264-410X(20)31048.
    >> Share

  1588. YITBAREK K, Abraham G, Girma T, Tilahun T, et al
    The effect of Bacillus Calmette-Guerin (BCG) vaccination in preventing sever infectious respiratory diseases other than TB: Implications for the COVID-19 pandemic.
    Vaccine. 2020 Aug 10. pii: S0264-410X(20)31049.
    >> Share

  1589. MARELLAPUDI A, King AR, Bednarczyk RA
    Presentation of caregiver-specific vaccine-related information on National Cancer Institute designated cancer center websites.
    Vaccine. 2020 Aug 1. pii: S0264-410X(20)30983.
    >> Share

    July 2020
  1590. VERDIJK P, van der Plas JL, van Brummelen EMJ, Jeeninga RE, et al
    First-in-human administration of a live-attenuated RSV vaccine lacking the G-protein assessing safety, tolerability, shedding and immunogenicity: a randomized controlled trial.
    Vaccine. 2020 Jul 25. pii: S0264-410X(20)30947.
    >> Share

    June 2020
  1591. BALZARINI F, Frascella B, Oradini-Alacreu A, Gaetti G, et al
    Does the use of personal electronic health records increase vaccine uptake? A systematic review.
    Vaccine. 2020 Jun 30. pii: S0264-410X(20)30738.
    >> Share

  1592. GUIDRY JPD, Coman IA, Vraga EK, O'Donnell NH, et al
    (S)pin the flu vaccine: Recipes for concern.
    Vaccine. 2020 Jun 24. pii: S0264-410X(20)30773.
    >> Share

  1593. BARAL R, Li X, Willem L, Antillon M, et al
    The impact of maternal RSV vaccine to protect infants in Gavi-supported countries: Estimates from two models.
    Vaccine. 2020 Jun 22. pii: S0264-410X(20)30822.
    >> Share

  1594. WOLFF GG
    Letter to the Editor.
    Vaccine. 2020;38:4651.
    >> Share

    May 2020
  1595. PLOTKIN SA, Caplan A
    Extraordinary diseases require extraordinary solutions.
    Vaccine. 2020;38:3987-3988.
    >> Share

  1596. BELL S, Chantler T, Paterson P, Mounier-Jack S, et al
    Is flu vaccination opt-out feasible? Evidence from vaccination programme implementers and managers in the English National Health Service.
    Vaccine. 2020 May 4. pii: S0264-410X(20)30506.
    >> Share

    April 2020
  1597. KAUFMAN J, Attwell K, Tuckerman J, O'Sullivan J, et al
    Feasibility and acceptability of the multi-component P3-MumBubVax antenatal intervention to promote maternal and childhood vaccination: A pilot study.
    Vaccine. 2020 Apr 19. pii: S0264-410X(20)30469.
    >> Share

    March 2020
  1598. DRISCOLL AJ, Arshad SH, Bont L, Brunwasser SM, et al
    Does respiratory syncytial virus lower respiratory illness in early life cause recurrent wheeze of early childhood and asthma? Critical review of the evidence and guidance for future studies from a World Health Organization-sponsored meeting.
    Vaccine. 2020;38:2435-2448.
    >> Share

    February 2020
  1599. MUELLER S, Stauft CB, Kalkeri R, Koidei F, et al
    A codon-pair deoptimized live-attenuated vaccine against respiratory syncytial virus is immunogenic and efficacious in non-human primates.
    Vaccine. 2020 Feb 24. pii: S0264-410X(20)30279.
    >> Share

  1600. HOSCHLER K, Maharjan S, Whitaker H, Southern J, et al
    Use of traditional serological methods and oral fluids to assess immunogenicity in children aged 2-16 years after successive annual vaccinations with LAIV.
    Vaccine. 2020 Feb 15. pii: S0264-410X(20)30221.
    >> Share

  1601. SAMY N, Reichhardt D, Schmidt D, Chen LM, et al
    Safety and immunogenicity of novel modified vaccinia Ankara-vectored RSV vaccine: A randomized phase I clinical trial.
    Vaccine. 2020 Feb 11. pii: S0264-410X(20)30081.
    >> Share

    January 2020
  1602. MCDONALD JU, Rigsby P, Atkinson E, Engelhardt OG, et al
    Expansion of the 1st WHO international standard for antiserum to respiratory syncytial virus to include neutralisation titres against RSV subtype B: An international collaborative study.
    Vaccine. 2020;38:800-807.
    >> Share

  1603. RAINISCH G, Adhikari B, Meltzer MI, Langley G, et al
    Estimating the impact of multiple immunization products on medically-attended respiratory syncytial virus (RSV) infections in infants.
    Vaccine. 2020;38:251-257.
    >> Share

    December 2019
  1604. GIESE H, Neth H, Moussaid M, Betsch C, et al
    The echo in flu-vaccination echo chambers: Selective attention trumps social influence.
    Vaccine. 2019 Dec 18. pii: S0264-410X(19)31563.
    >> Share

  1605. WILSON R, Zaytseva A, Bocquier A, Nokri A, et al
    Vaccine hesitancy and self-vaccination behaviors among nurses in southeastern France.
    Vaccine. 2019 Dec 3. pii: S0264-410X(19)31541.
    >> Share

    November 2019
  1606. WELLIVER RC, Papin JF, Preno A, Ivanov V, et al
    Maternal immunization with RSV fusion glycoprotein vaccine and substantial protection of neonatal baboons against respiratory syncytial virus pulmonary challenge.
    Vaccine. 2019 Nov 21. pii: S0264-410X(19)31510.
    >> Share

  1607. NUNEZ IA, Ross TM
    Human COBRA 2 vaccine contains two major epitopes that are responsible for eliciting neutralizing antibody responses against heterologous clades of viruses.
    Vaccine. 2019 Nov 13. pii: S0264-410X(19)31497.
    >> Share

  1608. BROWNE SK, Beeler JA, Roberts JN
    Summary of the Vaccines and Related Biological Products Advisory Committee meeting held to consider evaluation of vaccine candidates for the prevention of respiratory syncytial virus disease in RSV-naive infants.
    Vaccine. 2019 Nov 6. pii: S0264-410X(19)31428.
    >> Share

    October 2019
  1609. STURKENBOOM M, Bahri P, Chiucchiuini A, Grove Krause T, et al
    Why we need more collaboration in Europe to enhance post-marketing surveillance of vaccines.
    Vaccine. 2019 Oct 31. pii: S0264-410X(19)31002.
    >> Share

  1610. KOLB EA, Buterbaugh RE, Rinehart CL, Ensley D, et al
    Protection against bovine respiratory syncytial virus in calves vaccinated with adjuvanted modified live vaccine administered in the face of maternal antibody.
    Vaccine. 2019 Oct 24. pii: S0264-410X(19)31378.
    >> Share

  1611. ROBERTS NJ JR
    Respiratory syncytial virus suppression of the antiviral immune response: Implications for evaluation of candidate vaccines.
    Vaccine. 2019 Oct 10. pii: S0264-410X(19)31339.
    >> Share

    September 2019
  1612. GILES ML, Buttery J, Davey MA, Wallace E, et al
    Pregnant women's knowledge and attitude to maternal vaccination including group B streptococcus and respiratory syncytial virus vaccines.
    Vaccine. 2019 Sep 17. pii: S0264-410X(19)31173.
    >> Share

    August 2019
  1613. PATEL N, Massare MJ, Tian JH, Guebre-Xabier M, et al
    Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection.
    Vaccine. 2019 Aug 12. pii: S0264-410X(19)31010.
    >> Share

    May 2019
  1614. TORCEL-PAGNON L, Bauchau V, Mahy P, Tin Tin Htar M, et al
    Guidance for the governance of public-private collaborations in vaccine post-marketing settings in Europe.
    Vaccine. 2019 May 6. pii: S0264-410X(19)30561.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016